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ABSTRACT 
 
 
Candida albicans is a pathogenic fungi found in the mucosa, gastrointestinal, and 
urogenital tracts of humans.  Oropharyngeal candidiasis (OPC), an opportunistic mucosal 
infection caused by C. albicans, occurs most frequently in patients infected with human 
immunodeficiency virus (HIV).  OPC is usually treated with azole antifungals, a class of 
antifungals that target ergosterol biosynthesis, at low doses over long periods of time.  
This course of treatment allows for the development of azole resistance. 
 
Two major mechanisms of azole resistance exist in C. albicans, the up-regulation 
of genes encoding efflux pumps and the up-regulation of ERG11, a gene encoding the 
azole drug target lanosterol demethylase.  The overexpression of efflux pumps remain the 
major contributor of azole resistance.  The ATP binding cassette (ABC) transporter genes 
CDR1 and CDR2 have been shown to be regulated by a zinc cluster transcription factor 
Tac1p.  A gain-of-function mutation in the gene encoding this transcription factor is 
responsible for the overexpression of CDR1 and CDR2.  To identify the Tac1p regulon, 
we analyzed four matched sets of clinical isolates with gain-of-function mutations in 
TAC1 representing the development of CDR1- and CDR2-mediated azole resistance, 
using gene expression profiling.  We identified genes that were consistently up-regulated 
coordinately with CDR1 and CDR2, including TAC1 itself.  When a resistant strain 
disrupted for TAC1 was similarly examined, the expression of almost all of these genes 
returned to levels similar to those in the matched azole-susceptible isolate.  Using 
chromatin Immunoprecipitation microarray (ChIP-chip) analysis, we found genes whose 
promoters were bound by Tac1p in vivo, including CDR1 and CDR2.  Sequence analysis 
identified genes whose promoters contain the previously reported Tac1p drug-responsive 
element (DRE; CGGN4CGG), including TAC1.  Our results show that Tac1p is 
constitutively bound to the promoter of its targets, including to its own promoter.  They 
also suggest roles for Tac1p in regulating lipid metabolism (mobilization and trafficking) 
and oxidative stress response in C. albicans. 
 
Constitutive overexpression of the MDR1 gene, which encodes an efflux pump of 
the major facilitator superfamily, is another cause of resistance to fluconazole in clinical 
C. albicans strains.  The regulator of MDR1 gene expression has not been identified or 
characterized.  Using genome-wide gene expression profiling, we have identified a gene 
encoding a zinc cluster transcription factor, designated as MRR1 (multidrug resistance 
regulator), that was coordinately up-regulated with MDR1 in drug-resistant clinical C. 
albicans isolates.  The disruption of MRR1 in two resistant clinical isolates abrogated 
MDR1 expression and multidrug resistance.  MRR1 alleles were also sequenced and two 
gain-of-function mutations were identified (P683S and G997V).  The integration of the 
mutated alleles into the genome strain SC5314 resulted in the overexpression of MDR1 
and in the increase of drug resistance.  Microarray analysis of the resistant isolates, the 
disruption mutants and the reintegrated gain-of-function mutants allowed us to define a 
core group of genes regulated by Mrr1p.  In addition to conferring multidrug resistance, 
Mrr1p also regulates genes that encode oxidoreductases that play a role in the response to 
oxidative stress. 
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The second major resistance mechanism is the constitutive up-regulation of 
ERG11.  ERG11 encodes lanosterol demethylase, a cytochrome P-450 enzyme that is the 
target of the azole antifungals.  In C. albicans, the zinc cluster transcription factor Upc2p 
has been shown to regulate the expression of ERG11 and other ergosterol biosynthesis 
genes.  Overexpression of UPC2 increases azole resistance while disruption of UPC2 
results in hypersusceptibility.  Using genome-wide gene expression profiling, we found 
UPC2 and ergosterol biosynthesis genes to be coregulated with ERG11 in a fluconazole 
resistant clinical isolate.  Sequence analysis of the susceptible and resistant UPC2 alleles 
revealed that the resistant isolate contained one UPC2 allele harboring a single nucleotide 
substitution, resulting in a G648D exchange.  Introduction of the mutated UPC2 allele 
into the genome strain resulted in constitutive up-regulation of ERG11 and increased 
resistance to fluconazole.  By comparing the gene expression profiles of the fluconazole 
resistant isolate and of strains carrying wild-type and mutated UPC2 alleles, we identified 
target genes that are controlled by Upc2p.  We show for the first time that a gain-of-
function mutation in UPC2 leads to increased expression of ERG11 and imparts 
resistance to fluconazole in clinical isolates of C. albicans. 
 
By studying genetically matched sets of azole susceptible and resistant clinical 
isolates, we identified genes co-regulated with known resistance genes.  These core genes 
specific to particular resistance mechanisms allowed us to identify previously 
characterized but unknown transcriptional regulators that control this process.  Gain-of-
function mutations in these trans-regulatory elements are responsible for the development 
of azole resistance in these clinical isolates.  The target genes of each of these 
transcription factors provide insight into their function in addition to their role in azole 
resistance. 
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CHAPTER 1: INTRODUCTION 
 
 
CANDIDA ALBICANS 
 
 
Epidemiology of Infection 
 
Instances of fungal infections have increased dramatically in the past two decades due to 
the acquired immune deficiency syndrome (AIDS) epidemic, improved life-sustaining 
technologies, and anti-cancer therapies.  Unlike other pathogenic fungi with environmental 
niches, Candida species are found as a commensal organism in the mucosa, gastrointestinal, and 
urogenital tracts of 60-80% of humans (1).  The most common infections caused by Candida 
species are invasive or mucosal infections. 
 
Invasive candidiasis can range in severity from bloodstream infections to infections of 
one or more organs.  Candidemia, the most common form of invasive candidiasis, is the fourth 
leading cause of nosocomial bloodstream infections in the United States (2).  Candidemia usually 
occurs in patients hospitalized with serious underlying conditions.  Risk factors associated with 
candidemia include neutropenia, cancer chemotherapy, antimicrobial agents, and indwelling 
catheters  (3).  Neutropenic patients, patients undergoing cancer chemotherapy, and organ 
transplant patients are immunosuppressed and cannot fight off opportunistic infections.  Use of 
broad spectrum antimicrobial agents promotes increased colonization of fungal cells due to a 
decrease in competing flora.  Indwelling catheters facilitate candidemia and invasive candidiasis 
by disrupting the mucocutaneous barrier and allowing direct vascular access.  Catheters also 
provide a surface for the organism to adhere and create a focus for infection.  Candidemia has a 
high rate of morbidity and mortality, 30 to 70% among cancer patients and 26 to 75% among 
non-cancer patients (3).   
 
Mucosal candidiasis occurs mainly in the form of vulvovaginal candidiasis or 
oropharyngeal candidiasis.  In contrast to organs and tissues, mucosal surfaces tolerate the 
growth of a variety of potentially pathogenic and nonpathogenic indigenous flora (4).  Disease 
occurs when the balance of indigenous flora is disturbed, allowing for an overgrowth of Candida 
species.  Vulvovaginal candidiasis (VVC) occurs most frequently in women of childbearing age 
with an estimated 75% of all adult women having had at least one infection.  Candida species 
can be found as a commensal in the vagina in 10 to 25% of all women (1).  Other than pregnancy, 
infections can also occur due to antibiotic use, immunosuppressive therapy, hormone 
replacement therapy, or uncontrolled diabetes mellitus (4). 
 
Oropharyngeal candidiasis (OPC) occurs in several patient populations.  OPC occurs in 
elderly patients with dentures due to poor oral hygiene.  The dentures provide a surface on which 
Candida can adhere, and the resolution of the infection occurs with the removal of the dentures 
(5).  OPC occurs most frequently in patients infected with the human immunodeficiency virus 
(HIV) with an estimated 90% of patients developing OPC.  The occurrences of OPC increase as 
the CD4+ cell counts decrease usually to a threshold less than 200 cells/mm3 (6).  Although OPC 
has declined with the introduction of highly active antiretroviral therapy (HAART), the cost of 
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drug and the monitoring required makes widespread use of HAART difficult in third world 
nations where the majority of HIV-infected patients reside (7, 8).   
 
OPC is usually classified as pseudomembranous or erythematous.  Pseudomembranous 
OPC is characterized by smooth, white, papular lesions.  Erythematous OPC is characterized by 
diffuse, macular erythema of the palate, oropharynx, buccal mucosa, and dorsal tongue.  Hyphae 
and pseudohyphae found on the mucosal surface are generally associated with 
pseudomembranous OPC, whereas, hyphae are generally not seen on the mucosal surface in 
erythematous OPC (6). 
 
In invasive candidiasis, 60 to 75% of infections are caused by C. albicans (3).  In VVC, 
C. albicans causes 85 to 90% of infections, whereas in OPC, C. albicans causes 77 to 100% of 
infections (4, 6).  Although the instances of non-albicans species being the causative agent of 
infection is increasing in both invasive and mucosal candidiasis, C. albicans remains the most 
prevalent etiological agent of Candida infection. 
 
 
Treatment 
 
The treatment of fungal infections is limited to a few classes of antifungal agents.  These 
antifungal compounds must exploit the differences between host and fungal cells; however, this 
is difficult due to the many similarities between fungal and mammalian cells.  They are both 
eukaryotes with similar organelles, DNA replication, and protein synthesis.  A structural 
difference is the presence of a cell wall in fungal cells.  This makes it an optimal target for 
antifungal agents.  The cell wall protects against osmotic pressure and is composed of chitin, 
mannoproteins, glycosylphosphatidylinositol (GPI)- anchored proteins, and glucans.  The 
echinocandins (caspofungin), the newest class of antifungals, are thought to inhibit β-1,3-glucan 
synthase.  Most cell wall components are interconnected through β-1,3-glucans, making it an 
important component in cell wall structure (9).  By inhibiting β-1,3-glucan synthase, the cell wall 
destabilizes and the cell is  more susceptible to osmotic stress.  Caspofungin is fungicidal and 
effective against a large number of fungal pathogens including Candida.  However, it is only 
available for intravenous administration, and the cost limits the use in developing nations. 
 
Another difference between mammalian and fungal cells is the membrane sterol 
composition.  Sterols regulate the membrane fluidity and integrity of the cell.  Mammalian cell 
membranes consist mainly of cholesterol; fungal cell membranes depend on ergosterol as the 
major membrane sterol.  This difference makes ergosterol a prime target for antifungal drugs.  
The polyenes target the ergosterol in the plasma membrane directly.  The polyenes are fungicidal 
agents that bind the ergosterol in the membrane forming pores and disrupting the proton gradient 
(10).  Amphotericin B (AmB), the most effective polyene, is still widely used to treat systemic 
candidiasis.  However, high doses of, or long term treatment with, AmB can cause 
nephrotoxicity.  AmB is also administered intravenously, limiting the use of the drug to hospital 
settings.  Newer liposomal formulations of AmB have decreased the toxicity, but the increased 
cost precludes the widespread use of the drug (11). 
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The biosynthesis of ergosterol is another major target of antifungal agents.  Three 
antifungal drug classes function as ergosterol biosynthesis inhibitors, targeting different enzymes 
of the pathway.  The allylamines act as noncompetitive inhibitors of squalene epoxidase encoded 
by ERG1, causing squalene accumulation and ergosterol depletion.  Terbinafine, an allylamine, 
is used as a topical agent due to its fungicidal activity against dermatophytes; it is fungistatic 
against Candida species, so it is rarely used to treat Candida infections.  The morpholines 
(fenpropimorph, amorolfine) inhibit two enzymes in the ergosterol biosynthesis pathway, C-14 
sterol reductase, encoded by ERG24, and C-8 sterol isomerase, encoded by ERG2.  
Fenpropimorph is generally used as an agricultural fungicide.  Amorolfine, fungicidal against 
dermatophytes but fungistatic against yeast pathogens, is only used as a topical agent to treat 
dermatophytes and VVC.  The azoles are the largest class of antifungal agents, consisting of two 
subclasses, triazoles and imidazoles.  The azoles inhibit C-14 lanosterol demethylase encoded by 
ERG11 (5).  Lanosterol demethylase is a cytochrome P-450 enzyme with a heme in its active site.  
The azoles function by binding the iron of the heme through an unhindered nitrogen.  This 
prevents the activation of oxygen necessary for the demethylation of lanosterol (12).  The 
inhibition of lanosterol demethylase causes the accumulation of toxic sterol, 14α-methyl-3,6-diol, 
causing growth arrest (13).  Although the azoles are fungistatic, they are most effective against a 
broad spectrum of fungal pathogens.  Ketoconazole, an imidazole, was the first azole to be 
widely used due to its low toxicity.  Fluconazole, a triazole, is now the most widely used azole 
antifungal agent due to its water solubility, low toxicity, oral administration, and the ability to 
treat both mucosal and systemic candidiasis (5, 10). 
 
 
C. albicans Physiology 
 
C. albicans is a dimorphic fungus capable of several cell morphologies.  At temperatures 
less than 35°C grown with glucose as a carbon source, C. albicans grows as a blastospore, or 
yeast cell.  Blastospores are characterized as spherical, single cells that undergo mitotic cell 
division by budding.  Budding occurs at one spot on the blastospore, and once nuclear division 
occurs, a septum is formed between the parent and the daughter cell.  The cells separate 
completely to form two new cells.  At temperatures greater than 35°C grown in the presence of 
serum, C. albicans starts to filament.  C. albicans can form pseudohyphae and true hyphae under 
filamentous conditions.  Hyphal growth occurs when a blastospore forms a germ tube that 
continues to extend apically.  As the cell grows, mitosis occurs and a septum forms.  However, 
unlike blastospores, the cells do not separate; instead apical growth continues as the hypha 
continues to elongate.  The cell walls of true hyphae are parallel with no constrictions at the 
septum.  Pseudohyphae are differentiated from true hyphae by the constrictions that occur at the 
septum of pseudohyphae.  Pseudohyphae form from blastospores in a process similar to budding.  
As the daughter cell continues to grow, it takes on a more elongated shape like a hypha.  After 
the septum forms, the cells remain attached.  As the cells continue to undergo mitosis, the cells 
form a chain of blastospores resembling filaments (1). 
 
The change in cell morphology is thought to be a virulence factor of infection.  The 
reversible switch from blastospore to hypha is one method by which C. albicans is thought to 
penetrate the mucosal membrane and invade host tissue.  The hyphal form expresses various cell 
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wall proteins that allow for better adhesion to epithelial and endothelial cells.  Once in the 
bloodstream, the switch back to yeast cells allows for better dissemination (14). 
 
The morphological changes and the ability to form true hyphae play a large role in the 
formation of biofilms.  Biofilms generally occur on the surfaces of catheters, dentures, or other 
indwelling devices.  Biofilms create a focus of infection in invasive candidiasis and also creates 
an environment that confers drug resistance (5).  The Candida biofilm is a complex, multi-
layered growth structure.  A thin layer of blastospores adhere to the plastics, forming a thin 
biofilm.  The blastospores then start forming a thick hyphal layer and excreting an extracellular 
matrix of proteins and polysaccharides.  The ability to form hyphae allows for thicker biofilms 
and less penetration of drugs into the extracellular matrix.  Biofilms formed by yeast cells alone 
are less adherent and thinner.  Saccharomyces cerevisiae has the ability to form biofilms, but 
other than a thin basal layer of blastospores, no extracellular matrix is formed.  This allows for 
easier antifungal penetration and less development of antifungal resistance (15). 
 
 
Genetics 
 
Genetic manipulation in C. albicans has been difficult because C. albicans is a diploid 
yeast with no haploid stage in its cell cycle.  It has eight chromosomes with 6,354 putative genes 
(16).  It also does not have a conventional sexual cycle.  Although there is a mating type locus on 
chromosome 5 in C. albicans, meiotic recombination occurs very infrequently.  Instead, 
reproduction is largely clonal (5). 
 
The initial understanding of the C. albicans genome came from studying the better 
characterized yeast, S. cerevisiae.  Although C. albicans and S. cerevisiae diverged 140-841 
million years ago, many genes are highly conserved (14).  Hybridization to and complementation 
of S. cerevisiae genes were two methods used to characterize functions of genes in C. albicans.  
Complementation studies in S. cerevisiae mutants isolated genes that could restore function; 
studies in wild-type S. cerevisiae isolates found genes that conferred new function.  
Hybridization studies using S. cerevisiae DNA arrays only revealed genes that were most highly 
conserved between the two species (5).  With the sequencing of the C. albicans genome 
complete, DNA microarrays specific to C. albicans are now available.  Gene expression patterns 
under various conditions can now be studied independent of sequence homology to S. cerevisiae.  
Actual C. albicans gene expression along with S. cerevisiae homology allows for better 
characterization of cell function and pathways.  
 
Because of the diploid nature of C. albicans, it has historically been very difficult to 
isolate homozygous recessive mutants.  Mutants were generated using chemical mutagens or 
ultraviolet light and selected on media containing drugs.  This method often generated several 
undefined genomic alterations.  Candida, as a genus, also has unconventional codon usage.  The 
CUG codons are predominantly decoded as serines rather than leucines (17).  This codon 
reassignment makes it difficult to use S. cerevisiae vectors and reporter constructs that depend on 
translation of CUG codons to leucine.  Once specific auxotrophic strains were developed for C. 
albicans, gene disruptions could be performed more readily.  The most frequently used 
auxotrophic marker used in C. albicans is URA3, a gene that encodes orotidine 5’ phosphate 
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decarboxylase.  The strain CAI4, derived from clinical isolate and genome strain SC5314, has 
disruptions in both alleles of URA3 (18).  The URA3 marker allows for easy selection and 
counterselection of the correct transformants.  The URA-blaster method of gene disruption uses 
the selectable marker URA3.  The cassette was constructed by flanking URA3 with direct repeats 
of bacterial hisG sequences.  The 5’ and 3’ regions of the gene are then cloned on either side of 
the hisG repeats.  When the cassette is transformed into a ura- strain, homologous recombination 
occurs, replacing one allele of the gene with the cassette.  Correct transformants are selected by 
growth on media lacking uridine.  Counterselection then occurs when grown on plates containing 
5-fluoroorotic acid (FOA).  5-FOA selects for ura- strains which arise through homologous 
recombination at the hisG repeats.  The URA3 gene encodes orotidine 5’-phosphate 
decarboxylase, a gene required for uracil biosynthesis.  When a wild-type strain is grown on 5-
FOA, the URA3 gene product converts 5-FOA to 5-fluorouracil, a toxic gene product.  Because 
of this conversion, only strains that spontaneously lose the URA3 gene can grow on the selection 
media.  Once the cassette has been excised from the first allele, a second round of 
transformations can occur to disrupt the second allele (19). 
 
While auxotrophic strains have allowed for easier gene manipulation, the auxotrophs 
were derived from either the genome strain SC5314, or strain WO-1.  Gene disruption in clinical 
isolates would be problematic unless the clinical isolate happened to have an auxotrophic marker.  
Two new methods of gene disruption independent of auxotrophy has allowed for the disruption 
of genes in any isolates regardless of genetic background.  The first method relies on a dominant 
selection marker that confers resistance to mycophenolic acid fused to a site-specific 
recombinase FLP from S. cerevisiae modified to function in C. albicans.  The FLP gene is 
controlled by the SAP2 promoter, so FLP activity only occurs under inducing conditions (20, 21).  
The second method relies on a dominant selection marker that confers resistance to the antibiotic 
nourseothricin fused to the FLP recombinase under the control of the MAL2 promoter (22).  Both 
these methods effectively disrupt genes in isolates without requiring auxotrophic markers. 
 
 
AZOLE RESISTANCE 
 
 
Emergence of Clinical Resistance 
 
Clinical resistance occurs when an infection persists or progresses regardless of 
antifungal treatment.  Primary or intrinsic resistance occurs when the organism is resistant before 
treatment with an antifungal agent.  Secondary resistance arises in response to treatment (10).  
The most common antifungal drug resistance occurs to the azoles due to their widespread use in 
treating fungal infections.  Because of the fungistatic nature of the azoles, it is difficult to 
eradicate all of the Candida present in the infection particularly in the setting of an 
immunocompromised host, so relapses occur.  The Clinical and Laboratory Standards Institute 
(CLSI) Subcommittee for Antifungal Susceptibility Testing has established standard breakpoints 
for fluconazole susceptibility.  An isolate is considered sensitive with a minimum inhibitory 
concentration (MIC) <8 μg/ml; an isolate is resistant with an MIC ≥64 μg/ml.  An isolate with an 
MIC of 8 to 64 μg/ml is considered susceptible-dose dependent (23).  Infections due to such 
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isolates respond to treatment in the same manner as a susceptible strain provided a high enough 
dosage of fluconazole is administered. 
 
Secondary fluconazole resistance in C. albicans most often occurs in either AIDS 
patients with OPC or less frequently in immunosuppressed patients with systemic candidiasis.  
Resistance to fluconazole in systemic candidiasis is usually due to intrinsic azole resistance as a 
result from infection with C. glabrata or C. krusei.  Development of resistance in bloodstream 
infections by C. albicans is rare (8). 
 
Fluconazole resistance in OPC is due to secondary resistance with resistant C. albicans 
strains recovered from a third of the patients with advanced AIDS.  Recurrent OPC occurs most 
often in patients with CD4+ T cells <50/mm3 (24).  Patients with OPC are usually treated with 
fluconazole at low doses (100 mg per day) over a long period of time either continuously or 
intermittently (8, 24).  When a relapse of OPC occurs, the dose of fluconazole is increased (200, 
400, 800 mg per day) with a maximum dosage of 800 mg per day.  Before the use of HAART, 
fluconazole prophylaxis decreased the morbidity and mortality attributed to mucosal and 
invasive fungal infections.  With the use of HAART, incidences of OPC have decreased.  
However, in patients undergoing HAART who develop OPC, resistance has been shown to occur.  
Of the patients undergoing HAART and fluconazole treatment (continuous or episodic), 36 to 
45% developed fluconazole resistance (25).  Although HAART has decreased the incidence of 
OPC, the cost of therapy in developing nations is too high to make it widely available; poor 
compliance also limits the effectiveness of HAART.  Fluconazole prophylaxis is still necessary 
in resource-poor regions to control candidiasis, so development of resistance by C. albicans is 
still problematic. 
 
 
Molecular Mechanisms of Resistance 
 
Azole resistance in C. albicans occurs primarily due to the selection of resistance over 
time rather than replacement by a more resistant strain.  Several genotyping techniques are used 
to determine if an azole resistant strain was derived from a specific azole sensitive parent.  
Pulsed-field gene electrophoresis (molecular karyotyping), restriction fragment length 
polymorphism (RFLP), and repetitive marker Ca3 probe-based fingerprinting are three methods 
used to determine the genetic relationship between a susceptible and a resistant strain.  The 
karyotype and RFLP patterns between C. albicans of different patients are different, suggesting 
little relationship between strains.  However, serially-collected isolates recovered from a single 
patient typically indicate that the resistant isolate has the same karyotype and RFLP patterns as 
the previously susceptible isolate (26, 27).  Using these typing methods to identify matched 
isolate sets, specific mutations that cause azole resistance can be determined. 
 
There are several known mechanisms by which C. albicans can develop resistance to 
azoles.  A decrease in intracellular accumulation of azoles reduces the amount of drug that comes 
into contact with its target.  Differences in azole accumulation in the cell can be due to the 
uptake or the efflux of the drug.  Using tritium labeled fluconazole, [3H]fluconazole, differences 
in accumulation can be studied.  In a susceptible isolate, fluconazole accumulation as a function 
of concentration does not occur in a linear fashion.  This eliminates passive diffusion as a 
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mechanism of fluconazole uptake (28).  Fluconazole sensitive isolates pretreated with sodium 
azide and then exposed to fluconazole show little difference in drug accumulation (28, 29).  
Sodium azide, a metabolic inhibitor, interferes with energy dependent pumps by decreasing the 
amount of ATP generated by the mitochondria.  Because accumulation doesn’t change, drug 
import is not energy dependent suggesting that fluconazole enters the cell through facilitated 
diffusion (28).  In resistant isolates, [3H]fluconazole accumulation is significantly less than that 
of the susceptible parent isolate.  The resistant isolates pretreated with sodium azide shows 
increased fluconazole accumulation (28, 29).  Because fluconazole accumulation increases due 
to the disruption of energy dependent pumps and drug import seems to be energy independent, 
increased resistance due to decreased accumulation can be attributed to efflux pumps rather than 
impaired drug uptake. 
 
One class of efflux pumps found to be overexpressed in resistant isolates of C. albicans is 
the ATP-binding cassette (ABC) transporters.  ABC transporters can be found in all organisms, 
and most transporters are substrate specific. Multidrug resistance ABC transporters, however, 
have evolved to transport a wide variety of lipophilic molecules. Prokaryotes have ABC 
transporters that import and export various substrates; eukaryotic ABC transporters are 
predominately exporters (30).  All ABC transporters are composed of two six-transmembrane 
domains (TMD) and two cytoplasmic nucleotide-binding domains (NBD) that contain the ABC.  
The first and most well characterized ABC multidrug transporter was mammalian P-glycoprotein, 
responsible for the development of resistance in cancer cells to chemotherapy drugs (31). 
 
In C. albicans, ten efflux pumps have been identified as ABC multidrug transporters.  
These efflux pumps were named the Candida drug resistance (CDR) family of transporters (10). 
Of the ten CDR pumps, only two ABC transporters, encoded by CDR1 and CDR2, have been 
implicated in azole resistance.  CDR1 is highly homologous to PDR5, a multidrug transporter in 
S. cerevisiae, and the protein structures are almost identical (32).  PDR5 confers cycloheximide, 
chloramphenicol, and fluconazole resistance as a pdr5Δ double disruption mutant causes 
hypersensitivity to cycloheximide, chloramphenicol, and fluconazole (33).  CDR1 was first 
cloned and characterized for its ability to complement drug resistance in S. cerevisiae (29, 32).  
In C. albicans clinical matched sets, CDR1 was found to be expressed in both susceptible and 
resistant isolates.  In resistant isolates, the expression of CDR1 increased relative to the MIC of 
the isolates; the higher the MIC, the more CDR1 mRNA was detected (29, 34, 35).  The CDR1 
gene was also disrupted in a susceptible strain, CAF4, lacking both alleles of URA3.  In the 
absence of the ABC transporter, the strain became hypersusceptible to a variety of azoles (36).  
The overexpression of CDR1 using an inducible promoter in a cdr1Δ double mutant showed 
resistance to azoles (37). 
 
CDR2, another ABC transporter efflux pump 84% identical to CDR1, was also identified 
by its functional complementation of azole resistance in S. cerevisiae.  In matched isolates, 
CDR2 gene expression could not be detected in susceptible isolates.  In resistant isolates, the 
gene is expressed relative to the MIC (34, 35).  The expression of CDR2 in a resistant isolate is 
generally several fold higher than the expression of CDR1 in the same isolates.  Disruption of 
CDR2 in an auxotrophic strain of C. albicans showed little change in susceptibility in response to 
various drugs.  A double disruption construct, cdr1Δcdr2Δ, showed hypersusceptibility to azoles.  
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However, the lack of baseline expression levels of CDR2 in a susceptible isolate could explain 
the lack of hypersusceptibility to drugs (38). 
 
The second class of efflux pumps found in Candida is the major facilitator superfamily 
(MFS) transporters.  MFS transporters are energy dependent transporters that rely on the proton 
motive force generated by the proton gradient across membranes rather than ATP for energy.  
Like ABC transporters, MFS transporters can be symporters, antiporters, or uniporters, and they 
can be found in all cells of all organisms (39).  The MFS transporters have 12 to 14 
transmembrane domains and no NBD (10, 40). 
 
In C. albicans, the main MFS transporter contributing to fluconazole resistance is an 
antiporter multidrug resistance 1 (MDR1), formerly known as BEN1.  The Candida MDR1 is not 
to be confused with human MDR1, which is an ABC transporter.  MDR1 was first cloned for its 
ability to confer resistance in S. cerevisiae to benomyl and methotrexate (41).  Overexpression of 
MDR1 in S. cerevisiae under the control of an ADH1 promoter showed resistance to fluconazole 
but no ketoconazole or itraconazole (29).  Unlike the ABC transporters, fluconazole and 
voriconazole seems to be the only azole substrate for MDR1.  Disruption of MDR1 in wild-type 
isolates showed increased susceptibility to methotrexate, cycloheximide, and 4-nitroquinoline-N-
oxide.  The disruption mutants showed no changes in susceptibility to benomyl or fluconazole 
(20, 36, 42).  In clinical matched isolates, MDR1 mRNA is only detected in resistant isolates; 
there seems to be no baseline expression of MDR1 in susceptible isolates (34, 43).  The wild-type 
disruption mutants not being hypersusceptible to fluconazole are most likely due to the lack of 
baseline expression of MDR1. 
 
Changes in lanosterol demethylase, the target of azole antifungals, are another 
mechanism by which resistance develops.  Mutations in ERG11 translate into amino acid 
substitutions that change the three-dimensional structure of the enzyme or have decreased 
affinity for the azole.  Several point mutations have been identified in resistant isolates (27, 44, 
45).  One such point mutation causes an arginine to lysine substitution at position 467.  The 
R467K is highly conserved among lanosterol demethylase found in fungi and mammals and is 
located in the heme binding region of the enzyme (44, 46).  Using site directed mutagenesis, the 
R467K mutation was introduced into S. cerevisiae.  In the presence of the mutated Erg11p, 
fluconazole bound to the enzyme with a lower affinity (46).  Thus far, there have been thirteen 
additional point mutations that lead to amino acid substitutions and increased azole MIC have 
been identified (27, 44). 
 
Overexpression of ERG11 can also lead to resistance due to the increased production of 
lanosterol demethylase overwhelming the azole concentration in the cell.  In S. cerevisiae, the 
overexpression of ERG11 alone is sufficient to confer azole resistance.  The ERG11 gene, under 
the control of an inducible GAL1 promoter, could grow on galactose plates with 128μg/ml 
fluconazole (47).  In C. albicans, the up-regulation of ERG11 is generally found in conjunction 
with other resistance mechanisms.  Twenty-five percent of resistant isolates recovered from 
patients overexpressed ERG11 and one of the efflux pumps (27).  In response to azole treatment, 
ERG11 and several other ERG genes were up-regulated (48, 49). 
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TRANSCRIPTIONAL REGULATORS 
 
The overexpression of CDR1, CDR2, MDR1, and ERG11 can be due to three 
mechanisms: gene amplification, increased half-life of mRNA, or increased transcription due to 
promoter mutation or changes in transcriptional activators.  Gene amplification occurs when 
there are more than two copies of a certain gene due to chromosomal duplication.  While some 
isolates have been found to contain trisomies and isochromosomes, many clinical matched sets 
show overexpression with no chromosomal anomalies (50). 
 
The stability of mRNA also makes an impact on overexpression of resistance genes.  A 
recent study showed that resistant isolates had a slower turnover rate of CDR1 mRNA than 
susceptible isolates (51).  However, mRNA stability alone does not result in the increased 
mRNA levels in resistant isolates.  Nuclear run-on assays performed on susceptible and resistant 
isolates show an increased level of transcription in the resistant isolates (34, 51).  In the absence 
of chromosomal anomalies, the increase in transcription can be attributed to interactions between 
transcription factors and the promoter. 
 
 
Transcription Factor Classes 
 
There are two major classes of transcription factors involved in drug resistance in yeast.  
The bZip transcription factor class is found exclusively in eukaryotic cells, and the first bZip 
proteins were purified in mammalian cells in the late 1980’s (52).  These transcription factors are 
defined by a highly conserved basic leucine zipper (bZip) motif.  The bZip motif is a 60 to 80 
amino acid long bipartite α-helix that binds the major groove of DNA.  The N-terminal portion 
of the bZip motif contains the DNA binding domain (DBD) consisting of two basic amino acid 
clusters that are responsible for the binding of DNA.  The C-terminal domain is the leucine 
zipper with leucine residues every seven amino acids (52).  It is through the leucine zipper that 
dimerization occurs (52, 53).  The activator protein-1 (AP-1) transcription factor family falls into 
the bZip class of transcription factors.  AP-1 transcription factors can be heterodimers consisting 
of one Fos family and one Jun family of bZip protein or homodimers containing two Jun family 
proteins.  The dimers bind DNA at a specific AP-1 recognition element (ARE), TGA(C/G)TCA 
(53).  This ARE motif is a ubiquitous regulatory element found in promoter and enhancer regions 
of many genes regulating cell proliferation, differentiation, apoptosis, and oncogenesis. 
 
AP-1 transcription factors have been identified in several fungal species (54, 55).  These 
transcription factors are referred to as yeast AP-1 (yAP1) transcription factors.  The first yAP-1 
transcription factor cloned and characterized was the S. cerevisiae YAP1 (54, 56).   Yap1p was 
identified for its ability to bind an ARE derived from the Simian virus 40 (SV40) enhancer 
promoter known to be bound by mammalian AP-1 (56).  This yeast promoter motif is called the 
YAP1 response element (YRE).  YAP1 homologs were also found in Schizosaccharomyces 
pombe (PAP1), Kluveromyces lactis (KAP1), and C. albicans (CAP1) (57).  The yAP-1 
transcription factors have bZip DBDs homologous to that of mammalian AP-1 transcription 
factors.  In addition, yAP-1 transcription factors share two cysteine rich domains (CRD) 3’ of the 
bZip domain.  The amino terminal CRD (n-CRD) and the carboxyl terminal CRD (c-CRD) are 
found in only the yeast bZip transcription factors and play a role in the localization and 
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activation of the yAP-1 (58). The yAP-1 transcription factors regulate and mediate the response 
to oxidative stress and multidrug resistance.   
 
In S. cerevisiae, the c-CRD has been implicated as the oxidative stress sensor and the 
nuclear localization of Yap1p.  The c-CRD contains three conserved cysteine residues and a 
region rich in hydrophobic amino acids that resemble a nuclear export signal (58, 59).  Studies 
using a green fluorescent protein (GFP) tagged Yap1p showed that under normal conditions, 
GFP-Yap1p localizes to the cytoplasm.  Nuclear localization occurs when the cells are exposed 
to oxidative stress such as H2O2 or diamide.  The oxidative stress sensor function was elucidated 
when the c-CRD domain was fused to a GAL4 DBD and GFP.  This fused protein was found in 
the cytoplasm under unstressed conditions, but under oxidative stress conditions, the GFP was 
localized to the nucleus (60).  This shows that the c-CRD alone has the ability to localize the 
fused transcription factor to the nucleus in the presence of a stressor.  Mutations in or deletion of 
the c-CRD trapped the GFP-Yap1p in the nucleus independent of oxidative stress (58, 59, 60).  
Nuclear localization occurs either through the inhibition of nuclear export or increases in nuclear 
import.  In yeast, Crm1p has been identified as the nuclear export factor that interacts with yAP-
1 to export the proteins out of the nucleus (61).  Disulfide bonds form between the cysteine 
residues in the presence of H2O2 or diamide and prevents the interaction between Crm1p and 
Yap1p (62).  Mutations in the c-CRD also prevent the Crm1p-Yap1p interaction.  The n-CRD on 
the other hand determines the response to specific oxidative stresses.  In S. cerevisiae, disruption 
of the n-CRD conferred hypersusceptibility to H2O2 but resistance to diamide (63).  This points 
to the differences in disulfide bond formation between the cysteine residues in response to 
oxidative stress.  Under diamide stress, a disulfide bond forms between two cysteine residues in 
the c-CRD.  In the presence of H2O2, a disulfide bond forms between a cysteine residue in the c-
CRD and a cysteine residue in the n-CRD.  This disulfide bridge does not occur under diamide 
stress (59). 
 
The zinc finger protein family is the second major class of transcription factors 
responsible for drug resistance in yeast and are the largest family of transcriptional regulators in 
eukaryotes (64).  The first zinc finger protein was identified in Xenopus in the 1980’s (65).  This 
family of transcription factors is characterized as having the common zinc finger motif, 
consisting of one α helix and a pair of antiparallel β strands.  It also contains one or more zinc 
atoms bound by cysteines or histidines stabilizing the domain and contributing to the structure 
and function of the protein.  The majority of zinc finger proteins bind DNA as transcription 
factors, but some act as mediators of protein/protein interactions, chromatin remodeling, protein 
chaperoning, lipid binding, stress response, pleiotropic drug resistance (PDR), and zinc sensing 
(64). 
 
There are three classes of zinc finger proteins.  The Cys2His2 class is the classical zinc 
finger protein that binds DNA as monomers.  These proteins have the zinc finger structure Cys-
X2-4-Cys-X12-His-X3-5-His.  The second class of zinc finger proteins is the Cys4 (Cys-X2-Cys-Xn-
Cys-X2-Cys-Xn-Cys-X2-Cys-Xn-Cys-X2-Cys) class of proteins.  These zinc finger proteins bind 
DNA as homodimers or heterodimers.  The homodimers bind inverted repeats while the 
heterodimers bind direct repeats (64).  Cys6, the third class of zinc finger proteins, have six 
cysteines (Cys-X2-Cys-X6-Cys-X5-16-Cys-X2-Cys-X6-8-Cys) bound by two zinc atoms and are 
exclusive to fungi.  These proteins bind DNA as monomers, homodimers, and heterodimers.  
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This third class of zinc finger proteins is often referred to as zinc cluster proteins or zinc 
binuclear proteins (64, 66, 67). 
 
Zinc cluster transcription factors can be found in both the cytoplasm and the nucleus.  
The proteins found in the cytoplasm require a nuclear localization signal and importin β 
receptors (64).  More commonly, zinc cluster transcription factors remain in the nucleus and are 
often constitutively bound to the promoter.  Zinc cluster proteins contain a DBD, a regulatory 
domain, and an acidic domain.  The DBD consists of the zinc finger motif, the linker, and the 
dimerization domain (64).  The zinc finger motif binds as dimers to CGG nucleotide triplets 
through major groove interactions.  The CGG motifs can be everted, inverted, or direct repeats 
(64, 66).  The linker domain of the DBD has no homology between zinc cluster proteins, but this 
contributes to the specificity of DNA binding (68).  A previous study swapped the linker 
domains of three different zinc cluster transcription factors, and showed that it was the linker that 
determined the target DNA.  The dimerization domain is highly conserved with heptad repeats 
and resembles the leucine zipper in bZip proteins (64).  The regulatory domain, also known as 
the middle homology domain, spans 80 amino acids and is only found in zinc cluster 
transcription factors (69).  Deletions of this domain render the transcription factor constitutively 
active.  Partial and complete deletions of the regulatory domain in the S. cerevisiae transcription 
factor Leu3p renders it constitutively active (70).  The regulatory domain is not highly conserved 
among zinc cluster proteins.  Differences in the regulatory domain may determine the spacing of 
the CGG motif that the transcription factor binds (69).  The acidic domain acts as the activation 
domain of the protein.  Activation of zinc cluster transcription factors occur through 
phosphorylation or dephosphorylation events (64).  There is little homology between the acidic 
domains of different zinc cluster proteins and the function of the domain differs between proteins 
(64).  In S. cerevisiae, deletion of the acidic domain of Leu3p rendered the transcription factor 
inactive (70).  In the S. cerevisiae transcription factor Pdr3p, mutations in this domain results in a 
gain-of-function of the transcription factor (71). 
 
 
Transcription Factors and Resistance 
 
Increased transcription of azole resistance genes in C. albicans could be due to mutations 
in the promoter region that results in deregulation of the gene (cis-regulation) or mutations in a 
transcription factor that controls the expression of the gene (trans-regulation).  The promoter 
regions of clinical matched isolates known to overexpress CDR1/CDR2 or MDR1 were 
sequenced (72, 73).  In the clinical isolates DSY294 (susceptible parent) and DSY296 (resistant), 
there were no mutations in the promoter regions of the CDR genes (73).  In the MDR1 
overexpressing isolates, F and G, polymorphisms were found between the alleles of the two 
isolates.  However, the same polymorphisms were found in the susceptible and resistant allele of 
each isolate pair (72).  The lack of mutation suggests that the overexpression of the two efflux 
mechanisms do not occur through a cis-acting mechanism. 
 
In order to determine if a trans-regulatory element was responsible for the up-regulation 
of the efflux pumps, the wild-type promoter regions were fused to a reporter gene to determine 
transcriptional activation.  The promoters of CDR1 and CDR2 from genome strain SC5314 were 
fused to Renilla luciferase (RLUC), and the constructs were transformed into a resistant strain 
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(2090) derived from the resistant isolate DSY296 (73).  A high level of luciferase activity was 
detected in the cells transformed with the CDR1-RLUC and the CDR2-RLUC constructs even 
though the promoters were derived from a susceptible isolate.  Similarly, to examine the 
activation of MDR1, the promoter region of MDR1 from wild-type strain CAI4 was fused to GFP.  
The MDR1-GFP construct was transformed into two resistant isolates, F5 and G5, and their 
susceptible parent isolates, F2 and G2.  There was no fluorescence detected in the susceptible 
isolates, whereas fluorescence was detected in the resistant isolates (72).  The ability for the CDR 
and MDR promoters from susceptible isolates to be activated when transformed into resistant 
strains suggests that mutations in transcriptional regulators are responsible for the overexpression 
of resistance mechanisms. 
 
Regulatory networks and drug resistance have been better characterized in the model 
organism S. cerevisiae.  In S. cerevisiae, two networks of genes, YAP and pleiotropic drug 
resistance (PDR), are responsible for multidrug resistance.  The YAP network of genes is 
predominantly responsible for the oxidative stress response.  Yap1p, a bZip transcription factor 
described above, binds the YRE motif T(T/G)A(C/G)TAA.  Not only has Yap1p been shown to 
sense hydrogen peroxide and diamide stress and confer resistance to oxidative stress (62), but it 
has also been shown to protect against a variety of antimicrobial drugs through the 
overexpression of ABC transporters (YCF1) and MFS transporters (FLR1).  The overexpression 
of FLR1 specifically confers resistance to cycloheximide, 4-nitroquinoline N-oxide, benomyl, 
and fluconazole (55).  The deletion of YAP1 abolished the ability for induction of FLR1 by 
antimicrobial agents (74).  Three YRE motifs have been identified in the promoter region of 
FLR1, and increased activation of Yap1p increases the transcription of FLR1 (55, 74).  Yap1p 
has also been shown to bind directly to the three YRE motifs, and the deletion of the YREs 
abolished the induction of FLR1 by fluconazole (74). 
 
The PDR network is characterized by the overexpression of ABC transporters and MFS 
transporters.  The overexpression of the ABC transporter gene, PDR5, confers resistance to 
several antimicrobial agents including fluconazole.  The PDR target genes are controlled by two 
zinc cluster transcription factors, Pdr1p and Pdr3p.  Pdr1p and Pdr3p bind as homodimers or 
heterodimers to the pleiotropic drug response element (PDRE) motif, TCCGCGGA, with an 
everted CGG (64, 75).  The dimers can also bind degenerate PDRE motifs suggesting different 
specificities for homodimers versus heterodimers (76).  At least one PDRE motif has been found 
in all target genes of Pdr1p and Pdr3p (77).  Two PDRE motifs have been found in the promoter 
region of PDR3, suggesting autoregulation by Pdr3p and regulation by Pdr1p.  Hyperactive 
PDR1 and PDR3 mutants increase the expression of PDR5 and cause resistance to various drugs 
(78, 79).  The up-regulation of PDR1 and PDR3 also increases the expression of PDR3 (71).  
Deletion of PDR1 and PDR3 genes results in hypersusceptibility to drugs and decreased 
expression of PDR5 (79, 80). 
 
In addition to the efflux mechanisms, the ergosterol biosynthesis pathway is also better 
characterized in S. cerevisiae.  In S. cerevisiae, ergosterol biosynthesis genes are regulated by 
two zinc cluster transcription factors Upc2p and Ecm22p.  These transcription factors bind a 
sterol response element (SRE) motif, CTCGTATAAGC (81).  The up-regulation of UPC2 and 
ECM22 causes up-regulation of ERG2 and ERG3.  The SRE motif is present in the promoter 
regions of ERG2, ERG3, and other ergosterol biosynthesis genes. Deletion of UPC2 causes 
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hypersusceptibility to AmB and ketoconazole while deletion of ECM22 causes 
hypersusceptiblity to cycloheximide and calcofluor white (81, 82).    The disruption mutants also 
abolish the expression of the ERG genes (81). 
 
 
C. albicans Transcription Factors 
 
In C. albicans, CAP1 has been identified as a yAP-1 bZip transcription factor closely 
related to the S. cerevisiae YAP1.  Functionally, the overexpression of CAP1 in S. cerevisiae 
restores FLR1 expression and resistance to fluconazole (55).  The C-terminal region of Cap1p 
and Yap1p, including the c-CRD, are the most highly conserved.  As in S. cerevisiae, the 
activation and nuclear localization occurs through the c-CRD in response to oxidative stress (55, 
83).  The disruption of the c-CRD of Cap1p causes the protein to be constitutively active and 
remain localized to the nucleus (83, 84).  To examine the function of Cap1p in C. albicans, the 
CAP1 gene was deleted in the susceptible wild-type strain CAI4, and a wild-type or a 
constitutively active CAP1 gene was reintroduced into the knockout strain.  In the strains with or 
without CAP1, the cells were unable to respond to fluconazole.  However, with the constitutively 
active Cap1p, the strain was resistant to fluconazole, and increased expression of MDR1 was 
detected (84).  FLR1 is also homologous to C. albicans MDR1, a MFS transporter gene 
responsible for fluconazole resistance (55).  A YRE motif was found in the promoter region of 
MDR1 (85).  The promoter region of MDR1 was examined in a fluconazole resistant clinical 
strain disrupted for URA3 (F5U4).  In the absence of the YRE, MDR1 expression due to benomyl 
exposure decreased.  However, in the absence of the YRE in a resistant isolate, MDR1 is still 
expressed (86).  In another study, Cap1p regulation of MDR1 is examined in strains with and 
without CAP1.  In the absence of Cap1p, MDR1 gene expression still occurs in response to 
benomyl (87).  These studies indicate that in the absence of both the YRE motif and Cap1p, 
MDR1 gene expression still occurs in response to benomyl and in resistant isolates.  This 
suggests that while Cap1p regulates MDR1 expression, another regulator may also function in 
azole resistance. 
 
The ABC transporters CDR1 and CDR2 were identified for their ability to complement 
the PDR5 phenotype in S. cerevisiae.  However, there are no PDR1/PDR3 homologues in C. 
albicans.  The promoter regions of CDR1/CDR2 were examined, and a putative drug responsive 
element (DRE) motif, ACGG(A/T)TATCGGATA, was identified (73).  Genes with the DRE in 
their promoter region were shown to respond in response to oestradiol including CDR1/CDR2.  
In the absence of this motif, the expression of the genes could not be induced by oestradiol, 
amorolfine, and terbinafine.  In response to oestradiol, band shift assays showed specific protein 
interaction with the DRE (73).  Unlike the PDRE, the DRE has two CGG direct repeats separated 
by four nucleotides.  The two CGG motifs in the promoter region points to a zinc cluster 
transcriptional regulator.  TAC1 (transcriptional activator of CDR genes), a gene encoding a zinc 
cluster protein, was identified near the mating type locus (88).  The disruption of this gene 
abolished the expression of CDR1/CDR2 in response to fluphenazine.  The disruption strains also 
showed a hypersusceptibility to fluconazole and terbinafine.  When a TAC1 allele from a 
resistant isolate was reintroduced into the disruption strain, resistance to fluconazole was 
conferred.  The specific DRE previously identified was shown to be specifically bound by Tac1p, 
and the PDRE motif bound by Pdr1p/Pdr3p in S. cerevisiae was not bound by Tac1p (88).  
13 
Sequencing of the TAC1 alleles in susceptible and resistant clinical isolates showed an N977D 
mutation in the C-terminal activation domain (89).  While this mutation was found in one allele 
of TAC1 in the susceptible isolate, the resistant isolate carried two copies of this mutated allele.  
Because zinc cluster transcription factors function as dimers, the hyperactive allele and the wild-
type allele are codominant.  It is the loss of heterozygosity that causes overexpression of ABC 
transporters and increased azole resistance (89). 
 
Ergosterol biosynthesis in S. cerevisiae is controlled by two zinc cluster transcription 
factors Upc2p and Ecm22p.  In C. albicans, Upc2p is the only homolog of ScUpc2p and 
ScEcm22p.  Disruption of UPC2 in a wild-type strain conferred hypersusceptibility to sterol 
biosynthesis inhibitors (SBI), including fluconazole, itraconazole, ketoconazole, terbinafine, and 
fenpropimorph (82, 90).  In the absence of UPC2, there was also no transcription of ERG genes.  
The reintroduction of wild-type UPC2 restores baseline susceptibility in wild-type strains (90).  
The overexpression of UPC2 conferred resistance to ketoconazole and fluphenazine (82).  The 
promoter region of the ERG genes in C. albicans was examined for the SRE motif found in S. 
cerevisiae, and an SRE motif was found in all known ERG genes and in UPC2 itself (82, 90).  
Using the SRE motif found in ScERG2 and CaERG2, Upc2p was found to bind to both (82). 
 
 
CENTRAL HYPOTHESIS AND RESEARCH OBJECTIVES 
 
In S. cerevisiae, genes and their function have been better defined and characterized than 
in C. albicans.  Through the use of S. cerevisiae as a model organism, drug efflux mechanisms 
and ergosterol biosynthesis genes have been identified in C. albicans through homology and 
complementation.  Increased expression of ERG11 in C. albicans increases lanosterol 
demethylase concentrations in the cell, increasing the amount of enzyme not bound by azole 
antifungals.  Decreased accumulation of azoles in C. albicans due to increased expression of 
drug efflux pumps also decreases the efficacy of azole treatment.  In C. albicans, drug resistance 
genes have been shown to be controlled by trans-regulatory elements rather than cis-regulatory 
elements.  Several transcriptional regulators have been identified in S. cerevisiae to control drug 
efflux and sterol biosynthesis.  The transcription factors in S. cerevisiae have been shown to be 
co-regulated with the expression of resistance genes; many are also autoregulated.  Importantly, 
the transcriptional regulators in S. cerevisiae do not have homologs in C. albicans. 
 
I hypothesized that overexpression of resistance genes in C. albicans is due to gain-of-
function mutations in transcriptional regulators.  With the completion of the C. albicans genome 
sequencing project, microarray technology can now be used to study drug resistance.  By 
studying matched clinical isolates that overexpress either CDR1/CDR2, MDR1, or ERG11, genes 
that are co-regulated with these resistance genes can be identified.  Among these co-regulated 
genes, we have identified previously described as well as novel transcriptional regulators. 
 
Tac1p, a zinc cluster transcription factor, has been previously identified as the 
transcriptional regulator of the ABC transporters CDR1 and CDR2.  Gain-of-function mutations 
in TAC1 and loss of heterozygosity contribute to azole resistance.  Tac1p has also been shown to 
regulate the expression of genes co-regulated with CDR1 and CDR2.  Our first research objective 
(Chapter 2) was to examine matched clinical isolates known to overexpress CDR1/CDR2 by 
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gene expression and location profiling in an effort to identify additional genes potentially 
involved in azole resistance.  I hypothesized that a gain-of-function mutation in a transcription 
factor, now known to be Tac1p (88), regulates the expression of CDR1, CDR2, and co-regulated 
genes.  Our studies show that like many zinc cluster transcription factors in S. cerevisiae, TAC1 
is autoregulated and targets a subset of genes involved in multidrug resistance in C. albicans.  
Additionally, we identified the Tac1p regulon as it pertains to known mutations in TAC1 in 
clinical matched isolates. 
 
In research objective 2 (Chapter 3), we examined clinical matched isolates known to 
overexpress MDR1.  At the time, the transcriptional regulator responsible for MDR1 expression 
had yet to be identified.  I hypothesized that gain-of-function mutations in a transcription factor 
regulate the expression of MDR1 and MDR1 co-regulated genes.  Using expression profiling, we 
discovered and characterized a previously unidentified zinc cluster transcription factor MRR1 
that regulates the expression of MDR1 in clinical resistant isolates.  We also identified a core 
group of genes regulated specifically by the gain-of-function mutation in MRR1. 
 
In addition to the isolates that overexpress the CDR and/or MDR1 efflux pumps, several 
resistant isolates have been identified with unknown resistance mechanisms.  In research 
objective 3 (Chapter 4), we characterized a clinical matched isolate pair with no previously 
identified resistance mechanism by gene expression profiling.  I hypothesized that a gain-of-
function mutation in UPC2 is responsible for the regulation of the ERG genes in azole resistant 
clinical isolates.  In the resistant isolate, several ERG genes were found to be up-regulated.  
Additionally, UPC2 was also overexpressed.  We identified a gain-of-function mutation in UPC2 
responsible for the increased expression of ERG genes.  Using expression profiling, we defined a 
set of genes whose expression depended on the mutation found in UPC2.
CHAPTER 2: IDENTIFICATION OF THE TAC1P REGULON* 
 
 
INTRODUCTION 
 
Several mechanisms of resistance to the azole antifungal agents have been described in C. 
albicans including increased expression of genes encoding multi-drug efflux pumps (91, 92, 93, 
94, 95, 96, 97).  These include the gene encoding a transporter of the MFS (MDR1) and genes 
encoding two ABC transporters (CDR1 and CDR2) (91, 92, 94, 95, 96).  Over-expression of 
these efflux pumps is presumed to prevent accumulation of effective concentrations of the azole 
antifungal agents within the fungal cell.  Among studies examining multiple matched azole-
susceptible and -resistant sets of isolates, some isolates only over-express MDR1, whereas others 
only over-express CDR1 and CDR2 (91, 98).  These observations suggest that two distinct 
transcriptional pathways are involved in regulating these efflux pumps. 
 
Previous studies have shown that a wild-type CDR1 promoter fused to a luciferase 
reporter construct becomes activated when placed in an azole-resistant isolate that over-expresses 
CDR1 and CDR2 (99).  Using this system, it was shown that a conserved DNA sequence element 
in the CDR1 and CDR2 promoters, named drug response element (DRE; 5’-CGGAA/TATCGG), 
was necessary for CDR1 constitutive, as well as drug-inducible, transcriptional activation (99).  
These results suggested that a gain-of-function mutation in a transcription factor was the cause of 
CDR1 and CDR2 constitutive overexpression in azole-resistant isolates (99).  The zinc cluster 
transcription factor Tac1p was recently identified and shown to be responsible for CDR1 and 
CDR2 transcriptional activation (89, 100).  An amino acid change from an asparagine to aspartic 
acid at position 977 (N977D) in Tac1p was able to confer increased expression of CDR1 and 
CDR2 accompanied by decreased azole susceptibility (89).  It was also shown that the DBD of 
Tac1p fused to the glutathione S-transferase (GST) protein binds in vitro to the CDR1 and CDR2 
DRE (100).  Interestingly, increased azole resistance is observed when a gain-of-function 
mutation is present in both TAC1 alleles (89).  The TAC1 locus is on chromosome 5.  
Homozygosity at the TAC1 locus occurs either through mitotic recombination between copies of 
chromosome 5, or through the presence of extra copies of chromosome 5 harboring a gain-of-
function TAC1 allele and loss of chromosome 5 with the wild-type TAC1 allele (89).  Selmecki et 
al. demonstrated that a specific segmental aneuploidy, consisting of an isochromosome 
composed of the two left arms of chromosome 5, is associated with azole resistance.  Increases 
and decreases in azole resistance were found to be strongly associated with gain and loss of this 
isochromosome (50).  Recent work by Coste et al. showed that the effect of specific mutations in 
azole resistance genes located on chromosome 5 (TAC1, ERG11) can be further enhanced by 
loss-of-heterozygosity and/or addition of extra copies of chromosome 5 (101).   
 
In addition to CDR1 and CDR2, other targets of Tac1p (RTA3, HSP12, and IFU5) have 
been identified, all of which contain a putative DRE in their promoter region (100).  In a separate 
study, it was shown that PDR16, encoding a putative phosphatidylinositol transfer protein 
contributing to clinical azole resistance, is also a target of Tac1p (102, 103).  We used functional 
                                                 
*Liu, T. T., S. Znaidi, K. S. Barker, L. Xu, R. Homayouni, S. Saidane, J. Morschhauser, A. Nantel, M. 
Raymond and P. D. Rogers. 2007. Genome-wide expression and location analyses of the Candida albicans Tac1p 
regulon. Eukaryot Cell. 6: 2122-38.  Adapted by permission of publisher. 
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genomic approaches, namely genome-wide expression and location profiling, to identify the 
Tac1p regulon.  In collaboration with our group, the laboratory of Dr. Martine Raymond at 
Université de Montréal constructed the chromatin immunoprecipitation (ChIP) microarrays used 
in the study as well as the triple-HA-tagged Tac1p.  Our results provide a more comprehensive 
picture of the molecular effects of Tac1p mutations in azole-resistant clinical isolates and suggest 
other important cellular functions for Tac1p in C. albicans. 
 
 
MATERIALS AND METHODS 
 
 
Strains and Growth Media 
 
The C. albicans strains used in this study are listed in Table 2-1.  The matched clinical 
isolate sets and strain SZY31 were grown in yeast peptone dextrose (YPD) broth (Sigma-Aldrich, 
St. Louis, MO) at 30°C.  The CAI4 strain and its epitope-tagged derivatives were grown at 30˚C 
in YPD or, under selective conditions, in synthetic complete (SC) medium lacking uracil (104) 
supplemented or not with 100 μg.ml-1 of uridine and 1 mg.ml-1 of 5-fluoroorotic acid (5-FOA, 
Toronto Research Chemicals, Inc., Toronto, ON).  The Escherichia coli DH5α bacterial strain 
was used for DNA cloning and maintenance of the plasmid constructs. 
 
  
Construction of C. albicans Expression Microarrays 
 
The nucleotide sequences corresponding to 6,165 open reading frames (ORFs) for C. 
albicans were downloaded from the Galar Fungail European Consortium (Assembly 
6, http://www.pasteur.fr/Galar_Fungail/CandidaDB/).  We set out to design two non-overlapping 
probesets targeting the 3’- 600 bp region of each ORF. Each probeset consisted of 13 ‘perfect 
match’ 25-bp probes and their corresponding ‘mismatch’ control probes containing a single 
mismatch in the center of the oligonuclotide.  For ORFs less than 600 bp in length the sequence 
was divided in two equal segments for subsequent design procedures.  Optimum probesets were 
selected by the Affymetrix design team based on their model which, among other things, 
considers probe hybridization quality and cross-hybridization potential.  Consequently, in some 
cases, only one probeset was selected for a given ORF.  For quality control and normalization 
purposes, we made 2-3 additional probe sets spanning the entire sequence of the C.  albicans 18S 
rRNA (GenBank Accession M60302), genes encoding GAPDH, actin and Mdr1p (Bmr1p) in 
addition to the standard Affymetrix controls (BioB, C, D, cre, DAP, PHE, LYS, THR).  In the 
end, the GeneChip contained 10,736 probe sets including 9 controls, 6,123 unique ORFs and 
duplicate probe sets for 4,604 ORFs.  The duplicate probe sets are made to distinct regions of 
each particular ORF, thereby allowing 2 independent measurements of the mRNA level for that 
particular gene.  The C. albicans custom Affymetrix NimbleExpress Arrays (CAN04a530004N) 
were manufactured by NimbleGen Systems (105) per our specification. 
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Table 2-1. Strains used in this study. 
 
Strain Parental strain Genotype or Description 
Fluconazole 
MIC 
(µg/mL) 
Reference
C43 (DSY294)  Azole-susceptible clinical isolate 0.25a (97) 
C56 (DSY296) C43 Azole-resistant clinical isolate 128a (97) 
Gu2  Azole-susceptible clinical isolate 6.25b (95) 
Gu5 Gu2 Azole-resistant clinical isolate > 100b (95) 
3  2 Azole-susceptible clinical isolate 8c (106) 
17  16 Azole-resistant clinical isolate > 64c (106) 
5457  Azole-susceptible clinical isolate ≤ 0.5d (102) 
5674 5457 Azole-resistant clinical isolate 32.0d (102) 
SZY31 5674 tac1Δ::FRT/tac1Δ::FRT 0.5e (103) 
CAI4  ura3Δ::imm434/ura3Δ::imm434 2.0e (18) 
SZY51 CAI4 TAC1/TAC1::HA3-URA3-HA3 ND This study 
SZY63 SZY51 TAC1/TAC1::HA3 2.0e This study 
SZY103 SZY63 TAC1::HA3 2.0e This study 
SZY106 SZY63 TAC1::HA3 2.0e This study 
SZY91 SC5314 tac1Δ/TAC1N972D-MPAR-FLP 16.0e (103) 
 
a Fluconazole concentration yielding at least 90% growth inhibition after 24 h of growth 
compared with the growth of the control (96). 
b Lowest Fluconazole concentration in which little or no growth was visually detected after 48 h 
of growth. 
c MIC80 according to the CLSI macrodilution reference method or a microdilution modification 
of the CLSI method (106, 107). 
d MIC50 values, determined as the first concentration of the azole drug able to reduce growth by 
50% as compared with control cells grown in the absence of drug. 
e MIC70 values.  
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RNA Preparation for Microarrays 
 
The matched clinical isolate sets and strain SZY31 were grown in YPD broth at 30°C in a 
shaking incubator to mid-log phase as described previously (108).  The cell pellets were frozen 
and stored at -80°C prior to RNA preparation.  Experiments were repeated independently three 
times.  Total RNA was isolated using the hot SDS-phenol method (109).  Frozen cell pellets  
were suspended in 12 ml of 50 mM sodium acetate (pH 5.2), 10 mM EDTA at room temperature, 
after which 1 ml of 20% sodium dodecyl sulfate and 12 ml of acid phenol (Fisher Scientific, 
Waltham, MA) were added.  This mixture was incubated 10 min at 65°C with vortexing each 
minute, cooled on ice for 5 min, and centrifuged for 15 min at 12,000 x g.  Supernatants were 
transferred to new tubes containing 15 ml of chloroform, mixed and centrifuged at 200 x g for 10 
min.  The aqueous layer was removed to new tubes, RNA was precipitated with 1 volume 
isopropanol and 0.1 volume 2 M sodium acetate (pH 5.0), and then collected by centrifugation at 
17,000 x g for 35 min at 4°C.  The RNA pellet was suspended in 10 ml of 70% ethanol, collected 
again by centrifugation, and suspended in nuclease free water. 
 
 
cRNA Synthesis and Labeling 
 
Immediately prior to cDNA synthesis, the purity and concentration of RNA samples were 
determined from A260/A280 readings and RNA integrity was determined by capillary 
electrophoresis using the RNA 6000 Nano Laboratory-on-a-Chip kit and Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA) as per the manufacturer's instructions.  First and second 
strand cDNA was synthesized from 15 μg of total RNA using the SuperScript Double-Stranded 
cDNA Synthesis Kit (Invitrogen, Carlsbad, CA) and oligo-dT24-T7 primer (PrOligo: Sigma-
Aldrich) according to the manufacturer's instructions.  cRNA was synthesized and labeled with 
biotinylated UTP and CTP by in vitro transcription using the T7 promoter-coupled double 
stranded cDNA as template and the Bioarray HighYield RNA Transcript Labeling Kit (ENZO 
Diagnostics, New York, NY).  Double-stranded cDNA synthesized from the previous steps was 
washed twice with 70% ethanol and suspended in 22 μl of RNase-free water.  The cDNA was 
incubated as recommended with reaction buffer, biotin-labeled ribonucleotides, dithtiothreitol, 
RNase inhibitor mix and T7 RNA polymerase for 5 h at 37°C.  The labeled cRNA was separated 
from unincorporated ribonucleotides by passing through a CHROMA SPIN-100 column 
(Clontech, Mountain View, CA) and ethanol precipitated at −20°C overnight. 
 
 
Oligonucleotide Array Hybridization and Analysis 
 
The cRNA pellet was suspended in 10 μl of RNase-free water and 10 μg was fragmented 
by ion-mediated hydrolysis at 95°C for 35 min in 200 mM Tris-acetate (pH 8.1), 500 mM 
potassium acetate, 150 mM magnesium acetate.  The fragmented cRNA was hybridized for 16 h 
at 45°C to the C. albicans NimbleExpress GeneChip arrays.  Arrays were washed at 25°C with 6 
× SSPE, 0.01% Tween 20 followed by a stringent wash at 50°C with 100 mM MES, 0.1 M NaCl, 
0.01% Tween 20.  Hybridizations and washes employed the Affymetrix Fluidics Station 450 
using their standard EukGE-WS2v5 protocol.  The arrays were then stained with phycoerythrein-
conjugated streptavidin (Molecular Probes: Invitrogen) and the fluorescence intensities were 
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determined using the GCS 3000 high-resolution confocal laser scanner (Affymetrix, Santa Clara, 
CA).  The scanned images were analyzed using software resident in GeneChip Operating System 
v2.0 (GCOS; Affymetrix).  Sample loading and variations in staining were standardized by 
scaling the average of the fluorescent intensities of all genes on an array to a constant target 
intensity.  The signal intensity for each gene was calculated as the average intensity difference, 
represented by [Σ(PM – MM)/(number of probe pairs)], where PM and MM denote perfect-
match and mismatch probes. 
 
 
Expression Microarray Data Analysis 
 
The scaled gene expression values from GCOS software were imported into GeneSpring 
7.2 software (Agilent Technologies) for preprocessing and data analysis.  Probe sets were deleted 
from subsequent analysis if they were called absent by the Affymetrix criterion and displayed an 
absolute value below 20 in all experiments.  The expression value of each gene was normalized 
to the median expression of all genes in each chip as well as the median expression for that gene 
across all chips in the study.  Pairwise comparison of gene expression was performed for each 
matched experiment.  Data files of each scanned chip were submitted to the Gene Expression 
Omnibus database (GEO; www.ncbi.nlm.nih.gov/geo/).  The accession number for the series is 
GSE8727. 
 
 
Quantitative Real-Time PCR for Expression Data 
 
An aliquot of the RNA preparations from the samples used in the microarray experiments 
was saved for quantitative real-time reverse transcription (RT)-PCR follow-up studies.  First-
strand cDNAs were synthesized from 2 µg of total RNA in a 21-µl reaction volume using the 
SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) in accordance with the 
manufacturer's instructions.  Quantitative real-time PCRs were performed in triplicate using the 
7000 Sequence Detection System (Applied Biosystems, Inc.: ABI, Foster City, CA).  
Independent PCRs were performed using the same cDNA for both the gene of interest and the 
18S rRNA, using the SYBR Green PCR Master Mix (Applied Biosystems, Inc.).  Gene-specific 
primers were designed for the gene of interest and the 18S rRNA using Primer Express software 
(Applied Biosystems, Inc.) and the Oligo Analysis & Plotting Tool (QIAGEN, Valencia, CA) 
and are shown in Table 2-2.  The PCR conditions consisted of AmpliTaq Gold activation at 95°C 
for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s and annealing/extension at 
60°C for 1 min.  A dissociation curve was generated at the end of each PCR cycle to verify that a 
single product was amplified using software provided with the 7000 Sequence Detection System.  
The change in fluorescence of SYBR Green I dye in every cycle was monitored by the system 
software, and the threshold cycle (CT) above the background for each reaction was calculated.  
The CT value of 18S rRNA was subtracted from that of the gene of interest to obtain a ΔCT value.  
The ΔCT value of an arbitrary calibrator (e.g., untreated sample) was subtracted from the ΔCT 
value of each sample to obtain a ΔΔCT value.  The gene expression level relative to the calibrator 
was expressed as 2–ΔΔCT.  Statistical analysis was performed using R software version 2.5.0 
(www.r-project.org).  Fold enrichment was compared using Student’s t-test.  The statistical 
significance threshold was fixed at α=0.05. 
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Table 2-2. Primers used for quantitative real-time PCR expression analysis. 
 
Gene 
Name Primer Pairs
a Amplicon Size (bp) 
18S F, 5'-CACGACGGAGTTTCACAAGA-3' 135 
 R, 5'-CGATGGAAGTTTGAGGCAAT-3'  
CDR1 F, 5'-ATTCTAAGATGTCGTCGCAAGATG-3' 140 
 R, 5'-AGTTCTGGCTAAATTCTGAATGTTTTC-3'  
CDR2 F, 5'-TAGTCCATTCAACGGCAACATT-3' 76 
 R, 5'-CACCCAGTATTTGGCATTGAAA-3'  
PDR16 F, 5'-CTGCGGGACAAGATTCATTAGC-3' 62 
 R, 5'-TTGAGTACCAACAGGATGTGCTTTA-3'  
TAC1 F, 5'-TGGCAATGTATTTAGCAGATGAGG-3' 71 
  R, 5'-TGCTTGAACTGAGGTGAATTTTG-3'   
 
a F: forward, R: reverse  
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Generation of an HA-Tagged Tac1p-Expressing Strain 
 
A DNA fragment overlapping positions -402 to +937 of C. albicans URA3 ORF (URA3 
marker) was PCR-amplified with Pfu DNA polymerase (Stratagene, La Jolla, CA) from plasmid 
pCaEXP (110), using primers 5’-ATCATCTCTAGATAAGGATGGTATAAACGGAAAC 
(introduces an XbaI site, underlined) and 5’-GCCCCGGGAAGGACCACCTTTGATTG 
(introduces a SmaI site, underlined).  The resulting fragment (1,362 bp) was digested with XbaI 
and SmaI and used to swap the equivalent XbaI-XhoI fragment of plasmid pMPY-3×HA (1,078 
bp, containing the S. cerevisiae URA3 marker) (111), generating plasmid pCaMPY-3×HA.  A 
TAC1-tagging cassette was amplified from plasmid pCaMPY-3×HA using primers FWD: 5’- 
ttgattgataattcagctgtaaatttgccatttagtcaatttaataatttacccaattttttctttgacaataatttggggattAGGGAACAAA
AGCTGG-3’ (the lower case sequence corresponds to positions +2860 to +2943 of the TAC1 
ORF) and REV: 5’- 
taggaaaaaatatatgaaacaataaatatttacaaagatatacattatacatcgctttcaccaattacaactcttttttaacccCTATAGGG
CGAATTGG-3’ (the lower case sequence corresponds to positions  +2947 to +3030 of the TAC1 
ORF) which anneal specifically to the in-frame pCaMPY-3×HA vector sequences PET-up and 
PET-down (upper case sequences) as described previously (111).  The resulting fragment (1,821 
bp), containing the C. albicans URA3 marker flanked by direct repeats of the 3×HA epitope-
encoding sequences and 84 bp of sequences homologous to the 3’ end of the TAC1 gene, was 
used to transform strain CAI4.  Counterselection of the URA3 gene was carried out on plates 
containing 5-FOA as described previously (112) except that uracil was replaced with uridine. 
 
  
Candida albicans Transformation 
 
C. albicans transformations were performed as described previously (113) with minor 
modifications.  The cells were grown overnight in 15 ml of YPD medium, diluted to an OD600 of 
0.1 in 100 ml of fresh YPD and allowed to grow to an OD600 of 0.4.  The cells were harvested, 
washed once with 10 ml of sterile water and resuspended in 1ml of 1X LiAc solution (113).  
Cells (100 μl) were transferred to a sterile tube containing 6 µg of gel-purified PCR- fragment 
and 100 µg of denatured salmon sperm DNA as carrier.  A LiAc/40% PEG solution (700 µl of 
10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 100 mM LiAc, 40% (w/v) PEG4000) was added 
and the cell suspensions were incubated overnight at 30˚C with gentle rotation.  The cells were 
heat shocked at 42˚C for 15 min and plated on SC-ura plates. 
 
  
Genomic DNA Isolation and Southern Blot Analysis 
 
C. albicans genomic DNA was prepared as described for S. cerevisiae (114).  For the 
Southern hybridization, genomic DNAs (500 ng) were digested to completion with HindIII and 
EcoRV, electrophoresed on a 1% agarose gel and transferred to a nylon membrane (Hybond-N; 
Amersham Biosciences, Piscataway, NJ).  Prehybridization, hybridization and washing steps 
were carried out as previously described (102).  The TAC1 probe used consists of a 32P-
radiolabeled 927-bp PCR-amplified fragment from SC5314 genomic DNA overlapping positions 
+2020 to +2946 in the TAC1 ORF.  The membrane was exposed to a FUJIFILM Imaging Plate 
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screen.  The signal was quantified using the Multi Gauge program, version 2.3 (FUJIFILM).  
The membrane was subsequently exposed to a Kodak XAR film at -80°C. 
 
 
Total Protein Preparation and Western Blotting 
 
Total protein was prepared from 2 O.D. units of strains CAI4 and SZY63 grown 
overnight, as described for S. cerevisiae (114).  Extracts were boiled for 5 min, and 35 µl (out of 
100 µl total) was separated by electrophoresis on an SDS–8% polyacrylamide gel.  Proteins were 
transferred to a nitrocellulose membrane with a Trans Blot SD Semi-Dry transfer apparatus (Bio-
Rad, Hercules, CA) and analyzed with a mouse anti-HA monoclonal antibody (HA-probe (F-7): 
sc-7392, Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a dilution of 1:2000, using a 
chemiluminescence detection system under conditions recommended by the manufacturer 
(Pierce Biotechnology Inc., Rockford, IL). 
 
 
Chromatin Immunoprecipitation 
 
Three independent cultures (50 ml each) of strains CAI4 and SZY63 were grown in YPD 
medium to an OD600 of 0.8.  The cultures were then treated with 1.4 ml of 37% formaldehyde 
(final concentration 1%) to induce protein-DNA cross-links.  Cells were incubated 30 min at 
room temperature with agitation and the cross-linking stopped by adding 1.2 ml of 2.5 M glycine.  
Cells were harvested, washed 3 times with 40 ml of ice-cold TBS buffer (20 mM Tris-HCl pH 
7.5, 150 mM NaCl) and snap frozen in liquid nitrogen.  Total cell extracts were prepared by 
adding 0.7 ml of lysis buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% 
Triton X-100, 0.1% Na-deoxycholate, 1 mM PMSF, 1 mM benzamidine, 10 µg/mL aprotinin, 1 
ug/mL leupeptin, 1 ug/mL pepstatin), 0.5 ml of acid-washed glass beads (Sigma) and bead 
beating 4 times for 5 min at highest settings in a mini bead-beater (Biospec Products).  
Preparation of soluble chromatin fragments was performed by sonicating the extracts 4 times 
during 20 sec at power 2-3 (output power 8-9 RMS) using Sonic Dismembrator Model 100 
sonicator (Fisher Scientific).  Immunoprecipitation was performed by incubating the sonicated 
extracts (from both the tagged SZY63 strain and the untagged parental CAI4 strain) overnight 
with monoclonal mouse anti-HA antibody (Santa Cruz Biotech) coupled to magnetic beads 
(Dynabeads Pan Mouse IgG, Dynal Biotech, Brown Deer, WI) at 4°C.  Beads were then washed 
twice with lysis buffer, twice with lysis buffer supplemented with 360 mM NaCl, twice with 
wash buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% NP40, 0.5% Na-deoxycholate, 1 mM 
EDTA) and once with TE buffer (10 mM Tris pH 8.0, 1 mM EDTA).  The cross-links were 
reversed by incubating the washed beads overnight in 50 µl of TE/1% SDS at 65°C.  The eluted 
material was then treated with proteinase K, RNase A, extracted twice with 
phenol:chloroform:isoamyl-alcohol (25:24:1) and the DNA precipitated with 100% ethanol and 
resuspended in 50 µl of TE.  40 μl of the immunoprecipitated (IPed) DNA fragments were used 
for amplification and Cy5/Cy3 dye labeling prior to hybridization to C. albicans intergenic DNA 
microarrays. 
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DNA Labeling, Hybridization to Intergenic Microarrays and Data Analysis 
 
Labeling was conducted as described by Drouin et al. (115).  Briefly, the IPed DNA 
fragments were blunted with T4 DNA polymerase and ligated to unidirectional linkers.  The 
DNA was then amplified by LM-PCR in the presence of aminoallyl-modified dUTP.  The 
labeling was carried out post-PCR using monoreactive Cy-dye NHS esters (CyTM5/CyTM3 Mono-
Reactive Dye Packs, Amersham Biosciences) that react specifically with the aminoallyl-
modified dUTP (5-(3-aminoallyl)-2’ deoxyuridine-5’-triphosphate, Sigma-Aldrich).  Both pools 
of labeled IPed DNA from the tagged SZY63 strain (Cy5) and the untagged parental CAI4 strain 
(Cy3) were mixed and hybridized to a C. albicans intergenic DNA microarray that will be 
described elsewhere (H. Hogues, H. Lavoie, A. Sellam, M. Mangos, T. Roemer, E. Purisima, A. 
Nantel and M. Whiteway, submitted for publication).  Images of Cy5 and Cy3 fluorescence 
intensities were generated by scanning arrays using Axon 4000b scanner and were analyzed with 
GenePix Pro 4.1 software (Molecular Devices, formerly Axon Instruments, Inc, Downington, 
PA).  Normalization of the data was conducted using ArrayPipe 1.7 (116), and replicate slides 
(n=3) were combined using a weighted average method as described in Ren et al. (117).  
 
 
Quantitative Real-Time PCR Confirmation of the Genome-Wide Location Data 
 
Q-PCR was performed with three independent CAI4 and SZY63 ChIP samples prepared as 
described above, except that the cell cultures were carried out in the presence of DMSO (0.08%).  
Quantification of the DNA recovered from the CAI4 and SZY63 ChIPs was performed using the 
Quant-iT™ PicoGreen® dsDNA Assay Kit (Molecular Probes: Invitrogen).  A standard curve 
was prepared using C. albicans gDNA quantified by fluorometry and serially diluted in TE 
buffer (0, 0.1, 0.01, and 0.001 ng/μl).  The CAI4 and SZY63 ChIP samples (1 μl) were 
resuspended in 49 μl of TE buffer.  The samples (50 μl) were transferred, in duplicate, in a black 
96-well plate (Costar 3694, Corning Inc., Corning, NY) and 50 μl of the PicoGreen reagent was 
added.  The fluorescence was measured using the Envision luminometer (Perkin-Elmer, 
Waltham, MA) at an excitation and emission wavelength of 485 and 535 nm, respectively.  The 
DNA concentration of the ChIP samples was an average 500 pg/μl, yielding approximately 25 ng 
of total immunoprecipitated DNA per ChIP sample (50 μl). 
 
Q-PCR assays were designed using the Universal ProbeLibrary (Roche Applied Science, 
formerly Exiqon’s ProbeLibray, Indianapolis, IN) and the TaqMan (Integrated DNA 
Technologies, IDT, Coralville, IA) methodologies.  The different primers and probe 
combinations used for Q-PCR are listed in Table 2-3.  The CDR1, PDR16, TAC1 and FUR1 
promoter sequences were submitted to the Universal ProbeLibrary, using the web-based 
ProbeFinder software (version 2.34, Roche Applied Sciences) available on the Roche Applied 
Science website (www.universalprobelibrary.com).  The software assigned optimal PCR specific 
primer sequences to be combined with the corresponding Universal ProbeLibrary probe for each 
promoter sequence (Universal ProbeLibrary probes, Roche Diagnostics Corp., Basel, 
Switzerland).  We also used the PrimerQuest tool from the IDT website 
(http://www.idtdna.com/Scitools/Applications/Primerquest/) to design a custom TaqMan probe 
for the TAC1 promoter (with its corresponding forward and reverse primers) that binds closer to  
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Table 2-3. Primers used for quantitative real-time PCR binding assays. 
 
Promoter Primers/Probe Sequences 5'-3’ Amplicon Locationa 
CDR1 F: GGTGCACACACACACAAACACACA 
R: TTGAGCTCCCACTATCCGATCCCTA 
P: TaqMan probeb : 
CCGCCCTCACTCTGTTCCATACAAAT 
           -435 ? -341 
 
PDR16 F: GAAAAGAAAAAGAAATGGCAACAT 
R: TCGACACGTCTTTCCATCAC 
P: Universal ProbeLibraryc probe # 77 (cat.no. 
04689003001) : GGTGGTGG 
-424 ? -501 
TAC1 F: CACGAAGATAAAAATTGTGGTAGC 
R: AATTGTGCTGATATTTAATTGTTGGT 
P: Universal ProbeLibrary probe # 18 (cat.no. 
04686918001) : CAGCAGGA 
-1024 ? -948 
FUR1 F: GGTGCTTTTGGGAGAATGAA 
R: CTTCCTCAAAACAAAACTGCAA 
P: Universal ProbeLibrary probe # 27(cat.no. 
04687582001) : GCTGCCTG  
-987 ? -913 
SPS4d F: TACAGTTGCCCCAGTCAACA 
R: TGTCTTGGAACGGAAACTCA 
P: Universal ProbeLibrary probe # 15 (cat.no. 
04685148001) : TCCTGCTC  
-636 ? -574 
 
F: forward, R: reverse, P: probe.  
aposition according to the ATG start codon 
bTaqMan probe (42) 
cUniversal ProbeLibrary probe (64) 
d orf19.7568 
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the DRE motif than the Universal ProbeLibrary probe.  The C. albicans homologue of S. 
cerevisiae SPS4 (orf19.7568) was used as the reference promoter and FUR1 was used as a 
control, to perform statistical analyses.  The SPS4 and FUR1 genes were selected because i) they 
were not modulated in our microarray expression study and ii) their promoters were not enriched 
in the ChIP-chips experiments.  A set of probe and primers was designed for each of the SPS4 
and FUR1 promoters using the ProbeFinder software (Table 2-3). 
 
Q-PCR reaction mixtures were prepared using the TaqMan Universal PCR Master Mix 
(Applied Biosystems, Inc.) according to the manufacturer’s instructions.  For reactions using 
probes from the Universal ProbeLibrary, 200 pg of ChIP DNA, 250 nM of each forward and 
reverse primer, 100 nM of the probe, 5 μl of the TaqMan Universal PCR Master Mix and water 
were combined in a final volume of 10 μl.  Q-PCR reactions using the TaqMan probe were 
prepared using the same conditions except that the probe and the primers (forward and reverse) 
were added to a final concentration of 100 nM and 200 nM, respectively.  Reactions were 
performed in MicroAmp Optical 384-Well Reaction Plate (Applied Biosystems, Inc.) using an 
ABI 7900 HT Real-Time PCR instrument with 1 cycle at 95°C for 10 min and 40 cycles at (95°C 
for 15 sec and 60°C for 1 min).  Each biological replicate sample (three) was processed in 
triplicate. 
 
Data analysis was performed using the Sequence Detection System software (SDS 2.2.2; 
ABI).  For each sample, CT values were determined using the SDS software.  The fold 
enrichments of the targets (CDR1, PDR16 and TAC1 promoters) were calculated using the 
relative quantification according to the 2- ΔΔCt method, where ΔCT = CT target - CT reference(SPS4 
promoter) and ΔΔCT = ΔCT test (SZY63 ChIP sample) – ΔCt calibrator (CAI4 ChIP sample) (118).  The FUR1 
promoter was used as a negative control to confirm the fold enrichment obtained using the 2- ΔΔCt 
method.  Statistical analysis was performed using the R software (www.r-project.org version 
2.5.1) and the ΔΔCT's were compared using Welch's t-test.  The statistical significance threshold 
was fixed at α=0.001. 
 
 
DRE Motif Analysis 
 
The promoter sequences (1.5 kb upstream of the starting ATG) were retrieved from the 
Candida Genome Database (http://www.candidagenome.org) and analyzed for the presence of 
potential DRE motifs using the fuzznuc software from EMBOSS 
(http://emboss.bioinformatics.nl/). 
 
 
RESULTS 
 
 
Global Gene Expression Profile 
 
As a means to identify genes that are co-regulated with the CDR1 and CDR2 multidrug 
efflux pumps and thus potentially new transcriptional targets of Tac1p, we performed gene 
expression profiling analyses of four matched sets of azole- susceptible and -resistant C. albicans 
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clinical isolates in which the acquisition of azole resistance is associated with CDR1 and CDR2 
overexpression (Table 2-1).  Three of these azole-resistant isolates possess previously defined 
gain-of-function mutations in the C-terminus of TAC1: a N977D amino acid substitution in 
isolate C56 (also known as isolate DSY296) (89), a N972D amino acid substitution in isolate 
5674 (103), and an A736C amino acid substitution in one allele and L962-N969 deletion in the 
second allele of TAC1 in isolate 17 (101).  Isolate 17 is the last in a series of 17 clinical isolates 
taken from a single HIV-infected patient (92, 106).  Relative to the parental isolate 2, isolate 3 
exhibits increased expression of MDR1 whereas isolate 17 exhibits increased expression of 
CDR1 and CDR2 as well as MDR1 (92, 106).  We therefore compared isolate 17 to isolate 3 to 
identify the genes co-regulated with CDR1 and CDR2.  The other azole-resistant isolate, Gu5, 
overexpresses CDR1 and CDR2 and contains a G980E amino acid substitution in Tac1p 
(unpublished data).  The eight strains did not show major chromosomal rearrangements or 
aneuploidies, as determined by comparative genomic hybridization analyses (data not shown and 
J. Berman, personal communication). 
 
 Three independent RNA samples per strain were hybridized to custom designed 
Affymetrix C. albicans microarrays and the data analyzed as described in Materials and Methods.  
Genes were initially considered to be differentially expressed if 1) their average fold change in 
expression was ≥1.5 for each matched isolate, 2) their expression changed by at least 1.5-fold in 
at least 2 of the 3 experiments for each matched isolate, and 3) if the average fold change was 
statistically significant by t-test.  Using these criteria, there were 222 genes up-regulated and 150 
genes down-regulated in C56 as compared to C43, 104 genes up-regulated and 63 genes down-
regulated in Gu5 as compared to Gu2, 126 genes up-regulated and 92 genes down-regulated in 
17 as compared to 3, and 327 genes up-regulated and 243 genes down-regulated in 5674 as 
compared to 5457 (Table A-1 and Table A-2). Genes which met these criteria for all 4 matched 
isolates and whose average fold change was statistically significant by t-test in at least 2 of the 4 
matched isolates were included in a final data set (Table 2-4 and Table 2-5).  We found 31 genes 
to be up-regulated in all four matched clinical isolate sets (Table 2-4) including the known Tac1p 
targets CDR1, CDR2, IFU5, HSP12 and RTA3 (100).  Other up-regulated genes included GPX1 
(putative glutathione peroxidase), CHK1 (histidine kinase), LCB4 (Sphingoid long-chain base 
kinase), NDH2 (NADH dehydrogenase), SOU1 (sorbose dehydrogenase), orf19.3047 
(transcription cofactor), orf19.4531 (ABC transporter) as well as TAC1 itself, consistent with our 
previous proposition that TAC1 transcription is autoactivated, either directly or indirectly, as a 
consequence of gain-of-function mutations in Tac1p (103).  We also found 12 genes to be down-
regulated in all four matched clinical isolate sets.  These included FTR1 (iron transporter), IHD1 
(putative GPI-anchored protein of unknown function), and OPT6 (oligopeptide transporter) all of 
which encode integral membrane proteins, and SOD5 (superoxide dismutase) which encodes a 
cell wall protein (Table 2-5).  As judged from the expression data, clinical isolate 5674, which 
carries the Tac1p N972D amino acid substitution, results in the highest impact on gene 
expression among the isolates tested, as 38 out of the 43 genes modulated in a TAC1-dependent 
manner had the highest fold modulation in this strain (Table 2-4 and Table 2-5). 
 
 In order to determine which of these genes require Tac1p for their constitutive 
differential expression in these isolates, the gene expression profile of strain SZY31, a 
tac1Δ/tac1Δ derivative of the azole-resistant strain 5674 (Table 2-1), was compared with that of 
the azole-susceptible parental strain 5457 (85).  Genes whose expression was modulated in strain  
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Table 2-4. Genes up-regulated in all four matched clinical isolate sets. 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec 
GO Annotation 
(Molecular Function)d 
C56 
v 
C43 
Gu5 
v 
Gu2 
17 
v 
3 
5674 
v 
5457 
SZY31
v 
5457 
orf19.6000 CDR1 CDR1 Multidrug transporter 
activity 
1.7 3.0 2.4 4.4 -1.0 
orf19.5958 CDR2 CDR2 Transporter activity 50.6 14.1 17.1 50.5 -1.3 
orf19.86 -- GPX1 Glutathione peroxidase 
activity 
2.3 3.0 2.3 4.0 -1.2 
orf19.896 CHK1 HK1 Protein histidine kinase 
activity 
2.5 1.9 1.8 4.5 1.3 
orf19.3160 HSP12 HSP12 -- 5.3 2.9 3.1 16.7 -1.7 
orf19.157 -- IFA24.3 -- 1.5 1.7 1.6 2.1 1.1 
orf19.2568 IFU5 IFU5 -- 3.3 3.0 3.7 5.4 1.5 
orf19.5257 -- LCB4 D-erythro-sphingosine 
kinase activity 
2.2 1.7 2.2 4.0 1.1 
orf19.278 -- MTR -- 3.1 1.8 1.9 5.2 -1.1 
orf19.5713 YMX6 NDH2 NADH dehydrogenase 
activity 
5.3 3.1 2.9 15.3 1.2 
orf19.7218 RBE1 PRY2 -- 2.1 1.8 1.7 1.7 1.2 
orf19.23 RTA3 RTA3 Phospholipid-
translocating ATPase 
activity 
40.4 15.9 22.0 41.0 1.0 
orf19.2896 SOU1 SOU1 Sorbose dehydrogenase 
activity 
2.0 1.5 1.5 7.0 -2.0 
orf19.3104 -- YDC1 -- 3.3 1.6 2.1 5.3 1.4 
orf19.2726 -- IPF10262 -- 2.5 2.8 1.9 6.2 -2.9 
orf19.4459 -- IPF11849 -- 2.0 4.1 4.3 5.0 -1.5 
orf19.2244 -- IPF12897 -- 1.8 1.7 1.5 5.4 -1.7 
orf19.344 -- IPF1514 -- 15.5 4.7 4.0 28.9 1.9 
orf19.4907 -- IPF17283 -- 3.2 1.6 2.3 2.0 1.1 
orf19.5313 -- IPF19810 -- 36.0 29.4 18.1 143.1 1.7 
orf19.5777 -- IPF19961 -- 2.0 1.7 2.2 4.2 -1.3 
orf19.6840 -- IPF3535 -- 1.8 2.3 1.9 2.3 -1.4 
orf19.3047 SIP3 IPF3598 Transcription cofactor 
activity 
1.5 1.5 1.7 3.0 1.3 
orf19.2531 CSP37 IPF4991 ER to Golgi vesicle-
mediated transport 
2.5 1.8 5.5 6.8 -1.3 
orf19.7310 -- IPF5981 -- 4.9 2.7 2.0 16.8 1.2 
orf19.1887 -- IPF6464 -- 2.3 1.8 1.7 4.5 1.2 
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Table 2-4 (continued). 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec 
GO Annotation 
(Molecular Function)d 
C56 
v 
C43 
Gu5 
v 
Gu2 
17 
v 
3 
5674 
v 
5457 
SZY31
v 
5457 
orf19.2790 -- IPF7260 Histone-lysine N-
methyltransferase activity 
1.8 1.6 1.6 2.8 -1.0 
orf19.4531 -- IPF7530 ATPase activity 2.7 3.8 3.5 4.0 -1.6 
orf19.4898 -- IPF8950 -- 2.4 1.6 1.8 3.4 1.1 
orf19.3188 TAC1 IPF9191.3f -- 2.7 2.8 2.8 4.2 -11.7 
orf19.3644 -- IPF9683 -- 2.5 1.5 2.1 3.4 1.1 
 
a orf19 nomenclature according to the Assembly 19 version. 
b Gene name at CGD (http://www.candidagenome.org/). 
c Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
d GO annotation found at CGD (http://www.candidagenome.org/). 
Systematic names in bold designate overlap with ChIP-chip experiments. 
Gene expression values are represented as fold changes between resistant isolates and susceptible 
isolates. 
Gene expression values in bold designate statistical significance (p-value < 0.05) in all three 
experiments. 
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Table 2-5. Genes down-regulated in all four matched clinical isolate sets. 
 
Systematic 
Namea 
CGD 
Nameb 
Candida
DB 
Namec 
GO Annotation 
(Molecular Function)d 
C56 
v 
C43 
Gu5 
v 
Gu2 
17 
v 
3 
5674 
v 
5457 
SZY31
v 
5457 
orf19.7219 FTR1 FTR1 Ferrous iron transporter 
activity -2.7 -3.0 -2.1 -4.0 -1.6 
orf19.5025 MET3 MET3 Sulfate 
adenylyltransferase 
(ATP) activity -2.0 -7.9 -1.8 -2.5 -1.2 
orf19.2947 SNZ1 SNZ1 -- -3.7 -1.8 -1.7 -2.2 1.3 
orf19.5760 IHD1 IPF10662 -- -1.9 -2.2 -3.1 -9.0 1.7 
orf19.3475 -- IPF11725 -- -3.9 -2.1 -2.7 -5.8 -1.2 
orf19.4655 OPT6 IPF12193 Oligopeptide 
transporter activity -1.8 -2.0 -2.4 -3.1 -1.4 
orf19.2060 SOD5 IPF1222 Copper, zinc 
superoxide dismutase 
activity -2.3 -8.6 -17.8 -26.3 -1.4 
orf19.2059 -- IPF1228 -- -2.0 -1.7 -1.7 -2.9 1.2 
orf19.4749 -- IPF13921 -- -2.3 -1.8 -2.4 -3.0 -1.4 
orf19.670.2 -- IPF20159 -- -2.3 -2.0 -1.7 -4.9 -1.9 
orf19.6679 -- IPF2314 -- -1.5 -2.1 -1.8 -2.2 1.1 
orf19.7561 DEF1 IPF946 -- -3.4 -1.5 -1.6 -2.8 -1.4 
 
a orf19 nomenclature according to the Assembly 19 version. 
b Gene name at CGD (http://www.candidagenome.org/). 
c Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
d GO annotation found at CGD (http://www.candidagenome.org/). 
Gene expression values are represented as fold changes between resistant isolates and susceptible 
isolates. 
Gene expression values in bold designate statistical significance (p-value < 0.05) in all three 
experiments. 
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5674 as compared to strain 5457 and whose expression in strain SZY31 was returned to levels 
similar to those observed in strain 5457 were determined to be dependent upon Tac1p for their 
up- or down-regulation.  As shown in Table 2-4 and Table 2-5, the majority of commonly 
differentially expressed genes were found to be Tac1p-dependent. 
 
 We selected four genes of interest for confirmation of differential expression by real-time 
RT-PCR.  These included CDR1, CDR2, TAC1, and PDR16.  PDR16 was selected as it has been 
shown to be co-regulated with CDR1 and CDR2 in association with azole resistance, yet this is 
one of a limited number of genes not represented on the microarray used in this study (102, 119).  
As expected, all four genes were confirmed to be up-regulated in all four isolate sets (Figure 2-1).  
Likewise, up-regulation of all four of these genes in isolate 5674 was ablated in strain SZY31 
(Figure 2-1). 
 
 
Identification of Tac1p-Binding Sites in vivo 
 
To determine if the TAC1-dependent genes that were differentially expressed in the 
clinical isolates have their promoter bound in vivo by Tac1p and to identify additional direct 
targets of Tac1p, we conducted genome-wide location analyses (ChIP-chip), a procedure 
combining ChIP with hybridization to DNA intergenic microarrays (117).  For this purpose, 
Tac1p was tagged at its C-terminus with a triple hemaglutinin (HA) epitope, using homologous 
recombination at the TAC1 chromosomal locus (Figure 2-2).  First, we adapted the S. cerevisiae 
PCR epitope-tagging vector pMPY-3×HA (111) for its use in C. albicans, by substituting the S. 
cerevisiae URA3 marker with the C. albicans URA3 gene (see Materials and Methods for details).  
The resulting vector (pCaMPY-3×HA) contains the CaURA3 marker flanked by direct repeats of 
the HA3 epitope.  The TAC1-tagging cassette was amplified with 100-bp primers (16 bp of vector 
sequences and 84 bp from the gene to be tagged), allowing tagging of Tac1p at its C-terminus 
(Figure 2-2A).  After transformation of the CAI4 strain and integration of the cassette by 
homologous recombination, the marker was excised via recombination between the two directly 
repeated HA3 tags and the excision mutants were selected on 5-FOA medium (Figure 2-2A).  
The resulting pre-excision (strain SZY51) and post-excision (strain SZY63) strains were 
characterized by Southern hybridization using HindIII and EcoRV double-digested genomic 
DNA and the TAC1 probe (Figure 2-2B).  As predicted (Figure 2-2B), the probe detected two 
fragments, one of 3.3 kb and one of 1.4 kb in the CAI4 strain, corresponding to the wild-type 
TAC1-1 (orf19.3188) and TAC1-2 (orf19.10700) alleles, respectively (Figure 2-2C, lane 1).  
Integration of the HA3-tagging cassette occurred at the TAC1-2 allele in the pre-excision strain 
SZY51, as the 1.4-kb band was shifted to the 3.1-kb band (Figure 2-2C, lane 2).  Excision of the 
CaURA3 marker in strain SZY63 was confirmed by the presence of the 1.6-kb band (Figure 2-2C, 
lane 3).  To detect the Tac1p-HA3 fusion protein, Western blotting was performed in strains 
CAI4 and SZY63, using an anti-HA monoclonal antibody (Figure 2-2D).  A signal 
corresponding to the Tac1p-HA3 fusion protein was detected in the HA-tagged SZY63 strain but 
not in strain CAI4 (control) (Figure 2-2D).  The size of this band was approximately 120 kDa, 
consistent with the predicted molecular weight of the Tac1p-HA3 fusion protein (118 kDa).  The 
functionality of the Tac1p-HA3 protein was examined by the Raymond lab and there was change 
in Tac1p function. 
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Figure 2-1. Quantitative real-time RT-PCR analysis of selected genes differentially 
expressed in the microarray experiments. 
(A) Genes differentially expressed in each of the azole resistant clinical isolates as compared to 
their parent isolates.  (B) CDR2 gene expression in each of the azole resistant clinical isolates.  
Error bars denote standard error (n=3).  Asterisks denote statistical significance by t-test (p-value 
≤ 0.05). 
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Figure 2-2. Chromosomal tagging of Tac1p. 
(A) PCR epitope tagging strategy for C-terminally tagging transcription factor Tac1p with the 
triple HA epitope.  Top, 100-nt primers (FWD and REV, see Materials and Methods) are 
designed such that the 5’ 84 bases of the forward (FWD) and reverse primers are homologous to 
sequences of the TAC1 gene and the 3’ 16 bases are complementary and in-frame to unique 
sequences (open boxes) in the tagging cassette which contains the C. albicans URA3 marker 
(CaURA3, light gray box) flanked by direct repeats of the 3×HA-encoding sequences (HA, black 
boxes).  The Tac1p stop codon is indicated by the asterisk.  Middle, PCR amplification results in 
a fragment whose ends include the primer sequences, allowing integration by homologous 
recombination of the tagging cassette upstream of the TAC1 3’ untranslated region (horizontal 
thick line).  The orientation of the TAC1 ORF (dark gray box) is indicated by the arrow.  Bottom, 
CaURA3 marker excision results in the final product, TAC1-HA3.  (B) Schematic representations 
of the TAC1-1 (orf19.3188) and TAC1-2 (orf19.10700) alleles (gray boxes) in strain CAI4 and 
sizes of the HindIII, EcoRV double-digested fragments detected by the TAC1 probe (top, thick 
line) used for the Southern blot experiment are given for the TAC1-2 allele following integration 
of the HA3-tagging cassette (open box) and excision of the CaURA3 marker through HA3 
recombination.  (C) Southern blot of genomic DNA from the CAI4 strain and its URA3-pre-
(SZY51) and post-excision (SZY63) derivatives, digested with EcoRV and HindIII and 
hybridized with the TAC1 probe shown in (B).  Marker sizes are indicated on the left.  (D) 
Western blot analysis of protein extracts from strains CAI4 and the Tac1p-HA3 integrant SZY63 
with an anti-HA monoclonal antibody.  Molecular weights markers are indicated on the left. 
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ChIP-chip experiments were conducted using the CAI4 and SZY63 strains and intergenic 
DNA microarrays containing 70-mer oligonucleotides covering the promoter regions of the C. 
albicans genome.  Using a P-value < 0.001 (enriched binding ratio ≥ 1.5), we identified 37 
promoters bound by Tac1p (Table 2-6).  These included the promoters of genes known to be 
regulated by Tac1p: CDR1 (10.5), IFU5 (3.0), PDR16 (2.1), RTA3 (1.8) and CDR2 (1.7) (100, 
103), thus validating our ChIP-chip procedure and showing that Tac1p binds in vivo to the 
promoter of these genes to regulate their expression.  HSP12, also known to be regulated by 
Tac1p, had a binding ratio of 1.2 (P-value=0.09) and thus was not significantly bound by Tac1p.  
These experiments also identified several new targets, including genes involved in lipid 
metabolism, oxidative stress response as well as genes of unknown function.  On two 
occurrences, Tac1p binding was found at promoters of two genes located on opposite strands 
(thus sharing the same probe on the chip): UGA33 (orf19.7317) and SUC1 (orf19.7319) as well 
as LPE10 (orf19.3455) and KIC2 (orf19.3456) (Table 2-6).  While the expression data did not 
allow to discriminate which one of the LPE10 or KIC2 genes is regulated by Tac1p, we found 
that SUC1 was up-regulated in a TAC1-dependent manner in 3 out of the 4 clinical isolates tested 
by expression microarrays Table A-1 while UGA33 expression was unchanged in 3 out of the 4 
clinical isolates, suggesting that SUC1, a sucrose uptake zinc cluster regulator (120), is a target 
of Tac1p.  The identification of several promoters bound in vivo by Tac1p under non-activating 
conditions (i.e. in the absence of drugs or gain-of-function mutations) demonstrates that Tac1p is 
at least constitutively bound to its targets and suggests the possible involvement of post-binding 
mechanisms for Tac1p-mediated transcriptional activation. 
 
Using quantitative real-time PCR, we confirmed the binding of Tac1p to the CDR1 and 
PDR16 promoters, with enrichment ratios of 29.1 ± 4.0 and 4.1 ± 0.2, respectively (Figure 2-3).  
As a control, we investigated binding of Tac1p to the promoter of the FUR1 gene, which was not 
enriched in the ChIP-chip experiments nor modulated in the azole-resistant clinical isolates, and 
found no significant enrichment of that promoter by Q-PCR (1.1 ± 0.2), confirming the validity 
of the data obtained in the ChIP-chip experiments (Figure 2-3). 
 
Although our results suggested that the expression of the TAC1 gene is controlled by 
Tac1p in an autoregulatory loop, the ChIP-chip data showed no enrichment for Tac1p at its own 
promoter, supporting an indirect auto-regulation mechanism.  However, the fact that the TAC1 
promoter contains a DRE-like motif located between positions -1051 and -1060 relative to the 
ATG translation start codon (Table 2-7; see below) and that the TAC1 oligo printed on the 
intergenic chips is located at position -480 may have prevented us from detecting Tac1p binding 
at the TAC1 promoter.  Therefore, we used for Q-PCR a set of TaqMan probe and primers 
hybridizing close to this DRE motif (Table 2-2).  Under these conditions, we observed a strong 
enrichment of the TAC1 promoter (179.6 ± 25.2) (Figure 2-3).  These results strongly support a 
direct autoregulatory loop controlling TAC1 expression. 
 
 
Identification of Potential Tac1p-Binding Motifs 
 
Tac1p belongs to the fungal-specific family of zinc cluster transcription factors that 
contain a DBD formed by six cysteines coordinating two zinc atoms (121).  Zinc cluster factors 
can bind as homodimers to CGG triplets with various orientations (everted, inverted, or direct  
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Table 2-6. List of Tac1p-enriched promoters (P-value < 0.001). 
 
Systematic 
Namea 
CGD/ 
NRC 
Nameb 
Candida 
DB Namec 
S. cerevisiae 
Orthologd GO Terminology
e BRf Pg 
E 
5674/ 
5457h 
E 
SZY31/5457i 
orf19.6000 CDR1 CDR1 PDR5 Transporter activity 10.5 0.0000 4.4* -1.0 
orf19.6869 AST2 IPF8041 AST2 Peptidase activity 4.1 0.0000 1.6 1.9 
orf19.769 IFE1 IFE1 BDH2 -- 3.3 0.0000 -- -- 
orf19.2568 IFU5 IFU5 WWM1 -- 3.0 0.0000 5.4* 1.5 
orf19.86 GPX2 GPX1 HYR1 Glutathione peroxidase 
activity 
2.8 0.0000 4.0* -1.2 
orf19.3406 -- IPF9898 YHL008c -- 2.5 0.0000 -2.7* -1.5 
orf19.7166 -- IPF2186 YGR110w -- 2.8 0.0000 5.0 1.2 
orf19.7042 -- IPF3080 -- -- 2.1 0.0000 5.5* 1.3 
orf19.93 -- IPF14895 MIC17 -- 2.1 0.0000 1.5 -1.1 
orf19.1027 PDR16 PDR17 PDR16 Phosphotidylinositol 
transporter activity 
2.1 0.0000 20.0j 1.2j 
orf19.3395 -- IPF9483 YHR048w -- 2.0 0.0000 -- -- 
orf19.5877 ATF1 IPF1837 ATF1 Alcohol O-
acetyltransferase activity 
2.0 0.0000 2.8* 1.2 
orf19.6627 -- IPF2557 -- -- 1.9 0.0000 2.6* -1.0 
orf19.23 RTA3 RTA3 RSB1 Phospholipid-
translocating ATPase 
activity 
1.8 0.0000 41.0* 1.0 
orf19.6501 -- IPF3931 YJU3 -- 1.8 0.0000 4.6* 1.1 
orf19.5037 -- IPF17054  -- 1.8 0.0000 7.7 2.1 
orf19.4898 -- IPF8950 FMP52 -- 1.8 0.0001 3.4 1.1 
orf19.1267 CAJ1 IPF10278 CAJ1 Chaperone regulator 
activity 
1.7 0.0001 2.5 -1.2 
orf19.1887 -- IPF6464 YEH1 -- 1.7 0.0001 4.5 1.2 
         
37 
Table 2-6 (continued). 
 
Systematic 
Namea 
CGD/ 
NRC 
Nameb 
Candida 
DB Namec 
S. cerevisiae 
Orthologd GO Terminology
e BRf Pg 
E 
5674/ 
5457h 
E 
SZY31/5457i 
orf19.691 GPD2 GPD2 GPD1 Glycerol-3-phosphate 
dehydrogenase (NAD+) 
activity 
1.7 0.0001 1.1 1.1 
orf19.2175 -- IPF19998 AIF1 Oxioreductase activity 1.7 0.0001 3.3 1.3 
 
orf19.1444 ENT2 IPF17555.3 ENT2 Cytoskeletal adaptor 
activity 
1.7 0.0002 1.5 1.1 
orf19.5958 CDR2 CDR2 PDR5 Transporter activity 1.7 0.0003 50.5* -1.3 
orf19.3455k LPE10k IPF9782k LPE10 Magnesium ion 
transporter activity 
1.6 0.0003 1.7 -1.7 
orf19.1089 PEX11 PEX11 PEX11 Peroxisome organization 
and biogenesis 
1.6 0.0003 1.8* -2.4 
orf19.1665 MNT1 MNT1 KTR1 Alpha-1,2-
mannosyltransferase 
activity 
1.6 0.0003 -- -- 
orf19.7306 -- IPF5987 YPR127w -- 1.7 0.0003 2.1 1.1 
orf19.7319k SUC1k SUC1k MAL13 Transcription factor 
activity  
1.6 0.0003 5.1* 1.2 
orf19.1718 ZCF8 IPF19769 -- -- 1.7 0.0004 -1.6 -1.8 
orf19.406 ERG1 ERG1 ERG1 Squalene 
monooxygenase activity 
1.7 0.0005 -1.6 1.2 
orf19.7603 -- IPF660 YMR244c-A -- 1.6 0.0005 -- -- 
orf19.5005 OSM2 OSM2 OSM1 Fumarate reductase 
(NADH) activity 
1.6 0.0005 2.0* 1.2 
orf19.577 -- IPF7353 YDL057c -- 1.6 0.0006 2.3 1.5 
orf19.5257 LCB4 LCB4 LCB4 D-erythro-sphingosine 
kinase activity 
1.6 0.0007 4.0* 1.1 
orf19.5525 -- IPF4328 YMR315w -- 1.5 0.0008 2.3* 1.1  
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Table 2-6 (continued). 
 
Systematic 
Namea 
CGD/ 
NRC 
Nameb 
Candida 
DB Namec 
S. cerevisiae 
Orthologd GO Terminology
e BRf Pg 
E 
5674/ 
5457h 
E 
SZY31/5457i 
orf19.4476 IFD6 IFD6 YPL088w Aryl-alcohol 
dehydrogenase activity 
1.6 0.0009 2.2 1.2 
orf19.951 -- IPF1548 -- -- 1.6 0.0009 -1.5 1.1 
 
a orf19 nomenclature according to the Assembly 19 version; orfs in bold are modulated in the 
four sets of isolates whereas underlined orfs are modulated at least in strain 5674. 
b Gene name according to CGD (http://www.candidagenome.org/) or the NRC Candida albicans 
database (http://candida.bri.nrc.ca/candida/index.cfm?page=CaGeneSearch). 
c Gene name according to CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
d S. cerevisiae ortholog or best hit according to CGD (http://www.candidagenome.org/). 
e Gene ontology (GO) terminology according to CGD. 
f Binding ratio. Probes are spotted in duplicate on the ChIP-chip arrays (H. Hogues, H. Lavoie, A. 
Sellam, M. Mangos, T. Roemer, E. Purisima, A. Nantel and M. Whiteway, submitted for 
publication). Binding ratio with the most significant P-value is shown.   
g P-value of the corresponding binding ratio. 
h Fold expression of the gene in strain 5674 relative to strain 5457. An asterisk (*) indicates that 
fold expression is statistically significant (Table A-1). 
i Fold expression of the gene in strain SZY31 relative to strain 5457.  
j Value obtained by quantitative real-time RT-PCR. 
k The intergenic oligonucleotide probe corresponds to a common promoter of two adjacent genes. 
The orf19.3455 probe is shared by LPE10 and KIC2; the orf19.3719 probe is shared by SUC1 
and UGA33.  
39 
 
 
Figure 2-3. In vivo enrichment of Tac1p binding at the CDR1, PDR16 and TAC1 
promoters using Q-PCR. 
The CAI4 and SZY63 strains were submitted to ChIP (3 biological replicates) and the recovered 
DNA samples were analyzed by Q-PCR, using Universal ProbeLibrary probes (64) for the 
PDR16, TAC1, SPS4 and FUR1 promoters or a TaqMan probe (42) for the CDR1 promoter.  
Fold enrichments are presented in log scale: 3.8 for the PDR16 promoter (95% confidence 
interval: 4.0, 5.0), 28.8 for the CDR1 promoter (95% confidence interval: 21.4, 38.9), 189.3 for 
the TAC1 promoter (95% confidence interval: 128.6, 278.6) and 1.1 for the FUR1 promoter 
(95% confidence interval: 0.9, 1.3), which was used as a negative control. 
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Table 2-7. DRE motifs found in the Tac1p target promoters. 
 
SYSTEMATIC 
NAMEa CGD NAME
b MOTIFSc STRANDd POSITIONe
CGGN4CGG 
orf19.6000 CDR1 CGGATATCGG S -457 
orf19.6869 AST2 CGGCTAACGG A -262 
orf19.2568 IFU5 CGGAAATCGG A -235 
orf19.7166 -- CGGGTAACGG 
CGGAGAACGG 
S 
S 
-292 
-285 
orf19.7042 -- CGGATAACGG 
CGGTTACCGG 
CGGATTACGG 
S 
A 
A 
-731 
-632 
-639 
orf19.5877 ATF1 CGGATATCGG A -206 
orf19.6627 -- CGGATATCGG A -176 
orf19.23 RTA3 CGGAACTCGG S -595 
orf19.4898 -- CGGGTGACGG S -232 
orf19.5958 CDR2 CGGAAATCGG S -220 
orf19.1089 PEX11 CGGGGAACGG A -340 
orf19.4476 IFD6 CGGTTGTCGG A -339 
orf19.10700 TAC1 CGGAGCACGG A -1,054f 
Consensusg C G G A T A A C G G  1.0 1.0 1.0 0.6 0.6 0.7 0.5 1.0 1.0 1.0
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Table 2-7 (continued). 
 
SYSTEMATIC 
NAMEa CGD NAME
b MOTIFSc STRANDd POSITIONe
CGGN3CGG 
orf19.3406 -- CGGCAACGG A -332 
orf19.1027 PDR16 CGGATTCGG S -558 
orf19.5037 -- CGGTTCCGG 
CGGAACCGG 
CGGGGGCGG 
S 
A 
A 
-358 
-351 
 
-250 
orf19.2175 -- CGGAAGCGG A -167 
orf19.3455 LPE10 CGGCTGCGG S -246 
orf19.1718 ZCF8 CGGAATCGG S -797 
orf19.6869 AST2 CGGGCGCGG A -1,161 
orf19.10700h TAC1 CGGAAACGG  A -1,040 
Consensusg C G G A A G C G G  1.0 1.0 1.0 0.5 0.5 0.4 1.0 1.0 1.0
 
a orf19 nomenclature according to the Assembly 19 version. 
b Gene name at CGD (http://www.candidagenome.org/). 
c The underlined motifs have been previously described (16) 
d S denotes sense strand and A denotes antisense strand. 
e Nucleotide position from the ATG translation start site. 
f Position in contig19.20170, upstream of orf19.10700; position in contig.10170, upstream of orf19.3188 is -1,051 due to sequence 
polymorphisms. 
g The consensus sequence was obtained using the AlignX program (component of Vector NTI Advance 10.1.1, Invitrogen). 
Nucleotide frequency at each position is given below.  
h Present only in contig.20170 due to a sequence polymorphism (CCGAAACGG).  
repeats) and spacing (121).  The CDR1 and CDR2 DRE consists of a direct CGG repeat 
with 4 intervening nucleotides (CGGAA/TATCGG), a configuration also found in the 
promoter of the other Tac1p-regulated genes RTA3 and IFU5 (99, 100).  We thus looked 
for a DRE motif in the promoter of the 37 genes identified by the ChIP-chip experiments, 
using 1.5 kb of promoter sequence and the motif definition CGGN4CGG which allows 
for complete degeneracy for the 4 nucleotides between the CGG repeats.  In addition to 
CDR1, CDR2, RTA3 and IFU5, this analysis identified 8 new genes containing the 
CGGN4CGG sequence: AST2, ATF1, PEX11, IFD6 and 4 ORFs of unknown function 
(orf19.7166, orf19.7042, orf19.6627 and orf19.4898), for a total of 15 matches in 12 
genes (Table 2-7).  As a control, we searched the CGGN4CGG motif in 1.5 kb of 
promoter sequence from 6,068 orfs and found an average of 1.5 match per 37 promoters, 
yielding a 10-fold enrichment for the presence of the CGGN4CGG sequence in the 
Tac1p-bound promoters.  We also searched the 37 enriched promoters for the motif 
CGGN3CGG since our unpublished data indicated that a CGGATTCGG sequence in the 
PDR16 promoter is involved in its transcriptional activation by Tac1p.  This analysis 
identified 7 genes (including PDR16), one of them with three CGGN3CGG motifs (Table 
2-7).  Searching the 6,068 promoter sequences yielded an average of 2.2 genes per 37 
promoters, resulting in a 3.2-fold enrichment for that sequence in the Tac1p-bound 
promoters.   
 
Finally, we examined whether the CGGN3-4CGG motifs appear in the promoter 
region of the genes whose expression was modulated in all 4 resistant isolates (31 up-
regulated and 12 down-regulated) compared to their matched parental strains.  We found 
7 up-regulated genes containing the CGGN4CGG motif, 5 of which also identified by the 
ChIP-chip experiments (CDR1, CDR2, IFU5, RTA3, orf19.4898; the two other ones 
being TAC1 and orf19.3047) as well as two up-regulated genes with the CGGN3CGG 
motif (TAC1 and orf19.344) (Table 2-7).  Finally, searching the down-regulated genes 
identified one gene with the CGGN4CGG motif (SOD5) and one gene with the 
CGGN3CGG motif (OPT6). 
 
 
Expression and Location Data Mining 
 
When merging the expression and location data, we identified 8 genes whose 
promoters were bound by Tac1p in vivo and which were up-regulated in the four azole-
resistant clinical isolates in a TAC1-dependent manner, thus qualifying these genes as 
bona fide Tac1p targets.  These genes were CDR1 and CDR2, GPX1 (putative gluthatione 
peroxidase), LCB4 (putative sphingosine kinase), RTA3 (putative phospholipid flippase) 
as well as three genes of unknown function: IFU5, orf19.1887, and orf19.4898 (Table 2-6, 
in bold, and Table A-1).  We also identified 9 genes whose promoters were bound by 
Tac1p in vivo and that were significantly modulated in a TAC1-dependent manner in at 
least strain 5674, the isolate displaying the strongest fold change in gene expression.  
These genes were orf19.5877 (ATF1, alcohol acetyltransferase), orf19.1089 (PEX11, 
fatty acid oxidation), orf19.5005 (OSM2, fumarate reductase), orf19.7319 (SUC1, sucrose 
metabolism) as well as 5 ORFs of unknown function (orf19.6627, orf19.7042, orf19.5525, 
orf19.3406 and orf19.6501) (Table 2-6, underlined, and Table A-1).  These results 
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suggest that, in addition to its function in azole drug resistance, Tac1p regulates other 
cellular functions such as lipid metabolism and oxidative stress response. 
 
 
DISCUSSION 
 
To identify the Tac1p regulon, we combined genome-wide expression and 
location analyses, two technologies with complementary strengths and limitations.  
Expression profiling is extremely valuable since it can identify all of the changes in 
transcript abundance associated with the perturbation of a specific transcriptional 
regulator, however it cannot distinguish between direct or indirect effects at individual 
target promoters.  Location profiling is a very powerful tool to identify all the direct 
targets of a specific transcription factor, however it does not allow the determination of 
whether the bound factor acts as an activator or a repressor of these targets.  Each method 
also gives rise to false positives and false negatives.  Merging the results from the two 
approaches thus generates data that is most complete and cross-validated. 
 
While merging the expression and location data sets for Tac1p, we found that, out 
of 37 genes whose promoter was bound by Tac1p, 20 (64%) did not have their expression 
modulated (Table 2-6).  Possible technical explanations for this limited overlap are that 
some of these genes did not pass the stringent criteria applied to the expression 
microarray data or that they represent false positives.  However, a biological explanation 
could be that the expression of the bound promoters is not modulated in response to gain-
of-function mutations in Tac1p but rather in response to other potential Tac1p-activating 
signals.  We also found that, out of 43 modulated genes, 35 (81%) were not identified in 
the location profiling experiments, suggesting that these genes are indirect targets of 
Tac1p (i.e. controlled by Tac1p-regulated transcription factors and/or other 
transcriptional regulators) or that they are not bound by Tac1p under non-activating 
conditions (see below).  It is also possible that the detection of Tac1p binding to some of 
these targets may have been prevented by the fact that their Tac1p-binding site is too far 
from the oligonucleotide sequence printed on the intergenic chip, as we found for TAC1.  
Lastly, some of these genes could have been missed by using a P-value < 0.001 as the 
cut-off in the location array experiments.  This seems to be the case for the SIP3 gene 
whose expression was up-regulated in the four azole-resistant isolates in a TAC1-
dependent manner and which had a binding ratio of 1.6 but a P-value of 0.0014.  Taken 
together, combining the expression and location profiling data allowed us to identify 
many new genes which unambiguously belong to the Tac1p regulon and thereby gain 
new insights into the biological functions of Tac1p. 
 
Previously, we examined the gene expression profiles of matched isolates 2, 3, 15, 
and 17 using an earlier generation microarray (108).  In that analysis we identified 5 
genes as being co-regulated with CDR1 and CDR2.  Two of these, GPX1 and RTA3, were 
found in the present study to be up-regulated in all four matched isolate sets studied, 
whereas a third, ERG2, was found to be up-regulated in three of these isolate sets.  
Likewise, of the 14 genes we previously found to be down-regulated in association with 
azole resistance in isolate 17, orf19.3475, orf19.2060, and orf19.5760 were found to be 
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down-regulated in all four isolate sets, and FET34 was found to be down-regulated in 
three of the four in this study.  Using the same early generation arrays, Coste et al 
examined the gene expression profiles of isolate C56 as well as strain DSY2926 (isolate 
C43 expressing a TAC1 allele carrying a gain-of-function mutation) compared to that of 
their parent isolate C43 (100).  They identified 7 genes to be up-regulated in common 
between these two experimental conditions.  In addition to CDR1 and CDR2, these 
included RTA3 and HSP12, both of which were found to be up-regulated in all four 
matched isolate sets examined in the present study.  In a separate study by the same 
group, Karababa et al examined the gene expression profiles of isolate C56 compared to 
parent isolate C43 as well as strain CAF2-1 exposed to the CDR1- and CDR2-inducing 
agent fluphenazine compared to this strain grown in the absence of drug (122).  In 
addition to CDR1 and CDR2, they observed 7 genes to be commonly up-regulated 
between these two conditions.  These included HSP12, GPX1, RTA3, orf19.344, IFU5, 
orf19.1862 and orf19.7284, all of which were found in the present study to be up-
regulated in either three or all of the four clinical isolates examined.  In this report, we 
used a more recent generation microarray together with well-characterized sets of azole 
resistant clinical isolates and a tac1Δ/tac1Δ mutant, which allowed us to identify 36 
additional genes whose expression is modulated in azole-resistant strains, dependent 
upon Tac1p. 
 
Known Tac1p targets such as CDR1, CDR2, IFU5 and RTA3, are induced in a 
TAC1-dependent manner upon exposure of the cells to fluphenazine or estradiol or upon 
expression of a gain-of-function TAC1 allele in a tac1Δ/tac1Δ background (99, 100).  
This indicates that the activation of Tac1p by such inducers or by gain-of-function 
mutations is required for Tac1p-mediated transcriptional regulation.  Our ChIP-chip 
experiments were done with cells grown in rich media, under uninduced conditions (123).  
We found that, under these conditions, Tac1p binds to its target promoters, indicating that 
this binding is constitutive or at least partially constitutive since it cannot be excluded 
that Tac1p binding increases in the presence of an inducer or an activating mutation.  
Functional characterization of the epitope-tagged Tac1p strain showed that Tac1p binding 
to its targets is not due to an activating effect of introducing the HA tag at the C-terminus 
of Tac1p.  It was recently reported that the S. cerevisiae zinc cluster regulator Pdr1p, 
which controls the expression of the multidrug transporters PDR5, SNQ2 and YOR1 (124), 
also binds constitutively to its target promoters in vivo (125).  Likewise, the S. cerevisiae 
zinc cluster transcription factor War1p, which controls the expression of the ABC 
transporter Pdr12p in response to weak acid stress, has been shown to constitutively bind 
to the PDR12 promoter in vivo (126).  Thus, the mechanisms by which Tac1p activates 
transcription in response to drugs or to gain-of-function mutations appear to be similar to 
those already documented for zinc cluster factors in S. cerevisiae and most likely involve 
post-binding mechanisms such as loss of interaction with a repressor protein, as proposed 
for Upc2p and Ecm22p (127) or recruitment of coactivator complexes (SAGA, Mediator, 
SWI/SNF) as shown for Pdr1p (128). 
 
Our analyses of the Tac1p-bound promoters for the presence of a DRE-like motif 
CGGN4CGG allowed us to identify 8 new Tac1p targets, in addition to CDR1, CDR2, 
RTA3 and IFU5, containing this sequence (Table 2-7).  The fact that 25 of the Tac1p-
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bound promoters do not contain this motif suggests that Tac1p may recognize additional 
configurations of the CGG triplets, including monomeric CGG triplets or CGG triplets 
with different spacing and/or orientations (121).  The latest proposition is supported by 
our unpublished data that a CGGATTCGG sequence in the PDR16 promoter is involved 
in its transcriptional activation by Tac1p and the enrichment of the CGGN3CGG motif in 
the Tac1p-bound promoters (Table 2-7).  Alternatively, Tac1p may bind upstream or 
downstream of the DNA sequences analyzed (1.5 kb of upstream sequences).  Finally, it 
is also possible that Tac1p binds to some of its targets indirectly, through its association 
with other DNA-binding proteins.  For instance, the S. cerevisiae zinc cluster proteins 
Rsc30p and Rsc3p, which are part of the chromatin remodelling complex, have been 
shown to bind indirectly to DNA (129).  Whether or not the DRE motifs identified in the 
Tac1p-bound promoters are functional as well as the sequences/factors mediating Tac1p 
binding to its target promoters in the absence of a classical DRE remain to be 
experimentally determined. 
 
We previously showed that strain 5674 overexpresses the TAC1 gene and that 
introduction of a TAC1 allele carrying the N972D gain-of-function mutation in a 
tac1Δ/tac1Δ strain leads to the constitutive upregulation of the TAC1 transcript, which 
suggested that Tac1p is positively autoregulated, directly or indirectly (103).  We show in 
the present study that i) TAC1 is upregulated in three additional azole-resistant isolates in 
which the Tac1p pathway is activated (Table 2-4); ii) the TAC1 promoter contains a DRE 
motif, and iii) Tac1p binds in vivo to its own promoter (Figure 2-3).  Taken together, our 
findings support the proposition that TAC1 expression is controlled by a direct positive 
autoregulatory loop.  This situation is similar to S. cerevisiae Pdr3p, which binds in vivo 
to two PDRE located in the PDR3 promoter to transactivate its own expression (94).  It 
appears that direct self-regulatory loops are a common feature among zinc cluster 
transcription factors in yeast, including Pdr3p and Yrr1p (pleiotropic drug resistance), 
Hap1p (respiration) and Stb5p (pentose phosphate pathway) (121).  Studies in budding 
yeast have shown that transcription factor autoregulation is necessary to respond to 
environmental stresses.  As examples, autoregulation of PDR3 in a pdr1Δ background is 
crucial for growth on a medium containing cycloheximide (94) and autoregulation of the 
basic leucine zipper transcription factor Hac1p, which controls the unfolded protein 
response, is required to protect the cells from prolonged endoplasmic reticulum stress 
(130).  Similarly, autoregulation of C. glabrata AMT1, a copper-sensing transcription 
factor, is necessary to protect the cells upon exposure to high environmental copper levels 
(131).  Thus, one possible outcome of Tac1p autoregulation would be an amplifiable 
production of the Tac1p protein necessary for rapid and sustained response to drugs and 
yet unknown activating signals (123). 
 
Three previously identified Tac1p targets (CDR1, CDR2, PDR16) have been 
shown to play a role in azole drug resistance (38, 102, 132).  Thus Tac1p confers azole 
resistance by activating different effectors, each contributing to some extent to the overall 
azole resistance of the cells.  Additional Tac1p targets identified by our studies and co-
regulated with CDR1, CDR2 and PDR16 may also play a protective role against toxic 
injuries.  For instance, orf19.4531 is found among the group of genes differentially 
expressed under the gene ontology (GO) molecular function term “ATPase activity 
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coupled to movement of substances”, including CDR1, CDR2 and RTA3 (Table 2-4).  
orf19.4531 encodes a putative ABC transporter of the PDR subfamily (to which CDR1 
and CDR2 belong).  Whether this transporter impacts azole resistance, alone or in 
conjunction with Cdr1p and Cdr2p, remains to be determined.  This efflux pump may 
also protect the cell from other toxic compounds.  As another example, orf19.86 (GPX1), 
which encodes a putative glutathione peroxidase, is an integral component of the 
glutathione and glutathione-dependent enzyme system which has been implicated in the 
resistance of tumor cells to anticancer agents (133, 134).  Increased activity of this 
enzyme system is often observed in conjunction with increased activity of the ABC 
transporter P-glycoprotein in drug-resistant human cancer cells (135). 
  
Although not found among the 37 promoters observed to be bound by Tac1p, 
CHK1 was among the 31 genes that were consistently co-regulated with CDR1 and 
CDR2 in all four matched isolate sets.  Its up-regulation in these isolates is at least 
influenced by Tac1p as deletion of TAC1 in isolate 5674 reduced its expression to normal 
levels.  Chk1p is a histidine kinase involved in a two-component signaling pathway, 
along with the response regulator Ssk1p, that regulates cell wall biosynthesis (136, 137).  
Interestingly it was recently shown that strains of C. albicans lacking either of these 
signal transduction proteins are hypersensitive to fluconazole (138).  Up-regulation of 
CHK1 in association with CDR1- and CDR2-mediated azole resistance suggests that, in 
addition to its requirement for baseline azole tolerance in azole-susceptible cells, this 
protein may contribute to azole resistance in clinical isolates.  In the related fungal 
species C. glabrata, ATPase activity of the ABC transporter Cdr1p and the drug efflux 
activity of the ABC transporter Pdh1p (Cdr2p) are regulated by phosphorylation (139, 
140).  Likewise, phosphorylation has been shown to modulate transcriptional activity of 
the transcription factor Gal4p (141), and has been suggested to regulate the activity of the 
transcriptional regulator Pdr3p (142).  It is therefore tempting to speculate that Chk1p is 
involved in the phosphorylation and activity of the efflux pumps Cdr1p and Cdr2p, or 
possibly Tac1p itself.  Further investigation into the contribution of this signaling 
pathway to azole resistance will be required to address this question.  
 
Our genome-wide location experiments revealed that Tac1p binds to the promoter 
of a group of genes involved (or predicted to be involved) in lipid metabolism.  These 
genes are CDR1, CDR2, PDR16, RTA3, ATF1, ERG1, LCB4, orf19.6501, orf19.7166, 
and orf19.1887.  With the exception of ERG1, all these genes were significantly up-
regulated in a TAC1-dependent manner at least in one out of the four clinical isolates 
tested by expression microarrays, strongly suggesting i) that these genes are direct 
transcriptional targets of Tac1p and ii) a role for Tac1p in lipid metabolism.  It has been 
shown that Rsb1p, the S. cerevisiae orthologue of C. albicans Rta3p, plays an essential 
role in the translocation of long-chain bases across the plasma membrane (143), 
suggesting a role for Rsb1p , and thus potentially Rta3p, in regulating the sphingolipid 
composition of the plasma membrane.  Interestingly, S. cerevisiae LCB4 encodes a major 
sphingolipid long-chain base kinase required for synthesis of long-chain base phosphates 
and for the rapid incorporation of long chain bases from the culture medium into 
sphingolipids (144).  We also found that orf19.3104, the orthologue of S. cerevisiae 
YDC1 encoding an alkaline dihydroceramidase, is up-regulated in a TAC1-dependent 
47 
 
manner in all four sets of clinical isolates (Table 2-4), although binding of Tac1p to the 
promoter of this gene was not detected.  Ydc1p hydrolyzes dihydroceramide to free fatty 
acid and dihydrosphingosine, the substrate of LCB4 (145).  Taken together, these findings 
suggest a role for Tac1p in the synthesis and translocation of sphingolipids into the 
plasma membrane. 
 
Likewise, C. albicans Cdr1p and Cdr2p have been shown to function as plasma 
membrane energy-dependent translocators of phospholipids, mediating their in-to-out 
movement (floppases) (146).  Thus, Cdr1p and Cdr2p would act in concert with Rta3p to 
establish the asymetry of membrane lipids in the plasma membrane.  Interestingly, Tac1p 
binds to the promoter of the S. cerevisiae AST1 homologue, orf19.6869 (AST2).  S. 
cerevisiae Ast1p was shown to be required for the raft association and restoration of 
surface delivery of a mutant of the major plasma membrane proton ATPase, Pma1p, that 
was mistargeted to the vacuole (147).  Elsewhere, it has been shown that Cdr1p is a lipid 
raft associated protein (148).  An attractive model would be that Tac1p contributes to the 
raft association and proper routing of its target gene-products Cdr1p, Cdr2p and Rta3p to 
the plasma membrane by regulating AST2 expression.  Recent studies have demonstrated 
that both sphingolipids and sterols are important determinants of surface localization of 
Cdr1p, as reduced membrane localization of Cdr1p was associated to increased 
susceptibility of C. albicans to ketoconazole in mutants defective in ergosterol 
biosynthesis (149).  Interestingly, we found that Tac1p binding was enriched at the ERG1 
(1.7 fold, P-value 0.0005) and ERG2 (1.6 fold, P-value 0.0011) promoters.  Moreover, 
ERG2 gene expression was significantly up-regulated in a TAC1-dependent manner in 
isolates C56, Gu5 and 17 (Table A-1), suggesting a role of Tac1p in ergosterol 
biosynthesis.  PDR16, another target of Tac1p, is the functional homologue of the S. 
cerevisiae PDR16, encoding a lipid transfer protein of the Sec14 family (102, 150).  S. 
cerevisiae Pdr16p was shown to localize to lipid particles and to transport 
phosphatidylinositol (151).  There is strong evidence showing that lipid transfer proteins 
exchange lipid molecules between organelle membranes and plasma membrane at 
membrane contact sites (152).  Thus, by controlling the expression of the PDR16 gene, 
Tac1p would act as a regulator of phosphatidylinositol transfer within membrane contact 
sites, further supporting the role of Tac1p in membrane lipid traffic.  
 
Consistent with the potential role of Tac1p in membrane lipid metabolism, we 
found that the Tac1p targets orf19.7166, orf19.6501 and orf19.1887 encode three putative 
steryl ester hydrolases or triglycerides lipases as i) a Pfam analysis detected an α/β 
hydrolase fold in their primary sequences (Pfam Entries PF04083.6 for orf19.7166 and 
PF00561 for orf19.1887 and orf19.6501), ii) their primary sequences contain the lipase 
consensus sequence motif GXSXG (153) and iii) Kyte-Doolittle hydropathy plots 
revealed hydrophobic regions in the primary sequences suggesting that these proteins are 
potentially membrane-anchored to lipid particles (data not shown).  Steryl esters and 
triacylglycerols are neutral lipids stored in lipid particles and serve as an energy source as 
well as a rapid fatty acid source needed upon lipid depletion conditions (154).  The 
orf19.1887 protein is highly homologous to S. cerevisiae Yeh1p, a steryl ester hydrolase 
localized to lipid particles (155, 156), whereas the orf19.7166 and orf19.6501 proteins 
display moderate homology to the products of the S. cerevisiae YGR110W and YJU3 
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genes.  Yju3p was shown to be localized in lipid particles as well (157, 158).  Another 
Tac1p target whose product was shown in S. cerevisiae to be localized in lipid particles is 
ATF1, encoding an alcohol acetyl transferase (159).  This gene was significantly up-
regulated in a TAC1-dependent manner in strain 5674 (Table A-1).  The fact that Atf1p 
localizes to lipid particles and functions in esterification process suggests that it is 
involved in the metabolism of lipids probably by transferring acetyl groups to free 
hydroxyl groups of fatty acids.  Thus, in addition to be a potential regulator of membrane 
lipid traffic, Tac1p appears to be an important regulator of lipid mobilization in C. 
albicans, a function needed for rapid restoration of membrane lipids upon lipid depletion 
conditions (154). 
 
Our studies identified two Tac1p target genes, GPX1 and SOD5, which have been 
shown to be involved in the oxidative stress response.  We provide strong evidence that 
Tac1p directly regulates the expression of GPX1, which is implicated in response to 
oxidative stress (160).  Interestingly, although the C. albicans genome encodes two other 
putative gluthatione peroxidases (encoded by orf19.85 and orf19.87) with high homology 
to Gpx1p, only Gpx1p was found to be overproduced upon treatments with diamide or 
hydrogen peroxide (160), suggesting that, among the three putative gluthatione 
peroxidases, GPX1 plays an important role in oxidative stress response.  It was also 
shown that S. cerevisiae GPX1 encodes a phospholipid hydroperoxide glutathione 
peroxidase which protects the cell against phospholipid hydroperoxides during oxidative 
stress (161).  
 
SOD5, a copper, zinc superoxide dismutase found in the cell wall of C. albicans, 
has been shown to be important in protection against osmotic and oxidative stress (162).  
Since SOD5 seems to play an important role in this process, it is interesting that the gene 
is in fact down-regulated in all four azole resistant clinical isolates studied.  Martchenko, 
et al. showed that while deleting SOD5 does not decrease cell viability, susceptibility to 
hydrogen peroxide under nutrient poor conditions is increased (162).  Indeed, we have 
previously shown that azole resistant isolate 5674, while resistant to diamide, is 
hypersusceptible to hydrogen peroxide (163).  While this hypersusceptibility to hydrogen 
peroxide could be explained by the down-regulation of SOD5, resistance to diamide 
could be attributed to the up-regulation of the CDR2 gene by Tac1p since CDR2 
expression was shown to confer diamide resistance in S. cerevisiae (163).  Taken together, 
these observations indicate that TAC1 differentially protects the cell against different 
oxidative stresses. 
CHAPTER 3: GAIN-OF-FUNCTION MUTATIONS IN MRR1 REGULATE THE 
EXPRESSION OF MDR1† 
 
 
INTRODUCTION 
 
Long term treatment of C. albicans with azoles results in the development of 
resistance over time (27, 29, 35, 43, 91, 95).  One mechanism of resistance occurs due to 
changes in ERG11, the gene that encodes the azole drug target lanosterol demethylase.  
Mutations that occur in ERG11 result in amino acid substitutions in Erg11p that decrease 
the binding affinity of the azoles (45).  Up-regulation of ERG11 confers resistance by 
increasing the amount of enzyme in the cell to bind azoles, requiring more drugs to be as 
efficacious (27, 91).  Another mechanism of resistance is the up-regulation of genes 
encoding efflux pumps.  CDR1 and CDR2 encode two ABC transporters that are 
responsible for resistance to azoles (28, 32, 35, 37, 38, 73).  Tac1p, a zinc cluster 
transcription factor, has been recently identified as the transcriptional regulator of CDR1 
and CDR2 (88, 89).  The up-regulation of MDR1 is also responsible for azole resistance. 
 
MDR1 encodes a MFS transporter that has been implicated in fluconazole 
resistance in C. albicans (35, 39, 43, 72).  MDR1 was first cloned for its ability to confer 
resistance to benomyl and methotrexate (41).  In clinical matched isolates, MDR1 
expression can only be detected in resistant isolates (34, 43).  Disruption of MDR1 in 
wild-type isolates shows no hypersusceptibility to fluconazole, most likely due to the lack 
of MDR1 expression in susceptible isolates (20, 36, 42).  Disruption of MDR1 in a 
resistant isolate decreased resistance to fluconazole (21).  The promoter region of MDR1 
from a susceptible clinical isolate fused to the reporter GFP was transformed into a 
resistant isolate, and fluorescence was detected pointing to a trans-regulatory element as 
the regulator of the efflux pump (72). 
 
The bZip transcription factor Cap1p has been implicated in the overexpression of 
MDR1 in response to benomyl (84).  The promoter region of MDR1 has been shown to 
have a YRE motif (85).  Sequential disruption of the promoter region of MDR1 in a 
resistant isolate showed that the absence of the YRE motif decreased the expression of 
MDR1, but the expression was not completely abolished (86).  The disruption of CAP1 
did not abolish MDR1 expression in response to benomyl (87).  This indicates that while 
Cap1p does bind to the promoter of MDR1, the bZip transcription factor is not 
responsible for azole resistance in clinical isolates. 
 
In this study, we examined three clinical matched isolates known to overexpress 
MDR1.  Using genome-wide expression profiling, we identified genes co-regulated with 
MDR1, including a zinc cluster transcription factor encoded by MRR1 as the regulator of 
MDR1 mediated azole resistance.  In collaboration with our group, the lab of Joachim 
Morschhäuser at the Universität Würzburg sequenced MRR1 and constructed the 
                                                 
† Morschhauser, J., K. S. Barker, T. T. Liu, B. W. J. Bla, R. Homayouni and P. D. Rogers. 2007. The 
transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance 
in Candida albicans. PLoS Pathog. 3: e164.  Adapted by permission of authors. 
50 
 
disruption and reintegrated mutants used in this study.  In addition, the Morschhäuser lab 
also performed the drug susceptibility tests that showed MRR1 as the regulator of drug 
induced MDR1 gene expression. 
 
 
MATERIALS AND METHODS 
 
 
Strains and Growth Conditions 
 
C. albicans strains used in this study are listed in Table 3-1.  All strains were 
stored as frozen stocks with 15% glycerol at -80°C.  The strains were routinely grown in 
YPD medium (10 g yeast extract, 20 g peptone, 20 g glucose per liter) at 30°C. 
 
 
DNA Microarray Analysis 
 
The nucleotide sequences corresponding to 6,165 open reading frames (ORFs) for 
C. albicans were downloaded from the Galar Fungail European Consortium (Assembly 
6, http://www.pasteur.fr/Galar_Fungail/CandidaDB/).  We set out to design two non-
overlapping probesets targeting the 3’- 600 bp region of each ORF. Each probeset 
consisted of 13 ‘prefect match’ 25-bp probes and their corresponding ‘mismatch’ control 
probes containing a single mismatch in the center of the oligonucleotide.  For ORFs less 
than 600 bp in length the sequence was divided in two equal segments for subsequent 
design procedures.  Optimum probesets were selected by the Affymetrix design team 
based on their model which, among other things, considers probe hybridization quality 
and cross-hybridization potential.  Consequently, in some cases, only one probeset was 
selected for a given ORF.  For quality control and normalization purposes, we made 2-3 
additional probe sets spanning the entire sequence of the C.  albicans 18S rRNA 
(GenBank Accession M60302), genes encoding GAPDH, actin and Mdr1p (Bmr1p) in 
addition to the standard Affymetrix controls (BioB, C, D, cre, DAP, PHE, LYS, THR).  
In the end, the GeneChip contained 10,736 probe sets including 9 controls, 6,123 unique 
ORFs and duplicate probe sets for 4,604 ORFs.  The duplicate probe sets are made to 
distinct regions of the ORF, thereby allowing 2 independent measurements of the mRNA 
level for that particular gene.  The C. albicans custom Affymetrix NimbleExpress Arrays 
(CAN04a530004N) were manufactured by NimbleGen Systems (105) per our 
specification. 
 
 
RNA Preparation for Microarrays 
 
The matched clinical isolate sets and strain SZY31 were grown in YPD broth at 
30°C in a shaking incubator to mid-log phase as described previously (108).  The cell 
pellets were frozen and stored at -80°C prior to RNA preparation.  Experiments were 
repeated independently three times.  Total RNA was isolated using the hot SDS-phenol  
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Table 3-1. C. albicans strains examined in this study. 
 
Strain Parent Relevant Characteristics or 
Genotype 
Reference 
SC5314  Wild-type C. albicans model strain (164) 
CAI4 SC5314 ura3Δ::imm434/ura3Δ::imm434 (18) 
F1  Fluconazole-susceptible (43) 
F2  Fluconazole-susceptible (43) 
F5  Fluconazole-resistant (43) 
G1  Fluconazole-susceptible (43) 
G2  Fluconazole-susceptible (43) 
G5  Fluconazole-resistant (43) 
5833  Fluconazole-susceptible (102) 
6692  Fluconazole-resistant (102) 
SCMRR1M4A SC5314 mrr1Δ::FRT/mrr1Δ::FRT this study 
SCMRR1M4B SC5314 mrr1Δ::FRT/mrr1Δ::FRT this study 
F5MRR1M4A F5 mrr1Δ::FRT/mrr1Δ::FRT this study 
F5MRR1M4B F5 mrr1Δ::FRT/mrr1Δ::FRT this study 
G5MRR1M4A G5 mrr1Δ::FRT/mrr1Δ::FRT this study 
G5MRR1M4B G5 mrr1Δ::FRT/mrr1Δ::FRT this study 
SCMRR1M4K2A SCMRR1M4A mrr1Δ /MRR1F2-1-caSAT1 this study 
SCMRR1M4K2B SCMRR1M4B mrr1Δ /MRR1F2-1-caSAT1 this study 
SCMRR1M4K3A SCMRR1M4A mrr1Δ /MRR1F5-caSAT1 this study 
SCMRR1M4K3B SCMRR1M4B mrr1Δ /MRR1F5-caSAT1 this study 
SCMRR1M4K4A SCMRR1M4A mrr1Δ/MRR1G2-2-caSAT1 this study 
SCMRR1M4K4B SCMRR1M4B mrr1Δ/MRR1G2-2-caSAT1 this study 
SCMRR1M4K5A SCMRR1M4A mrr1Δ/MRR1G5-caSAT1 this study 
SCMRR1M4K5B SCMRR1M4B mrr1Δ/MRR1G5-caSAT1 this study 
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method (109).  Frozen cell pellets were suspended in 12 ml of 50 mM sodium acetate (pH 
5.2), 10 mM EDTA at room temperature, after which 1 ml of 20% sodium dodecyl 
sulfate and 12 ml of acid phenol (Fisher Scientific, Waltham, MA) were added.  This 
mixture was incubated 10 min at 65°C with vortexing each minute, cooled on ice for 5 
min, and centrifuged for 15 min at 12,000 x g.  Supernatants were transferred to new 
tubes containing 15 ml of chloroform, mixed and centrifuged at 200 x g for 10 min.  The 
aqueous layer was removed to new tubes, RNA was precipitated with 1 volume 
isopropanol and 0.1 volume 2 M sodium acetate (pH 5.0), and then collected by 
centrifugation at 17,000 x g for 35 min at 4°C.  The RNA pellet was suspended in 10 ml 
of 70% ethanol, collected again by centrifugation, and suspended in nuclease free water. 
 
 
cRNA Synthesis and Labeling 
 
Immediately prior to cDNA synthesis, the purity and concentration of RNA 
samples were determined from A260/A280 readings and RNA integrity was determined by 
capillary electrophoresis using the RNA 6000 Nano Laboratory-on-a-Chip kit and 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) as per the manufacturer's 
instructions.  First and second strand cDNA was synthesized from 15 μg of total RNA 
using the SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen, Carlsbad, CA) 
and oligo-dT24-T7 primer (PrOligo: Sigma-Aldrich) according to the manufacturer's 
instructions.  cRNA was synthesized and labeled with biotinylated UTP and CTP by in 
vitro transcription using the T7 promoter-coupled double stranded cDNA as template and 
the Bioarray HighYield RNA Transcript Labeling Kit (ENZO Diagnostics, New York, 
NY).  Double-stranded cDNA synthesized from the previous steps was washed twice 
with 70% ethanol and suspended in 22 μl of RNase-free water.  The cDNA was incubated 
as recommended with reaction buffer, biotin-labeled ribonucleotides, dithtiothreitol, 
RNase inhibitor mix and T7 RNA polymerase for 5 h at 37°C.  The labeled cRNA was 
separated from unincorporated ribonucleotides by passing through a CHROMA SPIN-
100 column (Clontech, Mountain View, CA) and ethanol precipitated at −20°C overnight. 
 
 
Oligonucleotide Array Hybridization and Analysis 
 
The cRNA pellet was suspended in 10 μl of RNase-free water and 10 μg was 
fragmented by ion-mediated hydrolysis at 95°C for 35 min in 200 mM Tris-acetate 
(pH 8.1), 500 mM potassium acetate, 150 mM magnesium acetate.  The fragmented 
cRNA was hybridized for 16 h at 45°C to the C. albicans NimbleExpress GeneChip 
arrays.  Arrays were washed at 25°C with 6 × SSPE, 0.01% Tween 20 followed by a 
stringent wash at 50°C with 100 mM MES, 0.1 M NaCl, 0.01% Tween 20.  
Hybridizations and washes employed the Affymetrix Fluidics Station 450 using their 
standard EukGE-WS2v5 protocol.  The arrays were then stained with phycoerythrein-
conjugated streptavidin (Molecular Probes: Invitrogen) and the fluorescence intensities 
were determined using the GCS 3000 high-resolution confocal laser scanner (Affymetrix, 
Santa Clara, CA).  The scanned images were analyzed using software resident in 
GeneChip Operating System v2.0 (GCOS; Affymetrix).  Sample loading and variations 
53 
 
in staining were standardized by scaling the average of the fluorescent intensities of all 
genes on an array to a constant target intensity.  The signal intensity for each gene was 
calculated as the average intensity difference, represented by [Σ(PM – MM)/(number of 
probe pairs)], where PM and MM denote perfect-match and mismatch probes. 
 
 
Microarray Data Analysis 
 
The scaled gene expression values from GCOS software were imported into 
GeneSpring 7.2 software (Agilent Technologies) for preprocessing and data analysis.  
Probe sets were deleted from subsequent analysis if they were called absent by the 
Affymetrix criterion and displayed an absolute value below 20 in all experiments.  The 
expression value of each gene was normalized to the median expression of all genes in 
each chip as well as the median expression for that gene across all chips in the study.  
Pairwise comparison of gene expression was performed for each matched experiment.  
Among direct comparisons between matched clinical isolates genes were considered to 
be differentially expressed if their change in expression was ≥ 1.5-fold in three 
independent experiments. 
 
 
Quantitative Real-Time RT-PCR 
 
An aliquot of the RNA preparations from the samples used in the microarray 
experiments was saved for quantitative real-time reverse transcription (RT)-PCR follow-
up studies.  First-strand cDNAs were synthesized from 2 µg of total RNA in a 21-µl 
reaction volume using the SuperScript First-Strand Synthesis System for RT-PCR 
(Invitrogen) in accordance with the manufacturer's instructions.  Quantitative real-time 
PCRs were performed in triplicate using the 7000 Sequence Detection System (Applied 
Biosystems, Inc.: ABI, Foster City, CA).  Independent PCRs were performed using the 
same cDNA for both the gene of interest and the 18S rRNA, using the SYBR Green PCR 
Master Mix (Applied Biosystems, Inc.).  Gene-specific primers were designed for the 
gene of interest and the 18S rRNA using Primer Express software (Applied Biosystems, 
Inc.) and the Oligo Analysis & Plotting Tool (QIAGEN, Valencia, CA) and are shown 
in Table 3-2.  The PCR conditions consisted of AmpliTaq Gold activation at 95°C for 10 
min, followed by 40 cycles of denaturation at 95°C for 15 s and annealing/extension at 
60°C for 1 min.  A dissociation curve was generated at the end of each PCR cycle to 
verify that a single product was amplified using software provided with the 7000 
Sequence Detection System.  The change in fluorescence of SYBR Green I dye in every 
cycle was monitored by the system software, and the threshold cycle (CT) above the 
background for each reaction was calculated.  The CT value of 18S rRNA was subtracted 
from that of the gene of interest to obtain a ΔCT value.  The ΔCT value of an arbitrary 
calibrator (e.g., untreated sample) was subtracted from the ΔCT value of each sample to 
obtain a ΔΔCT value.  The gene expression level relative to the calibrator was expressed 
as 2–ΔΔCT.   
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Table 3-2. Primers used for quantitative real-time RT-PCR. 
 
Gene 
Name Primer Pairs
a Amplicon Size (bp) 
18S F, 5'-CACGACGGAGTTTCACAAGA-3' 135 
 R, 5'-CGATGGAAGTTTGAGGCAAT-3'  
MDR1 F, 5'-ACATAAATACTTTGCCCATCCAGAA-3' 82 
 R, 5'-AAGAGTTGGTTTGTAATCGGCTAAA-3'  
MRR1 F, 5'-AGTGAAGAAGCCCAACAGCAAA-3' 59 
 R, 5'-GACTGCGAACTTGTAAACGGC-3'  
 
a F: forward, R: reverse  
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RESULTS 
 
 
Transcription Factor MRR1 Is Coordinately Regulated with MDR1 in Resistant 
Clinical C. albicans Isolates 
 
In order to identify the genes coordinately regulated with MDR1, we examined 
three clinical matched isolates using genome-wide expression profiling (Table 3-1).  
Previous studies have shown that F1, G1, and 5833 (azole susceptible isolates) do not 
express baseline MDR1; F5, G5, and 6692 (azole resistant isolates) have been shown to 
overexpress MDR1 (43, 102).  Three independent RNA samples were hybridized to 
custom C. albicans Affymetrix microarrays.  Genes were considered to be differentially 
expressed if genes changes 1.5-fold in all three independent experiments.  Using these 
criteria, there were 111 genes up-regulated and 90 genes down-regulated in F5 compared 
to F1 (Table B-1 and Table B-2).  In G5 compared to G1, there were 194 genes up-
regulated and 184 genes down-regulated.  In 6692 compared to 5833, 66 genes were up-
regulated and 84 genes were down-regulated.  The core genes considered to be co-
regulated with MDR1 were the genes in common among all three clinical isolates.  There 
were the 21 genes up-regulated including the previously identified genes GRP2, IFD1, 
IFD4, IFD5, IFD7, and MDR1 (Figure 3-1).  There were also 7 genes that were down-
regulated among all three clinical matched isolates (Figure 3-1).  Interestingly, one gene 
encoding a zinc cluster transcription factor, orf19.7372 or IPF1266, was up-regulated in 
all three resistant clinical isolates.  This zinc cluster transcription factor gene was named 
multidrug resistance regulator, MRR1. 
 
This transcription factor gene was disrupted in the resistant isolates F5 and G5 by 
the Morschhäuser lab, and genome-wide expression profiling performed on the disruption 
mutants.  In the mrr1Δ mutant in F5, 123 genes were down-regulated in the absence of 
MRR1; in the G5mrr1Δ mutant, 94 genes were down-regulated (Table B-3).  There were 
28 genes commonly down-regulated in the absence of MRR1.  Of these genes, MDR1 was 
down-regulated as well as 13 other genes that were up-regulated in all three resistant 
clinical isolates (Table 3-3).  Unlike the disruption of CAP1, the disruption of MRR1 
abolished the expression of MDR1. 
 
 
Identification of Mrr1p Target Genes  
 
The Morschhäuser lab identified a P683S mutation in one allele of MRR1 in F5 
and a G997V mutation in one allele in G5.  In order to identify the genes directly under 
the control of the mutated Mrr1p, the wild-type MRR1 allele (MRR1F2-1 or MRR1G2-1) or 
the constitutively active mutant allele (MRR1F5 and MRR1G5) was reintegrated into 
SC5314 with MRR1 disrupted.  In the MRR1F5 allele compared to MRR1F2-1 allele in 
SC5314, 20 genes were up-regulated specifically due to the P683S (Table 3-4).  Of these 
20 genes, 16 genes were also up-regulated in the clinical matched isolates.  Of the genes 
that were up-regulated in resistant isolate F5 and up-regulated in SC5314 with MRR1F5,  
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Figure 3-1. Identification of genes that are differentially expressed in MDR1 
overexpressing clinical C. albicans isolates. 
(A, B) Venn diagrams showing the number of genes that are up-regulated (A) or down-
regulated (B) in the MDR1 overexpressing, drug-resistant isolates F5, G5, and 6692 as 
compared with their matched drug-susceptible isolates F1, G1, and 5833, respectively.  
(C) Heat map showing genes that are up-regulated (106) or down-regulated (105) in all 
three MDR1 overexpressing isolates.  Results are from three independent experiments 
(Exp. 1 to Exp. 3) for each comparison.  The genes are ordered according to their relative 
degree of up- and down-regulation, as indicated by the brightness of the red and green 
fields. 
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IFD6 
IFD5 
IFD7 
IFD1 
IFD4 
BMR1c 
IPF5987 
IPF7817 
IPF9538 
IPF17186 
IPF2186 
GRP2 
IPF7863 
IFD2 
MRR1 
IPF19538 
NDH2 
GPX1 
IPF1837 
IPF9887 
DUR1-2 
IPF2710.repeat2 
IPF9483 
SEO2 
IPF409 
RBT2 
FTR1 
IPF3634 
F5 vs F1 G5 vs G1 6692 vs 5833 
Exp . 1 Exp . 2 Exp . 3 Exp . 1 Exp . 2 Exp . 3 Exp . 1 Exp. 2 Exp. 3 
orf19.4476 
orf19.1048 
orf19.629 
orf19.1048 
orf19.4477 
orf19.5604 
orf19.7306 
orf19.3131 
orf19.271 
orf19.251 
orf19.7166 
orf19.4309 
orf19.1449 
orf19.771 
orf19.7372 
orf19.6957.3 
orf19.5713 
orf19.86 
orf19.5877 
orf19.1240 
orf19.780 
orf19.2159 
orf19.3395 
orf19.700 
orf19.7502 
orf19.1415 
orf19.7219 
orf19.6720 
F5 vs. F1
70
14 6
21
G5 6692
vs. 148 11 28 vs.
G1 5833
F5 vs. F1
56
18 9
7
G5 6692
vs. 140 19 49 vs.
G1 5833
A. B.
C. 
Table 3-3. Genes commonly down-regulated by MRR1 deletion in F5 and G5. 
 
Gene Namea 
orf19 
Numberb GO Annotation (Molecular Function)c F5Δmrr1 G5Δmrr1 
IPF9538 orf19.271 2,4-dienoyl-CoA reductase (NADPH) activity -282.4 -17.7 
MDR1 orf19.5604 Multidrug transporter activity -46.9 -126.3 
MRR1 orf19.7372 RNA polymerase II transcription factor 
activity 
-50.7 -44.7 
IFD6 orf19.4476 Aryl-alcohol dehydrogenase activity -30.3 -31.4 
IPF5987 orf19.7306 -- -7.4 -9.8 
IFD5 orf19.1048 Aryl-alcohol dehydrogenase activity -13.2 -4.0 
IPF17186 orf19.251 -- -9.2 -7.0 
IPF7863 orf19.1449 -- -11.8 -3.7 
IFD7 orf19.629 Aryl-alcohol dehydrogenase activity -6.7 -8.1 
HGT11 orf19.4527 Glucose transporter activity -5.1 -5.9 
HGT12 orf19.3668 Glucose transporter activity -3.3 -7.2 
IPF525 orf19.7085 -- -6.2 -2.4 
IPF2186 orf19.7166 -- -3.4 -4.9 
IFK3 orf19.857 -- -4.6 -3.0 
IPF19538 orf19.6957.3 -- -2.0 -5.4 
IPF7817 orf19.3131 NADPH dehydrogenase activity -4.4 -3.0 
IFD1 orf19.1048 Aryl-alcohol dehydrogenase activity -2.6 -4.6 
IFD4 orf19.4477 Aryl-alcohol dehydrogenase activity -2.9 -3.7 
AAF1 orf19.7436 -- -3.1 -3.4 
FRE30.53 orf19.6140 Ferric-chelate reductase activity -3.5 -2.8 
FRE30.3 orf19.6139 Ferric-chelate reductase activity -3.2 -2.9 
IFD2 orf19.771 Aryl-alcohol dehydrogenase activity -3.1 -2.8 
IPF1634 orf19.6578 Inorganic phosphate transporter activity -2.4 -3.3 
GRP2 orf19.4309 Oxidoreductase activity -1.9 -3.4 
ARD8 orf19.6322 2,4-dienoyl-CoA reductase (NADPH) activity -2.3 -2.3 
FRE7 orf19.7077 Ferric-chelate reductase activity -2.2 -2.2 
GAP6 orf19.6659 Amino acid permease activity -2.1 -1.7 
AKL1 orf19.5357 Protein serine/threonine kinase activity -1.7 -1.7 
 
a Gene name according to CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b orf19 nomenclature according to the Assembly 19 version. 
c Gene ontology (GO) terminology according to CGD (http://www.candidagenome.org/). 
Gene expression values are represented as fold changes between disruption strain and 
resistant parent isolate. 
Genes in bold are genes found to be up-regulated in all three clinical matched isolates. 
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Table 3-4. Identification of Mrr1p target genes in F isolates by DNA microarray analysis. 
Genes that were up-regulated by the P683S mutation in the SC5314 genetic background (MRR1F5 vs. MRR1F2-1).  The genes are 
ordered according to their average degree of up-regulation in four repeat experiments performed with two independent transformants 
(strains A and B).  The fold changes in the expression level of these genes in the drug-resistant clinical isolate F5 as compared with a 
matched susceptible isolate (F5 vs. F1) and in two independently constructed mrr1Δ mutants (strains A and B) as compared with their 
wild-type progenitor F5 (F5mrr1Δ vs. F5) are shown for comparison.  Up-regulated genes are highlighted in red, down-regulated 
genes are highlighted in green, and genes that were not differentially expressed are not highlighted in all pairwise comparisons. 
 
Gene 
Name 
orf19 
Number 
GO Annotation 
(Molecular Function) 
MRR1F5 vs. MRR1F2‐1  F5 vs. F1  F5mrr1Δ vs. F5 
Strain A  Strain B  Strain A  Strain B 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 3 Exp. 1 Exp. 2 Exp. 1 Exp. 2 
IFD6 orf19.4476 Aryl-alcohol 
dehydrogenase activity 
256.4 1121.8 284.7 1147.1 965.7 1290.0 3064.8 -31.2 -41.8 -27.0 -21.3 
IFD1 orf19.1048 Aryl-alcohol 
dehydrogenase activity 
130.7 179.8 100.4 72.1 76.2 200.7 141.5 -3.3 -2.1 -2.6 -2.6 
BMR1 orf19.5604 Multidrug transporter 
activity 
114.8 114.4 118.2 39.7 47.8 152.1 112.2 -21.4 -47.5 -35.0 -83.7 
IFD7 orf19.629 Aryl-alcohol 
dehydrogenase activity 
56.3 75.9 184.2 35.3 113.1 338.2 332.4 -10.5 -4.3 -5.8 -6.0 
IFD5 orf19.1048 Aryl-alcohol 
dehydrogenase activity 
64.8 116.6 84.5 50.4 140.8 361.9 144.3 -15.0 -12.2 -15.8 -9.6 
IFD4 orf19.4477 Aryl-alcohol 
dehydrogenase activity 
15.4 13.6 21.4 56.6 21.3 37.9 75.5 -2.7 -4.6 -2.4 -1.9 
IPF5987 orf19.7306 -- 19.6 19.3 28.3 27.6 48.6 49.5 63.3 -7.4 -6.4 -9.0 -6.9 
IPF9538 orf19.271 2,4-dienoyl-CoA 
reductase (NADPH) 
activity 
16.3 24.6 5.2 6.4 108.9 279.5 131.7 -164.3 -548.1 -280.0 -137.2 
IPF17186 orf19.251 -- 10.4 11.9 10.2 11.2 20.7 38.9 39.7 -10.9 -11.0 -8.7 -6.2 
GRP2 orf19.4309 Oxidoreductase activity 4.2 6.9 7.0 6.5 3.0 5.3 3.4 -2.1 -1.9 -1.8 -1.8 
IPF7863 orf19.1449 -- 3.5 3.8 3.6 3.4 6.1 9.4 9.1 -16.9 -6.9 -15.5 -8.0 
ALS10 orf19.2355 Cell adhesion molecule 
binding 
2.0 3.7 2.7 1.9 1.2 1.7 1.1 -14.0 -27.2 -1.6 -1.2 
IPF19538 orf19.6957.3 -- 3.2 2.5 1.8 2.6 2.2 1.7 6.0 -1.5 -2.0 -2.1 -2.1 
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Table 3-4 (continued). 
 
Gene 
Name 
orf19 
Number 
GO Annotation 
(Molecular Function) 
MRR1F5 vs. MRR1F2‐1  F5 vs. F1  F5mrr1Δ vs. F5 
Strain A  Strain B  Strain A  Strain B 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 3 Exp. 1 Exp. 2 Exp. 1 Exp. 2 
ALS3.5eoc orf19.1816 Cell adhesion molecule 
binding 
2.2 3.6 2.1 1.5 1.4 1.8 1.2 -43.4 -22.9 -1.6 -1.2 
IPF2130 orf19.7204 -- 2.0 2.7 2.4 1.6 1.8 1.8 -1.4 -2.8 1.2 -2.4 -1.5 
IPF7940 orf19.6608 -- 1.9 2.2 2.1 2.0 5.4 4.3 10.3 -2.2 -1.9 1.1 1.0 
IPF9377 orf19.1428 -- 2.2 1.6 1.5 2.8 1.2 1.5 -1.1 1.1 1.6 1.1 -4.0 
IPF7817 orf19.3131 NADPH dehydrogenase 
activity 
2.2 2.0 2.1 1.7 9.4 13.7 13.4 -3.8 -4.7 -5.5 -3.6 
DUR1,2 orf19.780 Allophanate hydrolase 
activity 
2.0 1.5 1.6 2.4 1.7 1.9 2.2 -2.2 1.8 -2.0 1.5 
IPF2186 orf19.7166 -- 1.5 2.0 1.9 2.0 3.0 6.0 7.3 -2.9 -3.5 -3.7 -3.4 
 
 
 
14 genes were down-regulated in the absence of both alleles of MRR1.  In the MRR1G5 
allele compare to MRR1G2-1 allele in SC5314, 27 genes were up-regulated specifically 
due to the G997V mutation (Table 3-5).  Of these 27 genes, 20 genes were up-regulated 
in resistant isolate G5.  Of these 20 genes, 15 genes were down-regulated in the absence 
of both MRR1 alleles.  MDR1 and MRR1 gene expression was confirmed with real-time 
RT-PCR (Figure 3-2).  Interestingly, 14 genes were up-regulated in all three clinical 
resistant isolate, up-regulated in both MRR1F5 and MRR1G5, and down-regulated in the 
Δmrr1 disruption mutants.  These genes are considered the core genes regulated by 
Mrr1p. 
 
 
DISCUSSION 
 
Increased drug efflux due to the overexpression of efflux pumps is a major 
mechanism of resistance in C. albicans.  The up-regulation of CDR1 and CDR2 results in 
resistance to azole antifungal agents.  Gain-of-function mutations in the gene encoding 
the zinc cluster transcription factor Tac1p was recently identified as the cause of 
CDR1/CDR2 overexpression (88, 89).  The expression of the MFS transporter MDR1 is 
another resistance mechanism found in azole resistant clinical isolates.  While the 
regulator of MDR1 was previously unknown, studies have shown that a trans-regulatory 
element was responsible for the up-regulation of MDR1 (72).  Previously, the bZip 
transcription factor Cap1p was identified as the possible transcriptional regulator of 
MDR1 (84).  The promoter region of genes co-regulated with MDR1 as well as the 
promoter region of MDR1 contained a YRE motif.  However, promoter deletion studies 
performed in azole resistant isolates showed that the deletion of the YRE motif did not 
abolish the up-regulation of MDR1 (21, 86).  This suggested that the transcriptional 
regulator of azole resistance was not limited to CAP1. 
 
Genome-wide expression profiling of clinical matched isolates overexpessing 
CDR1/CDR2 identified TAC1 as a gene co-regulated with the azole resistance genes.  
Using this technology, we examined three clinical matched isolates that overexpressed 
MDR1.  Of the genes found to be differentially expressed in all three resistant isolates, a 
gene encoding the zinc cluster transcription factor MRR1 was moderately up-regulated.  
The degree by which MRR1 contributes to azole resistance was studied by looking at 
gene expression profiles of MRR1 disruption mutants.  Unlike the CAP1 disruption 
mutants, the resistant strains without MRR1 could no longer express MDR1 along with 
the MDR1 co-regulated genes. 
 
Additionally, in collaboration with our group the Morschhäuser lab demonstrated 
that the MRR1 deletion mutants in resistant isolates were more susceptible to fluconazole, 
cerulenin, brefeldin A, and diamide.  They also showed that the gain-of-function 
mutation in MRR1 was required for constitutive MDR1 expression and resistance to 
fluconazole, cerulenin, brefeldin A, and diamide.  MRR1 was also required for the 
induction of MDR1 by benomyl and hydrogen peroxide.  In the absence of CAP1, 
benomyl could still induce MDR1 expression; without MRR1 there was no induction by 
benomyl.  This suggests that while Cap1p may play a role in MDR1 gene expression,
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Table 3-5. Identification of Mrr1p target genes in G isolates by DNA microarray analysis. 
Genes that were up-regulated by the G997V mutation in the SC5314 genetic background (MRR1G5 vs. MRR1G2-1).  The genes are 
ordered according to their average degree of up-regulation in four repeat experiments performed with two independent transformants 
(strains A and B).  The fold changes in the expression level of these genes in the drug-resistant clinical isolate G5 as compared with a 
matched susceptible isolate (G5 vs. G1) and in two independently constructed mrr1Δ mutants (strains A and B) as compared with their 
wild-type progenitor G5 (G5mrr1Δ vs. G5) are shown for comparison.  Up-regulated genes are highlighted in red, down-regulated 
genes are highlighted in green, and genes that were not differentially expressed are not highlighted in all pairwise comparisons. 
 
Gene 
Name 
orf19 
Number 
GO Annotation 
(Molecular Function) 
MRR1G5 vs. MRR1G2-1 G5 vs. G1 G5mrr1Δ vs. G5 
Strain A Strain B Strain A Strain B 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 3 Exp. 1 Exp. 2 Exp. 1 Exp. 2 
IFD6 orf19.4476 Aryl-alcohol 
dehydrogenase activity 
179.0 617.6 1559.4 1735.9 565.4 818.4 1916.6 -12.8 -22.1 -12.6 -78.1 
IPF9538 2,4-dienoyl-CoA 
reductase (NADPH) 
activity 
125.7 99.9 128.9 219.6 7.8 24.5 18.1 -15.3 -16.6 -25.5 -13.3 
IFD1 orf19.1048 Aryl-alcohol 
dehydrogenase activity 
135.0 123.5 175.1 139.4 151.6 195.9 299.8 -6.1 -5.2 -4.5 -2.9 
IFD7 orf19.629 Aryl-alcohol 
dehydrogenase activity 
112.0 134.5 131.9 91.9 55.2 66.8 139.0 -8.0 -8.2 -9.6 -6.5 
BMR1 orf19.5604 Multidrug transporter 
activity 
103.8 73.8 135.4 68.3 116.2 181.2 210.3 -168.9 -149.4 -143.0 -43.9 
IFD5 orf19.1048 Aryl-alcohol 
dehydrogenase activity 
59.6 82.9 92.6 141.5 137.7 155.8 201.1 -4.9 -4.2 -4.1 -2.7 
IFD4 orf19.4477 Aryl-alcohol 
dehydrogenase activity 
29.3 44.7 21.2 31.1 81.0 115.9 149.7 -4.0 -4.4 -3.4 -2.9 
IPF5987 orf19.7306 -- 30.9 24.3 22.0 32.7 41.5 50.1 81.4 -8.6 -12.5 -7.4 -10.5 
IPF17186 orf19.251 -- 15.4 12.8 14.4 13.1 9.2 14.8 14.6 -5.5 -9.5 -5.6 -7.4 
GRP2 orf19.4309 Oxidoreductase activity 6.1 5.7 5.1 7.4 4.9 6.1 5.5 -3.7 -3.7 -3.5 -2.9 
IPF7863 orf19.1449 -- 4.1 4.6 7.7 7.8 7.2 7.2 5.7 -2.9 -4.5 -3.0 -4.3 
IPF11694 orf19.4355 Nicotinamide 
mononucleotide 
permease activity 
2.0 4.9 3.7 10.2 -1.5 -1.1 1.1 -2.0 -3.2 1.7 1.4 
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Table 3-5 (continued). 
 
Gene 
Name 
orf19 
Number 
GO Annotation 
(Molecular Function) 
MRR1G5 vs. MRR1G2-1 G5 vs. G1 G5mrr1Δ vs. G5 
Strain A Strain B Strain A Strain B 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 3 Exp. 1 Exp. 2 Exp. 1 Exp. 2 
IPF19538 orf19.6957.3 -- 3.4 4.6 5.1 5.2 8.5 4.4 2.3 -7.6 -6.8 -4.1 -3.1 
IPF2130 orf19.7204 -- 3.1 3.0 2.2 7.9 17.2 37.0 15.2 -2.1 -4.4 -1.5 -3.6 
IPF7940 orf19.6608 -- 5.5 2.3 1.6 3.9 4.3 5.2 20.2 -1.2 -1.9 -1.2 -4.9 
HST2 orf19.2580 NAD-dependent 
histone deacetylase 
activity 
1.7 2.0 2.8 3.7 1.4 1.1 1.5 -2.0 -1.2 -2.1 1.1 
DUR1,2 orf19.780 Allophanate 
hydrolase activity 
2.2 3.4 1.6 3.0 2.1 4.0 2.6 1.5 -1.2 1.9 -1.0 
ALS10 orf19.2355 Cell adhesion 
molecule binding 
2.1 3.4 1.9 2.5 -1.6 -2.0 -2.0 -1.5 -1.8 -1.6 1.7 
IPF2965 orf19.4287 (R,R)-butanediol 
dehydrogenase 
activity 
2.4 2.1 1.6 3.4 -1.0 2.1 1.7 4.4 1.1 3.5 1.5 
IPF2186 orf19.7166 -- 1.9 1.8 3.0 2.9 14.0 15.8 11.7 -7.0 -5.1 -4.8 -2.7 
IPF8976 orf19.1369 -- 2.2 1.6 1.5 4.1 6.2 7.3 4.0 1.3 -1.2 -1.4 -1.8 
ALS3.3eoc orf19.2355 Cell adhesion 
molecule binding 
2.1 2.9 1.8 2.3 -1.4 -1.5 -1.6 -1.7 -2.0 -1.6 1.6 
IPF7817 orf19.3131 NADPH 
dehydrogenase 
activity 
2.1 1.6 3.4 1.7 7.7 11.0 8.2 -3.6 -2.8 -3.3 -2.1 
ALS3.5eoc orf19.1816 Cell adhesion 
molecule binding 
2.0 2.8 2.0 2.0 -1.1 -1.3 -4.9 -2.0 -1.0 -2.0 2.1 
GBA1 orf19.4015 GTPase activity 1.6 1.6 1.5 3.5 41.8 21.8 20.5 -1.1 -1.2 -1.1 1.4 
PDC12 orf19.4608 Pyruvate 
decarboxylase 
activity 
1.6 1.6 1.8 2.3 1.6 -1.5 1.2 -1.7 -1.4 -4.8 -2.4 
IPF7456 orf19.2047 -- 1.8 1.7 1.5 2.1 1.6 2.1 1.7 1.6 -1.3 2.4 1.1 
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Figure 3-2. Quantitative real-time PCR analysis of MDR1 and MRR1. 
(A) Expression of MDR1 in the clinical resistant isolates F5, G5, and 6922.  (B) Expression of MRR1 in clinical resistant isolates F5, 
F5, and 6922.  (C) Expression of MDR1 in resistant isolate F5 and G5 as well as SC5314 with either P683S or G997V mutant alleles.  
(D) Expression of MRR1 in resistant isolate F5 and G5 as well as SC5314 with either P683S or G997V mutant alleles.  Error bars 
represent standard errors (n=3).
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MRR1 is more essential to the regulation of MDR1 and azole resistance. 
 
Examination of the gene expression profiles of the resistant isolates, the 
disruption mutants, and the MRR1 gain-of-function alleles reintegrated in a wild-type 
isolates revealed a core group of 14 genes whose expression depend on MRR1.  Of the 14 
co-regulated genes, six genes have been implicated in the catalysis of an oxidation-
reduction (redox) reaction.  IPF7817 has been shown to be important in the response to 
oxidative stress.  This gene has been shown to be up-regulated in response to hydrogen 
peroxide in a CAP1 dependent manner (164).  GRP2 is another gene that seems to play a 
role in oxidative stress response.  The expression of GRP2 has been shown to be induced 
by hydrogen peroxide and benomyl (122, 165).  A YRE motif has also been identified in 
the promoter region of GRP2 (122).  In S. cerevisiae, GRP2 is homologous to ScGRE2 a 
gene that encodes a stress-induced NADH-dependent methylglyoxal reductase.  In S. 
cerevisiae, ScGRE2 is regulated by the zinc cluster transcription factor Pdr1p.  The IFD 
family of genes has also been implicated in oxidative stress.  In the presence of hydrogen 
peroxide or benomyl, the IFD family of genes is up-regulated (122, 165).  The S. 
cerevisiae homolog YPL088w is regulated by the two zinc cluster transcription factors 
Yrr1p and Yrm1p (166).  Because a large portion of the MRR1 core genes respond to 
oxidative stress, MRR1 may play a role in oxidative stress response.  Because these 
oxidoreductase genes also have YRE motifs in their promoter regions, it is possible that 
MRR1 and CAP1 function in conjunction to respond to oxidative stresses. 
  
67 
 
CHAPTER 4: GAIN-OF-FUNCTION MUTATIONS IN UPC2 REGULATE THE 
EXPRESSION OF ERGOSTEROL BIOSYNTHESIS GENES AND IMPART 
FLUCONAZOLE RESISTANCE IN A CLINICAL ISOLATE OF CANDIDA ALBICANS 
 
 
INTRODUCTION 
 
The azole antifungals bind to and inhibit the activity of lanosterol demethylase (Erg11p), 
a key enzyme in the ergosterol biosynthesis pathway (167).  Mechanisms of resistance to the 
azole antifungal agents that have been described for C. albicans include increased expression of 
the gene encoding the MFS transporter Mdr1p and genes encoding two ABC transporters, Cdr1p 
and Cdr2p (29, 35, 43, 95, 168).  Other mechanisms of resistance involve the ERG11 gene itself. 
Mutations in ERG11 that interfere with the ability of the azole to bind to its target can confer 
resistance.  Furthermore, overexpression of ERG11 leads to increased production of lanosterol 
demethylase, which can also result in azole resistance (27, 35, 43, 169, 170, 171). 
 
Constitutive overexpression of CDR1 and CDR2 in azole-resistant clinical isolates has 
been shown to be due to gain-of-function mutations in the zinc cluster transcription factor Tac1p 
and loss of heterozygosity at the TAC1 locus (88, 89).  Recently, similar mutations and loss of 
heterozygosity in the zinc cluster transcription factor Mrr1p was demonstrated to cause 
constitutive overexpression of MDR1 in fluconazole resistant clinical isolates (172).  The 
comparison of gene expression in matched fluconazole-susceptible and -resistant isolates has 
proved a powerful tool to identify resistance mechanisms of clinical C. albicans isolates.  Such 
studies initially pointed to the involvement of efflux pump overexpression as well as ERG11 
overexpression in fluconazole-resistant strains (29, 35).  More recently, genome-wide 
transcriptional profiling experiments using DNA microarrays have revealed additional alterations 
that might be involved in the development of drug resistance (48, 173, 174).  This approach has 
led to the identification of the transcription factor Mrr1p, which controls expression of the MDR1 
efflux pump (172). 
 
In the present study we performed genome-wide gene expression profiling of a matched 
pair of azole-susceptible and -resistant isolates from a series in which no overexpression of 
CDR1/CDR2 or MDR1 in resistant isolates was detected by Northern hybridization in a previous 
study (95).  We observed up-regulation of the gene encoding Upc2p as well as known target 
genes of this transcription factor.  In collaboration with our group, the Morschhäuser lab 
sequenced the UPC2 genes and described a gain-of-function mutation in UPC2.  They also 
created the disruption and reintegrated UPC2 mutants used in the study.  In addition, we show 
for the first time that a gain-of-function mutation in UPC2 leads to increased expression of 
ERG11. 
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MATERIALS AND METHODS 
 
 
Strains and Growth Conditions 
 
C. albicans strains used in this study are listed in Table 4-1.  All strains were stored as 
frozen stocks with 15% glycerol at -80°C and subcultured on YPD agar plates (10 g yeast extract, 
20 g peptone, 20 g glucose, 15 g agar per liter) at 30°C.  For routine growth of the strains YPD 
liquid medium was used. 
 
 
Construction of C. albicans Affymetrix® Expression Arrays 
 
We developed a new Affymetrix custom expression array (CAN07, 49-5241 array format 
with 11 micron features) for C. Albicans.  The nucleotide sequences corresponding to 6,165 open 
reading frames (ORFs) for C. albicans were downloaded from the Galar Fungail European 
Consortium (Assembly 6, http://www.pasteur.fr/Galar_Fungail/CandidaDB). We planned to 
design two separate probe sets for each ORF, each consisting of 11 perfect match and 11 
mismatch overlapping 25 bp oligonucleotides, to the 3’ 600 bp region. For ORFs less than 
600 bp in length the sequence was divided in two equal segments for subsequent design 
procedures. For quality control and normalization purposes, we made additional control 
probesets corresponding to GAPDH (1 probeset), actin (1 probeset) and the 5’ and middle region 
of Mdr1p (Bmr1p) transcript in addition to the standard Affymetrix controls (BioB, C, D, cre, 
DAP, PHE, LYS, THR). The probe selection was performed by the Chip Design group at 
Affymetrix, Inc. using their proprietary algorithm to calculate probe set scores, which includes a 
probe quality metric, cross-hybridization penalty and gap penalty. The probe sets were then 
examined for cross-hybridization against all other sequences in the C. albicans genome as well 
as a number of constitutively expressed genes and rRNA from other common organisms. 
Consequently, for some target regions we were not able to design high quality probe sets. In the 
end, the GeneChip contained 10,014 probesets, corresponding to 5,806 unique ORFs. Two 
probes were represented for 4,208 ORFs, allowing 2 independent measurements of the mRNA 
level for that particular gene. 
 
 
RNA Preparation for Microarrays 
 
Total RNA was isolated using the hot SDS-phenol method (175).  Frozen cells were 
suspended in 12 ml of 50 mM sodium acetate (pH 5.2), 10 mM EDTA at room temperature, after 
which 1 ml of 20% sodium dodecyl sulphate and 12 ml of acid phenol (Fisher Scientific) were 
added.  This mixture was incubated 10 min at 65 °C with mixing each minute, cooled on ice for 
5 min, and centrifuged for 15 min at 12,000g.  Supernatants were transferred to new tubes 
containing 15 ml of chloroform, mixed, and centrifuged at 200g for 10 min.  The aqueous layer 
was removed to new tubes, RNA was precipitated with 1 volume isopropanol and 0.1 volume 2 
M sodium acetate (pH 5.0), and then collected by centrifugation at 17,000g for 35 min at 4 °C.  
The RNA pellet was suspended in 10 ml of 70% ethanol, collected again by centrifugation, and 
suspended in nuclease-free water. 
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Table 4-1. C. albicans strains used in this study. 
 
Strain Parent Relevant characteristics or genotype Reference 
S1  Susceptible isolate from patient S (95) 
S2  Resistant isolate from patient S (95) 
SC5314  Wild-type C. albicans model strain (176) 
UPC2M1A SC5314 upc2-1Δ::SAT1-FLIP a/UPC2-2 this study 
UPC2M1B SC5314 UPC2-1/upc2-2Δ::SAT1-FLIP this study 
UPC2M2A UPC2M1A upc2-1Δ::FRT/UPC2-2 this study 
UPC2M2B UPC2M1B UPC2-1/upc2-2Δ::FRT this study 
UPC2M3A UPC2M2A upc2-1Δ::FRT/upc2-2Δ::SAT1-FLIP this study 
UPC2M3B UPC2M2B upc2-1Δ::SAT1-FLIP/ upc2-2Δ::FRT this study 
UPC2M4A UPC2M3A upc2-1Δ::FRT/upc2-2Δ::FRT this study 
UPC2M4B UPC2M3B upc2-1Δ::FRT/ upc2-2Δ::FRT this study 
UPC2M2K21A UPC2M2A upc2-1Δ::FRT/UPC2S1-1-caSAT1 this study 
UPC2M2K21B UPC2M2B UPC2-1S1-1-caSAT1/upc2-2Δ::FRT this study 
UPC2M2K22A UPC2M2A UPC2-1S1-1-caSAT1/UPC2-2 this study 
UPC2M2K22B UPC2M2B UPC2-1/UPC2S1-1-caSAT1 this study 
UPC2M2K31A UPC2M2A upc2-1Δ::FRT/UPC2S2-1-caSAT1 this study 
UPC2M2K31B UPC2M2B UPC2-1S2-1-caSAT1/upc2-2Δ::FRT this study 
UPC2M2K32A UPC2M2A UPC2-1S2-1-caSAT1/UPC2-2 this study 
UPC2M2K32B UPC2M2B UPC2-1/UPC2S2-1-caSAT1 this study 
 
a SAT1-FLIP denotes the SAT1 flipper cassette. 
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cRNA Synthesis and Labeling 
 
Immediately prior to cDNA synthesis, the purity and concentration of RNA samples were 
determined from A260/A280 readings, and RNA integrity was determined by capillary 
electrophoresis using the RNA 6000 Nano Laboratory-on-a-Chip kit and Bioanalyzer 2100 
(Agilent Technologies) as per the manufacturer's instructions.  First and second strand cDNA 
was synthesized from 15 μg total RNA using the SuperScript Double-Stranded cDNA Synthesis 
Kit (Invitrogen) and oligo-dT24-T7 primer (PrOligo) according to the manufacturer's 
instructions.  cRNA was synthesized and labeled with biotinylated UTP and CTP by in vitro 
transcription using the T7 promoter-coupled double-stranded cDNA as template and the Bioarray 
HighYield RNA Transcript Labeling Kit (ENZO Diagnostics).  Double-stranded cDNA 
synthesized from the previous steps was washed twice with 70% ethanol and suspended in 22 μl 
of RNase-free water.  The cDNA was incubated as recommended with reaction buffer, biotin-
labeled ribonucleotides, dithtiothreitol, RNase inhibitor mix, and T7 RNA polymerase for 5 h at 
37 °C.  The labeled cRNA was separated from unincorporated ribonucleotides by passing 
through a CHROMA SPIN-100 column (Clontech) and ethanol precipitated at −20 °C overnight. 
 
 
Oligonucleotide Array Hybridization and Analysis 
 
The cRNA pellet was suspended in 10 μl of RNase-free water and 10 μg was fragmented 
by ion-mediated hydrolysis at 95 °C for 35 min in 200 mM Tris-acetate (pH 8.1), 500 mM 
potassium acetate, 150 mM magnesium acetate.  The fragmented cRNA was hybridized for 16 h 
at 45 °C to the C. albicans NimbleExpress GeneChip arrays.  Arrays were washed at 25 °C with 
6 × SSPE, 0.01% Tween 20 followed by a stringent wash at 50 °C with 100 mM MES, 0.1 M 
NaCl, 0.01% Tween 20.  Hybridizations and washes employed the Affymetrix Fluidics Station 
450 using their standard EukGE-WS2v5 protocol.  The arrays were then stained with 
phycoerythrein-conjugated streptavidin (Molecular Probes) and the fluorescence intensities were 
determined using the GCS 3000 high-resolution confocal laser scanner (Affymetrix).  The 
scanned images were analyzed using software resident in GeneChip Operating System v2.0 
(Affymetrix).  Sample loading and variations in staining were standardized by scaling the 
average of the fluorescent intensities of all genes on an array to a constant target intensity (250).  
The signal intensity for each gene was calculated as the average intensity difference, represented 
by [Σ(PM − MM)/(number of probe pairs)], where PM and MM denote perfect-match and 
mismatch probes. 
 
 
Microarray Data Analysis 
 
The scaled gene expression values from GeneChip Operating System v2.0 software were 
generated using the MAS5.0 algorithm.  The value of each probe set is generated using a Tukey 
Biweight computation.  The algorithm considers the contribution of each match and mismatch 
probe corrected for the background of the average of the probe set.  A weighted mean is then 
calculated for each probe pair.  The raw signal values are then log2 transformed and the array 
normalized to this value.  Probe sets were deleted from subsequent analysis if they were called 
absent by the Affymetrix criterion.  Pairwise comparison of gene expression was performed for 
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each matched experiment.  Among direct comparisons between matched clinical isolates, genes 
were considered to be differentially expressed if their change in expression was 1.5-fold in three 
independent experiments. 
 
 
Quantitative Real-Time PCR 
 
An aliquot of the RNA preparations from the samples used in the microarray experiments 
was saved for quantitative real-time RT-PCR follow-up studies.  First-strand cDNAs were 
synthesized from 2 μg of total RNA in a 21-μl reaction volume using the SuperScript First-
Strand Synthesis System for RT-PCR (Invitrogen) in accordance with the manufacturer's 
instructions.  Quantitative real-time PCRs were performed in triplicate using the 7000 Sequence 
Detection System (Applied Biosystems).  Independent PCRs were performed using the same 
cDNA for both the gene of interest and the 18S rRNA, using the SYBR Green PCR Master Mix 
(Applied Biosystems).  Gene-specific primers were designed for the gene of interest and the 18S 
rRNA using Primer Express software (Applied Biosystems) and the Oligo Analysis & Plotting 
Tool (QIAGEN) and are shown in Table 4-2.  The PCR conditions consisted of AmpliTaq Gold 
activation at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 15 s and 
annealing/extension at 60 °C for 1 min.  A dissociation curve was generated at the end of each 
PCR cycle to verify that a single product was amplified using software provided with the 7000 
Sequence Detection System.  The change in fluorescence of SYBR Green I dye in every cycle 
was monitored by the system software, and the threshold cycle (CT) above the background for 
each reaction was calculated.  The CT value of 18S rRNA was subtracted from that of the gene of 
interest to obtain a ΔCT value.  The ΔCT value of an arbitrary calibrator (e.g., untreated sample) 
was subtracted from the ΔCT value of each sample to obtain a ΔΔCT value.  The gene expression 
level relative to the calibrator was expressed as 2−ΔΔCT. 
 
 
Bioinformatics Analysis 
 
The promoter sequences (1kb upstream of the start codon) were downloaded from the 
Candida Genome Database (http://www.candidagenome.org).  Using the fuzznuc application 
from EMBOSS (http://emboss.bioinformatics.nl), the promoter sequences were examined for 
putative SRE motifs. 
 
 
RESULTS 
 
 
Expression of the Transcription Factor UPC2 Is Coordinately Up-Regulated with ERG11 
in Azole Resistant C. albicans Clinical Isolate S2 
 
The C. albicans isolates S1 (fluconazole-susceptible) and S2 (fluconazole-resistant) were 
recovered from an AIDS patient who failed fluconazole therapy for treatment of oropharyngeal 
candidiasis and are the first two isolates of a series in which no overexpression of the transporter 
genes CDR1/CDR2 and MDR1 was detected by Northern hybridization (95).  In order to identify 
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Table 4-2. Primers used for quantitative real-time PCR analysis. 
 
Gene 
Name Primer Paira 
Amplicon 
Size 
18S F, 5'-CACGACGGAGTTTCACAAGA-3' 135 
 R, 5'-CGATGGAAGTTTGAGGCAAT-3'  
CDR1 F, 5'-ATTCTAAGATGTCGTCGCAAGATG-3' 140 
 R, 5'-AGTTCTGGCTAAATTCTGAATGTTTTC-3'  
CDR2 F, 5'-TAGTCCATTCAACGGCAACATT-3' 76 
 R, 5'-CACCCAGTATTTGGCATTGAAA-3'  
MDR1 F, 5'-ACATAAATACTTTGCCCATCCAGAA-3' 82 
 R, 5'-AAGAGTTGGTTTGTAATCGGCTAAA-3'  
ERG11 F, 5'-TTTAGTTTCTCCAGGTTATGCTCAT-3' 100 
 R, 5'-ATTAGCTTTGGCAGCAGCAGTA-3'  
UPC2 F, 5'-TCCATCCTTGACCCCTAGTCCT-3' 52 
  R, 5'-CGGCTGAGTTTTGATGTCTTGA-3'   
 
a F: forward, R: reverse  
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genes that are differentially expressed between these two isolates we compared their 
transcriptional profiles using DNA microarrays.  As can be seen in Table C-1 and Table C-2, 138 
genes were up-regulated and 173 genes were down-regulated in isolate S2 as compared with S1.  
Interestingly, among the up-regulated genes were several that are involved in ergosterol 
biosynthesis (ERG1, ERG3, ERG4, ERG7, ERG24, ERG26, ERG27, POT14, and NCP1) as well 
as UPC2, which encodes a transcription factor that controls expression of ergosterol biosynthesis 
genes and induces their expression in the presence of azoles (82, 90, 177).  ERG11, the gene 
encoding the target of fluconazole, was not found to be differentially expressed between these 
isolates by microarray analysis.  However, real-time RT-PCR analysis revealed increased 
expression of ERG11 in isolate S2 (Figure 4-1). 
 
 
Resistant Isolate S2 Contains a Gain-of-Function Mutation in UPC2 
 
In collaboration with our group, the Morschhäuser lab sequenced the UPC2 alleles in 
both the resistant isolate S2 and the susceptible isolate S1.  Two different alleles were found in 
isolate S1.  Allele one was found to be similar to the UPC2 allele in the wild-type genome strain 
SC5314; allele two had several mutations, four of which resulted in amino acid substitutions 
(R68K, I142S, S190N, S228N).  Isolate S2 contained the same alleles as S1, with the exception 
of a G1943A mutation in allele one.  This mutation resulted in a G648D amino acid substitution 
in Upc2p.  UPC2 was then disrupted in the wild-type isolate SC5314, and one copy of either 
wild-type allele one from S1 or gain-of-function mutant allele one from S2 was reintegrated into 
the disruption strain. 
 
These mutants in the wild-type background were then exposed to the ergosterol 
biosynthesis inhibitors fluconazole and terbinafine.  In the absence of one or both alleles UPC2, 
the strains were hypersusceptible to fluconazole and terbinafine (Figure 4-2).  In the presence of 
the gain-of-function allele, the strain because resistant to fluconazole and terbinafine.  When the 
wild-type allele was reintegrated into the upc2Δ strain, the strain exhibited hypersusceptibility to 
fluconazole similar to the UPC2 heterozygous disruption strain.  In the strain with the wild-type 
allele reintegrated into a heterozygous UPC2 disruption strain, fluconazole susceptibility 
returned to the levels found in SC5314. 
 
 
Identification of UPC2 Target Genes 
 
In order to identify target genes of Upc2p, we compared the gene expression profiles of 
strains expressing either a wild-type UPC2 allele (UPC2S1-1) or its constitutively active, mutated 
counterpart (UPC2S2-1) in the SC5314 background. As shown in Table C-1, 93 genes were 
consistently up-regulated in the transformants expressing the UPC2S2-1 allele. Thirty two of these 
were also up-regulated in azole-resistant isolate S2 as compared to isolate S1 (Table 4-3). Sixty-
six genes were consistently downregulated in the transformants expressing the UPC2S2-1 allele. 
Of these, only eleven were also downregulated in isolate S2 (Table 4-4). These represent the core 
set of Upc2p target genes.  Among these, 18 genes contained at least one SRE motif within their 
promoters (Table 4-5). 
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Figure 4-1. Quantitative real-time PCR for genes of interest. 
Genes differentially expressed in clinical matched isolate (S2 vs. S1) and two strains with the 
UPC2S2-1 or UPC2S1-1 allele in SC5314.  Asterisks denote statistical significance by t-test (p-
value≤0.05).  Error bars represent standard error (n=3). 
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Figure 4-2. Susceptibilities to fluconazole and terbinafine of wild-type and gain-of-
function mutant UPC2 strains by spot assay. 
All strains were in the SC5314 background.  Serial 10-fold dilutions of YPD overnight cultures 
of the strains were spotted on YPD plates without or with 2 µg ml-1 fluconazole or 2 µg ml-1 
terbinafine and incubated for 2 days at 30°C. 
 
Table 4-3. Genes up-regulated by the G648D mutation in Upc2p. 
 
CandidaDB 
Namea 
Common 
Nameb 
orf19 
Numberc 
GO Annotation (Molecular 
Function)d 
S2 vs. S1 
UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 1 Exp. 2 
BMR1 MDR1 orf19.5604 Multidrug transporter activity 2.1 3.7 5.4 3.5 2.5 5.1 
DDR48 DDR48 orf19.4082 -- 7.1 8.0 2.4 3.4 2.4 3.8 
ECM3 ECM3 orf19.1563 -- 1.6 1.5 1.7 4.1 2.9 3.2 
ERG1 ERG1 orf19.406 Squalene monooxygenase activity 2.4 1.6 1.5 1.7 1.6 1.8 
ERG24 ERG24 orf19.1598 Delta 14-sterol reductase activity 2.3 2.0 3.2 2.9 3.5 2.9 
ERG26 ERG26 orf19.2909 C-3 sterol dehydrogenase (C-4 sterol 
decarboxylase) activity 
2.0 1.6 2.0 2.0 1.9 2.0 
ERG27 ERG27 orf19.3240 3-keto sterol reductase activity 2.3 2.1 2.2 3.6 3.0 2.8 
FEN2 -- orf19.5535 Pantothenate transporter activity 2.2 2.2 2.3 2.7 2.7 2.8 
FTH1 FTH1 orf19.4802 -- 1.5 1.5 1.8 4.3 2.4 3.7 
IDP2 IDP2 orf19.3733 Isocitrate dehydrogenase (NADP+) 
activity 
3.6 2.1 1.8 1.6 1.8 1.7 
IFA24.3 FGR51 orf19.156 -- 1.8 1.9 1.7 1.7 1.6 1.7 
NCP1 NCP1 orf19.2672 NADPH-hemoprotein reductase 
activity 
2.5 1.5 1.9 2.2 1.7 1.8 
QRI8 -- orf19.7329 Ubiquitin-protein ligase activity 1.5 2.0 1.6 1.7 1.5 1.7 
TEF41 TEF4 orf19.2652 Translation elongation factor activity 4.1 3.4 18.8 28.9 19.0 14.9 
IPF12101 PGA7 orf19.5635 -- 1.6 2.7 5.4 8.8 6.0 9.0 
IPF1218 SOD4 orf19.2062 Copper, zinc superoxide dismutase 
activity 
2.3 2.3 2.2 1.7 1.8 1.6 
IPF14119 DAG7 orf19.4688 -- 1.8 1.6 1.7 1.6 1.7 1.8 
IPF14652 -- orf19.2653 -- 4.3 1.6 1.7 2.8 4.3 1.9 
IPF18080 -- orf19.7357 -- 1.9 1.6 1.5 1.8 1.6 1.6 
IPF20010 -- orf19.5799 -- 2.0 2.2 2.2 2.8 1.6 2.0 
IPF20169 PGA10 orf19.5674 Heme binding 4.1 10.8 5.6 13.0 7.0 11.1 
IPF2903 -- orf19.7456 -- 1.8 2.3 2.0 1.7 2.2 1.6 
IPF3352 -- orf19.4013 -- 2.3 2.3 2.0 2.5 1.9 2.0 
IPF4059 -- orf19.1865 -- 1.6 2.1 2.7 2.5 1.9 2.4 
IPF4721 -- orf19.3737 -- 1.5 1.6 2.3 1.5 1.8 1.6 
IPF6298 -- orf19.1964 -- 3.0 1.6 1.7 1.7 2.3 1.7 
IPF6518 -- orf19.1691 -- 3.3 5.3 1.7 2.3 2.0 2.7 
IPF7289 UPC2 orf19.391 Transcription factor activity 1.6 2.4 2.1 2.5 2.4 2.5 
IPF7397 -- orf19.1800 -- 2.9 2.6 1.8 1.7 1.6 2.2 
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Table 4-3 (continued). 
 
CandidaDB 
Namea 
Common 
Nameb 
orf19 
Numberc 
GO Annotation (Molecular 
Function)d 
S2 vs. S1 
UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 1 Exp. 2 
IPF7432 -- orf19.6219 -- 2.0 2.3 1.9 2.4 2.1 2.2 
IPF867 SET3 orf19.7221 NAD-dependent histone deacetylase 
activity 
2.1 1.7 3.6 2.9 3.2 2.4 
IPF8970 -- orf19.496 -- 1.9 2.5 2.2 1.9 1.6 1.8 
 
a Gene name from CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b Gene name from CGD (http://www.candidagenome.org/). 
c orf19 nomenclature according to Assembly 19. 
d Gene Ontology (33) annotation found at CGD (http://www.candidagenome.org/). 
Gene expression values are represented as fold changes between resistant isolates and susceptible isolates. 
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Table 4-4. Genes down-regulated by the G648D mutation in Upc2p. 
 
CandidaDB 
Namea 
Common 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2 vs. S1 
UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 1 Exp. 2 
COQ1 -- orf19.7478 Trans-hexaprenyltranstransferase activity -2.8 -2.9 -1.5 -2.5 -2.4 -3.8 
MAS2 -- orf19.6295 Mitochondrial processing peptidase 
activity 
-1.6 -1.7 -1.6 -2.3 -2.7 -2.9 
MET14 MET14 orf19.946 Adenylylsulfate kinase activity -5.6 -6.9 -2.3 -2.9 -3.5 -3.7 
MET3 MET3 orf19.5025 Sulfate adenylyltransferase (ATP) activity -4.2 -3.8 -3.3 -4.0 -3.5 -5.9 
PET127 -- orf19.2309 RNA binding -1.7 -1.8 -2.0 -4.4 -7.7 -5.9 
IPF11801 -- orf19.2798 Helicase activity -1.6 -1.7 -2.3 -2.2 -2.0 -1.8 
IPF14872 -- orf19.4133 -- -2.0 -1.8 -1.8 -3.5 -2.3 -4.0 
IPF20118 -- orf19.3846 -- -3.8 -4.4 -3.6 -3.1 -1.7 -1.6 
IPF525 -- orf19.7085 -- -2.4 -2.2 -1.7 -3.1 -1.7 -1.7 
IPF6504 -- orf19.1544 -- -2.1 -2.0 -1.8 -1.5 -1.7 -1.6 
IPF7334 -- orf19.3724 -- -2.3 -2.2 -1.6 -3.1 -1.8 -3.4 
 
a Gene name from CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b Gene name from CGD (http://www.candidagenome.org/). 
c orf19 nomenclature according to Assembly 19. 
d Gene Ontology (33) annotation found at CGD (http://www.candidagenome.org/). 
Gene expression values are represented as fold changes between resistant isolates and susceptible isolates. 
Table 4-5. Genes up-regulated in both isolate S2 and transformants expressing 
the UPC2S2-1 allele with SRE motifs in their promoter. 
 
CandidaDB 
Namea 
Common 
Nameb 
orf19 
Numberc SRE Motifs Coordinates 
DDR48 DDR48 orf19.4082 TGTTCGTATAACT -661 to -649 
ECM3 ECM3 orf19.1563 ATGTATACGATGA -312 to -300 
ERG1 ERG1 orf19.406 TCATCGTATATTT -376 to -364 
ERG11 ERG11 orf19.922 ATCTATACGACGA -489 to -477 
   ATGTCGTATATTC -235 to -223 
ERG24 ERG24 orf19.1598 CGTTATACGACCG -142 to -130 
ERG26 ERG26 orf19.2909 CTCTATACGACAA -283 to -271 
ERG27 ERG27 orf19.3240 GTTTATACGATCG -154 to -142 
QRI8 -- orf19.7329 ATTTCGTATATCT -367 to -355 
TEF41 TEF4 orf19.2652 TGCTATACGATGG -308 to -296 
IPF18080 -- orf19.7357 CCCTCGTATAGCG -910 to -898 
IPF2903 -- orf19.7456 ATTTATACGACAT -278 to -266 
IPF4059 -- orf19.1865 CGATCGTATATAC -215 to -203 
IPF6518 -- orf19.1691 TTCTATACGACAG -716 to -704 
IPF7289 UPC2 orf19.391 AGCTATACGACTT -440 to -428 
IPF7397 -- orf19.1800 TGATCGTATAGAT -566 to -554 
IPF7432 -- orf19.6219 CACTATACGACGA -353 to -341 
IPF867 SET3 orf19.7221 TCGTCGTATAGAC -544 to -532 
   TGATCGTATAGAG -685 to -673 
   GTCTATACGACCA -721 to -709 
IPF8970 -- orf19.496 CAGTCGTATACTG -348 to -336 
     TATTATACGATGG -211 to -199 
 
a Gene name from CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b Gene name from CGD (http://www.candidagenome.org/). 
c orf19 nomenclature according to Assembly 19. 
The SRE is in bold.  
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Disruption of UPC2 in wild-type strain SC5314 also provided the opportunity to 
identify genes whose base-line expression requires Upc2p under the growth conditions 
used in our study. We therefore compared the gene expression profile of strain SC5314 to 
that of the two independently constructed homozygous upc2Δ mutants UPC2M4A and 
UPC2M4B. Surprisingly only 5 genes were expressed at higher levels in strain SC5314 
as compared to the disruption mutants (Table C-3), suggesting that Upc2p is not required 
for base-line expression of the core target genes listed in Table 4-3 and Table 4-4. 
Previous studies have shown that disruption of UPC2 in C. albicans results in no baseline 
changes in expression of ERG2, ERG7, ERG11, and ERG25 (82, 90). Interestingly 
disruption of UPC2 in strain SC5314 resulted in up-regulation of 41 genes (Table C-4). 
This raises the possibility that Upc2p may also have a role as a transcriptional repressor. 
Alternatively, this may simply reflect compensatory changes in gene expression. 
 
 
DISCUSSION 
 
Zinc cluster transcription factors constitute a large family of transcription factors 
that is specific to fungi.  In S. cerevisiae mutations in the zinc cluster transcription factor 
Pdr1p result in constitutive up-regulation of its target genes, including the ABC 
transporter Pdr5p, and cause the pleiotropic drug resistance phenotype.  Azole-resistant 
clinical C. albicans isolates that overexpress the ABC transporters Cdr1p and Cdr2p have 
acquired mutations in the zinc cluster transcription factor Tac1p and become 
homozygous for the mutated TAC1 alleles (88, 89, 178).  Likewise, fluconazole resistant 
clinical isolates that constitutively overexpress the major facilitator superfamily 
transporter Mdr1p contain mutations in the zinc cluster transcription factor Mrr1p and 
have also become homozygous for the mutated MRR1 alleles (172).  In addition to 
decreased drug accumulation via efflux pumps, resistance to azoles can occur due to 
changes in the ergosterol biosynthesis pathway.  Point mutations in the ERG11 gene, 
encoding the drug target lanosterol demethylase, results in amino acid substitutions that 
decrease the binding affinity of the enzyme to azoles (27, 35, 44). 
 
 Increased transcription of ergosterol biosynthesis genes has also been associated 
with resistance.  Overexpression of ERG11 has been observed in azole-resistant isolates.  
In S. cerevisiae, overexpression of ERG11 alone is sufficient to confer azole resistance.  
A strain containing the ERG11 gene placed under the control of an inducible GAL1 
promoter could grow on galactose plates at fluconazole concentrations of 128μg/ml (47).  
The overexpression of ERG11 in serially collected clinical C. albicans isolates coincided 
with increases in the MIC (27, 168).  In a series of isolates described by Lopez-Ribot et al, 
resistant isolate 2307 (MIC >128 μg/ml) expressed more ERG11 than both parent isolate 
412 (MIC=0.5 μg/ml) and isolate 1907 (MIC=8 μg/ml).  There was increased expression 
of CDR1 and CDR2 in isolate 1907 compared to parent isolate 412, but the expression of 
the ABC transporters were not present in resistant isolate 2307 even though the MIC 
increases (168).  In another study, a clinical resistant C. albicans isolate 3795 (MIC>64 
μg/ml) overexpressed ERG11 as compared to the parent isolate 1002 (MIC=0.25 μg/ml).  
There was no evidence of any other known resistance mechanisms, and there were no 
point mutations in ERG11 (27).   
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Although ERG11 alone can cause azole resistance in C. albicans, the up-
regulation of ERG11 is often found in conjunction with other resistance mechanisms.  In 
the study by Perea et al., of the twelve patients from which clinical isolates were 
collected, eleven isolates had point mutations in ERG11 in conjunction with another 
resistance mechanism.  Seven isolates exhibited up-regulation of CDR1 and CDR2, seven 
isolates exhibited up-regulation of MDR1, and three isolates exhibited up-regulation of 
both classes of efflux pumps (27).   
 
In this study, we characterized the gene expression profile of the matched clinical 
isolate pair S1 and S2.  The gene expression profile of S2 showed a number of ergosterol 
biosynthesis genes up-regulated as compared to susceptible parent S1.  Transcriptional 
profiling and real-time RT-PCR showed that 8 ERG genes were up-regulated in S2.  In 
addition to the ERG genes, UPC2 was also coordinately regulated.  Sequence analysis of 
the UPC2 alleles identified a G1943A mutation in allele 1 of S2 that was not present in 
S1.  This resulted in a G648D substitution in Upc2p in S2.  Transcriptional profiling of 
the mutated UPC2S2-1 allele expressed in SC5314 as compared to the wild-type UPC2S1-1 
allele showed 9 genes up-regulated.  UPC2 was also up-regulated in the isolate 
expressing the UPC2S2-1 allele.  In total, 12 ERG genes were differentially expressed in 
either S2 or UPC2S2-1 expressed in SC5314 with four ERG genes up-regulated in both 
cases. 
 
C. albicans UPC2 is homologous to two zinc cluster transcription factor genes 
UPC2 and ECM22 in S. cerevisiae.  Upc2p and Ecm22p both play a role in the regulation 
of sterol biosynthesis and uptake of sterols from the environment (81, 82, 90, 179, 180).  
Deletion of ScUPC2 causes hypersusceptibility to AmB and ketoconazole while deletion 
of ScECM22 causes hypersusceptibility to cycloheximide and calcofluor white (81, 82).  
In addition to drug resistance, ScUPC2 and ScECM22 are also involved in sterol uptake.  
Under aerobic conditions, ergosterol is synthesized and no exogenous sterols are 
imported.  Under anaerobic conditions, the heme in lanosterol demethylase cannot be 
activated and sterol biosynthesis is inhibited.  However, in the absence of oxygen, S. 
cerevisiae has the ability to import exogenous sterols.  The mutant hyperactive allele, 
upc2-1, has a G888D mutation that causes exogenous sterol uptake under aerobic 
conditions.  Strains that carry this allele have the ability to take up ten times more 
exogenous sterols than the wild-type parental strain (181).  A G790D mutation was 
introduced into a wild-type ECM22 allele that duplicated the mutation present in 
hyperactive allele upc2-1 (180).  This mutation resulted in aerobic sterol uptake similar to 
that of upc2-1.  Deletion of ScUPC2 and ScECM22 did not change aerobic sterol uptake, 
but it decreased the amount of sterol imported under anaerobic condition (179).  
Sequence alignment showed that the G648D mutation that we identified in one of the 
UPC2 alleles of C. albicans isolate S2 corresponds exactly to the G888D and G790D 
mutations that result in hyperactive UPC2 and ECM22 alleles, respectively, in S. 
cerevisiae. It is striking that the same mutation has been selected for in a clinical C. 
albicans isolate during fluconazole therapy. 
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In response to azole antifungals (fluconazole, itraconazole, ketoconazole), wild-
type C. albicans strains overexpress ERG11, UPC2, and other ERG genes as well as 
NCP1 and DDR48 (48, 174, 182).  Forced overexpression of UPC2 using a MET3 
promoter confers resistance to azoles, whereas disruption of UPC2 in wild-type isolates 
causes hypersusceptibility to the azoles and other sterol biosynthesis inhibitors such as 
terbinafine and fenpropimorph (82, 90).  In response to sterol biosynthesis inhibitors, 
UPC2 disruption strains show no induction of ERG genes (90).  The disruption strain 
accumulates lower levels of exogenous sterols than the wild-type and the reconstituted 
strains (90), demonstrating the role of UPC2 in the uptake of exogenous sterols.  Strains 
without UPC2 also show a growth defect under anaerobic conditions (82), presumably 
due to the inability to take up sterols in the absence of UPC2. 
 
S. cerevisiae Upc2p and Ecm22p were first identified for their ability to regulate 
ScERG2 and ScERG3.  An 11-bp SRE was identified in the promoters of ScERG2 and 
ScERG3 and was found to be bound directly by Upc2p or Ecm22p.  Analysis of the 
promoter region of other ergosterol biosynthesis genes identified the same SRE motifs 
(81).  Mammalian cells contain sterol regulatory element binding proteins (SREBP) to 
regulate cholesterol synthesis.  There are no homologous SREBPs in yeast, but ScUPC2 
and ScECM22 regulate ergosterol biosynthesis.  Promoter analysis on C. albicans ERG 
genes was performed with known S. cerevisiae SRE (TCGTATA) (81).  Several ERG 
genes contained the putative SRE motif in their promoters.  The DBD of C. albicans 
Upc2p was purified and used to test direct binding to the SRE found in the promoter 
region of S. cerevisiae and C. albicans ERG2.  Upc2p could bind the SREs of both S. 
cerevisiae and C. albicans, and no binding occurred when the SRE was mutated (82).  Of 
the 12 ERG genes up-regulated in S2 or by UCP2S2-1 in SC5314, nine (ERG1, ERG2, 
ERG5, ERG6, ERG10, ERG11, ERG24, ERG26, and ERG27) have been previously 
identified to have the S. cerevisiae putative SRE core motif, TCGTATA (82, 90).  In 
addition, ERG7 and UPC2 were previously identified as having a putative SRE (82). 
While our analyses did not find an SRE motif in the promoter of ERG7, we did find the 
TCGTATA motif in UPC2 itself, suggesting this gene may be directly or indirectly 
autoregulated. 
 
In addition to the ERG genes, UPC2 regulates a host of other genes.  One gene of 
particular interest that was found to be up-regulated by the G648D mutation in Upc2p is 
MDR1.  Constitutive overexpression of this efflux pump leads to fluconazole resistance 
and represents a major mechanism of resistance in clinical isolates (27, 28, 29, 35, 43, 95, 
168).  Previous Northern hybridization analyses showed no MDR1 up-regulation in 
isolates of the S series, although isolate S2 itself was not tested in that study (95).  
However, in the present study, microarray analysis revealed MDR1 to be up-regulated in 
isolate S2 by between 2- and 4-fold.  This observation was confirmed by real-time RT-
PCR.  This is modest in comparison to isolates in which MDR1 has been shown to 
contribute to fluconazole resistance.  Such isolates exhibit increased expression of MDR1 
on the order of 100-fold.  It is therefore unlikely that enhanced expression of MDR1 
contributes significantly to fluconazole resistance in isolate S2.  Moreover, as MDR1-
mediated resistance appears to be specific for fluconazole, but not other ergosterol 
biosynthesis inhibitors, it is unlikely that it contributes to the UPC2-dependent changes in 
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susceptibility to terbinafine observed in the present study.  Although we were unable to 
identify an SRE motif in the promoter region of MDR1, these data suggest that Upc2p 
may play a role in the regulation of MDR1 expression.  
 
Another gene that was highly up-regulated by the G648D mutation in Upc2p is 
PGA10, a gene required for hemoglobin-iron utilization (183).  FTH1, a gene 
homologous to ScFTH1 that encodes a putative high affinity iron transporter, was also 
overexpressed.  Several other iron permease genes were overexpressed 1.5- to 40-fold in 
either isolate S2 or strains expressing the UPC2S2-1 allele, including FET34, FRE5, 
FRE10, and FTR1. FRE10 and FTR1 were up-regulated in S2 whereas FRP1 was up-
regulated in transformants expressing the UPC2S2-1 allele.   FET34 appears to be up-
regulated in both cases, because FET34 and FET5 are two alleles of FET34 according to 
the Candida Genome Database (CGD; http://www.candidagenome.org).  A previous 
study determined that under iron deprivation conditions, C. albicans down-regulates 
ERG11 and is more susceptible to fluconazole, cycloheximide, nystatin, and anisomycin.  
The down-regulation of ERG11 decreases the amount of membrane ergosterol, causing 
decreased membrane fluidity and increased drug susceptibility (184).  In the present 
study, the expression of ERG11 seems to be coordinately regulated with the genes that 
transport iron into cells, even though the iron uptake genes do not contain an SRE in the 
promoter.  The ERG11 gene product, lanosterol demethylase, has a heme molecule in the 
active site that is required in order for it to bind molecular oxygen.  Because iron is 
central to this heme, up-regulation of ERG11 may necessitate an increase of iron uptake.  
It is tempting to speculate that differential expression of these iron metabolism genes may 
be a direct result of altered ergosterol production, and not directly regulated by Upc2p.  
 
In the azole resistant isolate S2, the most highly up-regulated gene was DDR48 
which was also found to have a putative SRE in its promoter region.  Previous studies 
have shown DDR48, a gene associated with cell stress response, to be differentially 
expressed in resistant isolates overexpressing CDR1, CDR2, and MDR1 (172, 178).  It 
has also been found to be overexpressed in response to fluconazole, itraconazole, 
ketoconazole, AmB, and caspofungin treatment (48, 174, 182).  DDR48 was also found 
to be up-regulated under hypoxic conditions (185).  Interestingly, DDR48 was also one of 
the 41 genes up-regulated in the SC5314 upc2Δ/upc2Δ disruption mutants.  While the 
biological role of DDR48 requires further study, our data suggest it may be both 
positively and negatively regulated by Upc2p. 
 
As mentioned above, ScUPC2 has been implicated in the uptake of exogenous 
sterols. Sterol uptake is mediated by an ABC transporter, ScAUS1 (186).  In C. albicans, 
ScAUS1 is homologous to a number of ABC transporters including CDR1 and CDR2.  
However, the actual mechanism of sterol uptake in C. albicans is unknown.  By 
microarray analysis we found genes encoding ABC transporters to be up-regulated by the 
UPC2 gain-of-function mutation.  In the resistant isolate S2, the ABC transporter gene 
CDR12 is up-regulated 1.5- to 3.0-fold, and in SC5314 transformants expressing the 
UPC2S2-1 allele the ABC transporter gene CDR11 is up-regulated 1.5- to 3.5-fold.  
According to the CGD, CDR11 and CDR12 are two different alleles of the gene CDR11.  
Because of the homology of CDR11 to ScAUS1, Cdr11p is a strong candidate for the 
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transporter that mediates the uptake of exogenous sterols in C. albicans.  This hypothesis 
is currently under investigation. 
  
CHAPTER 5: DISCUSSION 
 
 
With advancements such as highly active antiretroviral therapy (HAART), the 
morbidity and mortality of Candida infections have decreased.  Incidences of OPC have 
decreased especially in developed countries where newer drugs are available (187, 188).  
However, in developing nations, the cost of the drugs and the long term course of 
treatment become prohibitive and impractical (7, 8).  Without effective HAART, HIV 
patients develop OPC at pre-HAART rates (189).  In these situations, OPC is still often 
treated with azole antifungals, and the development of resistance remains a problem. 
 
Because azoles are fungistatic, the development of resistance can occur, 
especially when treatment spans a long period of time.  In C. albicans, several common 
resistance mechanisms can develop through antifungal treatment.  The azoles bind 
lanosterol demethylase, a cytochrome P-450 enzyme essential to the synthesis of 
ergosterol in the cell.  One resistance mechanism occurs through mutations in ERG11, the 
gene that encodes lanosterol demethylase.  Several nonsynonymous mutations have been 
identified in ERG11 that affect drug resistance (44, 45, 46).  Mutations in ERG11 change 
the conformation or spatial structure of Erg11p, altering the enzyme-drug interaction 
without necessarily changing the enzyme function.  Another mechanism of resistance is 
the overexpression of the azole target gene ERG11 (27, 43, 168).  By increasing the 
amount of drug target, fewer enzymes are bound by the drug.  In order to achieve the 
same level of inhibition, the dosage of the drug would need to be increased.  In S. 
cerevisiae, the regulation of ergosterol biosynthesis genes occurs through the zinc cluster 
transcription factors ScUpc2p and ScEcm22p (81).  One homologous gene UPC2 is 
present in C. albicans, and Upc2p regulates ergosterol genes in C. albicans (82, 90). 
 
The major mechanism of azole resistance involves active efflux of the drug from 
the cell.  The two major classes of efflux pumps in C. albicans are the ABC transporters 
and the MFS transporters.  The ABC transporters responsible for azole drug resistance 
are Cdr1p and Cdr2p (32, 35, 37, 38, 51).  The expression and regulation of CDR1 and 
CDR2 have been identified to be determined by the zinc cluster transcription factor 
Tac1p (88, 89).  Gain-of-function mutations in TAC1 result in azole resistance.  One 
hyperactive allele of TAC1 is insufficient to cause azole resistance.  In high level azole 
resistance, two hyperactive TAC1 alleles are present due to the loss of heterozygosity.  
TAC1 is found on chromosome 5 near the mating type locus (MTL).  Recent genetic 
studies have shown that the loss of heterozygosity of the MTL may be the mechanism by 
which TAC1 alleles become homozygous, but the homozygosity of the MTL is not 
sufficient in itself to cause resistance (89).  The overexpression of the MFS transporter 
Mdr1p also confers resistance (21, 35, 39, 43, 72, 168).  C. albicans MDR1 is not to be 
confused with the human MDR1, an ABC transporter.  The substrate also differs between 
C. albicans Mdr1p and Cdr1p/Cdr2p.  The CDR efflux pumps have the ability to 
transport all azole antifungals; Mdr1p is specific to fluconazole.  The bZip transcription 
factor Cap1p was originally thought to be responsible for the expression of MDR1 in 
resistance.  However, deletion of CAP1 in a resistance isolate overexpressing MDR1 does 
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not abrogate MDR1 gene expression.  The deletion of CAP1 also does not prevent the 
induction of MDR1 in response to benomyl exposure (83, 84). 
 
In S. cerevisiae, transcriptional regulators of drug resistance have been shown to 
be co-regulated with their target genes as well as autoregulated (75, 76, 78).  As is the 
case with S. cerevisiae, we hypothesized that the azole resistance mechanisms developed 
in clinical isolates of C. albicans is due to gain-of-function mutations in a transcriptional 
regulator.  Using custom Affymetrix microarrays specific to C. albicans, we were able to 
examine the genome-wide expression profile of clinical matched susceptible and resistant 
isolates.  By studying matched isolates, we were able to identify specific changes that 
occurred between susceptible and resistant isolates.  Because of the precedence of 
transcription factors being differentially expressed in S. cerevisiae, we looked for 
putative transcriptional regulators in our co-regulated genes. 
 
Our first objective was to better characterize the genes co-regulated with CDR1 
and CDR2 using our new microarrays designed from the newly completed C. albicans 
genome sequencing project.  Previous studies have shown several genes consistently co-
regulated with the expression of CDR1 and CDR2.  With the new arrays, we confirmed 
the co-regulation of CDR1/CDR2 with previously identified genes.  In addition, we also 
discovered the co-regulation of the zinc cluster transcription factor Tac1p.  Although 
Tac1p had been shown to be the transcriptional regulator of CDR1 and CDR2, it had not 
been shown to be autoregulated.  Using expression profiling of four matched isolates 
from four different patients in conjunction with a tac1Δ mutant in a resistant isolate, we 
were able to narrow down the list of genes considered to be Tac1p dependent.  The 
development of a Tac1p ChIP-chip assay allowed us to examine the genes whose 
promoters were directly bound by Tac1p.  Tac1p-HA3 binding was found to occur in both 
inducing (mutant TAC1 allele) and noninducing (wild-type TAC1 allele) conditions.  This 
binding occurred independent of the HA3 tagging as no gain- or loss-of-function mutation 
was detected by the Raymond lab.  These data suggest that Tac1p is constitutively bound 
to the promoter region of the target genes.  The gain-of-function mutation does not 
increase affinity of binding or act as a nuclear localization signal.  Instead, the mutation 
could prevent the binding of a repressor element or act as an activator of transcription.  
By utilizing both expression and location profiling, we could identify the co-regulated 
genes that were directly bound by Tac1p (Figure 5-1). 
 
Interestingly, there were genes that were up-regulated in the presence of the gain-
of-function allele whose expression was abolished in the absence of TAC1 but whose 
promoters were not bound by Tac1p.  These data suggest the possibility of another 
transcriptional factor involved in gene regulation.  Because Tac1p is a zinc cluster 
transcription factor, it binds to the DRE motif as homo- or hetero-dimers (64).  The genes 
that are dependent on the presence of TAC1 for expression could require a Tac1p hetero-
dimer to bind to the promoter motif.  Conversely, there were genes whose promoters 
were bound by Tac1p but the genes were not differentially expressed in resistant isolates.  
This suggests that Tac1p also acts as a transcriptional regulator for other cellular 
functions. 
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Figure 5-1. Proposed model for Tac1p-mediated fluconazole resistance in C. 
albicans. 
(A)  Schematic of a fluconazole susceptible isolate expressing baseline levels of Cdr1p.  
Tac1p is constitutively bound to the DRE of target genes, including CDR1, CDR2, and 
TAC1. The lack of Tac1p-mediated transcription of CDR1, CDR2, TAC1, and other co-
regulated genes could be due to the inefficient recruitment of an enhancer or the binding 
of a repressor.  (B)  Schematic of a fluconazole resistant cell expressing increased levels 
of CDR1, CDR2, TAC1, and co-regulated genes.  The gain-of-function mutation (amino 
acid substitution) results in increased expression of Tac1p target genes and fluconazole 
resistance possibly through preventing the binding of a repressor or through the increased 
recruitment of enhancers or cofactors.  Additional Tac1p target genes may also contribute 
to fluconazole resistance. 
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The gain-of-function mutation in TAC1 in addition to the constitutive binding of 
Tac1p to the promoter region of its target genes warrants further study.  The gain-of-
function mutation does not increase binding of Tac1p to the promoter region of target 
genes.  However, the gain-of-function mutation in TAC1 clearly increases the expression 
of CDR1 and CDR2.  The more efficient recruitment of an enhancer or the 
incompatibility of a repressor due to the mutation could result in the constitutive 
activation of Tac1p.  The identification of this cofactor could provide further insight on 
how C. albicans responds to drug stresses.  
 
Because the identification of transcriptional regulators was possible by gene 
expression profiling, we next examined three clinical matched isolate pairs known to 
overexpress MDR1.  Our results in Chapter 3 showed a smaller number of genes co-
regulated with MDR1, with significant overlap between all three resistant isolates.  Our 
experiments confirmed previously identified co-regulated genes.  In addition, we found a 
zinc cluster transcription factor we named MRR1.  A gain-of-function mutation was 
identified in each resistant allele.  The deletion of MRR1 abrogates the expression of 
MDR1 in resistant isolates and in response to cerulenin, brefeldin A, hydrogen peroxide, 
diamide, and fluconazole.  Reintegration of gain-of-function MRR1 in wild-type SC5314 
restored the overexpression of MDR1 in response to cerulenin, brefeldin A, diamide, and 
fluconazole.  A loss of heterozygosity of MRR1 alleles also contributes to resistance.  In 
the fluconazole resistant isolates, both alleles of MRR1 carry the gain-of-function 
mutation.  Similar to TAC1, both MRR1 alleles containing the gain-of-function mutation 
confer higher drug resistance than heterozygous MRR1 alleles. 
 
A large number of genes regulated by MRR1 are homologous to S. cerevisiae 
genes implicated in the oxidative stress response.  Additionally, these S. cerevisiae genes 
have also been identified as being controlled by Yrr1p and Yrm1p, two zinc cluster 
transcription factors found in the PDR family of drug resistance.  These genes have not 
been shown to be regulated by YAP1.  The oxidative stress response in C. albicans has 
been shown to be mediated by CAP1.  The resistance to azole antifungal agents depends 
partly on CAP1, but the disruption of CAP1 does not abrogate the expression of MDR1.  
Our group, in collaboration with the Morschhäuser lab, has shown that MRR1 mediates 
the hydrogen peroxide and benomyl response through the control of MDR1 gene 
expression; the disruption of MRR1 completely abolishes MDR1 gene expression in the 
presence of hydrogen peroxide and benomyl.  However, in the absence of MRR1, the 
strains retain the ability to respond to hydrogen peroxide stress (data not shown).  The 
redundancy of these two transcriptional regulators could be a consequence of the 
mechanism of transcriptional activation.  Cap1p binds promoter regions of genes only if 
the transcription factor is localized to the nucleus in response to oxidative stress.  
Mutations in the nuclear localization signal domain can also cause constitutive activation 
of the Cap1p.  The mechanism of MRR1 activation by azole antifungals is still unknown.  
However, a gain-of-function mutation in MRR1 constitutively activates the transcription 
factor and up-regulates MDR1.  The schematics in Figure 5-2 show the possible 
mechanisms by which Mrr1p transcriptional regulation occurs. 
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Figure 5-2. Proposed model for Mrr1p-mediated fluconazole resistance in C. 
albicans. 
(A)  Schematic of a fluconazole susceptible isolate with no baseline Mdr1p.  The lack of 
Mrr1p-mediated transcription of MDR1, MRR1, and co-regulated genes could be due to 
the cytoplasmic localization of Mrr1p, the inactivation of Mrr1p that prevents binding to 
the promoter, inefficient recruitment of an enhancer, or the binding of a repressor.  (B)  
Schematic of a fluconazole resistant isolate expressing increased levels of MDR1, and co-
regulated genes.  The gain-of-function mutation (amino acid substitution) results in 
increased expression of Mrr1p target genes and fluconazole resistance possibly through 
a) increased nuclear localization of Mrr1p, b) by preventing the binding of a repressor or 
c) through the increased recruitment of enhancers or cofactors.  Additional Mrr1p target 
genes may also contribute to fluconazole resistance. 
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Further study is needed to determine the relationship between the gain-of-function 
mutation and the activation of MRR1.  Mrr1p could behave similar to Tac1p in that it 
binds constitutively to the promoter of the target genes.  However, the gain-of-function 
mutation could result in increased affinity of the protein to the binding site.  Mrr1p 
location profiling would allow us to study the binding of Mrr1p to promoter regions of 
MDR1 co-regulated genes.  By finding a core set of genes that are bound directly by 
Mrr1p, a binding motif can also be defined.  Another important study would be to 
examine the interaction between MRR1 and CAP1 regulon.  As it stands, MRR1 seems to 
be responsible for drug resistance while CAP1 is responsible for the oxidative stress 
response.  However, these two transcription factors have overlapping functions and how 
they interact requires further study. 
 
In our collection of clinical matched isolate pairs, we had a susceptible and 
resistant isolate which did not express known resistance genes (CDR1, CDR2, MDR1).  
Using genome-wide expression profiling, we looked to characterize the resistance 
mechanisms.  Because high level azole resistance is most likely due to gain-of-function 
mutations in a trans-regulatory element, we examined the gene expression profile for 
putative transcriptional regulators.  The resistant isolate overexpressed a large number of 
ergosterol biosynthesis genes including ERG11.  Additionally, we found UPC2 up-
regulated in conjunction with the ERG genes (Figure 5-3).  Sequencing of the UPC2 
alleles identified a gain-of-function mutation identical to the mutation found in ScUPC2 
(upc2-1) and ScECM22.  The gain-of-function mutation reintegrated in a susceptible 
isolate conferred fluconazole resistance and increased the expression of ERG genes.  The 
UPC2 disruption strains conferred hypersusceptibility to fluconazole. 
 
Interestingly, fluconazole resistance in clinical isolates as a result of gain-of-
function mutations in UPC2 is unlike the gain-of-function mutations in TAC1.  One 
mutant allele of UPC2 is sufficient in conferring fluconazole resistance in this clinical 
isolate.  Loss of heterozygosity in addition to the gain-of-function mutations in the TAC1 
alleles contributed to high level azole resistance in fluconazole resistant clinical isolates.  
One MRR1 allele containing a gain-of-function mutation is also sufficient in conferring 
azole resistance (Morschhäuser lab, personal communication), although the resistant 
isolates used in our study demonstrated a loss of heterozygosity and higher levels of azole 
resistance.  It is possible that two mutant UPC2 alleles could confer higher levels of azole 
resistance; however, we did not examine this possibility at this time. 
 
Another gene of interest identified in this study was the gene encoding the ABC 
transporter CDR11.  In our microarray data, we found the resistant clinical isolate to 
overexpress the ABC transporter Cdr12p; in the reintegrated gain-of-function mutant, 
Cdr11p was up-regulated.  According to the newly assembled Candida genome database 
(CGD), CDR11 and CDR12 are actually two alleles of the CDR11 gene.  This ABC 
transporter may be responsible for uptake of exogenous sterols.  In S. cerevisiae, the 
ABC transporter ScAUS1 has been implicated in the utilization of exogenous sterols 
under sterol starvation conditions.  While sterol uptake in C. albicans has not been well 
characterized, previous studies have shown that sterol uptake is possible (90).  The 
expression of different CDR11 alleles in response to the same UPC2 mutation could be  
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Figure 5-3. Proposed model for Upc2p-mediated fluconazole resistance in C. 
albicans. 
(A)  Schematic of a fluconazole susceptible isolate with baseline ergosterol biosynthesis 
gene expression.  The lack of overexpression of ERG11, UPC2, and other ergosterol 
biosynthesis genes could be due to the localization of Upc2p to the membrane of the 
endoplasmic reticulum (ER) or the binding of a repressor.  (B)  Schematic of a 
fluconazole resistant cell expressing increased levels of ERG11, other ergosterol 
biosynthesis genes, and other Upc2p target genes.  The gain-of-function mutation (amino 
acid substitution) results in increased expression of Upc2p target genes and fluconazole 
resistance possibly through a) increased nuclear localization of Upc2p, b) by preventing 
the binding of a repressor or c) through the increased recruitment of enhancers or 
cofactors.  Additional Upc2p target genes may also contribute to fluconazole resistance. 
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due to the background strain.  The resistant clinical isolate and the genome strain SC5314 
are not isogenic, so different CDR11 alleles may be present in different C. albicans 
strains. 
 
Further study is necessary to determine if CDR11 is in fact responsible for the 
uptake of exogenous sterols by C. albicans.  Because the UPC2 gain-of-function 
mutation in C. albicans is the same as the UPC2 and ECM22 gain-of-function mutations 
in S. cerevisiae and the gain-of-function mutations in S. cerevisiae confers sterol uptake 
under aerobic conditions, the same phenotype may occur in C. albicans.  The loss of 
heterozygosity of UPC2 alleles in the development of azole resistance also requires 
further study.  Our resistant clinical isolate only contained one gain-of-function mutation 
allele.  Currently, no isolates have been characterized to contain two homozygous gain-
of-function mutations in UPC2. 
 
By studying matched susceptible and resistant clinical isolates, we were able to 
identify genes specific to the development of resistance.  We successfully identified 
several gain-of-function mutations in transcriptional regulators of clinical azole resistance, 
and characterized core genes affected by these specific mutations.  We have also 
identified a previously uncharacterized transcriptional regulator of MDR1.  This 
transcription factor, Mrr1p, was also shown to contain gain-of-function mutations that 
constitutively activate its target genes conferring high level azole resistance.  We also 
identified gain-of-function mutations in a known transcriptional regulator in a clinical 
matched set with an undefined resistance mechanism.  These results demonstrate the 
importance of using genome-wide analysis to identify gain-of-function mutations in zinc 
cluster transcription factors in the development of azole resistance in C. albicans. 
 
The discovery and identification of gain-of-function mutations in the 
transcriptional regulators of fluconazole resistance, combined with known azole 
resistance mutations in the ERG11 gene itself, may allow for the development of more 
efficient diagnostic tools to better predict clinical success of azole therapy against a 
specific isolate.  Theoretically, if all (or most) relevant mutations that confer azole 
resistance were identified in C. albicans, single nucleotide polymorphism (SNP) 
detection assays could be developed to quickly identify the presence of these mutations in 
clinical isolates.  If such an assay could be created, it is quite possible that such genetic 
information would better correlate with clinical outcomes as compared to in vitro 
susceptibility testing.  Moreover, the speed and efficiency with which such assays could 
be performed would allow for quicker initiation of optimal antifungal therapy.  Major 
challenges will be the ability to first identify the majority of mutations that contribute to 
azole resistance in the overall clinical isolate population and the current cost of routine 
use of such technology. 
 
The discovery of the transcription factors that regulate the major resistance 
mechanisms in C. albicans also has significant therapeutic ramifications.  Tac1p, Mrr1p, 
and Upc2p are all zinc cluster transcription factors which are a class of zinc finger 
proteins unique to fungi.  If inhibitors of this fungal-specific class of proteins could be 
identified, such compounds could be used in combination with the azole antifungals to 
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inhibit expression of azole resistance genes, or to prevent the development of azole 
resistance from the time of initiation of therapy. 
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APPENDIX A: TAC1 SUPPLEMENTAL DATA 
 
 
Table A-1. Genes up-regulated in at least one matched clinical isolate. 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.6229 CAT1 CTA1 Catalase activity 1.7 1.1 -1.0 -1.1 -1.1 
orf19.3682 CWH8 CWH8 Pyrophosphatase activity 2.0 1.1 -1.0 1.1 -1.1 
orf19.7056 -- DIP53.exon2 Amino acid permease activity 2.1 -1.0 1.2 2.6 1.1 
orf19.781 -- DUR31 Urea transporter activity 2.0 -1.4 -1.0 1.4 1.6 
orf19.5017 -- DUR32 Urea transporter activity 1.8 -1.4 -1.2 1.2 1.1 
orf19.767 ERG3 ERG3 C-5 sterol desaturase activity 1.5 1.1 1.4 -1.2 1.0 
orf19.1631 ERG6 ERG6 Sterol 24-C-methyltransferase activity 1.8 1.2 1.4 -1.7 -1.3 
orf19.460 CEK2 ERK2 MAP kinase activity 1.8 1.2 1.8 1.7 2.8 
orf19.4015 CAG1 GBA1 GTPase activity 30.8 1.1 -1.3 2.3 30.8 
orf19.1392 -- IPF11068 Protein disulfide isomerase activity 1.6 1.1 -1.6 -1.1 1.0 
orf19.1616 FGR23 IPF12262 -- 2.3 1.3 1.1 8.4 19.6 
orf19.3180 -- IPF12790 Inositol-polyphosphate 5-phosphatase activity 1.9 1.0 1.4 1.5 1.2 
orf19.2646 ZCF13 IPF13024 Specific RNA polymerase II transcription factor activity 1.7 1.4 1.2 2.8 -1.3 
orf19.209 DFG10 IPF13438 -- 1.7 -1.0 1.0 1.2 -1.0 
orf19.3380 HWP2 IPF14331 -- 1.5 1.2 1.3 -2.1 2.1 
orf19.3586 -- IPF14773.exon2 -- 1.5 -1.2 1.0 1.1 -1.3 
orf19.4134 -- IPF14985 -- 1.5 1.2 1.2 1.4 -1.1 
orf19.4795 -- IPF16501 -- 1.8 1.0 -2.1 5.9 2.5 
orf19.720 GST3 IPF17507 Transcription corepressor activity 1.6 -1.2 -1.2 2.2 1.0 
orf19.6469 -- IPF19295.3f -- 1.8 -1.0 -1.1 -1.1 1.9 
orf19.5194.1 -- IPF20014 -- 1.5 -1.1 1.3 -1.0 1.2 
orf19.3563 -- IPF3189 -- 1.8 -1.3 -1.1 2.5 1.1 
orf19.7522 -- IPF364 Arylformamidase activity 1.6 1.2 1.1 -1.1 1.1 
orf19.296 -- IPF3833 -- 1.6 -1.1 1.4 1.3 1.7 
orf19.538 -- IPF4293 -- 1.7 1.0 1.4 -1.2 -1.1 
orf19.6534 -- IPF5158 -- 1.7 1.0 1.0 5.3 1.1 
orf19.5655 -- IPF5268.exon2 -- 1.7 -1.2 1.1 15.0 1.7 
orf19.7105 FAR1 IPF568 Cyclin-dependent protein kinase inhibitor activity 16.9 1.1 1.5 1.3 12.0 
orf19.5952 -- IPF65 -- 2.0 -1.5 -2.0 2.5 -1.5 
orf19.6468 -- IPF6617.repeat1 -- 2.0 -1.7 1.5 -1.1 1.1 
orf19.1171 -- IPF7635 -- 1.8 -2.0 1.2 2.8 1.3 
orf19.5342 -- IPF768 -- 2.3 1.0 1.4 1.4 1.5 
orf19.31 -- IPF8878 Structural constituent of cell wall 2.0 -1.3 -1.3 1.8 2.1 
orf19.2836 -- IPF9098 -- 1.9 -1.6 3.7 2.5 1.9 
orf19.3713 -- IPF9211.5f -- 1.7 -1.2 1.3 7.2 1.2 
orf19.2494 STE3 IPF9230 Mating-type a-factor pheromone receptor activity 4.1 -1.4 1.8 11.4 5.4 
-- -- IPF9851 -- 7.1 1.9 2.9 18.5 12.0 
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Table A-1 (continued). 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.5172 LIP9 LIP9.exon2 Lipase activity 2.1 1.1 1.8 4.5 1.1 
orf19.7420 -- MED6 RNA polymerase II transcription mediator activity 1.7 -1.0 1.2 1.1 -1.1 
orf19.3197 PAP1 PAP12 RNA binding 1.8 -1.0 1.2 1.1 2.1 
orf19.4599 PHO89 PHO89 High affinity phosphate transporter activity 1.6 -1.6 -1.6 -2.3 -1.1 
orf19.3199 PIKA PIK1 1-phosphatidylinositol 4-kinase activity 2.0 1.1 -1.1 1.3 2.3 
orf19.756 SAP7 SAP7 Aspartic-type endopeptidase activity 2.7 -1.1 1.1 -1.4 -1.1 
orf19.3893 SCW11 SCW11.3eoc Glucan 1,3-beta-glucosidase activity 1.6 1.2 -1.0 1.1 -1.1 
orf19.2179 SIT1 SIT1 Ferrichrome transporter activity 1.6 -1.3 -1.7 1.1 1.2 
orf19.5820 UGA6 UGA6.3eoc L-gamma-aminobutyric acid transporter activity 3.8 2.0 2.0 2.6 1.5 
orf19.1163 -- IPF13079 -- -1.2 1.5 1.0 -1.0 -1.1 
orf19.7034 -- IPF3069 -- -1.1 1.6 1.2 1.1 1.7 
orf19.4608 PDC12 PDC12.exon2 Pyruvate carboxylase activity 1.2 2.1 1.3 3.7 -1.1 
orf19.3796 -- RNT1 Ribonuclease III activity -1.2 1.7 -1.5 1.1 1.1 
orf19.6053 CIS2 CIS2 Protein-glutamine gamma-glutamyltransferase activity 1.2 1.3 1.9 1.1 1.3 
orf19.7652 CKA1 CKA1 Protein kinase CK2 activity 1.1 1.2 1.9 -1.1 -1.1 
orf19.1448.1 -- DYN2.3 -- -1.0 1.1 1.7 1.3 -1.5 
orf19.5535 -- FEN2 Pantothenate transporter activity 1.6 1.4 1.7 -1.0 1.1 
orf19.4182 -- IPF11898 -- 1.1 1.1 1.5 -1.2 -1.1 
orf19.3466 -- IPF13112 -- -1.0 -1.2 1.6 2.4 -1.3 
orf19.1804 -- IPF14864 Transporter activity -1.3 1.0 1.5 1.2 -1.5 
orf19.1177 -- IPF15134 -- 1.1 1.2 1.5 -1.1 1.5 
orf19.4884 WOR1 IPF15255 Transcription regulator activity 2.1 2.2 2.3 2.4 1.2 
orf19.4159 -- IPF15660 Transporter activity -1.0 1.2 1.6 -1.7 -1.5 
orf19.7468 -- IPF2511 -- 1.0 1.0 1.7 1.8 -1.2 
orf19.7456 -- IPF2903 -- 1.3 1.5 2.2 4.4 1.1 
orf19.5523 -- IPF4325 -- -1.2 -1.0 1.7 1.2 -1.0 
orf19.5276 -- IPF4708 -- -1.0 1.3 1.6 1.7 -1.3 
orf19.3615 -- IPF5192 -- 1.0 1.2 1.5 2.1 1.1 
orf19.1109 -- IPF6338 -- -1.3 -1.1 1.6 -1.5 -1.6 
orf19.480 -- IPF7097 -- 1.0 1.0 1.5 -1.0 -1.4 
orf19.2104 -- JAC1 Chaperone binding -1.1 1.0 1.6 -1.1 -1.1 
orf19.6044 -- MOB2 Protein kinase activator activity 1.0 1.1 1.5 -1.2 -1.0 
orf19.6041 RPO41 RPO41 DNA-directed RNA polymerase activity -1.4 1.1 1.5 -2.1 -1.2 
orf19.514 SNP3 SNP3 RNA splicing factor activity, transesterification mechanism -1.1 1.0 1.7 -1.3 -2.4 
orf19.854 -- UGA11.exon2 4-aminobutyrate transaminase activity 1.1 1.1 1.8 -1.2 1.1 
orf19.7436 AAF1 AAF1 -- 1.0 1.2 1.2 1.5 1.5 
orf19.3417 ACF2 ACF2 Glucan 1,3-beta-glucosidase activity 1.3 1.1 1.1 1.9 1.1 
orf19.2608 ADH5 ADH5 Alcohol dehydrogenase activity 1.3 1.2 1.4 1.7 1.2 
orf19.4679 AGP2 AGP2 Hydrogen:amino acid symporter activity 1.4 1.3 1.4 1.8 -1.1 
orf19.5742 ALS9 ALS11.3f -- 1.5 1.3 1.1 2.7 2.9 
orf19.7400 ALS7 ALS7 Carbohydrate binding 1.0 -1.0 1.0 1.5 1.5 
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orf19.4413 CMD1 CMD1 Calcium ion binding 1.0 1.1 1.2 1.7 -1.2 
orf19.4555 ALS4 CPS2.3f Gly-X carboxypeptidase activity 1.1 1.2 1.2 1.6 1.3 
orf19.4610 -- CPS2.5f Gly-X carboxypeptidase activity 1.2 -1.0 1.2 1.9 1.5 
orf19.6755 -- DLD2 D-lactate dehydrogenase (cytochrome) activity 1.3 1.2 1.1 2.4 1.5 
orf19.780 DUR1,2 DUR1,2 Allophanate hydrolase activity -1.1 1.1 1.1 1.9 2.8 
orf19.5999 DYN1 DYN1 Minus-end-directed microtubule motor activity 1.1 1.1 1.0 2.9 2.7 
orf19.7495 -- EBP6 NADPH dehydrogenase activity -1.1 -1.2 2.3 3.5 -1.0 
orf19.5816 EBP7 EBP7 NADPH dehydrogenase activity 1.2 1.1 -1.1 2.4 1.4 
orf19.7379 FAA2 FAA22 Long-chain-fatty-acid-CoA ligase activity 1.4 1.1 1.3 5.1 -1.3 
orf19.3653 FAT1 FAT1 Long-chain-fatty-acid-CoA ligase activity 1.1 1.1 1.2 1.5 -1.1 
orf19.6178 FBP1 FBP1 Fructose-bisphosphatase activity 1.2 1.1 1.3 1.8 1.2 
orf19.1153 GAD1 GAD1 Glutamate decarboxylase activity 1.0 -1.1 -1.0 2.0 1.1 
orf19.5880 -- GEF1.3f Voltage-gated chloride channel activity 1.3 1.2 1.1 1.6 1.6 
orf19.734 GLK1 GLK1 Glucokinase activity 1.2 1.2 1.1 1.5 1.2 
orf19.4309 GRP2 GRP2 Oxidoreductase activity -1.1 1.2 1.3 3.1 1.4 
orf19.5059 GCS1 GSH1.exon1 Glutamate-cysteine ligase activity 1.0 1.0 1.3 2.7 1.4 
orf19.7419 HNT2 HNT2 Hydrolase activity 1.4 1.2 1.3 1.9 1.2 
orf19.6323 -- HPA3 Histone acetyltransferase activity 1.4 1.3 1.4 3.0 1.1 
orf19.1191 -- HRD3 Ubiquitin-protein ligase activity 1.2 1.2 -1.1 1.6 1.7 
orf19.931 -- IFA13 -- 1.0 1.2 1.3 2.3 1.1 
orf19.996 -- IFA15 Adenylate cyclase activity -1.0 -1.1 1.4 5.2 2.3 
orf19.3919 -- IFA23 Cysteine-type endopeptidase activity 1.0 -1.0 -1.0 1.6 1.5 
orf19.570 IFF8 IFF8 -- 1.4 -1.2 1.4 1.6 1.4 
orf19.428 -- IKS1 Protein kinase activity 1.2 -1.1 -1.0 1.6 1.1 
orf19.4590 -- IPF1009 -- -1.1 1.7 1.3 2.1 -1.5 
orf19.4575 -- IPF1031 -- 1.3 -1.0 1.0 2.0 -1.1 
orf19.3364 -- IPF10394 -- -1.1 -1.3 1.1 2.6 -1.3 
orf19.424 TRP99 IPF10482.exon1 Alkyl hydroperoxide reductase activity 1.3 1.1 -1.5 1.5 -1.1 
orf19.1287 -- IPF10595 -- -1.7 1.1 1.1 12.0 -1.3 
orf19.5413 -- IPF1104 -- 1.1 1.1 1.2 1.6 -1.1 
orf19.1421 -- IPF11234 Ureidoglycolate hydrolase activity 1.8 1.2 -2.2 2.9 1.0 
orf19.3661 -- IPF11332 Ubiquitin-specific protease activity 1.1 1.1 1.3 2.0 1.1 
orf19.5295 -- IPF11876 -- 1.4 1.4 2.0 4.5 -1.3 
orf19.4234 -- IPF11954 -- 1.1 1.1 1.0 1.8 -1.0 
orf19.5644 -- IPF12127 -- 1.1 1.4 1.2 2.0 1.5 
orf19.3872 -- IPF12179 -- 1.2 1.1 1.1 1.7 -1.3 
orf19.3508 -- IPF12233 -- 1.1 1.1 1.2 2.3 1.1 
orf19.5070 -- IPF12312 -- 1.2 2.9 1.7 11.0 1.3 
orf19.7344 -- IPF12537 -- 2.0 -1.4 1.5 3.3 1.8 
orf19.2515 -- IPF12799 -- 1.3 -1.1 -1.2 1.9 1.6 
orf19.1162 -- IPF13081 -- -1.1 1.2 -1.3 1.9 1.9 
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orf19.1181 -- IPF13097 Phosphatidate phosphatase activity 3.6 -1.4 -1.0 11.3 14.4 
orf19.5729 FGR17 IPF13158 Transcription factor activity 1.1 1.1 1.1 2.1 -1.3 
orf19.6420 PGA13 IPF1341 -- 1.3 -1.1 -1.1 4.9 -1.7 
orf19.1656 -- IPF13675 Phosphatidylinositol binding -1.0 -1.2 1.5 2.0 -1.2 
orf19.6443 -- IPF1380 Dodecenoyl-CoA delta-isomerase activity -1.2 -1.1 1.1 2.1 2.2 
orf19.2344 ASR1 IPF13836 -- 2.8 1.8 1.4 18.3 1.7 
orf19.1120 FAV2 IPF13879 -- 1.4 1.1 1.4 2.3 -1.8 
orf19.914 -- IPF14094.repeat4 -- 1.1 -1.0 1.1 1.5 -1.3 
orf19.3586 -- IPF14773 -- 1.4 -1.1 -1.2 1.8 1.1 
orf19.4376 -- IPF15098 -- 1.2 1.1 1.6 3.4 1.2 
orf19.2607 -- IPF15672 -- 1.4 -1.1 -1.3 1.9 -1.2 
orf19.972 -- IPF1588 -- 1.2 1.3 1.1 1.9 -1.5 
orf19.1946 -- IPF16194 -- 1.3 1.2 -1.1 1.8 -1.0 
orf19.3922 -- IPF16228 Nucleotidase activity 1.1 -1.1 1.0 2.0 1.1 
orf19.3932 -- IPF16253 -- 1.2 1.2 -1.0 6.4 -1.2 
orf19.5877 -- IPF1837 Alcohol O-acetyltransferase activity 1.3 1.2 -1.1 2.8 1.2 
orf19.5620 -- IPF18418 -- 1.3 1.5 1.1 2.3 -1.2 
orf19.5727 -- IPF18553 -- 1.5 1.1 -1.0 2.1 -1.5 
orf19.2737 -- IPF18712 -- 1.4 1.4 1.4 2.8 1.0 
orf19.711 -- IPF18732 -- 1.4 1.4 1.2 3.0 1.3 
orf19.7317 UGA33 IPF1960.5f Transcription factor activity 1.3 -1.1 1.1 1.6 1.0 
orf19.7322 -- IPF1969 -- -1.1 1.1 1.2 1.8 -1.2 
orf19.5517 -- IPF20104 Alcohol dehydrogenase (NADP+) activity 1.2 1.1 1.2 1.7 -1.2 
orf19.4077 MIT1 IPF2067 Mannosyltransferase activity 1.0 1.2 1.1 1.8 2.1 
orf19.5980 -- IPF21 -- 1.4 1.1 -1.1 2.0 1.2 
orf19.6662 -- IPF2287 -- 1.1 -1.1 1.0 3.2 -1.8 
orf19.2158 NAG3 IPF2710.repeat2 Monosaccharide transporter activity -2.4 -1.7 -1.5 2.4 6.1 
orf19.7297 -- IPF2837 -- 1.1 1.2 -1.1 2.1 1.1 
orf19.3273 -- IPF285.3f -- 1.3 -1.1 1.0 2.0 1.2 
orf19.7281 -- IPF2861 -- 1.3 1.4 1.8 12.6 3.3 
orf19.4305.1 -- IPF2930 -- 1.2 -1.2 -1.1 2.1 -1.0 
orf19.3282 -- IPF300 -- 1.0 1.1 1.3 1.5 -1.2 
orf19.4438 RME1 IPF3121 Transcription factor activity 1.2 1.1 -1.3 5.7 1.7 
orf19.6758 -- IPF3484 Aldo-keto reductase activity 2.4 -1.1 -1.5 2.9 1.1 
orf19.6757 -- IPF3485 Aldo-keto reductase activity 1.1 1.2 1.4 2.0 -1.1 
orf19.675 -- IPF3964 -- 1.2 1.1 1.2 4.2 2.4 
orf19.535 RBR1 IPF4299 -- 1.3 -1.1 1.3 1.7 1.3 
orf19.2204 -- IPF5496 -- 1.3 1.1 1.1 1.8 -1.3 
orf19.6325.1 -- IPF5730 -- 1.3 1.1 1.1 1.6 -1.8 
orf19.5213 -- IPF5866 -- 1.1 1.2 1.2 2.7 1.4 
orf19.7631 -- IPF610 -- 1.1 -1.1 1.0 1.7 -1.1 
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orf19.3292 -- IPF6231 Protein-methionine-R-oxide reductase activity 1.2 1.0 -1.3 2.0 1.1 
orf19.1461 -- IPF6257 -- 1.2 -1.1 1.0 2.5 1.1 
orf19.6318 -- IPF6280 -- 1.3 1.1 1.1 1.6 -1.6 
orf19.2724 -- IPF6339 -- 1.2 1.3 -1.3 4.3 -1.6 
orf19.384 -- IPF6367 -- 1.2 1.2 1.3 1.7 1.6 
orf19.1573 -- IPF6387.3 -- 1.2 1.1 -2.3 1.6 -1.1 
orf19.6489 FMP45 IPF6624 -- 1.3 -1.4 1.2 4.8 2.2 
orf19.2762 AHP1 IPF6629 Alkyl hydroperoxide reductase activity 1.2 1.2 -1.2 2.5 -1.3 
orf19.7596 -- IPF673 -- 1.7 1.0 -2.0 15.2 1.1 
orf19.320 -- IPF6755 -- 1.4 -1.1 1.3 4.6 1.0 
orf19.3813 -- IPF6945.3f -- 1.3 -1.0 1.3 2.4 1.2 
orf19.5770 OPT8 IPF6990 Oligopeptide transporter activity -1.0 -1.1 1.1 2.0 -1.0 
orf19.1562 -- IPF7141 -- 1.2 1.4 1.4 2.3 1.2 
orf19.1564 -- IPF7145 -- 1.2 1.3 2.4 1.8 -1.2 
orf19.860 -- IPF7647 -- 1.2 1.3 1.4 2.4 1.6 
orf19.2693 -- IPF7968 Transcription corepressor activity -1.1 1.1 1.3 5.0 1.6 
orf19.1719 SGA1 IPF8402 Glucan 1,4-alpha-glucosidase activity 1.1 1.0 1.6 2.4 -1.4 
orf19.6952 -- IPF8666 -- 1.1 1.3 1.2 1.9 1.2 
orf19.4903 -- IPF8860 N-acetylglucosaminylphosphatidylinositol deacetylase activity -1.1 1.1 -1.1 1.7 -1.3 
orf19.5943 -- IPF91 -- 1.2 1.1 -1.0 1.8 1.2 
orf19.4370 -- IPF9450 -- 1.1 1.1 -1.1 2.4 1.0 
orf19.4911 -- IPF9618 -- 1.2 1.1 1.0 2.3 -1.3 
orf19.4593.1 -- IPF995 -- -1.1 -1.0 1.4 1.6 -1.5 
orf19.184 -- MDM10 -- 1.0 1.4 1.3 2.0 1.2 
orf19.478 -- MON1.3 -- 1.3 -1.1 -1.0 1.9 -2.4 
orf19.4044 MUM2 MUM2 -- 1.1 1.3 3.8 2.4 1.5 
orf19.5005 OSM2 OSM2 Fumarate reductase (NADH) activity 1.3 -1.0 -1.3 2.0 1.2 
orf19.2769 -- PBI2 Endopeptidase inhibitor activity 1.3 1.2 1.1 3.3 -1.2 
orf19.4186 PCT1 PCT1 Choline-phosphate cytidylyltransferase activity -1.2 1.3 -1.2 1.9 1.2 
orf19.2094 PDR6 PDR6 Protein carrier activity -1.1 -1.0 -1.0 1.7 -1.1 
orf19.1089 -- PEX11 -- -1.0 1.3 1.0 1.8 -2.4 
orf19.5285 PST3 PST2 -- 1.1 -1.1 1.2 2.3 1.0 
orf19.6341 -- RIB7 -- 1.1 1.0 -1.1 2.2 1.2 
orf19.2087 -- SAS2 Acetyltransferase activity -1.2 1.3 1.4 1.9 -1.3 
orf19.2770.1 SOD1 SOD1.3 Copper, zinc superoxide dismutase activity -1.0 1.1 -1.1 2.2 -1.1 
orf19.2299 -- URM1 -- -1.1 1.0 1.0 1.7 1.6 
orf19.5634 FRP1 FRE5 Ferric-chelate reductase activity 2.6 2.6 1.6 1.7 -1.2 
orf19.2176 IFM3 IFM3 -- 1.7 1.5 1.1 1.2 1.0 
orf19.6219 -- IPF7432 -- 1.8 1.5 1.1 -1.1 1.1 
orf19.1878 -- IPF9160 RNA polymerase II transcription mediator activity 1.5 2.4 -1.0 1.0 -1.5 
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orf19.5169 -- AMD21 Amidase activity 1.8 -1.5 1.5 3.5 1.3 
orf19.393 -- APS3 -- 1.7 1.2 1.5 1.5 1.0 
orf19.7053 GAC1 GAC1 Protein phosphatase type 1 activity 2.0 -1.2 1.7 1.0 1.5 
orf19.5431 -- IPF1129 -- 1.7 1.1 2.2 1.2 1.1 
orf19.7316 -- IPF5971 -- 1.5 1.3 1.5 1.0 -1.1 
orf19.5362 PSO2 IPF730 -- 6.9 -1.1 1.5 1.7 10.0 
orf19.1725 -- IPF9336.3eoc -- 1.8 1.1 1.5 1.1 1.5 
orf19.3112 ZRT1 ZRT1 Low-affinity zinc ion transporter activity 1.7 -1.6 1.5 3.9 1.2 
orf19.4774 AOX1 AOX1 Alternative oxidase activity 2.2 -1.1 1.3 3.2 -1.1 
orf19.4788 ARG5,6 ARG5,6 N-acetyl-gamma-glutamyl-phosphate reductase activity 1.6 1.1 2.3 2.3 -1.9 
orf19.6214 ATC1 ATH1 Alpha, alpha-trehalase activity 1.8 1.3 1.1 5.1 2.6 
orf19.2401 -- AUT2 Microtubule binding 1.5 -1.2 1.1 1.7 1.1 
orf19.5604 MDR1 BMR1 Multidrug transporter activity 1.8 -1.1 1.1 1.8 1.3 
orf19.113 CIP1 CIP1 -- 1.5 1.2 1.4 2.2 1.7 
orf19.6956 DAL9 DAL51 Allantoate transporter activity 1.9 1.1 1.2 2.9 1.6 
orf19.3234 -- EBP5 NADPH dehydrogenase activity 1.8 1.0 1.2 2.5 -1.1 
orf19.6958 ECM18 ECM18 -- 2.7 1.1 -1.0 3.4 1.2 
orf19.4589 -- FMS1 -- 1.6 1.1 -1.1 1.8 -1.2 
orf19.6995 -- FRP7 -- 1.7 1.3 1.7 2.2 1.5 
orf19.313 DAL4 FUR4 Allantoin permease activity 2.4 -1.2 1.3 4.5 2.1 
orf19.7021 GPH1 GPH1 Glycogen phosphorylase activity 1.8 1.2 1.2 1.6 1.8 
orf19.1582 -- HOL5.5f Transporter activity 1.5 -1.3 1.3 5.3 6.2 
orf19.1048 -- IFD1 Aryl-alcohol dehydrogenase activity 2.1 1.3 -1.1 3.5 1.2 
orf19.3311 IFD3 IFD3 Aryl-alcohol dehydrogenase activity 1.7 -1.1 1.3 2.1 1.2 
orf19.1048 IFD6 IFD5 Aryl-alcohol dehydrogenase activity 1.6 1.2 1.5 3.7 1.5 
orf19.7472 IFF4 IFF4 -- 2.6 1.3 1.2 3.0 -1.1 
orf19.5840 -- IPF11222 -- 1.8 1.2 1.4 2.4 -1.3 
orf19.5210 -- IPF11259 Transcription factor activity 2.3 1.7 1.2 1.8 2.1 
orf19.1405 PHO13 IPF11589 4-nitrophenylphosphatase activity 1.7 1.1 1.2 1.6 -1.8 
orf19.1152 -- IPF11713 -- 1.6 1.2 -1.3 1.7 -1.1 
orf19.2076 -- IPF1197 -- 1.7 1.1 1.1 2.3 1.6 
orf19.1950 -- IPF12138 -- 1.6 -1.0 -1.0 3.4 1.6 
orf19.2064 -- IPF1216 Transcription factor activity 1.5 -1.1 2.7 1.7 1.5 
orf19.2131 -- IPF12244 -- 1.6 1.1 1.4 1.7 1.2 
orf19.4356 HGT3 IPF12946 Glucose transporter activity 1.5 1.2 -1.0 1.8 1.3 
orf19.6366 -- IPF13450 -- 1.6 2.7 2.0 10.6 1.6 
orf19.5925 -- IPF138 -- 2.4 1.1 -1.0 3.0 1.7 
orf19.5204 -- IPF13971 -- 1.7 1.2 1.5 2.5 1.8 
orf19.4688 DAG7 IPF14119 -- 2.4 1.1 1.1 1.5 1.2 
orf19.4132 -- IPF14871 -- 1.6 1.3 -1.1 2.1 -1.3 
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orf19.348 -- IPF1505 -- 2.6 1.2 1.2 3.7 1.8 
orf19.3053 -- IPF15297 -- 1.5 1.2 -1.1 1.8 1.1 
orf19.3910 -- IPF15494 -- 1.6 -1.3 1.1 3.0 2.2 
orf19.6586 -- IPF1617 -- 1.5 1.1 1.2 9.9 -1.0 
orf19.69 -- IPF17131 -- 1.8 1.1 1.3 5.5 1.4 
orf19.5879 -- IPF1839 Acylglycerone-phosphate reductase activity 1.6 1.0 1.4 6.0 -1.0 
orf19.4334 PGA58 IPF19706 -- 2.3 1.3 -1.3 1.6 1.1 
orf19.7288 -- IPF2852 -- 1.9 -1.2 1.0 2.8 2.6 
orf19.4439 -- IPF3105 -- 1.8 1.2 1.0 2.5 -1.2 
orf19.2870 -- IPF3250 -- 1.5 -1.4 -1.2 3.3 -1.0 
orf19.3839 SAP10 IPF4089 Aspartic-type signal peptidase activity 1.6 1.0 -1.3 2.5 1.6 
orf19.5449 -- IPF4176 -- 1.5 1.3 1.2 3.3 1.1 
orf19.1632 -- IPF4256 -- 2.3 1.5 1.4 2.7 -1.0 
orf19.6329 -- IPF5723.exon1 -- 1.6 1.0 1.3 1.6 -1.5 
orf19.1307 -- IPF6678 -- 6.9 -1.4 -2.3 3.5 1.2 
orf19.4246 -- IPF6881 -- 1.7 1.3 1.3 2.2 -1.1 
orf19.2966 -- IPF7778 Carboxymethylenebutenolidase activity 1.6 1.2 1.3 2.0 1.2 
orf19.6025 -- IPF7900 -- 1.6 1.2 1.0 2.4 -1.3 
orf19.6869 -- IPF8041 Peptidase activity 1.6 -1.1 1.6 1.6 1.9 
orf19.4543 UGA2 IPF8048 Succinate-semialdehyde dehydrogenase [NAD(P)+] activity 1.8 1.4 1.1 2.7 1.1 
orf19.7235 -- IPF846 -- 1.6 1.4 1.2 2.0 1.2 
orf19.2302 -- IPF8814 -- 1.5 1.1 -1.3 2.0 1.1 
orf19.7214 -- IPF885 -- 2.4 1.4 1.3 4.6 1.5 
orf19.4905 -- IPF8862 -- 1.5 1.1 -1.4 1.7 1.2 
orf19.1360 -- IPF8914 -- 1.8 1.4 -1.7 8.2 4.1 
orf19.7210 -- IPF893 -- 1.8 -1.3 1.4 2.6 1.3 
orf19.2737 -- IPF9167 -- 1.6 1.3 1.4 2.3 1.2 
orf19.5942 -- IPF96 -- 1.6 1.4 1.1 1.7 1.5 
orf19.4910 FGR41 IPF9616 -- 1.5 1.2 1.3 1.6 1.1 
orf19.3499 -- IPF9955 -- 2.1 1.3 -1.1 4.8 -1.0 
orf19.7447 JEN1 JEN1 Lactate transporter activity 1.7 -1.1 1.1 2.0 1.2 
orf19.7498 LEU1 LEU1 3-isopropylmalate dehydratase activity 1.6 -1.0 1.3 1.6 1.9 
orf19.4584 PHO114 PHO12 Acid phosphatase activity 1.5 -1.2 1.1 1.9 -1.1 
orf19.1586 FGR22 PLC3 Phosphoinositide phospholipase C activity 1.6 1.2 -1.0 1.5 -2.4 
orf19.2969 RAD16 RAD16 DNA-dependent ATPase activity 1.6 1.2 1.0 1.9 1.6 
orf19.5636 RBT5 RBT5 Heme binding 2.4 1.2 1.3 3.3 1.7 
orf19.5714 SAP1 SAP1 Aspartic-type endopeptidase activity 2.0 1.3 1.1 2.2 1.5 
orf19.5542 SAP6 SAP6 Aspartic-type endopeptidase activity 2.1 1.1 1.1 3.6 1.2 
orf19.6928 SAP9 SAP9 Aspartic-type endopeptidase activity 1.5 1.2 1.0 1.6 1.3 
orf19.2812 -- SNG2 -- 2.7 -1.3 1.3 3.6 1.2 
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orf19.2897 SOU2 SOU2 2,4-dienoyl-CoA reductase (NADPH) activity 1.7 1.1 1.1 1.6 1.2 
orf19.4980 HSP70 SSA4 Unfolded protein binding 2.1 1.1 1.5 3.1 3.2 
orf19.7637 YHB4 YHB2 Nitric oxide dioxygenase activity 1.5 -1.1 1.1 1.9 1.6 
orf19.4476 -- IFD6 Aryl-alcohol dehydrogenase activity 1.6 4.8 2.3 2.2 1.2 
orf19.1865 -- IPF4059 -- 1.2 1.8 1.6 -1.4 -1.1 
orf19.6996 -- IPF4514 Alpha-1,3-mannosyltransferase activity 1.1 1.6 2.1 1.1 1.0 
orf19.3737 -- IPF4721 -- 1.3 1.5 1.9 1.1 -1.2 
orf19.2652 TEF4 TEF41 Translation elongation factor activity 1.3 3.7 2.9 -1.1 -2.4 
orf19.3195 HIP1 GAP7.3eoc Amino acid permease activity 1.2 1.5 1.1 1.6 1.5 
orf19.3133 GUT2 GUT2 Glycerol-3-phosphate dehydrogenase activity 1.0 1.5 1.3 1.8 1.2 
orf19.4763 -- IPF10916 -- -1.1 1.5 1.0 3.7 -1.3 
orf19.1395 -- IPF11059 Inorganic phosphate transporter activity 1.3 1.5 -1.1 9.7 -1.4 
orf19.1698 -- IPF13217 -- 1.1 1.5 1.0 1.5 1.3 
orf19.956 -- IPF1566 -- -1.2 1.5 1.4 1.7 1.3 
orf19.5145 SSP96 IPF18316.3f -- -1.0 1.6 -1.4 3.4 1.5 
orf19.909 STP4 IPF4553 Transcription factor activity -1.0 1.9 1.0 1.9 -1.5 
orf19.2184 -- IPF5534 -- -1.0 1.6 1.5 1.9 1.8 
orf19.3338 -- IPF7374 -- -1.1 2.1 2.3 5.8 1.5 
orf19.4670 CAS5 IPF7414 Transcription factor activity 1.3 1.6 1.5 4.2 1.9 
orf19.1424 -- IPF9370 -- 1.3 1.8 1.9 2.8 1.6 
orf19.4478 -- MSD1 Aspartate-tRNA ligase activity 1.1 1.7 1.1 1.6 1.2 
orf19.5614 -- RNH1 Ribonuclease H activity -1.0 1.5 1.1 1.5 -1.0 
orf19.6951 -- DPL1 -- 1.2 1.1 1.7 2.0 1.0 
orf19.932 -- DRS24 Phospholipid-translocating ATPase activity 1.2 1.3 1.6 1.6 1.1 
orf19.629 IFD7 IFD7 Aryl-alcohol dehydrogenase activity 5.2 1.7 2.0 1.8 -1.1 
orf19.2574 -- IFU4 -- 1.2 1.0 1.5 2.2 1.8 
orf19.1676 -- IPF12501 -- 1.1 1.2 1.8 1.7 -1.3 
orf19.2910 PGA43 IPF13139 -- 1.3 1.1 2.2 2.2 -1.2 
orf19.4347 -- IPF14273 Receptor signaling protein serine/threonine kinase activity -1.8 -1.1 1.5 2.1 1.2 
orf19.3461 -- IPF14968 -- 1.1 1.5 2.4 2.6 1.1 
orf19.5612 -- IPF15015 -- 1.5 1.4 4.8 3.3 1.3 
orf19.6754 -- IPF3490 -- -1.1 1.3 1.6 1.7 -1.1 
orf19.3743 -- IPF4729 -- 1.4 1.2 1.6 2.5 -1.0 
orf19.3826 -- IPF5830 -- 1.1 1.3 1.9 1.6 -1.2 
orf19.3859 -- IPF6600 -- 1.1 1.3 1.7 2.0 1.2 
orf19.5587 -- IPF6812 -- 1.4 1.0 1.5 3.7 -1.3 
orf19.4539 -- IPF8055 Rho GDP-dissociation inhibitor activity -1.1 1.1 2.3 2.1 1.5 
orf19.6220.3 -- MMD1.3 -- 1.0 1.2 1.5 1.6 1.1 
orf19.5731 -- PAD1 Carboxy-lyase activity 1.4 1.2 2.5 3.0 -2.4 
orf19.7389 REV3 REV3.3f Zeta DNA polymerase activity 1.0 1.1 1.7 1.7 -1.0 
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Table A-1 (continued). 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.732 -- SOU3 2,4-dienoyl-CoA reductase (NADPH) activity 1.3 1.2 1.7 2.3 -1.1 
orf19.6026 ERG2 ERG2 C-8 sterol isomerase activity 1.8 3.0 2.5 1.6 -1.4 
orf19.1598 ERG24 ERG24 Delta 14-sterol reductase activity 1.6 1.8 2.1 -1.2 -1.0 
orf19.3421.1 -- IPF17743 RNA polymerase II transcription mediator activity 1.6 1.6 1.9 1.2 -1.5 
orf19.2849 AQY1 AQY1 Water channel activity 3.6 2.4 1.7 8.4 2.4 
orf19.3442 -- EBP2 NADPH dehydrogenase activity 1.7 1.5 2.1 2.4 1.4 
orf19.4255 ECM331 ECM331 -- 2.7 1.6 1.3 4.2 -1.4 
orf19.2613 ECM4 ECM41.3 -- 1.6 2.0 2.0 4.6 -1.0 
orf19.2990 XOG1 EXG1 Glucan 1,3-beta-glucosidase activity 2.9 2.2 1.2 1.8 1.0 
orf19.2952 EXG2 EXG2 Glucan 1,3-beta-glucosidase activity 1.5 1.5 -1.2 2.4 1.0 
orf19.6659 GAP6 GAP6 Amino acid permease activity 1.6 1.5 1.2 4.0 1.1 
orf19.4477 CSH1 IFD4 Aryl-alcohol dehydrogenase activity 2.9 2.3 -1.0 4.6 1.6 
orf19.6678 -- IFJ5 -- 2.1 1.5 1.2 12.3 1.6 
orf19.2280 ZCF10 IPF10079 Transcription factor activity 1.6 1.8 1.5 6.1 2.1 
orf19.5635 PGA7 IPF12101 -- 3.2 1.7 1.5 2.8 1.0 
orf19.251 -- IPF17186 -- 2.0 1.8 1.2 4.2 1.1 
orf19.2175 -- IPF19998 Oxidoreductase activity 2.4 1.6 1.3 3.3 1.3 
orf19.7284 ASR2 IPF2857 -- 5.2 2.3 10.5 17.6 1.5 
orf19.7042 -- IPF3080 -- 2.1 1.5 1.2 5.5 1.3 
orf19.1862 -- IPF4065 -- 3.5 1.7 1.1 9.0 -1.1 
orf19.5525 -- IPF4328 -- 1.5 1.6 1.2 2.3 1.1 
orf19.2296 -- IPF7715 -- 2.3 1.5 1.2 4.1 1.7 
orf19.3131 -- IPF7817 NADPH dehydrogenase activity 1.7 1.8 1.4 5.1 1.4 
orf19.2691 -- IPF7970 -- 1.6 1.6 1.2 4.9 3.0 
orf19.744 GDB1 IPF9740 4-alpha-glucanotransferase activity 1.7 1.5 1.1 3.1 1.7 
orf19.1240 -- IPF9887.3eoc -- 1.5 1.6 1.2 2.6 1.6 
orf19.2285 -- IPF9996 -- 4.6 2.2 1.6 8.1 1.2 
orf19.1149 MRF1 MRF1 DNA binding 1.8 1.6 -1.1 8.0 1.5 
orf19.1655 PXP2 PXP2 Acyl-CoA oxidase activity 2.1 2.1 1.1 3.0 1.2 
orf19.6202 RBT4 RBT4 -- 1.7 1.7 -1.1 2.6 -1.1 
orf19.5585 SAP5 SAP5 Aspartic-type endopeptidase activity 1.8 1.5 -1.1 5.4 -1.0 
orf19.2991 HOL1 HOL1 Transporter activity 2.3 1.3 1.8 2.5 1.1 
orf19.7585 INO1 INO1 Inositol-3-phosphate synthase activity 3.1 1.3 1.8 6.1 1.3 
orf19.1266 -- IPF10280 -- 1.6 1.4 2.0 2.2 1.1 
orf19.1180 -- IPF13098 -- 1.7 1.2 1.5 1.8 2.2 
orf19.2296 -- IPF14282 -- 1.8 1.4 2.3 6.1 2.4 
orf19.3929 -- IPF14603 -- 1.9 1.0 1.9 1.9 -1.1 
orf19.347 RSN1 IPF1506 -- 2.0 1.1 1.7 2.0 1.8 
orf19.3190 HAL9 IPF16067 Specific RNA polymerase II transcription factor activity 1.9 1.2 1.6 1.8 1.6 
orf19.94 -- IPF19749 -- 2.0 1.1 1.5 2.8 -1.0 
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Table A-1 (continued). 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.3846 -- IPF20118 -- 1.6 -1.1 3.8 2.6 -1.5 
orf19.6627 -- IPF2557 -- 1.7 1.2 2.2 2.6 -1.0 
orf19.3043 -- IPF3594 Triacylglycerol lipase activity 1.5 -1.1 1.8 1.6 1.1 
orf19.3544 -- IPF6438 -- 1.6 1.3 2.8 2.7 1.6 
orf19.4533 -- IPF7533 -- 1.5 1.3 1.6 1.6 1.1 
orf19.1395 -- IPF7686 Inorganic phosphate transporter activity 1.5 1.4 2.1 6.3 -1.5 
orf19.3188 TAC1 IPF9191.5f -- 2.5 1.5 2.4 45.4 -11.7 
orf19.3071 -- IPF9605 Protein tyrosine phosphatase activity 1.5 1.0 1.5 1.7 1.5 
orf19.5102 PLB5 PLB5 Lysophospholipase activity 1.5 1.3 1.6 3.6 1.1 
orf19.2046 POT1-2 POT13 Acetyl-CoA C-acyltransferase activity 1.5 1.3 1.6 1.7 1.2 
orf19.7319 SUC1 SUC1 Transcription factor activity 2.0 1.2 1.8 5.1 1.2 
orf19.1974 TFS1 TFS1 Lipid binding 1.5 1.4 1.7 2.4 -1.0 
orf19.345 -- UGA2 Succinate-semialdehyde dehydrogenase activity 1.8 1.3 1.6 4.0 3.0 
orf19.4082 DDR48 DDR48 -- 1.2 2.5 2.6 2.5 -1.6 
orf19.6445 ECI1 IPF1384 Dodecenoyl-CoA delta-isomerase activity 1.3 1.8 1.6 4.4 1.2 
orf19.354 -- IPF1493 -- -1.0 1.5 1.7 1.8 1.2 
orf19.1365 -- IPF16016 -- 1.2 1.6 1.6 2.1 -1.2 
orf19.5799 -- IPF20010 -- 1.4 1.8 1.6 1.7 1.7 
orf19.6770 -- IPF2804 Cytoskeletal adaptor activity 1.3 1.6 1.5 2.7 -1.0 
orf19.3045 -- IPF3597 Aldehyde dehydrogenase (NAD) activity 1.4 1.6 1.6 1.6 1.2 
orf19.6501 -- IPF3931 -- 2.0 3.1 7.4 4.6 1.1 
orf19.6734 TCC1 IPF6067 General transcriptional repressor activity -1.1 1.8 1.6 1.7 -1.0 
orf19.4056 GAT2 IPF7666 Transcription factor activity 1.2 2.1 2.3 5.4 -1.7 
orf19.2248 ARE2 ARE2 Sterol O-acyltransferase activity 2.1 1.7 1.5 3.0 1.7 
orf19.6000 CDR1 CDR1 Multidrug transporter activity 1.7 3.0 2.4 4.4 -1.0 
orf19.5958 CDR2 CDR2 Transporter activity 50.6 14.1 17.1 50.5 -1.3 
orf19.86 -- GPX1 Glutathione peroxidase activity 2.3 3.0 2.3 4.0 -1.2 
orf19.896 CHK1 HK1 Protein histidine kinase activity 2.5 1.9 1.8 4.5 1.3 
orf19.3160 HSP12 HSP12 -- 5.3 2.9 3.1 16.7 -1.7 
orf19.157 -- IFA24.3 -- 1.5 1.7 1.6 2.1 1.1 
orf19.2568 IFU5 IFU5 -- 3.3 3.0 3.7 5.4 1.5 
orf19.2726 -- IPF10262 -- 2.5 2.8 1.9 6.2 -2.9 
orf19.1267 -- IPF10278 Chaperone regulator activity 1.8 1.7 1.8 2.5 -1.2 
orf19.4459 -- IPF11849 -- 2.0 4.1 4.3 5.0 -1.5 
orf19.2244 -- IPF12897 -- 1.8 1.7 1.5 5.4 -1.7 
orf19.851 -- IPF14030 -- 1.7 1.9 1.9 4.0 -1.3 
orf19.344 -- IPF1514 -- 15.5 4.7 4.0 28.9 1.9 
orf19.4907 -- IPF17283 -- 3.2 1.6 2.3 2.0 1.1 
orf19.5313 -- IPF19810 -- 36.0 29.4 18.1 143.1 1.7 
orf19.5777 -- IPF19961 -- 2.0 1.7 2.2 4.2 -1.3 
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Table A-1 (continued). 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.7166 -- IPF2186 -- 4.2 2.2 1.5 5.0 1.2 
orf19.6840 -- IPF3535 -- 1.8 2.3 1.9 2.3 -1.4 
orf19.3047 -- IPF3598 Transcription cofactor activity 1.5 1.5 1.7 3.0 1.3 
orf19.2531 CSP37 IPF4991 ER to Golgi vesicle-mediated transport 2.5 1.8 5.5 6.8 -1.3 
orf19.3007.2 -- IPF5360.3 -- 2.0 1.6 1.9 2.8 1.1 
orf19.7310 -- IPF5981 -- 4.9 2.7 2.0 16.8 1.2 
orf19.1887 -- IPF6464 -- 2.3 1.8 1.7 4.5 1.2 
orf19.2790 -- IPF7260 Histone-lysine N-methyltransferase activity 1.8 1.6 1.6 2.8 -1.0 
orf19.4531 -- IPF7530 ATPase activity 2.7 3.8 3.5 4.0 -1.6 
orf19.4898 -- IPF8950 -- 2.4 1.6 1.8 3.4 1.1 
orf19.3188 TAC1 IPF9191.3f -- 2.7 2.8 2.8 4.2 -11.0 
orf19.3644 -- IPF9683 -- 2.5 1.5 2.1 3.4 1.1 
orf19.5257 -- LCB4 D-erythro-sphingosine kinase activity 2.2 1.7 2.2 4.0 1.1 
orf19.278 -- MTR -- 3.1 1.8 1.9 5.2 -1.1 
orf19.5713 YMX6 NDH2 NADH dehydrogenase activity 5.3 3.1 2.9 15.3 1.3 
orf19.7218 RBE1 PRY2 -- 2.1 1.8 1.7 1.7 1.2 
orf19.23 RTA3 RTA3 Phospholipid-translocating ATPase activity 40.4 15.9 22.0 41.0 1.0 
orf19.2896 SOU1 SOU1 Sorbose dehydrogenase activity 2.0 1.5 1.5 7.0 -2.0 
orf19.1290 -- XKS1 Xylulokinase activity 1.6 1.7 1.6 2.7 1.6 
orf19.3104 -- YDC1 -- 3.3 1.6 2.1 5.3 1.4 
 
a orf19 nomenclature according to the Assembly 19 version. 
b Gene name at CGD (http://www.candidagenome.org/). 
c Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
d GO annotation found at CGD (http://www.candidagenome.org/). 
Gene expression values in bold designate statistical significance (p-value < 0.05) in all three experiments. 
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Table A-2. Genes down-regulated in at least one matched clinical isolate. 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.7043 -- ACB1.exon2 Acyl-CoA binding -2.0 1.6 1.9 1.4 1.1 
orf19.798 -- ANC1 General RNA polymerase II transcription factor activity -1.8 -1.0 1.1 -1.1 -2.5 
orf19.5345 -- DSK2 Protein binding -1.5 -1.0 1.2 -1.1 1.6 
orf19.4295 -- HIR2 Transcription corepressor activity -2.3 1.1 1.7 1.0 1.2 
orf19.4051 HTS1 HTS1 Histidine-tRNA ligase activity -1.5 1.1 1.2 -1.5 1.2 
orf19.3691 -- IPF10716 -- -1.5 -1.0 1.3 1.1 1.1 
orf19.2356 CRZ2 IPF10795 Transcription factor activity -2.2 2.1 -1.4 1.4 1.3 
orf19.2827 -- IPF10963 Structural constituent of cytoskeleton -2.2 1.5 -1.0 5.3 3.9 
orf19.4658 -- IPF11006 -- -1.5 1.0 2.5 2.6 1.4 
orf19.3198 OBPA IPF11167 Oxysterol binding -85.5 1.1 1.3 2.1 -1.8 
orf19.5241 SNT1 IPF12584 NAD-dependent histone deacetylase activity -1.5 1.1 1.3 -1.2 1.2 
orf19.7371 ZCF35 IPF1264 Transcription factor activity -1.7 1.8 1.3 1.1 -1.6 
orf19.2363 -- IPF12845 -- -1.5 1.2 1.2 -1.4 1.1 
orf19.3551 -- IPF13370 Structural constituent of cytoskeleton -1.8 -1.0 1.4 1.6 -1.7 
orf19.4474 -- IPF14379 -- -1.8 -1.7 4.2 -1.1 1.1 
orf19.4342 -- IPF14623 Specific RNA polymerase II transcription factor activity -3.2 1.3 1.1 -1.0 -1.7 
orf19.954 -- IPF1557 -- -1.5 1.1 -1.2 -1.3 -1.2 
orf19.4698 -- IPF15977 -- -1.8 -1.0 1.2 -1.9 -1.2 
orf19.5297 -- IPF19753 General RNA polymerase II transcription factor activity -1.8 1.3 1.6 -1.1 -1.0 
orf19.6920 -- IPF2195 -- -2.2 -1.2 -1.3 1.1 1.3 
orf19.3260 -- IPF256 -- -1.7 2.0 1.1 1.9 1.7 
orf19.871 -- IPF3950 -- -2.1 -1.0 1.6 1.1 1.0 
orf19.7506 -- IPF404.5f Protein binding -1.7 1.2 1.1 -1.2 -1.0 
orf19.6934 -- IPF4206 -- -1.5 1.1 2.4 -1.0 -1.6 
orf19.5908 TEC1 IPF4351 Specific RNA polymerase II transcription factor activity -1.6 1.0 -1.1 1.1 -1.6 
orf19.5910 -- IPF4356 -- -1.6 -1.3 1.4 1.5 -1.2 
orf19.7675 -- IPF4955 Structural constituent of ribosome -1.6 1.2 1.2 -1.5 1.0 
orf19.2529 -- IPF4988 -- -1.6 -1.4 1.2 1.1 1.0 
orf19.7256 -- IPF5243 -- -1.6 1.0 1.5 1.2 -1.5 
orf19.7085 -- IPF525 -- -1.5 1.0 -1.0 1.2 1.8 
orf19.7314 CDG1 IPF5972 -- -1.9 1.5 -1.1 -1.2 -1.5 
orf19.1542 HEX3 IPF6497 -- -1.7 -1.0 -1.3 -1.1 -1.1 
orf19.7545 -- IPF7010.3 -- -1.7 1.1 1.2 -1.0 -1.6 
orf19.5368 -- IPF714 -- -1.9 1.2 4.6 1.1 1.4 
orf19.1449 -- IPF7863 -- -1.7 -1.2 1.1 2.7 1.4 
orf19.2939 -- IPF8114 -- -1.8 -1.3 -1.4 1.2 -2.8 
orf19.3714 -- IPF8295 -- -1.5 1.0 -1.8 -1.4 -1.2 
orf19.4066 -- IPF9466 -- -2.1 -1.3 -1.1 1.1 1.0 
orf19.4144 -- IPF9825 -- -2.1 1.1 1.3 1.5 1.0 
orf19.585 -- MRPL17 Structural constituent of ribosome -1.8 1.6 1.2 1.0 -1.7 
orf19.3321 -- MRS7 -- -1.8 1.3 1.7 1.4 -1.1 
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Table A-2 (continued). 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.6294 -- MYO1 Microfilament motor activity -1.6 1.0 1.7 1.1 -1.2 
orf19.3181.1 -- NCE11 -- -2.7 -1.1 1.3 -1.0 -1.5 
orf19.7279 -- NIT2 -- -1.6 -1.1 -1.1 -1.3 1.1 
orf19.3197 PAP1 PAP11 RNA binding -108.1 1.2 -1.1 -1.2 -50.0 
orf19.3974 PUT2 PUT2 1-Pyrroline-5-carboxylate dehydrogenase activity -1.6 -1.0 1.1 -1.3 -1.1 
orf19.607 -- RAD26 DNA-dependent ATPase activity -1.7 -1.0 1.8 1.6 1.1 
orf19.5968 RDI1 RDI1 Rho GDP-dissociation inhibitor activity -1.6 1.0 -1.0 1.0 -1.4 
orf19.2823 RFG1 ROX1 DNA bending activity -1.5 1.2 1.0 -1.0 -1.0 
orf19.6933 -- RRD2 Protein phosphatase type 2A regulator activity -1.5 -1.2 1.0 -1.1 -1.1 
orf19.2555 URA5 URA5 Orotate phosphoribosyltransferase activity -1.5 1.1 1.1 -1.3 -2.0 
orf19.1495 -- UTR4 -- -2.0 1.4 -1.2 1.8 -2.2 
orf19.6169 -- FRP2 -- 1.2 -1.6 1.5 2.2 -1.1 
orf19.4570 -- IPF1038 -- 1.1 -2.0 6.7 1.6 -1.6 
orf19.6308 -- IPF12227.3f -- 1.2 -1.5 -1.0 1.1 1.1 
orf19.3905 -- IPF17642 -- -1.0 -3.9 1.7 1.6 1.6 
orf19.2336 -- IPF8682 -- 1.7 -1.7 1.4 2.8 -1.2 
orf19.2028 MXR1 MXR1 Protein-methionine-S-oxide reductase activity -1.2 -1.6 -1.3 -1.5 -1.2 
orf19.6031 -- VPS27 -- -1.2 -1.5 -1.1 1.3 1.2 
orf19.1816 ALS3 ALS3.3eoc Cell adhesion molecule binding 1.0 -1.4 -2.4 1.0 -1.5 
orf19.2419 -- DOM34 -- 1.1 1.1 -1.7 -1.1 -1.1 
orf19.3433 OYE23 EBP4 NADPH dehydrogenase activity 1.0 1.0 -2.0 -1.7 2.0 
orf19.3374 ECE1 ECE1 -- 1.9 1.5 -3.8 5.6 1.5 
orf19.1774 -- FDH13.5f Formate dehydrogenase activity -1.1 -1.7 -1.5 -1.1 -1.8 
orf19.6947 -- GTT1.3 Glutathione transferase activity -1.4 -1.2 -1.5 1.3 -1.0 
orf19.6706 GYP7 GYP7 Rab GTPase activator activity -1.4 -1.1 -1.9 1.2 1.6 
orf19.779 -- HAT1 H3/H4 histone acetyltransferase activity -1.3 1.1 -1.6 1.0 -1.0 
orf19.1979 GIT1 IFN1 Phospholipid transporter activity -1.3 -1.1 -1.5 -1.0 1.2 
orf19.2283 -- IPF10071 -- 1.1 -1.1 -1.5 1.1 -1.2 
orf19.1392 -- IPF11068 Protein disulfide isomerase activity 1.6 1.1 -1.6 -1.1 1.0 
orf19.4771 -- IPF11667 -- -1.4 -1.4 -1.7 -1.4 1.2 
orf19.4457 BNI4 IPF11847 -- -1.0 1.2 -1.5 -1.1 1.6 
orf19.3222 -- IPF162 -- -1.2 -1.1 -1.6 -1.0 1.9 
orf19.2989 -- IPF16795 -- -1.0 1.0 -1.9 1.5 2.0 
orf19.4997 KIS2 IPF1792 AMP-activated protein kinase activity -1.0 -1.0 -1.6 -1.1 1.5 
orf19.730 -- IPF20142 -- -1.1 -1.0 -1.5 -1.3 1.7 
orf19.588 -- IPF6380 -- 1.2 1.2 -1.8 1.3 -1.6 
orf19.1573 -- IPF6387.3 -- 1.2 1.1 -2.3 1.6 -1.1 
orf19.6077 -- IPF8369 -- 1.2 -1.2 -1.7 -1.1 1.5 
orf19.1187 CPH2 IPF9062 Double-stranded DNA binding -1.1 -1.0 -1.6 -1.5 -1.1 
orf19.4374 -- IPF9438 -- -1.0 -1.0 -1.5 -1.3 -1.7 
orf19.6671 LAP4 LAP42 Aminopeptidase I activity 1.0 -1.2 -1.7 -1.1 1.5 
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Table A-2 (continued). 
 
Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.3796 -- RNT1 Ribonuclease III activity -1.2 1.7 -1.5 1.1 1.1 
orf19.5750 SHM2 SHM2 Glycine hydroxymethyltransferase activity -1.2 -1.1 -1.6 -1.5 1.2 
orf19.2179 SIT1 SIT1 Ferrichrome transporter activity 1.6 -1.3 -1.7 1.1 1.2 
orf19.6260 -- UBP12 Ubiquitin-specific protease activity -1.1 1.1 -1.6 1.9 1.2 
orf19.559 FGR14 Zorro1a -- 1.1 1.1 -2.9 -1.1 -1.1 
orf19.3331 ABC1 ABC1 -- -1.1 1.2 1.7 -2.1 -1.2 
orf19.6632 ACO2 ACO2 Aconitate hydratase activity -1.2 -1.0 1.1 -1.9 1.1 
orf19.3468 ALG11 ALG11 Alpha-1,2-mannosyltransferase activity 1.3 -1.0 -1.3 -1.9 1.0 
orf19.7551 ALO1 ALO1 D-arabinono-1,4-lactone oxidase activity -1.2 -1.0 1.1 -2.0 1.1 
orf19.2848 -- APG13 Protein binding -1.0 -1.1 -1.1 -1.5 1.3 
orf19.5487 CDC46 CDC46 ATP-dependent DNA helicase activity 1.1 -1.2 1.1 -1.7 1.1 
orf19.5870 CTP1 CTP1 Tricarboxylate carrier activity -1.2 -1.0 1.0 -1.7 -1.3 
orf19.4870 -- DBP3 ATP-dependent RNA helicase activity -1.2 1.1 -1.0 -1.9 -1.0 
orf19.3393 -- DBP9 ATP-dependent RNA helicase activity -1.3 1.1 1.1 -2.2 -1.6 
orf19.6702 DED81 DED81 ATP binding -1.1 -1.0 -1.1 -1.9 1.2 
orf19.5164 ECM39 ECM39 Alpha-1,6-mannosyltransferase activity 1.0 1.0 -1.2 -2.3 1.7 
orf19.7332 ELF1 ELF1 ATP binding -1.3 1.5 1.1 -2.2 -1.6 
orf19.333 FCY2 FCY22 Cytosine-purine permease activity -1.3 1.1 -1.3 -2.0 1.3 
orf19.7231 FTR2 FTR2 Iron ion binding -1.2 1.1 -1.1 -2.2 1.0 
orf19.481 GCD1 GCD1 Translation initiation factor activity -1.3 1.1 1.1 -1.9 -1.0 
orf19.500 -- GCD10 tRNA methyltransferase activity -1.2 1.2 -1.2 -2.2 -1.3 
orf19.2003 HNM1 HNM1 Choline transporter activity 1.0 -1.4 -1.0 -2.3 -1.7 
orf19.4889 -- HOL2 Transporter activity -1.3 -1.1 -1.2 -2.6 -1.2 
orf19.3476 -- HRR25 Casein kinase activity -1.2 1.3 1.1 -1.5 -1.0 
orf19.6515 HSP90 HSP90 ATPase activity, coupled -1.1 -1.0 1.1 -1.7 1.3 
orf19.7488 -- IMP3 snoRNA binding -1.1 1.1 -1.1 -1.7 -2.6 
orf19.5071 NRP1 IPF10092 -- -1.1 1.1 -1.0 -1.8 -1.2 
orf19.5034 -- IPF10424 -- -1.2 -1.1 -1.2 -1.6 -1.0 
orf19.5987 -- IPF11 -- -1.1 1.1 -1.1 -1.6 -1.1 
orf19.4623 -- IPF11090.exon2 -- -1.3 1.1 -1.1 -1.6 1.2 
orf19.51 -- IPF11177 Translation initiation factor activity -1.4 1.1 1.2 -1.9 -1.5 
orf19.1418 SEC15 IPF11236.3f -- -1.1 1.1 -1.1 -1.5 -1.1 
orf19.4518 -- IPF11424 -- 1.0 1.1 -1.1 -1.6 -1.0 
orf19.6463 -- IPF11432 -- -1.3 1.1 -1.1 -1.5 1.0 
orf19.1646 -- IPF11615 rRNA primary transcript binding -1.2 -1.1 1.1 -2.3 -1.5 
orf19.3412 ATG15 IPF12033 Lipase activity 1.0 -1.0 -1.2 -1.7 1.2 
orf19.4787 -- IPF12091 ATPase activator activity -1.1 1.3 1.1 -2.0 -1.2 
orf19.2667 RPF1 IPF12428 -- -1.3 1.1 -1.1 -1.9 -1.7 
orf19.5238 -- IPF12577 -- -1.2 -1.0 -1.0 -1.9 1.2 
orf19.2898 -- IPF13465 -- 1.1 1.0 -1.2 -2.3 1.5 
orf19.2451 PGA45 IPF14109 -- 1.3 1.2 1.1 -2.2 1.1 
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orf19.2452 -- IPF14850 -- -1.1 -1.1 -1.4 -3.8 -1.1 
orf19.2108 SOD6 IPF15423 Copper, zinc superoxide dismutase activity 1.5 -1.0 1.1 -1.7 1.5 
orf19.2256 -- IPF15468 -- -1.2 -1.0 -1.2 -1.8 -1.3 
orf19.6539 -- IPF15737 ATPase activity -1.2 1.0 -1.2 -1.7 1.4 
orf19.6581 -- IPF1629 -- 1.1 1.1 1.2 -1.6 1.0 
orf19.6566 -- IPF1660 -- 1.0 -1.1 1.2 -1.8 1.2 
orf19.2917 -- IPF16748 -- -1.2 1.9 -1.0 -1.8 -1.4 
orf19.2664 -- IPF16761 -- -1.0 1.1 1.5 -1.8 1.2 
orf19.2143 -- IPF17094 -- -1.2 1.1 1.2 -2.0 -1.2 
orf19.3553 -- IPF17139 -- -1.3 1.2 -1.4 -1.8 -1.5 
orf19.6707 -- IPF17904.3 -- -1.3 1.1 -1.1 -4.8 1.2 
orf19.7028 -- IPF18125 -- 1.2 -1.0 -1.1 -1.7 1.9 
orf19.5884 -- IPF1846 -- -1.1 1.3 -1.2 -1.8 -1.1 
orf19.3159 UTP20 IPF18641.exon2 -- 1.0 1.1 1.0 -2.0 -1.4 
orf19.7154 -- IPF1948 -- -1.1 -1.0 1.1 -2.1 -1.1 
orf19.5559 STE23 IPF19660 -- 1.1 -1.2 -1.4 -1.7 -1.3 
orf19.6789 -- IPF19818 Structural constituent of cytoskeleton -1.1 1.1 2.0 -2.0 -1.1 
orf19.7182 -- IPF2166 -- -1.2 1.1 -1.1 -2.1 -1.0 
orf19.6902 -- IPF2228 ATP-dependent RNA helicase activity -1.3 -1.1 -1.1 -2.8 1.2 
orf19.7022 -- IPF2359 -- -1.0 -1.1 -1.2 -1.6 1.2 
orf19.6818 -- IPF2409 Helicase activity -1.1 1.1 1.3 -2.1 -1.4 
orf19.7424 -- IPF2441 -- -1.3 1.3 -1.1 -2.3 -1.5 
orf19.6625 -- IPF2560 -- -1.1 -1.2 -1.1 -1.6 -1.3 
orf19.3559 -- IPF3184.exon1 -- -1.3 -1.0 -1.1 -1.7 -1.4 
orf19.3559 -- IPF3184.exon2 -- -1.0 1.0 1.0 -1.8 -1.6 
orf19.4384 HXT5 IPF3282 Fructose transporter activity 1.2 1.0 -1.1 -1.6 -1.3 
orf19.7398 -- IPF3309.3eoc -- -1.2 1.2 -1.4 -2.0 -1.4 
orf19.7388 PBS2 IPF3329 MAP kinase kinase activity -1.1 1.1 1.2 -2.0 1.1 
orf19.6752 -- IPF3492 Structural constituent of ribosome -1.1 -1.0 1.0 -1.5 -1.5 
orf19.28 -- IPF3853 Transporter activity -1.2 -1.2 -1.2 -1.9 -1.3 
orf19.768 SYG1 IPF3887 -- 1.1 -1.1 -1.2 -2.5 1.7 
orf19.6503 -- IPF3928 -- -1.3 1.5 1.0 -1.8 1.2 
orf19.671 PSP1 IPF3970 -- -1.3 -1.1 -1.2 -1.6 1.2 
orf19.1630 -- IPF4253 -- -1.2 1.1 -1.0 -1.6 2.2 
orf19.1633 -- IPF4257 snoRNA binding -1.3 1.1 -1.0 -1.7 -1.3 
orf19.549 -- IPF4276 Structural constituent of ribosome -1.2 1.1 1.1 -1.8 -1.2 
orf19.541 -- IPF4290 -- -1.2 -1.4 -1.3 -2.1 1.0 
orf19.5279 -- IPF4703 -- -1.3 1.0 1.1 -1.7 -1.9 
orf19.6276 -- IPF4859 -- 1.1 1.2 -1.4 -1.6 1.7 
orf19.6392 -- IPF5129 -- 1.0 1.3 1.2 -1.7 -1.2 
orf19.5681 -- IPF5469 -- 1.2 -1.1 1.2 -1.8 -1.3 
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orf19.7098 -- IPF556 -- -1.1 -1.2 -1.2 -1.8 1.2 
orf19.7107 -- IPF5615 -- -1.1 1.7 -1.1 -1.9 -1.0 
orf19.4176 -- IPF6175 Structural constituent of ribosome -1.3 1.0 -1.1 -2.2 -1.5 
orf19.1971 -- IPF6286 DNA binding -1.1 1.0 1.5 -2.3 -1.5 
orf19.1964 -- IPF6298 -- -1.1 1.3 1.1 -2.3 -1.3 
orf19.7618 -- IPF630 -- -1.2 1.3 -1.0 -2.3 -1.4 
orf19.1693 CAS4 IPF6521.3eoc Transcription factor activity -1.2 1.2 1.1 -1.6 1.1 
orf19.7599 -- IPF668 snoRNA binding -1.3 1.2 -1.0 -1.9 -1.1 
orf19.1565 -- IPF7147 tRNA dihydrouridine synthase activity -1.2 -1.2 -1.0 -1.9 1.2 
orf19.386 SAM4 IPF7279 Homocysteine S-methyltransferase activity -1.2 -1.0 -1.0 -2.2 1.0 
orf19.2447 -- IPF7472 -- -1.3 -1.2 -1.3 -1.5 -1.4 
orf19.2936 -- IPF8110 -- -1.0 -1.3 -1.1 -2.3 -1.7 
orf19.3327 -- IPF8326 tRNA methyltransferase activity -1.2 1.1 1.0 -1.8 -1.7 
orf19.3977 -- IPF8652 -- -1.4 -1.1 -1.2 -1.6 -1.4 
orf19.2487 -- IPF9225 -- -1.1 1.0 1.3 -1.6 -1.0 
orf19.4375 -- IPF9435 -- -1.2 1.1 -1.1 -1.8 -1.2 
orf19.6092 KEL1 KEL1 -- -1.4 -1.0 -1.1 -2.1 1.8 
orf19.6086 LEU4 LEU41 2-isopropylmalate synthase activity 1.2 1.2 -1.1 -2.0 1.2 
orf19.3540 MAK5 MAK5 ATP-dependent RNA helicase activity -1.2 -1.2 -1.1 -1.8 -1.5 
orf19.2551 MET6 MET6 5-methyltetrahydropteroyltriglutamate-homocysteine S-methyltransferase activity 1.0 -1.1 -1.1 -1.9 -1.0 
orf19.7383 MNN9 MNN9 Mannosyltransferase activity -1.0 1.2 1.2 -1.7 -1.1 
orf19.1662 -- MRP1.3f Structural constituent of ribosome -1.3 1.2 1.1 -1.5 -1.4 
orf19.185 -- MRP51 Structural constituent of ribosome -1.2 1.1 -1.1 -1.8 -2.7 
orf19.3532 MRPL10 MRPL10.3 Structural constituent of ribosome -1.5 1.7 1.2 -2.1 -1.5 
orf19.2019 -- MRPL16 Peptidyltransferase activity -1.1 1.1 -1.1 -1.7 -1.3 
orf19.6129 MRPL8 MRPL8 Structural constituent of ribosome -1.1 1.1 -1.2 -1.6 -1.0 
orf19.706 NMD3 NMD3 RNA binding -1.2 1.2 1.0 -2.5 -1.0 
orf19.1199 NOP5 NOP58 snoRNA binding -1.1 1.2 1.2 -1.6 1.0 
orf19.3000 -- ORC1 ATPase activity -1.0 3.1 1.1 -3.2 -1.1 
orf19.2199 PHO86 PHO86 -- -1.1 -1.3 -1.2 -1.8 1.1 
orf19.5847 -- RET1 DNA-directed RNA polymerase activity -1.2 1.2 1.0 -2.0 1.0 
orf19.2320 -- RIO1 Amino acid kinase activity -1.4 1.3 -1.1 -2.1 -1.6 
orf19.5420 -- RML2 Structural constituent of ribosome -1.2 1.2 1.2 -1.8 -1.0 
orf19.2594 -- RPA43 DNA-directed RNA polymerase activity -1.3 1.1 1.0 -2.2 -1.8 
orf19.443 -- RPC25 DNA-directed RNA polymerase activity -1.3 1.2 1.3 -1.8 -1.5 
orf19.2830 -- RRP9 snoRNA binding -1.3 -1.0 1.5 -1.7 -1.7 
orf19.6355 -- RSA2 -- -1.3 1.2 -1.1 -1.9 -1.2 
orf19.24 RTA2 RTA2 Phospholipid-translocating ATPase activity 1.5 -1.2 -1.1 -2.1 1.1 
orf19.642 -- SAP155 Protein serine/threonine kinase activity -1.0 -1.2 1.2 -2.1 -1.1 
orf19.6558 -- SEC231 GTPase activator activity -1.2 1.4 1.1 -1.7 1.4 
orf19.5263 SER33 SER33 Phopshoglycerate dehydrogenase activity -1.0 -1.2 -1.1 -1.7 1.2 
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orf19.5953 -- SFP1 Transcription factor activity 1.0 1.2 1.2 -1.6 1.3 
orf19.7569 -- SIK1 snoRNA binding -1.2 1.2 -1.0 -1.5 -1.0 
orf19.4367 SMC1 SMC1 ATP DNA binding 1.2 -1.1 1.1 -1.6 -1.1 
orf19.5407 -- SOF1 snoRNA binding -1.2 1.1 -1.0 -1.6 -1.6 
orf19.4960 -- SPE4 -- -1.2 1.0 1.0 -2.5 -1.2 
orf19.1139 -- SVL3 -- -1.2 1.1 1.2 -1.6 -1.1 
orf19.1352 -- TIM22 Protein transporter activity -1.2 1.0 -1.0 -1.9 -1.7 
orf19.5143 -- TIM54 Protein transporter activity -1.3 1.2 1.5 -2.0 1.2 
orf19.1532 -- TOM37 -- 1.2 1.4 1.5 -2.0 -1.5 
orf19.429 -- TRF4 DNA-directed DNA polymerase activity -1.4 1.2 1.4 -2.1 -1.5 
orf19.802 -- UGA12.5f 4-aminobutyrate transaminase activity -1.3 -1.1 1.1 -2.3 1.8 
orf19.3363 VTC4 VTC4 -- -1.1 -1.0 -1.0 -1.6 1.0 
orf19.7036 -- WHI2 -- -1.1 -1.1 1.3 -1.5 1.1 
orf19.3300 ZPR1 ZPR1 Transcription factor activity -1.3 1.0 -1.1 -1.8 -1.1 
orf19.4773 AOX2 AOX2 Alternative oxidase activity -2.6 -2.1 -1.1 1.1 -2.7 
orf19.1078 HBR2 IPF14203.5f -- -1.6 -1.5 -1.1 -1.1 -1.2 
orf19.2158 NAG3 IPF2710.repeat2 Monosaccharide transporter activity -2.4 -1.7 -1.5 2.4 6.1 
orf19.2948 SNO1 SNO1 Imidazoleglycerol-phosphate synthase activity -2.6 -1.6 -1.4 -1.2 1.3 
orf19.7111 -- SOD21.5f Manganese superoxide dismutase activity -1.6 -1.8 -1.1 2.3 2.0 
orf19.7111 -- SOD22.3f Manganese superoxide dismutase activity -1.6 -2.4 1.3 1.0 1.9 
orf19.5531 CDC37 CDC37 Unfolded protein binding -1.7 -1.0 -2.4 -1.0 -1.2 
orf19.3915 -- IPF10029.5eoc -- -1.8 -1.3 -1.5 -1.4 1.5 
orf19.2246 -- IPF12900 -- -1.6 -1.2 -1.7 1.0 -1.5 
orf19.3050 AGE1 IPF3610 ARF GTPase activator activity -1.5 -1.3 -1.5 -1.3 1.2 
orf19.4900 -- IPF8854 Alpha-1,3-mannosyltransferase activity -1.9 1.1 -1.6 -1.3 -1.3 
orf19.1769 -- PLP2 -- -1.9 -1.0 -2.0 -1.4 -1.0 
orf19.5906 ADE2 ADE2 Phosphoribosylaminoimidazole carboxylase activity -1.5 -1.3 -1.3 -1.8 1.6 
orf19.5806 ALD5 ALD5 3-chloroallyl aldehyde dehydrogenase activity -1.6 -1.3 1.2 -4.1 -1.0 
orf19.1623 CAP1 CAP1 Transcription factor activity -1.7 1.1 -1.0 -1.7 -1.1 
orf19.2876 CBF1 CBF1 Centromeric DNA binding -1.8 -1.1 -1.2 -1.7 1.1 
orf19.6948 CCC1 CCC1 -- -1.8 -1.4 -1.0 -2.3 -1.2 
orf19.1055 CDC3 CDC3 Nucleotide binding -1.6 1.2 -1.1 -1.6 1.2 
orf19.1996 CHA1 CHA12 L-serine ammonia-lyase activity -5.3 -1.1 -1.2 -2.6 -1.9 
orf19.7478 -- COQ1 Trans-hexaprenyltranstransferase activity -1.7 1.1 1.0 -1.6 -1.6 
orf19.6652 DBP8 DBP8 ATP-dependent RNA helicase activity -1.5 1.2 -1.1 -2.1 -1.1 
orf19.7635 DRS1 DRS1 ATP-dependent RNA helicase activity -1.7 1.0 -1.1 -2.1 1.2 
orf19.3670 GAL1 GAL1 Galactokinase activity -1.6 -1.1 -1.3 -1.8 1.3 
orf19.385 GCV2 GCV2 Glycine dehydrogenase (decarboxylating) activity -1.7 -1.1 -1.1 -1.9 1.1 
orf19.2396 IFR2 IFR2 -- -1.7 -1.3 -1.2 -1.7 1.3 
orf19.473 TPO4 IPF11142 -- -1.5 -1.4 -1.1 -1.7 1.6 
orf19.512 -- IPF11315 -- -1.6 1.2 1.0 -2.0 1.1 
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orf19.1715 IRO1 IPF11363 -- -1.7 -1.0 -1.2 -1.7 1.3 
orf19.4337 -- IPF11698 Monocarboxylic acid transporter activity -1.6 -1.3 -1.3 -1.6 1.8 
orf19.2067 -- IPF1210 -- -1.5 1.1 1.3 -1.6 -1.2 
orf19.2185 -- IPF12457 -- -1.7 1.5 1.1 -2.1 -1.4 
orf19.2330 -- IPF13361 snoRNA binding -1.6 1.1 -1.1 -1.8 1.0 
orf19.4746 JIP5 IPF14019 -- -1.7 1.1 1.1 -2.2 -1.8 
orf19.4931 -- IPF15618 Cysteine-tRNA ligase activity -1.5 1.0 -1.1 -1.7 1.1 
orf19.4751 -- IPF16405 Structural constituent of ribosome -1.6 1.2 -1.3 -2.4 -1.6 
orf19.3547 -- IPF16996 -- -1.6 1.2 -1.1 -1.8 -2.1 
orf19.2778 -- IPF18002 -- -1.7 1.2 -1.2 -1.8 -1.4 
orf19.4929 -- IPF19785 Translation regulator activity -1.6 1.3 1.9 -1.6 1.0 
orf19.4093 -- IPF2093 -- -1.5 1.1 -1.1 -2.5 1.0 
orf19.4105 -- IPF2109 -- -2.1 -1.2 -1.3 -1.9 -1.3 
orf19.4835 -- IPF4485 snoRNA binding -1.8 1.1 1.1 -1.9 -1.1 
orf19.6648 -- IPF5009 -- -1.8 -1.2 1.1 -1.9 -1.2 
orf19.3448 -- IPF5330 -- -10.5 1.3 1.2 -3.0 -1.6 
orf19.7091 -- IPF538 -- -1.6 1.1 1.0 -1.8 -1.1 
orf19.5680 -- IPF5471 -- -1.6 -1.2 -1.3 -1.7 1.3 
orf19.4805 -- IPF6117 -- -1.5 1.1 -1.1 -2.5 1.1 
orf19.7621 -- IPF625 -- -1.7 1.5 2.0 -1.8 -1.3 
orf19.4191 -- IPF7998 -- -1.6 1.1 -1.1 -2.3 -1.6 
orf19.4268 -- IPF9525 snoRNA binding -1.5 1.2 -1.3 -1.6 -1.2 
orf19.3406 -- IPF9898 -- -1.9 -1.2 -1.5 -2.7 -1.5 
orf19.1244 GYP2 MDR1 Rab GTPase activator activity -1.6 -1.1 1.0 -1.7 1.2 
orf19.7384 -- NOG1 GTPase activity -1.5 1.3 1.0 -2.8 -1.5 
orf19.1030 -- NPI46 Peptidyl-prolyl cis-trans isomerase activity -2.2 1.0 1.2 -1.6 -1.0 
orf19.1687 -- PRP43 ATP-dependent RNA helicase activity -1.5 1.3 -1.0 -1.6 -1.1 
orf19.4274 PUT1 PUT1 Proline dehydrogenase activity -2.1 1.0 1.9 -1.5 1.2 
orf19.4593 RGA2 RGA2 Rho GTPase activator activity -1.7 1.1 1.1 -2.0 -1.3 
orf19.3867 RPL7 RLP7 rRNA binding -1.8 1.0 -1.2 -1.9 -1.7 
orf19.6041 RPO41 RPO41 DNA-directed RNA polymerase activity -1.5 1.1 1.5 -2.1 -1.2 
orf19.1923 RRN3 RRN3 RNA polymerase I transcription factor activity -1.7 1.6 1.6 -2.2 -1.0 
orf19.1161 PLD1 SPO14.5eoc Phospholipase D activity -1.6 1.3 1.0 -2.4 1.6 
orf19.6109 TUP1 TUP1 General transcriptional repressor activity -1.8 1.1 1.1 -1.7 1.5 
orf19.1536 -- ZRC1 Di-, tri-valent inorganic cation transporter activity -1.6 1.0 -1.0 -1.7 -1.1 
orf19.1816 ALS3 ALS10 Cell adhesion molecule binding -1.1 -1.5 -3.2 1.2 -1.5 
orf19.1816 ALS3 ALS3.5eoc Cell adhesion molecule binding 1.1 -1.6 -2.3 1.0 1.0 
orf19.1264 CFL2 CFL2 Ferric-chelate reductase activity 1.6 -2.0 -1.6 -1.3 -1.6 
orf19.1587 HGT20 IPF13131.3 Glucose transporter activity 1.1 -1.6 -1.9 1.2 2.9 
orf19.1121 -- IPF2329 -- -1.4 -1.7 -1.5 -1.1 -1.3 
orf19.6636 -- IPF2524 -- -1.5 -1.6 -1.7 -1.4 1.0 
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orf19.6249 HAK1 IPF9136.5eoc Potassium ion transporter activity 1.1 -3.6 -3.1 -1.3 -1.5 
orf19.5591 ADO1 ADO1 Adenosine kinase activity 1.0 -1.5 -1.1 -2.1 -1.2 
orf19.4099 ECM17 ECM17 Sulfite reductase (NADPH) activity -1.2 -1.7 -1.4 -2.2 1.2 
orf19.6570 NUP IPF1651 Nucleoside permease activity -1.1 -1.7 -1.1 -1.8 2.1 
orf19.6957.3 -- IPF19538 -- -1.3 -1.6 -1.3 -1.5 1.1 
orf19.7046 MET28 IPF3087 Specific RNA polymerase II transcription factor activity -1.1 -1.9 -1.1 -1.8 1.3 
orf19.1789.1 LYS1 LYS1.5eoc Saccharopine dehydrogenase (NAD+, L-lysine-forming) activity -1.2 -1.5 -1.4 -2.4 1.0 
orf19.3870 ADE13 ADE13 Adenylosuccinate lyase activity -1.2 -1.2 -1.5 -1.9 1.4 
orf19.5789 ADE8 ADE8 Phosphoribosylglycinamide formyltransferase activity -1.3 -1.4 -1.5 -2.0 -1.2 
orf19.2337 ALP1 ALP1 Basic amino acid transporter activity -1.1 -1.5 -1.8 -2.2 -1.0 
orf19.6459 -- DPP3 Phosphatidase phosphatase activity -1.2 -1.2 -1.8 -2.2 1.4 
orf19.4215 FET34 FET5 Ferroxidase activity 1.1 -1.4 -2.7 -1.8 1.0 
orf19.4456 GAP4 GAP5 Amino acid permease activity 1.0 -1.1 -1.5 -2.9 -1.0 
orf19.7566 -- GNP1 Amino acid permease activity -1.0 -1.5 -1.6 -2.8 1.2 
orf19.2020 HGT6 HXT61 Fructose transporter activity 1.1 -1.0 -1.7 -4.3 1.1 
orf19.2923 -- IPF11448 -- -1.1 -1.2 -1.6 -2.5 1.3 
orf19.1961 -- IPF14506 -- 1.2 1.1 -3.0 -1.5 -2.8 
orf19.3581 -- IPF3227 -- 1.0 1.0 -1.9 -1.7 -1.7 
orf19.6936 RAD53 RAD53 Protein serine/threonine kinase activity -1.1 1.1 -1.5 -1.6 -1.0 
orf19.5838 -- SER2 Phosphoserine phosphatase activity -1.3 -1.3 -1.6 -2.1 1.1 
orf19.844 STE11 STE11 MAP kinase kinase kinase activity -1.1 1.2 -1.5 -1.5 1.1 
orf19.34 -- GIT1 Phospholipid transporter activity -2.0 -2.8 -2.5 -1.4 -1.0 
orf19.7370 -- IPF1261 -- -1.8 -1.5 -1.5 -1.0 -1.3 
orf19.2738 SUL2 SUL1 Sulfate transporter activity -2.0 -4.3 -2.1 -1.0 1.5 
orf19.4669 AAT22 AAT22 Aspartate transaminase activity -1.8 -1.5 -1.3 -2.8 -1.6 
orf19.993 -- IPF20135 -- -1.5 -1.5 -1.3 -1.7 1.1 
orf19.847 -- IPF3415 Mitochondrial inner membrane peptidase activity -1.8 -1.7 -1.0 -1.5 1.7 
orf19.3040 -- IPF3589 -- -1.8 -1.5 -1.0 -1.5 1.2 
orf19.3529 ABP2 IPF4463 -- -2.8 -1.5 1.0 -2.0 -1.2 
orf19.1847 ARO10 IPF4667 Carboxy-lyase activity -3.4 -1.7 -1.0 -2.6 1.5 
orf19.7422 -- LCP5 -- -1.5 -1.9 -1.1 -2.0 1.0 
orf19.5519 GCV1 GCV1 Glycine dehydrogenase (decarboxylating) activity -1.8 -1.1 -1.8 -1.7 1.7 
orf19.5392 NGT1 IPF1065 N-acetylglucosamine transporter activity -1.5 -1.4 -1.8 -2.7 -1.2 
orf19.4779 -- IPF12884 Multidrug transporter activity -2.2 -1.1 -1.7 -2.2 1.3 
orf19.4450.1 -- IPF6551 -- -1.7 -1.3 -1.5 -1.9 -1.0 
orf19.1510 -- IPF9282 -- -1.6 -1.4 -1.9 -3.4 1.7 
orf19.3810 -- MTD1 Methylenetetrahydrofolate dehydrogenase (NAD+) activity -1.5 -1.4 -1.9 -1.9 1.6 
orf19.3599 TIF4631 TIF4631 Translation initiation factor activity -1.6 1.0 -1.5 -1.5 -1.1 
orf19.3122 ARR3 ARR3 Arsenite transporter activity -1.2 -1.6 -1.6 -1.8 -1.1 
orf19.111 CAN2 CAN2 Basic amino acid transporter activity -1.0 -2.1 -2.5 -2.2 1.1 
orf19.4215 FET34 FET34.3eoc Ferroxidase activity 1.1 -1.5 -2.2 -3.2 -1.1 
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Systematic 
Namea 
CGD 
Nameb 
CandidaDB 
Namec GO Annotation (Molecular Function)d 
C56 vs. 
C43 
Gu5 vs. 
Gu2 
17 vs. 
3 
5674 vs. 
5457 
SZY31 vs. 
5457 
orf19.1978 GIT2 IFN3 Phospholipid transporter activity 1.4 -1.6 -2.6 -2.3 1.1 
orf19.3902 -- IPF11503 -- 1.2 -2.6 -2.3 -2.2 1.6 
orf19.2475 PGA26 IPF7204 -- -1.2 -2.0 -1.9 -4.0 1.3 
orf19.288 -- MET13 Structural constituent of ribosome -1.2 -2.4 -1.8 -2.6 -1.1 
orf19.946 MET14 MET14 Adenylylsulfate kinase activity -1.2 -2.7 -2.0 -2.1 -2.0 
orf19.638 FDH1 FDH12 Formate dehydrogenase activity -1.6 -3.8 -1.8 -2.4 -1.5 
orf19.7219 FTR1 FTR1 Ferrous iron transporter activity -2.7 -3.0 -2.1 -4.0 -1.6 
orf19.4527 HGT1 HGT11 Glucose transporter activity -1.7 -1.5 -1.6 -2.5 -1.1 
orf19.2461 PRN4 IFS1 -- -1.7 -1.7 -1.6 -1.8 -1.2 
orf19.5760 IHD1 IPF10662 -- -1.9 -2.2 -3.1 -9.0 1.7 
orf19.3475 -- IPF11725 -- -3.9 -2.1 -2.7 -5.8 -1.2 
orf19.4655 OPT6 IPF12193 Oligopeptide transporter activity -1.8 -2.0 -2.4 -3.1 -1.4 
orf19.2060 SOD5 IPF1222 Copper, zinc superoxide dismutase activity -2.3 -8.6 -17.8 -26.3 -1.4 
orf19.2059 -- IPF1228 -- -2.0 -1.7 -1.7 -2.9 1.2 
orf19.5673 OPT7 IPF12736 Oligopeptide transporter activity -1.6 -1.7 -1.5 -1.6 1.8 
orf19.4749 -- IPF13921 -- -2.3 -1.7 -2.4 -3.0 -1.4 
orf19.670.2 -- IPF20159 -- -2.3 -2.0 -1.7 -4.9 -1.9 
orf19.6679 -- IPF2314 -- -1.5 -2.1 -1.8 -2.2 1.1 
orf19.7296 -- IPF2839 -- -1.6 -3.4 -2.5 -5.4 1.2 
orf19.7561 DEF1 IPF946 -- -3.4 -1.5 -1.6 -2.8 -1.4 
orf19.2618 MET2 MET2 Homoserine O-acetyltransferase activity -1.5 -1.5 -1.6 -1.6 1.2 
orf19.5025 MET3 MET3 Sulfate adenylyltransferase (ATP) activity -2.0 -7.9 -1.8 -2.5 -1.2 
orf19.700 SEO1 SEO2 Transporter activity -2.3 -2.5 -3.0 -2.1 -1.2 
orf19.2947 SNZ1 SNZ1 -- -3.7 -1.8 -1.7 -2.2 1.3 
 
a orf19 nomenclature according to the Assembly 19 version. 
b Gene name at CGD (http://www.candidagenome.org/). 
c Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
d GO annotation found at CGD (http://www.candidagenome.org/). 
Gene expression values in bold designate statistical significance (p-value < 0.05) in all three experiments. 
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Table B-1. Genes up-regulated in at least one clinical matched isolate overexpressing MDR1. 
 
CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
AAF1 orf19.7436 -- 1.4 1.3 1.0 1.9 2.1 2.2 1.2 1.8 1.2 
AAH1 orf19.2251 Adenine deaminase activity -2.0 -1.6 1.6 1.5 1.7 2.6 1.5 -1.2 3.0 
ACB1.3f orf19.7043 Acyl-CoA binding -1.0 -2.3 4.9 1.6 2.3 10.6 1.7 -1.1 2.0 
ADH5 orf19.2608 Alcohol dehydrogenase activity 1.3 2.0 1.0 -1.0 1.3 -1.1 1.6 1.7 2.9 
ALD4 orf19.6306 Aldehyde dehydrogenase (NAD) activity -1.4 -1.2 1.2 1.5 1.9 1.9 1.2 1.6 -1.1 
ALS10 orf19.2355 Cell adhesion molecule binding 1.2 1.7 1.1 -1.6 -2.0 -2.0 5.9 5.3 8.7 
ALS10 orf19.2355 Cell adhesion molecule binding 1.3 1.8 1.2 -1.4 -1.5 -1.6 4.9 4.8 18.0 
ALS3.5eoc orf19.1816 Cell adhesion molecule binding 1.4 1.8 1.2 -1.1 -1.3 -4.9 4.1 4.3 7.9 
ALS6 orf19.7414 Cell adhesion molecule binding 1.8 2.7 3.0 -8.1 -10.4 -8.1 1.2 1.1 2.3 
AMD21 orf19.5169 Amidase activity 1.0 1.5 -1.2 1.8 2.4 2.1 1.1 -1.0 1.2 
ARE2 orf19.2248 Sterol O-acyltransferase activity -1.3 2.0 1.6 1.6 2.1 1.2 1.8 1.6 3.0 
ARO9 orf19.1237 Aromatic-amino-acid transaminase activity 2.2 2.3 20.0 -1.1 1.0 1.2 -1.0 1.0 -2.5 
AUT1 orf19.6020 -- -1.5 -1.1 -1.3 1.6 1.5 1.8 -1.2 -1.5 1.3 
BMR1 orf19.5604 Multidrug transporter activity 47.8 152.1 112.2 116.2 181.2 210.3 97.1 169.5 132.3 
CBP1 orf19.7323 Steroid binding 1.6 2.1 1.4 1.6 2.0 1.8 1.5 1.5 1.8 
CDR11.5f orf19.918 ATP binding 2.1 2.3 1.4 1.3 1.9 -1.3 1.7 2.3 1.7 
CDR12 orf19.2802 ATPase activity 1.7 2.3 2.0 2.4 2.6 2.7 2.1 1.6 -1.3 
CFL11 orf19.701 Ferric-chelate reductase activity 1.6 1.7 1.9 -1.7 -1.7 1.3 -4.8 1.7 1.1 
CHA12.3f orf19.1996 L-serine ammonia-lyase activity -1.3 -1.5 -1.6 -1.1 1.2 1.4 1.7 1.8 2.7 
Cirt2 orf19.3820 -- 1.1 1.4 -1.1 1.8 1.6 1.8 1.7 1.0 -1.3 
CLN2 orf19.1960 Cyclin-dependent protein kinase regulator activity -1.0 1.4 1.4 -1.6 -1.2 -3.5 1.5 2.0 2.1 
CLN21 orf19.6028 Cyclin-dependent protein kinase regulator activity 7.2 2.6 1.9 -3.2 1.1 1.1 1.4 4.7 2.2 
CRD1 orf19.4784 Copper ion binding 1.2 1.7 -1.1 -1.7 1.5 1.5 1.5 1.6 1.5 
CRN1.3f orf19.6534.2 Actin filament binding -1.3 1.1 1.1 1.7 1.8 2.7 1.4 1.4 1.4 
CTR9 orf19.7067 RNA polymerase II transcription factor activity -1.4 -2.0 1.5 1.6 1.6 1.9 1.1 1.1 2.1 
DAL1 orf19.5454 Allantoinase activity 1.6 1.2 2.8 2.7 2.4 2.5 2.0 1.5 4.9 
DDR48 orf19.4082 -- 1.9 4.3 2.3 -1.4 -1.1 1.0 -2.2 -1.2 -1.9 
DFR1 orf19.5142 Dihydrofolate reductase activity 1.3 1.1 -1.3 1.9 1.7 2.1 1.5 -1.1 -1.7 
DIP51.5f orf19.2942 Amino acid permease activity 1.7 2.5 1.6 3.0 -1.0 -6.3 -2.0 -1.3 1.0 
DLD2 orf19.6755 D-lactate dehydrogenase (cytochrome) activity 1.3 1.2 -1.1 2.9 2.2 1.9 1.2 2.1 -1.2 
DPB11 or19.1434 Epsilon DNA polymerase activity 1.3 1.7 1.6 1.9 1.5 2.0 1.4 1.1 -3.3 
DSK2 orf19.5345 Protein binding 1.3 -1.2 -1.3 1.5 1.8 1.7 1.3 1.1 1.0 
DUR1,2 orf19.780 Allophanate hydrolase activity 1.7 1.9 2.2 2.1 4.0 2.6 1.7 2.0 1.5 
EBP4 orf19.3433 NADPH dehydrogenase activity 1.1 2.4 2.8 1.8 2.5 2.0 7.9 8.0 11.4 
ECE1 orf19.3374 -- 25.6 16.4 38.9 1.4 1.1 2.4 2.7 -1.3 2.1 
ECM29.5f orf19.6773 -- 2.6 1.6 1.5 -1.0 -1.0 -22.7 -1.1 1.0 2.7 
ERG24 orf19.1598 Delta 14-sterol reductase activity 1.5 1.6 1.6 1.4 1.6 1.4 1.0 -1.2 1.5 
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Table B-1 (continued). 
 
CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
ERG26 orf19.2909 C-3 sterol dehydrogenase (C-4 sterol decarboxylase) activity 1.6 1.5 2.1 -1.4 1.4 1.8 -1.3 -1.2 -1.3 
ERG27 orf19.3240 3-keto sterol reducatase activity 1.5 1.6 1.9 1.1 1.2 1.1 1.0 -1.1 -1.4 
EXG2 orf19.2952 Glucan 1,3-beta-glucosidase activity 2.2 2.4 1.8 1.9 2.0 1.6 1.3 1.5 -1.0 
FAA24 orf19.7156 Long-chain-fatty-acid-CoA ligase activity 1.4 2.7 1.4 2.3 1.9 3.0 -1.3 -1.1 2.5 
FEN2 orf19.5535 Pantothenate transporter activity 1.5 2.1 1.5 1.7 1.4 1.1 -1.1 -1.0 -1.4 
FET34.3eoc orf19.4215 Ferroxidase activity -2.2 -1.4 -1.0 1.6 1.6 4.0 -1.9 -2.5 -1.7 
FMS1 orf19.4589 -- 1.7 1.6 -1.0 2.6 2.4 2.3 1.0 1.2 -1.3 
FRE30.3f orf19.6139 Ferric-chelate reductase activity -1.8 1.3 -2.5 1.5 1.5 1.5 1.6 1.5 1.9 
FRE30.53f orf19.6140 Ferric-chelate reductase activity -1.2 1.2 -1.8 2.7 1.6 -5.2 1.5 2.0 1.7 
FRE7 orf19.7077 Ferric-chelate reductase activity -1.5 1.2 -2.1 1.7 1.7 2.8 -1.0 1.3 2.4 
FRP2 orf19.6169 -- 1.7 7.4 2.5 1.1 -1.5 -1.5 -1.8 1.3 -1.4 
FTH2 orf19.3227 Iron ion transporter activity 1.5 1.9 2.3 -1.2 1.2 2.1 1.2 1.3 1.4 
GAL1 orf19.3670 Galactokinase activity 1.5 2.4 2.4 -1.5 -1.4 -1.4 -1.5 -1.2 -1.2 
GBA1 orf19.4015 GTPase activity -1.6 -1.2 1.3 41.8 21.8 20.5 -1.2 -1.2 1.3 
GDI1 orf19.7261 Rab GDP-dissociation inhibitor activity 1.4 1.6 -1.1 1.7 1.6 2.0 1.2 1.1 -1.1 
GPH1 orf19.7021 Glycogen phosphorylase activity -1.2 1.5 -1.7 -1.5 1.3 1.5 1.6 1.6 3.8 
GPR1 orf19.1944 G-protein coupled receptor activity 2.5 1.6 1.8 1.5 -1.7 -1.7 -1.6 -1.2 -1.0 
GPX1 orf19.86 Glutathione peroxidase activity 2.1 3.5 5.2 3.1 3.5 4.9 2.4 3.2 8.8 
GRP2 orf19.4309 Oxidoreductase activity 3.0 5.3 3.4 4.9 6.1 5.5 7.6 8.6 18.6 
HBS1 orf19.7144 -- -1.1 -1.0 -1.4 1.7 1.6 1.7 -1.2 1.5 1.4 
HEM1 orf19.2601 5-aminolevulinate synthase activity 1.7 2.2 1.8 -1.4 1.1 -1.7 -1.2 1.1 1.1 
HGT11 orf19.4527 Glucose transporter activity 3.0 4.4 1.7 1.7 -1.3 -1.6 -2.1 -1.5 -2.5 
HGT12 orf19.3668 Glucose transporter activity 2.4 14.0 4.4 6.8 2.6 1.8 -3.1 -3.1 -3.0 
HIK1 orf19.5181 Osmosensor activity 1.6 1.8 1.6 3.8 1.5 -1.6 1.2 1.3 2.0 
HIK1 orf19.5181 Osmosensor activity 2.5 1.8 1.8 2.5 1.4 -7.0 -1.2 1.5 1.7 
HWP1 orf19.1321 -- 1.5 3.0 1.5 1.0 -1.1 -1.1 3.2 1.4 -1.6 
IFA18.53f orf19.4508 -- 2.0 1.8 1.6 -1.2 1.3 -1.2 1.6 -1.5 -2.0 
IFA24.3eoc orf19.156 -- 1.1 1.4 2.2 1.7 2.1 2.8 -1.1 -1.4 2.3 
IFD2 orf19.771 Aryl-alcohol dehydrogenase activity 13.8 14.7 23.7 5.4 8.2 10.9 3.5 3.8 5.1 
IFD4 orf19.4477 Aryl-alcohol dehydrogenase activity 21.3 37.9 75.5 81.0 115.9 149.7 129.0 97.7 212.5 
IFD5 orf19.1048 Aryl-alcohol dehydrogenase activity 76.2 200.7 141.5 151.6 195.9 299.8 263.9 333.2 247.6 
IFD5 orf19.1048 Aryl-alcohol dehydrogenase activity 140.8 361.9 144.3 137.7 155.8 201.1 307.3 274.7 964.2 
IFD6 orf19.4476 Aryl-alcohol dehydrogenase activity 965.7 1290.0 3064.8 565.4 818.4 1916.6 1220.6 2580.4 2890.9 
IFD7 orf19.629 Aryl-alcohol dehydrogenase activity 113.1 338.2 332.4 55.2 66.8 139.0 575.5 311.7 656.4 
IFK2 orf19.856 -- 2.0 1.4 1.2 1.5 1.7 2.2 1.8 -1.2 1.2 
IFK2 orf19.856 -- 2.6 2.5 4.3 1.8 -1.0 -1.3 1.3 -1.3 5.2 
IFK3.3f orf19.857 -- 2.0 2.2 2.2 1.1 1.3 1.8 -1.4 -1.4 1.5 
IFM1 orf19.5167 Translation initiation factor activity 1.8 -1.3 -1.0 2.6 1.7 2.7 1.2 -1.1 1.5 
IFU6.5f orf19.5167 -- 2.2 2.8 1.8 1.5 2.0 1.6 -1.3 1.3 -1.4 
IFV9.5f orf19.3144 -- 1.7 1.7 1.6 2.6 -1.1 -8.1 -1.0 1.1 1.9 
INO1 orf19.7585 Inositol-3-phosphate synthase activity 1.1 1.8 1.0 1.9 2.3 1.6 -1.2 1.2 1.2 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
IPF1009 orf19.4590 -- 1.2 1.5 1.9 -1.4 -1.3 -1.2 2.1 2.0 1.7 
IPF10124 orf19.276 -- 1.7 1.8 1.5 1.1 1.0 -1.2 1.3 1.8 4.6 
IPF10168 orf19.643 -- 1.9 1.5 2.0 2.0 1.5 1.5 -1.3 -1.1 2.5 
IPF10262 orf19.2726 -- 1.2 1.9 8.3 1.7 2.3 1.8 -1.0 1.7 2.2 
IPF10300 orf19.2274 -- 2.1 1.7 1.9 2.0 -1.5 -2.1 1.0 1.3 2.0 
IPF10333 orf19.1835 Cytoskeletal regulatory protein binding 1.6 1.5 1.7 1.2 -1.7 -1.3 1.1 2.3 -1.9 
IPF10394 orf19.3364 -- 1.0 -1.1 1.9 1.5 1.7 2.9 1.5 1.5 2.1 
IPF10595 orf19.1287 -- -1.7 -1.4 -1.1 -1.3 1.0 1.6 2.1 1.7 1.7 
IPF10735 orf19.6790 RNA binding 1.9 2.9 5.0 -1.0 1.2 -1.0 -1.1 -1.1 -1.2 
IPF10795 orf19.2356 Transcription factor activity 18.2 -1.3 1.4 2.1 1.6 1.9 1.8 2.0 -1.9 
IPF11006 orf19.4658 -- 1.6 1.1 1.5 3.4 2.0 4.9 -1.0 1.1 3.2 
IPF11101 orf19.4615 -- 1.2 1.6 1.6 1.9 1.6 1.7 -1.1 1.3 -1.1 
IPF11161.3 orf19.3201 Transcription factor activity 1.9 -1.5 -2.6 4.4 2.0 2.6 -1.2 -1.1 1.5 
IPF11167 orf19.3198 Oxysterol binding 2.2 3.2 -1.7 1.8 1.8 2.6 1.1 1.0 1.1 
IPF1118 orf19.5422 -- -1.5 1.0 -1.2 1.0 1.2 -1.8 3.4 2.4 7.3 
IPF11222 orf19.5840 -- -1.1 1.0 1.3 -1.1 -1.0 -1.2 2.3 2.7 4.6 
IPF11432 orf19.6463 -- -1.3 -1.8 -1.1 1.8 1.7 1.9 -1.2 -1.1 1.3 
IPF11435 orf19.6461 -- -1.1 1.4 1.5 2.6 1.6 1.5 1.5 -1.1 -1.1 
IPF11694 orf19.4355 Nicotinamide mononucleotide permase activity 1.8 9.9 8.4 -1.4 -1.1 -1.2 -2.1 -2.0 1.4 
IPF11821 orf19.6552 Thiol oxidase activity -2.0 -1.4 1.3 1.9 2.0 3.2 1.4 -1.1 2.3 
IPF1264 orf19.7371 Transcription factor activity 3.8 3.2 2.8 2.0 1.7 1.2 1.5 2.2 2.4 
IPF1272 orf19.7376 -- -1.5 -3.7 2.4 2.3 1.5 2.0 1.2 1.3 1.5 
IPF12963 orf19.5094 -- 2.6 3.3 2.8 -1.3 1.4 -1.4 1.7 2.1 21.4 
IPF1321 orf19.6413 -- 1.7 -1.1 -1.2 4.8 2.8 1.9 1.0 1.0 1.9 
IPF13319 orf19.740 Transcriptional activator activity 2.5 1.9 2.1 1.6 -1.8 -1.4 -1.7 -1.3 -1.4 
IPF13423 orf19.4128 -- 2.1 1.4 1.2 1.7 2.2 3.9 1.9 -1.9 -5.0 
IPF13609 orf19.6526 -- -1.8 -1.3 1.1 1.8 1.6 1.8 1.3 1.3 1.8 
IPF13723 orf19.260 -- 1.5 1.5 1.6 -1.5 2.5 1.9 1.5 -1.2 1.7 
IPF13883 orf19.5502 -- -1.3 -1.4 -1.6 2.3 1.9 1.7 1.4 1.4 -1.9 
IPF14030 orf19.851 -- -1.5 -1.0 -1.9 5.7 2.4 1.6 -1.3 -1.2 -4.4 
IPF14119 orf19.4688 -- -1.6 -1.2 1.4 1.2 1.2 -1.2 1.8 2.1 2.6 
IPF14379 orf19.4474 -- -1.1 -4.2 3.0 1.6 1.5 2.9 1.3 -1.2 1.2 
IPF14448 orf19.5601 -- 2.1 1.3 1.8 1.6 1.7 3.3 1.2 -1.1 -1.5 
IPF14968 orf19.3461 -- 1.7 1.5 2.0 1.6 1.1 1.4 -1.1 1.3 -1.3 
IPF14981 orf19.3483 -- 5.1 1.8 2.0 3.3 1.8 3.0 1.8 1.1 1.7 
IPF15255 orf19.4884 Transcription regulator activity 2.1 3.3 1.6 -1.7 -3.8 -1.7 1.2 -2.1 1.2 
IPF15273 orf19.1822 Transcription factor activity 2.5 2.1 2.1 -1.4 -1.8 -1.3 1.4 4.8 -2.1 
IPF15890 orf19.6349 Cytoskeletal protein binding 1.9 1.5 1.6 1.1 3.0 2.9 1.5 -1.4 1.3 
IPF1621 orf19.6585 -- -1.9 1.1 -1.1 2.8 2.4 2.8 -1.2 1.4 5.8 
IPF1632 orf19.6579 -- 1.2 -1.3 1.0 1.5 1.6 1.6 1.3 -1.1 -1.5 
IPF16320 orf19.5131 -- -1.1 1.1 1.0 1.6 2.6 2.2 1.5 1.3 -1.1 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
IPF16323 orf19.6460 ATPase activity 1.7 -1.8 2.3 3.1 1.6 1.6 1.7 -1.8 -1.2 
IPF1651 orf19.6570 Nucleoside permease activity -1.4 1.2 -1.4 3.8 2.7 2.5 -1.3 1.2 1.6 
IPF1674 orf19.6559 -- -1.0 -1.1 -1.8 2.1 3.2 2.7 1.5 -1.0 -1.3 
IPF1674 orf19.6559 -- 1.0 1.4 -1.5 1.9 2.5 3.2 1.6 -1.3 -1.0 
IPF17186 orf19.251 -- 20.7 38.9 39.7 9.2 14.8 14.6 20.8 31.4 21.0 
IPF17255 orf19.696 Mating-type alpha-factor pheromone receptor activity -1.5 5.6 -3.4 8.6 41.6 17.3 -3.9 -1.9 -4.3 
IPF18161 orf19.6587 -- -2.1 -2.4 1.1 2.6 1.6 2.0 1.2 1.1 -2.0 
IPF18316 orf19.5145 -- 1.3 1.4 1.5 4.0 2.2 1.5 -1.6 -1.1 -1.6 
IPF1837 orf19.5877 Alcohol O-acetyltransferase activity 2.1 1.9 1.9 1.7 1.6 2.1 3.8 4.3 6.0 
IPF18385 orf19.4143 -- 4.4 3.4 1.4 1.0 2.4 1.0 1.5 1.5 3.0 
IPF18418 orf19.5620 -- 1.3 2.4 2.4 2.0 2.8 1.7 2.4 2.7 3.6 
IPF1862.5f orf19.5894 -- 1.7 1.3 -1.6 2.4 1.7 2.1 -7.7 1.9 1.4 
IPF18641.5f orf19.3159 -- 1.9 1.9 14.6 -1.5 -2.2 -9.5 -1.1 -1.2 2.0 
IPF1899 orf19.7131 -- -1.1 1.5 -1.5 2.0 1.8 2.1 1.0 1.1 2.1 
IPF1912 orf19.7140 -- -1.6 -1.3 -1.6 1.8 1.7 1.9 -1.5 1.2 1.6 
IPF19295.5f orf19.4649 -- -1.3 -1.5 -2.7 1.9 3.0 2.2 1.4 1.0 -1.8 
IPF19513 orf19.6476 -- -1.0 -1.4 -1.2 1.5 1.6 1.7 -1.5 -1.0 -1.3 
IPF19538.3f orf19.6957.3 -- 2.2 1.7 6.0 8.5 4.4 2.3 3.1 2.2 2.7 
IPF19908 orf19.1344 -- 1.2 2.7 1.8 3.2 2.2 4.2 -1.6 -1.5 -1.0 
IPF19997 orf19.6458.1 -- -1.6 -1.3 1.5 1.9 1.8 2.4 1.5 1.5 1.9 
IPF19998 orf19.2175 Oxidoreductase activity 1.0 1.1 -1.0 1.6 1.9 1.8 1.3 1.2 1.8 
IPF20010 orf19.5799 -- 1.9 1.9 1.6 1.6 1.5 1.4 1.0 1.2 -1.4 
IPF20015 orf19.499 -- 1.5 1.6 1.5 1.1 -1.1 -1.1 -1.2 -1.3 -1.3 
IPF20157 orf19.6696 -- 1.9 3.8 2.0 1.2 2.4 10.5 1.8 1.6 -10.0 
IPF2021 orf19.5245 -- 1.6 2.2 1.6 -1.3 -1.2 -1.4 -1.3 1.4 2.2 
IPF2050 orf19.5265 Structural constituent of cytoskeleton 1.7 1.7 2.3 1.2 -1.0 -1.3 1.4 1.5 -1.9 
IPF2130 orf19.7204 -- 1.8 1.8 -1.4 17.2 37.0 15.2 5.0 7.4 3.0 
IPF2150 orf19.7193 -- -1.1 1.2 -1.1 1.7 1.8 2.8 -1.3 1.1 -1.3 
IPF2170 orf19.7179 -- 1.1 -1.2 -1.1 3.0 1.5 2.5 2.5 -1.7 -1.0 
IPF2175 orf19.7175 -- 1.1 -1.1 -1.2 1.5 1.6 1.6 1.1 -1.1 -1.1 
IPF2186 orf19.7166 -- 3.0 6.0 7.3 14.0 15.8 11.7 11.8 11.1 22.5 
IPF2189 orf19.7165 -- 1.1 -1.5 -1.1 3.1 2.5 1.9 1.2 1.3 -1.0 
IPF2190 orf19.7164 -- -1.5 1.4 -1.5 1.5 1.7 2.0 -1.2 -1.4 -1.0 
IPF2228 orf19.6902 ATP-dependent RNA helicase activity -1.2 -1.8 -1.0 2.1 1.5 1.6 -1.0 1.0 1.7 
IPF2280 orf19.6658 -- 1.1 2.6 -1.0 1.9 2.0 1.5 -1.2 1.1 -1.3 
IPF2361 orf19.7023 -- 1.2 -1.5 1.1 1.6 2.5 1.7 1.2 1.5 2.2 
IPF2557 orf19.6627 -- -1.1 1.3 1.1 1.5 1.7 1.7 1.4 2.0 2.2 
IPF2582 orf19.5504 -- -1.3 -1.7 -1.1 1.8 1.6 2.8 1.2 1.4 1.8 
IPF2905 orf19.7457 -- 1.8 -1.4 1.4 1.7 2.5 2.0 -1.4 -1.2 1.1 
IPF300 orf19.3282 -- 1.0 -1.3 1.2 1.5 2.2 1.7 -1.1 1.4 3.6 
IPF3014 orf19.5030 -- 2.2 1.6 2.3 1.4 1.4 -1.5 1.2 -1.4 3.1 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
IPF3069 orf19.7034 -- 1.0 1.3 -1.2 1.6 1.5 1.5 -1.1 1.4 1.5 
IPF3080 orf19.7042 -- 2.3 1.0 2.7 6.2 4.7 5.5 10.7 11.3 12.2 
IPF3081 orf19.7043 -- -1.2 -1.1 1.4 1.5 2.3 2.9 1.1 -1.6 1.6 
IPF3121 orf19.4438 Transcription factor activity -1.1 1.9 -1.1 3.0 8.0 3.9 1.1 1.1 -7.2 
IPF3277 orf19.4384 Fructose transporter activity 2.5 5.3 2.3 -1.1 1.2 -2.0 -1.5 -1.4 -1.5 
IPF3277 orf19.4384 Fructose transporter activity 1.7 4.0 1.7 -1.0 -1.8 -3.3 -1.4 -1.2 -1.7 
IPF3282.3eoc orf19.4384 Fructose transporter activity 1.7 4.5 1.6 -1.3 -1.7 -2.5 -1.6 -1.3 -1.6 
IPF3352 orf19.4013 -- 1.1 1.3 1.3 1.8 2.2 2.8 -1.0 -1.1 -1.0 
IPF3491 orf19.6753 -- 1.0 1.3 1.3 1.8 1.7 1.5 -1.1 1.1 -1.1 
IPF3535 orf19.6840 -- 1.8 2.2 4.2 2.4 1.7 1.8 -1.6 -1.5 1.7 
IPF3679 orf19.889 Transcription factor activity 2.3 1.5 1.8 1.0 1.0 -1.0 -1.6 -1.6 -1.1 
IPF3836 orf19.279 Hydrolase activity, acting on ester bonds -1.2 1.2 -1.4 -1.1 -1.1 1.5 1.5 1.5 1.7 
IPF3866 orf19.21 -- -1.4 1.0 -1.0 2.0 1.6 1.6 -1.0 1.3 1.5 
IPF3876 orf19.775 -- 1.9 1.8 1.1 1.5 1.9 2.9 1.6 1.0 1.3 
IPF3927 orf19.6506 -- 1.3 -1.6 -1.4 1.6 1.5 3.1 1.0 1.1 -1.5 
IPF4059 orf19.1865 -- 1.5 1.6 1.5 1.3 1.3 1.3 -1.1 1.0 1.1 
IPF4325 orf19.5523 -- 1.5 1.6 1.9 1.5 2.3 2.9 1.1 -1.4 -1.8 
IPF448 orf19.7051 -- -1.8 -1.7 1.6 2.6 2.2 1.9 -1.6 -1.2 6.7 
IPF4567.3f orf19.6525 -- -1.1 -1.1 -1.2 1.9 1.5 1.9 -1.3 -1.1 -1.1 
IPF474 orf19.7060 -- 1.4 1.6 -2.0 1.5 2.0 2.0 -1.3 -1.3 -1.2 
IPF480 orf19.7063 -- -1.4 -1.0 -1.2 2.0 1.8 1.8 -1.1 -1.0 1.2 
IPF4835 orf19.5992 Transcription factor activity 1.3 1.3 1.1 2.8 2.0 3.9 2.3 1.7 1.7 
IPF4890 orf19.6263 Monocarboxylic acid transporter activity -1.1 1.1 -1.0 -1.8 -1.0 1.0 1.5 1.7 3.4 
IPF511 orf19.7078 -- -1.6 1.2 1.2 1.9 1.7 1.8 1.0 1.2 1.8 
IPF525 orf19.7085 -- 1.3 1.4 1.0 2.5 1.7 2.3 1.5 1.4 -1.6 
IPF538 orf19.7091 -- -1.1 -1.4 -1.2 1.5 1.7 2.3 1.0 -1.0 1.2 
IPF539 orf19.7092 -- 1.3 1.4 -1.1 1.5 1.7 2.0 1.2 1.2 1.2 
IPF5426 orf19.6378 -- -1.1 -1.3 -1.2 1.7 1.5 2.3 1.5 -1.0 -1.6 
IPF553 orf19.7096 -- -1.1 1.4 -1.3 1.5 1.9 1.9 -1.2 -1.1 1.1 
IPF5567 orf19.5160 Protein phosphatase regulator activity 1.0 -1.4 1.1 2.0 1.7 2.4 1.3 1.0 1.4 
IPF5625 orf19.7112 Ferric-chelate reductase activity 1.4 1.3 1.8 2.0 2.2 2.8 -1.3 -1.2 1.3 
IPF568 orf19.7105 Cyclin-dependent protein kinase inhibitor activity 1.3 1.1 -2.0 30.5 21.8 21.0 -1.1 1.1 -1.5 
IPF5723 orf19.6329 -- -1.4 1.2 -1.3 -2.4 -1.3 -1.3 1.6 1.5 3.7 
IPF5987 orf19.7306 -- 48.6 49.5 63.3 41.5 50.1 81.4 45.5 38.2 35.7 
IPF6032 orf19.4607 -- 1.6 2.0 3.3 1.7 1.6 1.4 1.5 2.0 1.6 
IPF6041 orf19.4612 -- -1.3 1.6 1.2 1.7 2.3 2.2 2.2 -1.2 3.1 
IPF6050 orf19.6737 -- 1.5 1.5 2.0 -1.1 -1.4 -1.8 1.0 1.0 1.3 
IPF610 orf19.7631 -- 1.5 1.8 1.6 -1.0 -1.2 -1.6 -1.2 1.5 -1.1 
IPF6203 orf19.4166 -- 1.6 2.1 1.5 1.1 -1.1 1.2 -1.0 1.2 -1.4 
IPF6235 orf19.5372 -- 1.0 1.2 -1.1 1.9 3.4 3.4 -1.0 1.1 4.5 
IPF6238 orf19.2374 -- 1.2 1.0 1.3 2.2 3.4 2.8 1.3 1.0 3.9 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
IPF6318 orf19.1664 -- 1.0 1.4 -1.2 1.5 1.9 3.5 1.5 -1.1 1.3 
IPF643 orf19.7610 Protein tyrosine phosphotase activity 1.3 -1.1 1.2 -1.3 1.1 1.8 1.9 1.7 3.0 
IPF6444 orf19.1900 -- 1.2 -1.3 1.4 2.3 3.1 1.6 1.3 1.1 -1.5 
IPF6518 orf19.1691 -- 1.5 3.5 3.5 2.0 3.2 4.4 1.2 -1.2 2.6 
IPF7171.3f orf19.5372 -- 1.9 2.2 1.8 2.6 -1.2 -1.0 -1.1 -1.2 -2.0 
IPF730 orf19.5362 -- -1.1 -1.1 -1.9 13.3 3.7 3.9 1.1 -1.1 -1.5 
IPF7397 orf19.1800 -- 2.2 1.9 2.4 1.6 1.5 1.3 -1.2 -1.6 -2.5 
IPF7456 orf19.2047 -- -1.2 1.7 -1.1 1.6 2.1 1.7 1.3 1.6 1.4 
IPF7493 orf19.4682 Glucose transporter activity 1.5 11.3 9.5 5.8 2.1 3.2 -2.8 -2.0 -2.7 
IPF7602 orf19.6837 -- -1.1 1.1 -1.3 -1.8 -1.0 1.1 1.6 1.8 1.9 
IPF7666 orf19.4056 Transcription factor activity 2.5 3.9 3.3 2.3 1.0 1.3 3.2 2.3 3.5 
IPF7686 orf19.1395 Inorganic phosphate transporter activity 1.9 3.3 2.3 1.4 1.3 -1.0 2.6 2.0 5.0 
IPF7686 orf19.1395 Inorganic phosphate transporter activity 1.7 2.3 1.9 -1.2 1.2 1.4 -1.1 1.1 -1.0 
IPF7770 orf19.3881 -- 1.5 1.6 -1.1 1.8 1.6 2.1 1.0 1.0 -1.7 
IPF7817 orf19.3131 NADPH dehydrogenase activity 9.4 13.7 13.4 7.7 11.0 8.2 11.8 13.3 84.2 
IPF7863 orf19.1449 -- 6.1 9.4 9.1 7.2 7.2 5.7 6.5 9.5 5.7 
IPF7940 orf19.6608 -- 5.4 4.3 10.3 4.3 5.2 20.2 6.4 2.6 -1.0 
IPF7947 orf19.6602 -- -1.5 -1.2 2.1 1.6 1.5 1.9 1.3 -1.1 1.6 
IPF7968 orf19.2693 Transcription corepressor activity -1.1 1.4 1.3 1.5 1.7 1.8 1.4 1.5 -1.1 
IPF8016 orf19.1336.2 -- -1.0 -1.9 1.8 1.7 1.7 4.3 2.2 -1.2 13.7 
IPF8024 orf19.1334 -- -1.5 -1.4 -1.3 1.6 1.8 2.3 -1.2 -1.0 1.0 
IPF8067 orf19.3697 -- 1.6 1.4 2.6 3.0 2.4 1.7 3.5 1.5 1.2 
IPF8147 orf19.6200 -- 2.4 8.5 1.6 -2.6 -1.9 3.6 2.6 1.2 -1.7 
IPF8378 orf19.6072 -- 1.9 -1.4 1.3 1.9 1.5 1.6 1.2 1.1 1.1 
IPF8439 orf19.6498 -- 1.3 -1.0 -1.5 1.7 1.8 2.7 -1.5 -1.1 1.2 
IPF8591 orf19.5862 Arginase activity 2.5 3.1 7.0 1.0 2.0 1.9 1.8 -1.3 -1.2 
IPF8627 orf19.3969 Specific transcriptional repressor activity 2.8 2.7 1.8 1.2 -1.1 1.3 1.3 1.3 2.3 
IPF867 orf19.7221 NAD-dependent histone deacetylase activity 2.4 1.6 1.5 2.1 1.5 1.6 -1.1 1.0 -2.0 
IPF8951 orf19.4897 -- 1.7 1.3 2.1 2.1 2.1 2.3 2.0 1.6 -1.1 
IPF8970 orf19.496 -- 2.8 2.1 1.4 3.6 2.5 2.9 1.0 -1.1 -1.6 
IPF8976 orf19.1369 -- 5.2 5.7 14.9 6.2 7.3 4.0 1.2 2.3 -1.2 
IPF9370 orf19.1424 -- 1.6 2.0 2.1 1.1 1.2 1.3 -1.3 1.2 -4.2 
IPF9410 orf19.6148 Structural constituent of cytoskeleton 2.5 1.6 1.7 1.4 1.4 1.1 -1.8 -1.1 -2.1 
IPF9450 orf19.4370 -- -1.1 1.1 -1.0 2.3 1.6 1.9 1.4 1.9 1.3 
IPF9496 orf19.2809 Carnitine O-acetyltransferase activity 2.3 5.8 2.5 2.2 1.5 2.9 -2.2 -2.2 -1.2 
IPF9538 orf19.271 2,4-dienoyl-CoA reductase (NADPH) activity 108.9 279.5 131.7 7.8 24.5 18.1 29.2 29.3 27.6 
IPF9704 orf19.4882 General RNA polymerase II transcription factor activity 1.5 -1.3 1.2 1.5 1.8 2.1 1.2 -1.0 1.5 
IPF9748 orf19.746 -- 2.8 -1.2 1.5 1.5 1.8 3.8 1.5 -1.5 -2.1 
IPF9828 orf19.6861 Protein binding 1.1 -2.5 -1.1 1.8 1.9 3.5 1.1 -1.7 -2.4 
IPF9887 orf19.1240 -- 2.8 3.1 3.8 2.9 4.2 5.8 4.1 4.2 5.5 
IQG1 orf19.6536 Cytoskeletal protein binding -1.0 -1.0 1.2 1.7 1.8 2.8 1.1 1.2 2.7 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
KAP114 orf19.7086 Protein carrier activity -1.1 -1.2 -1.1 1.5 1.9 2.5 1.0 -1.1 1.9 
KEX1 orf19.7020 Carboxypeptidase D activity 1.0 1.0 -1.0 1.5 1.8 2.2 1.3 1.4 3.1 
KIN3 orf19.5325 Protein kinase activity -1.3 -1.2 -1.1 2.0 1.8 3.6 1.4 1.4 -1.1 
LPI9 orf19.6544 -- 1.1 1.0 -1.3 2.2 1.8 1.8 -1.1 1.2 -4.2 
LYS21 orf19.4506 Homocitrate synthase activity -2.3 -2.5 -1.2 -1.2 -1.2 -1.2 1.5 2.8 3.4 
MDM12 orf19.6900 -- 1.4 -1.2 -1.1 2.0 1.7 2.3 1.3 -1.3 1.2 
MDN1 orf19.4697 ATPase activity 2.5 1.6 3.7 2.1 -1.2 -1.7 1.1 -1.3 -1.0 
MET13 orf19.288 Structural constituent of ribosome -1.0 -1.2 1.4 -4.1 -1.4 -1.3 1.8 1.7 2.8 
MGM1 orf19.2690 GTPase activity 1.1 -1.1 1.4 1.7 1.5 2.2 1.4 1.1 1.5 
MRE11 orf19.6915 3'-5' exonuclease activity 1.2 -1.3 -1.2 2.0 1.9 1.7 -1.0 1.0 2.1 
MRF1 orf19.1149 DNA binding 1.6 1.7 2.7 -1.7 -1.1 1.1 -1.0 -1.0 1.2 
MRR1 orf19.7372 RNA polymerase II transcription factor activity 2.8 1.8 5.7 2.9 1.8 1.9 2.3 3.4 4.7 
MSD1 orf19.4478 Aspartate-tRNA ligase activity 1.1 1.0 -1.1 1.5 1.5 1.8 -1.0 -1.1 -1.2 
MSK1 orf19.6533 Lysine-tRNA ligase activity -1.1 -1.0 -1.2 1.5 1.6 2.4 1.0 1.0 -1.3 
NDH2 orf19.5713 NADH dehydrogenase activity 2.0 2.6 1.6 2.9 4.0 4.7 2.1 2.5 10.9 
OPT1 orf19.2602 Oligopeptide transporter activity -1.6 1.1 -2.2 -4.5 -2.4 -4.4 1.8 2.4 3.0 
PAP11 orf19.3197 RNA binding 4.7 -3.8 -1.5 2.2 2.3 2.5 -1.3 1.5 2.2 
PET112 orf19.2494 -- 1.2 1.4 -1.4 2.4 1.5 1.7 1.4 1.1 1.3 
PET8 orf19.7082 Transporter activity -1.0 1.1 -1.2 1.5 1.7 2.3 1.1 1.1 -2.5 
PEX17 orf19.3605 -- 2.5 1.6 1.5 1.7 1.2 1.6 -1.5 -1.4 1.1 
PEX4 orf19.4041 Ubiquitin conjugating enzyme activity -1.0 1.8 -1.5 1.5 1.5 1.8 -1.6 -1.1 -3.6 
PGA10 orf19.5674 Heme binding 1.8 4.3 1.2 2.0 3.9 3.2 1.2 -1.1 -1.1 
PGA26 orf19.2475 -- -3.2 -1.4 -1.6 2.8 6.0 2.9 1.5 1.1 1.4 
PHR1 orf19.3829 1,3-beta-glucanosyltransferase activity 1.9 2.4 1.5 -1.1 -1.4 -2.1 -1.0 1.4 1.2 
PIB1 orf19.7547 Ubiquitin-protein ligase activity 1.5 1.5 -1.4 1.7 2.0 2.9 -1.0 -1.3 -1.5 
PLB4.3f orf19.1442 Lysophospholipase activity -1.8 1.1 1.0 1.9 2.6 4.3 -1.2 -1.3 -1.2 
POL0 orf19.5373 -- 1.4 1.3 1.4 3.0 4.2 3.9 -1.0 -1.0 1.7 
POL3 orf19.5182 Delta DNA polymerase activity 1.8 1.9 1.6 2.9 1.7 -4.3 1.5 -1.2 -1.2 
POT13 orf19.2046 Acetyl-CoA C-acyltransferase activity 1.1 1.8 1.4 1.5 1.5 2.2 -1.1 -1.0 -1.1 
PRE10 orf19.6582 Endopeptidase activity -1.2 -1.3 1.7 1.9 1.9 2.4 1.3 -1.1 -1.2 
PRE5 orf19.7178 Endopeptidase activity -1.2 1.1 -1.0 1.5 1.5 1.6 -1.3 -1.1 -2.2 
PRY2 orf19.7218 -- 1.1 1.1 -1.1 3.4 2.7 2.6 -1.3 1.1 -1.3 
PYC2.3f orf19.789 Pyruvate carboxylase activity 1.3 -1.3 1.1 -1.4 1.2 1.7 1.6 1.8 1.5 
PYC2.5f orf19.789 Pyruvate carboxylase activity 2.1 1.5 4.8 1.4 1.5 -5.8 1.6 1.7 2.1 
RBT1 orf19.1327 -- -1.2 1.2 -1.2 -1.4 -1.3 -2.3 1.8 1.5 2.1 
RBT4 orf19.6202 -- 3.6 3.3 3.2 1.2 -1.5 -2.4 -1.1 1.4 1.4 
RPN4 orf19.1069 Transcription factor activity 2.4 2.6 2.2 2.8 2.8 2.0 1.5 1.4 1.1 
SLA2 orf19.7201 Structural constituent of cytoskeleton -1.6 -1.5 -1.2 2.0 2.2 4.1 1.4 1.1 1.2 
SNF31 orf19.7094 Glucose transporter activity -1.0 14.4 3.2 1.9 1.7 3.4 -3.0 -1.1 -1.5 
SNZ1 orf19.2947 -- 1.5 2.1 1.9 2.3 -1.2 -1.3 -1.5 1.3 1.0 
SOD21 orf19.7111 Manganese superoxide dismutase activity -1.1 2.7 -2.0 2.0 2.3 1.6 3.2 2.2 2.6 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
SOD21 orf19.7111 Manganese superoxide dismutase activity -1.0 4.8 -5.0 5.9 2.6 3.1 2.9 2.3 1.7 
SOU3 orf19.732 2,4-dienoyl-CoA reductase (NADPH) activity 1.9 2.5 1.5 2.2 2.2 2.0 -1.5 -1.1 -1.4 
STL2 orf19.7093 Glucose transporter activity 1.4 1.9 -1.1 1.5 2.0 2.2 -1.3 -1.1 -2.4 
TAF19 orf19.5174 General RNA polymerase II transcription factor activity 1.0 1.1 1.2 2.0 1.8 2.1 -1.2 -1.0 -1.5 
TEF41 orf19.2652 Translation elongation factor activity 3.4 3.9 13.6 5.0 5.2 7.0 -1.1 -1.5 -1.7 
TERT2 orf19.5089 Telomeric template RNA reverse transcriptase activity 2.0 2.5 1.4 8.1 2.7 1.7 -1.6 -2.1 -3.2 
TES12 orf19.4122 -- 2.4 1.5 1.7 -2.8 -2.1 -2.0 1.2 -1.1 -1.4 
TIM9 orf19.6696 Protein transporter activity -1.3 1.3 1.6 3.0 1.8 3.1 1.2 -1.4 2.1 
TOM72 orf19.3700 Protein transporter activity 1.0 -1.5 1.0 1.9 1.7 1.8 1.3 -1.2 3.1 
TRP4 orf19.3099 Anthranilate phosphoribosyl transferase activity 1.5 1.2 1.2 1.2 1.2 2.2 1.5 1.7 1.9 
UFD1 orf19.5833 -- -1.5 1.0 -1.1 1.5 1.5 2.0 -1.1 1.0 -2.1 
UGA2 orf19.345 Succinate-semialdehyde dehydrogenase activity 1.8 2.9 16.0 1.2 1.0 -1.1 2.4 2.5 3.4 
UGT51 orf19.2616 Sterol 3-beta-glucosyltransferase activity 1.1 1.8 -4.4 3.3 1.8 4.7 1.2 1.1 5.7 
YAR1 orf19.7160 -- -1.6 -1.9 2.2 1.6 1.7 2.5 1.6 -1.0 1.1 
YOX1 orf19.7017 -- 1.5 1.5 1.7 1.3 1.2 -1.1 1.3 1.9 1.9 
 
a Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b orf19 nomenclature according to the Assembly 19 version. 
c GO annotation found at CGD (http://www.candidagenome.org/). 
 
Table B-2. Genes down-regulated in at least one clinical matched isolate overexpressing MDR1. 
 
CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
AAT1 orf19.3554 Aspartate transaminase activity -1.3 1.1 -1.0 -1.5 -1.2 -1.1 -2.1 -1.6 -1.8 
AAT21 orf19.6287 Aspartate transaminase activity -1.4 1.1 -1.2 -1.9 -1.6 -2.0 -1.4 1.0 1.1 
ADE1 orf19.7484 Phosphoribosylaminoimidazolesuccino carboxamide synthase 
activity 
-1.7 -1.8 -1.5 -1.3 -1.2 -1.1 -2.1 -1.9 -4.8 
ADE13 orf19.3870 Adenylosuccinate lyase activity -1.7 -1.7 -1.8 -1.4 -1.2 -1.1 -2.2 -1.9 -1.8 
ADE2 orf19.5906 Phosphoribosylaminoimidazole carboxylase activity -1.3 -1.3 -2.2 -1.1 -1.3 -1.4 -2.1 -1.7 -2.3 
ADE6 orf19.6317 Phosphoribosylformylglycinamidine synthase activity -1.5 -1.6 -1.5 -1.8 -1.2 1.1 -1.6 -1.7 -1.4 
ADE8 orf19.5789 Phosphoribosylglycinamide formyltransferase activity -2.2 -1.8 -1.5 -1.1 -1.6 -1.7 -2.2 -1.8 -3.1 
AGP2 orf19.4679 Hydrogen:amino acid symporter activity -2.5 -2.0 -2.2 -6.9 -6.0 -7.6 -1.1 1.6 4.6 
AKR1 orf19.4950 -- -1.2 -1.2 -2.4 -1.8 1.0 1.5 -1.5 -1.7 -1.6 
ALP1 orf19.2337 Basic amino acid transporter activity -2.8 -2.3 -1.9 -3.3 -1.6 -1.6 1.0 -1.1 -1.0 
ALS1 orf19.5741 Cell adhesion molecule binding -1.9 -1.0 -2.4 -2.3 -2.1 -3.1 1.2 1.6 1.0 
ALS6 orf19.7414 Cell adhesion molecule binding 1.0 2.2 1.3 -6.3 -7.2 -1.9 -1.1 -1.2 1.2 
AOX1 orf19.4774 Alternative oxidase activity 1.1 -1.9 -2.4 -1.6 -1.3 1.2 -1.6 -2.2 -2.2 
AOX2.3f orf19.4773 Alternative oxidase activity 1.4 1.6 1.7 -3.2 -6.3 -4.9 -2.0 -1.6 1.3 
AQY1 orf19.2849 Water channel activity -3.2 1.1 -2.2 -6.6 -3.3 -2.9 -3.2 -2.3 -2.0 
ARO3 orf19.1517 3-deoxy-7-phosphoheptulonate synthase activity -1.4 1.2 -1.4 -1.5 -1.5 -1.7 -1.0 1.9 1.8 
ARR3 orf19.3122 Arsenite transporter activity -2.1 -1.5 -1.5 -4.5 -2.0 -2.1 -1.5 -1.4 -1.9 
AUR1 orf19.1945 Inositol phosphoceramide synthase activity -1.4 -1.1 -1.0 -3.0 -1.5 -2.3 -1.3 -1.0 1.5 
AXL2 orf19.5292 -- 1.2 -1.6 3.4 -2.2 -1.7 -1.6 1.6 1.2 -2.7 
AYR2 orf19.5615 Acylglycerone-phosphate reductase activity -1.8 -1.1 -1.7 -3.1 -1.5 -2.1 -1.3 -1.2 -1.5 
CAN1 orf19.97 L-arginine transporter activity -1.7 -1.1 -1.5 -2.8 -1.9 -2.7 -1.8 -2.1 1.1 
CAN2 orf19.111 Basic amino acid transporter activity -1.6 1.0 -4.0 -4.9 -2.8 -4.9 -3.7 -3.0 -6.3 
CAP1 orf19.1623 Transcription factor activity 1.2 1.1 -1.0 -1.9 -1.6 -1.8 -1.2 1.2 -1.1 
CAT2 orf19.4591 Carnitine O-acetyltransferase activity -1.0 1.0 -1.3 1.1 -1.4 -1.6 -1.7 -1.9 -2.5 
CFL1 orf19.1263 Ferric-chelate reductase activity -1.5 -1.5 -2.0 -1.4 1.1 -1.5 -1.7 -2.4 -2.4 
CPA1 orf19.4630 Carbamoyl-phosphate synthase activity -1.8 -2.0 -1.9 -2.4 -1.3 -1.7 -1.4 -1.1 -1.3 
CPA2 orf19.3221 Carbamoyl-phosphate synthase activity -1.4 -1.7 1.4 -2.2 -2.4 -1.5 1.1 -1.0 -1.2 
CTA1 orf19.6229 Catalase activity -1.9 1.6 -1.8 -1.6 -2.0 -2.5 -2.3 -1.3 -1.2 
CTA211.5f orf19.362 -- -1.8 -1.7 -1.8 -2.2 -1.3 1.8 -1.2 1.1 17.7 
CYB3 orf19.5000 L-lactate dehydrogenase activity 1.4 2.9 2.5 1.2 1.0 -1.1 -2.4 -1.9 -1.7 
CYT2 orf19.4578 Holocytochrome-c synthase activity 1.0 1.3 -1.3 -2.4 -2.1 -2.4 -1.0 1.0 -1.2 
DAK2 orf19.4777 Glycerone kinase activity -1.5 -1.6 -2.7 -1.9 1.1 1.7 2.4 1.1 -1.7 
DBP2 orf19.171 RNA helicase activity 1.0 -1.4 1.1 -1.5 -1.8 -3.3 -1.0 1.3 -1.1 
DOG2 orf19.3392 2-deoxyglucose-6-phosphatase activity -1.1 -1.0 1.0 -1.9 -1.5 -2.1 1.4 1.4 1.6 
DPP1 orf19.656 Phosphatidase phosphatase activity -1.4 1.3 1.7 -2.3 -1.6 -1.8 -1.2 1.1 1.0 
DRS21.5eoc orf19.783 Calcium-transporting ATPase activity -1.1 -1.2 -1.3 -1.6 -1.2 -1.1 -1.8 -1.5 -1.6 
DUR32 orf19.5017 Urea transporter activity 2.0 1.3 1.1 -4.2 -1.6 -2.1 -1.4 -1.8 -1.9 
DUR33.5eoc orf19.7205 Urea transporter activity -1.6 1.1 1.0 -2.3 -1.8 -1.9 1.3 -1.1 -2.2 
EBP1 orf19.125 NADPH dehydrogenase activity -5.5 -4.2 -2.9 -4.5 -2.8 -2.7 -2.9 -2.8 -3.9 
ECM17 orf19.4099 Sulfite reductase (NADPH) activity 1.1 -1.1 -1.3 -1.6 -1.7 -2.1 -1.2 -1.1 1.4 
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ECM22 orf19.2623 Transcription factor activity -2.1 -1.3 -2.2 -2.8 -2.3 -2.5 -1.8 -1.5 -1.3 
ECM42 orf19.6500 Amino-acid N-acetyltransferase activity -2.2 -1.8 -1.8 1.2 1.4 1.7 1.1 1.1 -1.0 
ENA22 orf19.6070 ATPase activity -1.7 -1.4 -2.1 -2.9 -1.5 -1.7 -1.5 -1.4 -1.0 
FAA21 orf19.272 Long-chain-fatty-acid-CoA ligase activity 1.6 1.1 1.5 -3.0 -2.4 -1.8 -1.4 -1.1 1.6 
FCR1 orf19.6817 Transcription factor activity -2.0 -1.5 -2.0 -2.1 -1.6 -2.3 1.0 1.1 1.1 
FDH12 orf19.638 Formate dehydrogenase activity -1.7 1.8 -2.2 -2.4 -3.0 -2.4 -2.4 -2.4 -1.8 
FDH2 orf19.1117 Formate dehydrogenase activity 1.2 -4.1 -12.0 -2.3 -7.5 -4.6 -2.5 -1.5 -2.0 
FDH3.3f orf19.1774 Formate dehydrogenase activity -1.9 -1.1 -2.2 -2.5 -4.7 -4.7 -3.1 -3.6 -4.3 
FDH3.5f orf19.1774 Formate dehydrogenase activity 1.4 -12.4 -5.1 -2.6 -4.6 -2.1 -2.3 -4.4 -2.8 
FET33 orf19.4211 Ferroxidase activity 1.5 1.4 1.1 -1.8 -1.7 -2.8 -1.7 -1.5 -2.3 
FOX2 orf19.1288 3-hydroxyacyl-CoA dehydrogenase activity -1.2 3.8 -1.5 -2.0 -1.9 -1.8 -1.9 -1.4 -1.4 
FTR1 orf19.7219 Ferrous iron transporter activity -4.3 -3.0 -2.8 -3.8 -3.2 -5.2 -5.6 -3.9 -5.4 
GAD1 orf19.1153 Glutamate decarboxylase activity -1.4 -1.3 -1.7 -2.3 -1.2 -1.0 -1.6 -1.5 -2.6 
GAL10 orf19.1153 UDP-glucose 4-epimerase activity 1.2 2.1 1.6 -2.4 -1.8 -1.7 -1.7 -1.2 -2.0 
GAL7 orf19.3675 UTP:galactose-1-phosphate uridylyltransferase activity -1.0 1.8 2.3 -2.2 -2.4 -2.3 -1.7 -1.3 -1.7 
GAP4 orf19.1799 Amino acid permease activity -1.6 -1.6 -1.6 -1.5 -1.1 -1.3 -1.2 -1.2 5.0 
GCV1 orf19.5519 Glycine dehydrogenase (decarboxylating) activity -1.9 -2.1 -2.2 -1.6 -1.2 1.2 -2.3 -3.1 -2.5 
GCV2 orf19.385 Glycine dehydrogenase (decarboxylating) activity -1.4 -1.5 -2.4 1.3 -1.1 -1.1 -2.8 -1.8 -2.5 
GNP1 orf19.7566 Amino acid permease activity 1.0 2.4 -1.7 -1.5 -1.4 -1.7 -2.2 -1.7 -1.8 
GPT1 orf19.4063 L-gamma-aminobutyric acid transporter activity 1.9 -1.5 -1.6 -2.1 -1.6 -1.7 1.1 -1.1 -1.8 
GRP4 orf19.3150 Oxidoreductase activity -1.4 1.3 1.7 -1.9 -1.5 -2.3 -1.9 -1.7 -1.1 
GSL22 orf19.2495 1,3-beta-glucan synthase activity -1.4 1.1 1.0 -2.0 -1.5 -2.4 -1.1 1.2 1.9 
GSL23.3f orf19.3269 1,3-beta-glucan synthase activity -1.0 -1.1 -1.2 -1.9 -1.6 -2.2 -1.1 -1.1 -1.3 
GTT1 orf19.6947 Glutathione transferase activity -1.5 1.2 1.0 -1.8 -1.5 -1.7 -1.1 1.1 -1.3 
GYP1 orf19.3811 Rab GTPase activator activity 1.1 1.4 -1.3 -1.1 -1.1 1.2 -1.6 -1.5 -1.9 
HGT11 orf19.4527 Glucose transporter activity 3.1 4.4 1.7 1.8 -1.2 -1.5 -2.3 -1.5 -3.0 
HGT12 orf19.3668 Glucose transporter activity 2.4 14.0 4.4 6.8 2.6 1.8 -3.1 -3.1 -3.0 
HIP1 orf19.4940 L-histidine transporter activity -1.6 -1.6 1.1 -2.2 -1.7 -1.7 -1.0 1.0 -1.6 
HIS3 orf19.183 Imidazoleglycerol-phosphate dehydratase activity 1.3 -1.2 1.7 -2.0 -3.0 -2.9 -1.1 -1.1 1.7 
HNM1 orf19.2003 Choline transporter activity -1.4 -1.1 -1.1 -1.7 -1.6 -2.1 -1.4 -1.1 -1.2 
HOL1 orf19.2991 Transporter activity -1.2 -1.1 -1.6 -2.2 -1.7 -2.2 1.3 1.5 2.1 
HSP12 orf19.3160 -- -2.2 1.1 -3.0 -12.3 -4.4 -3.5 -7.0 -1.7 -1.6 
HSP31 orf19.3664 -- -2.8 -2.3 -2.5 -1.5 -1.3 -1.6 1.4 -1.2 -3.1 
HXT5.3f orf19.2021 Fructose transporter activity -1.6 -1.2 -1.6 -3.8 -2.5 -3.1 -1.6 -1.1 -1.3 
HXT5.5f orf19.2021 Fructose transporter activity -1.6 -1.2 -2.0 -3.7 -3.0 -6.2 -1.4 -1.3 -1.5 
IFC3 orf19.3749 Oligopeptide transporter activity -2.1 -1.6 -3.0 -6.7 -1.4 1.0 -1.2 -2.1 -1.7 
IFF4 orf19.7472 -- 1.2 1.4 -1.5 -1.6 -1.1 1.5 -2.0 -1.8 -12.4 
IFN1 orf19.1979 Phospholipid transporter activity -3.1 -1.9 -1.8 -2.8 -1.5 -1.6 -1.0 -1.2 -1.9 
IFN3 orf19.1978 Phospholipid transporter activity -1.5 -1.4 -1.5 -3.9 -2.0 -2.0 -1.1 1.1 -1.1 
IFR2 orf19.2396 -- -1.8 -1.6 -1.8 -2.0 -1.5 -2.4 -1.1 -1.1 1.1 
IFY2.5f orf19.2158 Monosaccharide transporter activity -2.0 -1.9 -2.1 -3.1 -1.5 -1.6 -1.6 -1.7 -1.5 
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IPF10029.5eoc orf19.3915 -- -1.4 -1.7 -1.1 -1.5 -1.5 -5.3 1.1 -1.0 -1.0 
IPF10153 orf19.2170 -- -1.4 -1.0 -1.2 -2.3 -1.7 -2.2 -1.2 -1.1 -1.6 
IPF10355 orf19.3809 Transcription factor activity 1.5 1.1 -1.3 1.5 1.2 -1.6 -2.0 -1.6 -1.8 
IPF11105 orf19.2262 -- -2.4 1.6 1.1 -1.9 -1.6 -1.9 -2.5 -1.9 -2.4 
IPF11142 orf19.473 -- -1.5 -1.9 -2.4 -1.8 -1.2 -1.5 -1.1 1.1 -1.1 
IPF11448 orf19.2923 -- -1.5 -1.7 -1.8 -2.1 -1.3 -1.3 1.0 1.0 1.3 
IPF11503 orf19.3902 -- -2.1 -1.1 -1.9 -4.1 -1.7 -2.6 -4.8 -3.2 -3.6 
IPF11548 orf19.3854 Protein kinase activity 1.0 -2.4 1.0 -1.6 -1.9 -1.6 -1.1 -1.3 -1.4 
IPF11713.3f orf19.1152 -- -2.1 -1.2 -2.3 -5.1 -2.2 -3.5 -1.2 -1.0 1.5 
IPF11725 orf19.3475 -- -1.3 1.0 -1.1 -1.9 -1.6 -1.8 -1.1 -1.2 1.1 
IPF11759.3f orf19.4737 -- -1.8 -1.9 -4.3 -2.7 -1.0 -1.7 -1.1 -1.2 -2.2 
IPF11849 orf19.4559 -- 1.1 1.4 1.4 -1.2 -5.5 -2.1 -1.5 -1.5 -2.8 
IPF11858 orf19.1277 -- -1.0 1.1 -1.2 -2.0 -1.8 -2.4 -1.4 -1.6 1.1 
IPF1193 orf19.2079 -- -1.4 -1.1 1.1 -2.4 -1.8 -2.0 -1.0 -1.1 1.1 
IPF12082.3f orf19.6832 -- -1.7 -2.1 -2.1 1.2 1.7 -1.0 1.3 -1.0 1.4 
IPF12568 orf19.3516 -- -1.2 1.1 1.3 -1.6 -1.7 -1.9 -1.3 -1.1 -1.2 
IPF12577 orf19.5238 -- -1.7 -1.6 -1.5 -1.7 1.0 1.3 -1.0 -1.1 1.2 
IPF12579 orf19.5239 -- -1.1 -1.9 1.0 -1.7 -1.0 -1.2 -1.9 -1.6 -5.3 
IPF12758.5f orf19.334 -- -1.2 1.4 -1.3 -1.9 -1.7 -1.7 -1.8 -1.4 -1.5 
IPF12887 orf19.4780 -- -2.0 -1.8 -2.4 -1.8 -1.1 -1.6 -1.1 1.1 1.3 
IPF1292 orf19.7381 Transcription factor activity 1.3 -1.2 1.4 -4.6 -3.0 -3.5 1.2 1.1 1.0 
IPF13131.3 orf19.1587 Glucose transporter activity -2.0 -1.2 -3.4 -1.9 -1.7 -2.0 -2.9 -3.8 -7.4 
IPF13377 orf19.2350 -- -2.1 -1.5 -2.3 -1.6 1.2 1.1 -1.8 1.0 1.2 
IPF13493 orf19.5063 -- -4.3 -3.0 -1.5 -1.3 -1.1 -1.1 -1.7 -1.9 -2.5 
IPF13769 orf19.6209 Monocarboxylic acid transporter activity -1.1 -1.3 -1.6 -1.5 -1.8 -2.5 -1.6 -1.6 -1.9 
IPF1384 orf19.6445 Dodecenoyl-CoA delta-isomerase activity -1.1 1.3 -1.7 1.0 -2.1 1.5 -1.8 -1.8 -1.8 
IPF13879 orf19.1120 -- 2.2 3.5 1.3 -2.0 -1.5 -1.5 1.2 1.3 3.9 
IPF1390 orf19.6449 -- -1.5 2.1 -1.4 -1.3 -1.0 -2.0 -4.3 -1.8 -2.0 
IPF13921 orf19.4749 -- -1.9 -1.7 -1.5 -3.6 -2.9 -2.2 -1.2 -1.0 1.0 
IPF13971 orf19.5204 -- -1.3 1.0 -2.6 -2.2 -1.5 -2.8 -1.5 -1.2 -3.1 
IPF1401 orf19.6066 -- -1.7 -1.0 -1.7 -1.5 -1.5 -1.5 -1.7 -1.0 -1.3 
IPF14501.5f orf19.2455 -- 1.3 1.6 -1.1 -1.6 -1.5 -2.0 -1.1 -1.3 -1.2 
IPF1471 orf19.304 -- -1.5 -1.5 -1.2 -1.6 -1.5 -1.7 1.1 1.1 -1.3 
IPF14744 orf19.5125 -- -1.3 2.5 -1.7 1.2 1.1 -1.4 -3.5 -2.7 -1.5 
IPF14773.5f orf19.3586 -- -1.1 1.4 1.3 1.4 -1.7 -5.5 -1.6 -1.7 -2.0 
IPF1505 orf19.348 -- -2.9 -1.3 -2.1 -3.2 -1.5 -1.7 -1.0 -1.2 -8.9 
IPF15051 orf19.1258 -- -1.4 -2.7 1.2 -2.2 1.2 1.9 -2.5 -1.6 -2.7 
IPF15153 orf19.5867 -- 1.0 1.2 1.2 -1.9 -1.7 -2.6 1.1 1.2 1.4 
IPF15177 orf19.750 -- -1.0 1.1 -1.0 -1.7 -1.6 -2.0 1.1 1.1 -1.5 
IPF15575 orf19.1247 -- -1.7 -1.5 -1.5 -1.2 -1.2 -1.3 -1.5 1.1 -1.2 
IPF15632 orf19.3469 -- -1.7 -1.2 -1.8 -2.2 -1.6 -1.5 -1.4 -1.1 -1.2 
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IPF16067 orf19.3190 Specific RNA polymerase II transcription factor activity -1.1 -1.2 -1.9 -1.6 -1.8 -2.4 -2.4 -1.4 -1.7 
IPF1615.3eoc orf19.980 -- -1.1 -1.0 -1.8 -1.2 -1.2 -1.8 -1.8 -1.5 -2.4 
IPF16253 orf19.3932 -- -1.5 -1.3 -1.5 -2.1 -3.3 -1.7 -2.8 -1.7 1.4 
IPF16752 orf19.2711 RNA polymerase II transcription elongation factor activity -1.3 -1.6 1.1 -1.6 -1.5 -1.7 1.1 1.0 -1.2 
IPF17050 orf19.1049 -- -2.7 -8.2 -5.6 -11.4 -2.3 -17.6 -1.9 -2.4 1.1 
IPF17074 orf19.2792 -- -1.8 -1.3 -1.4 -2.3 -1.5 -1.9 -1.0 -1.1 -1.7 
IPF17094 orf19.2143 -- -1.2 -1.1 -1.3 -1.5 -1.6 -2.7 -1.2 1.2 1.1 
IPF17190 orf19.3869 -- -1.5 -1.1 -1.3 -2.2 -2.0 -1.5 -1.0 1.3 -1.1 
IPF17430.5eoc orf19.73 -- 1.2 -9.5 3.6 -1.5 -1.6 -6.1 1.1 -1.0 1.2 
IPF17706 -- -- 1.1 1.2 -1.0 -3.5 -11.2 -4.7 -1.6 -1.1 -1.9 
IPF18474 orf19.6610 Sturctural constituent of cytoskeleton 1.1 -1.1 -1.7 -1.3 -1.3 -1.6 -1.8 -1.7 -1.8 
IPF18732 orf19.711 -- 1.4 1.5 -1.2 -1.3 1.1 1.0 -2.4 -1.7 -1.9 
IPF19749 orf19.94 -- -1.5 1.0 -1.4 -1.4 -2.0 1.1 -2.6 -1.9 -3.0 
IPF19772 orf19.5602 -- -1.1 -1.5 -1.2 -1.3 -1.1 1.1 -1.5 -1.8 -2.0 
IPF19814 orf19.7106 -- -1.7 -1.7 -1.8 1.1 1.6 1.7 1.1 -1.3 1.0 
IPF19859 orf19.3375 -- -1.3 1.8 -1.6 -1.9 -1.7 -1.6 -1.0 1.2 -1.1 
IPF20135 orf19.993 -- -2.4 -1.7 -1.6 -1.8 -1.7 -2.0 1.2 1.2 -1.3 
IPF2053 orf19.5267 -- -5.5 -5.3 -6.8 -1.1 1.0 -1.3 -1.0 1.3 -1.5 
IPF2275.5eoc orf19.6654 -- -2.2 -1.9 -2.0 -1.9 -2.0 -4.1 -1.1 1.2 1.1 
IPF2283 orf19.6660 -- -2.6 -2.4 -2.4 -2.8 -1.5 -1.7 1.2 -1.4 1.9 
IPF2319 orf19.6680 Transcription factor activity 1.0 -1.0 1.0 -1.5 -1.7 -1.6 1.1 1.1 1.8 
IPF2374 orf19.6805 -- -1.7 -2.4 2.0 -2.1 -2.1 -2.3 -1.5 -1.5 1.1 
IPF2383 orf19.6808 -- -1.7 -2.4 -2.2 -1.2 1.1 1.1 -1.1 -1.4 -1.9 
IPF2522 orf19.7460 -- -1.7 -1.5 -2.1 1.2 1.1 1.2 -1.4 -1.0 1.0 
IPF2542 orf19.6629 Phospholipase C activity -1.3 -1.6 1.1 -1.6 -1.5 -2.0 -1.0 -1.1 1.0 
IPF2645 orf19.7405 -- -1.8 -1.5 -1.9 -1.2 -1.3 -1.4 -1.1 1.2 -1.7 
IPF2795 orf19.6763 -- -1.8 -1.6 -1.8 -1.4 -1.5 -1.3 1.2 1.2 -1.1 
IPF2822 orf19.6781 Transcription factor activity -2.4 -2.4 -1.1 -2.2 -3.1 -2.2 1.5 -1.4 -1.4 
IPF2839 orf19.7296 -- -2.1 -1.6 -3.7 -1.7 -1.5 -1.7 -1.9 -1.8 -5.4 
IPF3092 orf19.4445 -- 1.1 1.6 1.0 -1.2 -1.9 -1.4 -2.4 -2.0 -1.5 
IPF3506 orf19.6741 -- -1.6 -1.3 -1.1 -6.4 -3.6 -5.0 1.1 1.5 2.8 
IPF3539 orf19.2813 -- -2.1 7.3 -1.1 -1.2 -1.4 -7.6 -2.1 -2.2 -1.6 
IPF3624 orf19.6713 -- 1.2 1.4 -1.5 -1.9 -1.9 -2.8 -2.4 -1.5 -2.1 
IPF3631 orf19.6718 -- -1.3 -1.7 -1.1 -12.6 -4.5 -6.2 1.8 -1.3 1.2 
IPF3634 orf19.6720 -- -3.9 -3.5 -5.8 -4.2 -3.8 -6.0 -3.0 -2.7 -3.2 
IPF3661 orf19.899 -- -2.5 -1.6 -1.9 -1.3 1.1 -1.0 -1.4 -1.1 -1.8 
IPF3937 orf19.868 -- -1.0 1.0 -1.3 -3.0 -2.0 -2.2 -1.2 -1.1 -1.3 
IPF4065 orf19.1862 -- -2.9 -1.6 -2.1 -8.3 -1.9 -1.9 1.3 1.5 -1.1 
IPF407 orf19.7504 -- 1.2 1.5 1.1 1.2 1.2 2.3 -1.5 -1.7 -2.4 
IPF409 orf19.7502 -- -7.2 -2.8 -4.0 -3.3 -2.7 -2.1 -2.4 -2.7 -3.8 
IPF4430 orf19.2959.1 -- -1.6 -1.0 -2.4 -5.0 -3.0 -4.6 -2.2 -1.5 1.7 
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IPF4537 orf19.905 -- -2.2 -1.7 -1.6 -2.5 -1.1 -1.3 -1.0 -1.0 1.4 
IPF4667 orf19.1847 Carboxy-lyase activity -2.2 -1.6 -1.8 -3.6 -3.3 -2.9 -1.0 -1.2 3.2 
IPF4674 orf19.1852 -- -1.4 -1.1 -1.4 -1.5 -1.5 -1.9 -1.4 1.0 -1.1 
IPF4704 orf19.5278 -- -1.6 1.1 -1.2 -1.1 -1.1 -1.1 -1.7 -1.6 -2.0 
IPF4928 orf19.7660 -- -1.1 1.0 -1.5 -1.7 -1.6 -1.5 -1.4 -1.6 -1.2 
IPF4991 orf19.2531 -- -1.5 1.1 -2.1 -5.6 -6.5 -8.3 -2.3 -1.8 1.1 
IPF4999 orf19.5843 -- -1.4 -2.2 1.0 -6.6 -6.7 -7.8 -1.2 -1.1 1.7 
IPF5282 orf19.5663 -- -1.5 -1.6 -2.6 -2.1 1.1 -1.3 -1.0 1.1 1.3 
IPF5330 orf19.3448 -- -1.9 -6.0 -1.8 -4.1 -1.7 1.9 2.1 -2.1 1.7 
IPF5353 orf19.3003 -- -1.3 -1.2 -1.4 -1.7 -1.7 -1.9 -1.1 1.1 -1.1 
IPF5360 orf19.3007.2 -- 1.1 1.0 -2.0 -2.9 -2.0 -3.1 -2.2 -1.9 -2.0 
IPF5453 orf19.5692 -- 1.1 1.1 -1.3 -2.3 -1.8 -1.9 1.1 1.1 1.1 
IPF5806 orf19.815 -- -1.4 1.0 1.2 -1.7 -1.8 -2.1 -1.1 1.2 1.2 
IPF5849 orf19.5496 -- -2.1 -1.6 -1.7 -2.1 -1.1 -1.2 1.2 1.1 2.0 
IPF5966 orf19.6793 -- -1.2 -1.1 -2.0 -1.7 -2.0 -1.7 -1.5 1.4 2.4 
IPF5972 orf19.7314 -- -1.3 1.0 -1.3 -1.6 -1.7 -2.2 -1.5 -1.1 -1.8 
IPF5988 orf19.7305 -- -3.1 -2.9 -3.3 -8.4 -5.1 -5.0 -1.8 -1.7 1.1 
IPF6003 orf19.1490 -- 1.0 1.2 -1.0 -1.7 -1.5 -1.8 1.2 1.2 2.3 
IPF6108 orf19.4811 -- -1.8 -2.4 -1.5 1.0 -1.1 -1.2 1.0 1.0 1.2 
IPF6181 orf19.4174 Nucleoside transporter activity -1.8 -1.6 -2.2 -2.7 -1.2 1.1 -1.0 -1.1 -1.3 
IPF6274 orf19.6316 -- -1.8 -1.2 -1.5 -2.5 -2.0 -3.0 1.1 -1.0 1.7 
IPF6339 orf19.2724 -- -1.0 1.0 -1.8 -3.3 -3.8 -4.3 -3.2 -2.3 -2.4 
IPF6459 orf19.1890 -- -1.5 -1.1 -1.3 -2.0 -1.7 -1.7 -1.1 1.0 -1.1 
IPF6572 orf19.6874 -- -1.2 -1.1 -1.4 -1.4 -1.3 -2.6 -1.9 -1.6 -1.5 
IPF6679 orf19.1306 -- -1.6 -1.3 -1.4 -1.1 -1.2 -1.1 -2.4 -2.1 -1.7 
IPF6881 orf19.4246 -- -1.2 1.1 1.1 -2.6 -1.8 -1.9 -1.5 -1.1 -1.4 
IPF6960 orf19.6654 -- -1.9 -1.8 -2.0 -2.6 -1.3 -1.2 -1.1 1.1 1.2 
IPF7109 orf19.7350 -- 1.0 1.1 -1.3 -1.9 -1.6 -2.3 -1.5 -1.2 -1.8 
IPF7405 orf19.4666 -- -2.0 -1.5 1.0 -2.8 -2.2 -1.9 -1.0 1.0 1.9 
IPF7452 orf19.2045 -- -2.1 -2.2 -1.6 -1.6 -1.5 -1.3 -1.0 -1.0 2.1 
IPF7530 orf19.4531 ATP binding -1.3 -1.6 1.1 -2.4 -2.5 -2.1 -1.4 -1.0 -1.1 
IPF7616 orf19.1159 Homoserine O-acetyltransferase activity 1.3 1.6 -1.2 -2.3 -2.5 -2.0 -1.4 -1.3 -1.6 
IPF7681 orf19.1397 Electron carrier activity -1.2 1.0 1.3 -1.8 -1.8 -1.9 1.1 1.0 1.4 
IPF7711 orf19.681 -- -1.1 -1.6 -2.3 -1.4 -1.3 -2.6 -1.5 -1.5 -1.9 
IPF7715.3eoc orf19.2296 -- -1.4 1.3 -2.1 -2.4 -1.7 -2.2 -1.6 -1.3 -3.3 
IPF7721 orf19.431 Transcription factor activity -1.4 -1.1 -1.5 -1.7 -1.6 -2.2 -1.1 -1.1 -1.3 
IPF7733 orf19.4855 -- -1.7 -1.5 -2.0 -1.1 -1.1 1.0 1.3 -1.4 1.6 
IPF7785 orf19.2962 -- -2.4 -3.6 1.5 -2.0 -1.1 1.2 -1.5 -1.5 -2.0 
IPF7999 orf19.4190 -- -1.3 -1.5 -1.2 -1.9 -2.5 -2.1 1.3 1.0 1.1 
IPF8302 orf19.6007 -- -2.3 -2.0 1.2 -2.0 -1.6 -1.5 -1.0 -1.2 1.6 
IPF8307 orf19.6005 Glucose transporter activity -1.2 1.1 -1.4 -2.2 -1.5 -2.4 -1.4 -1.4 -3.2 
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Table B-2 (continued). 
 
CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
IPF8369 orf19.6077 -- -2.5 -1.5 -3.2 -3.5 -1.9 -2.2 -2.1 -1.4 1.0 
IPF8901 orf19.3758 -- -6.2 -3.4 -4.1 -1.6 -1.5 -3.5 1.2 -2.1 -1.3 
IPF9057 orf19.1189 DNA bending activity -3.0 -2.3 -2.6 -1.9 1.0 1.8 -3.2 -1.9 -3.0 
IPF9126 orf19.5537 -- 1.1 -1.2 -1.6 -1.8 -1.6 -1.6 1.3 1.4 1.8 
IPF9132 orf19.5541 -- -1.3 1.0 1.4 -2.3 -1.5 -2.3 -1.1 1.2 1.1 
IPF9145 orf19.6245 -- -1.4 -1.3 -1.3 -2.3 -1.5 -1.7 -1.8 1.3 -3.3 
IPF9167 orf19.2737 -- -1.5 1.3 -1.7 -3.1 -1.7 -1.8 -1.2 -1.2 -1.3 
IPF9167 orf19.2737 -- -1.4 1.6 -1.8 -1.8 -1.8 -1.6 -1.3 -1.1 -2.0 
IPF9282 orf19.1510 -- -1.3 -1.1 -1.4 -1.7 -1.5 -2.9 -1.6 -1.4 -2.4 
IPF9425.3 orf19.6888 -- 2.0 1.4 -1.3 -1.5 -1.7 -2.4 -1.2 -1.4 -1.3 
IPF946 orf19.7561 -- 1.6 1.2 -1.2 -2.1 -4.5 -5.5 1.1 1.2 -2.6 
IPF9483 orf19.3395 -- -2.6 -1.6 -2.5 -2.7 -2.0 -2.3 -2.2 -2.0 -1.8 
IPF9605 orf19.3071 Protein tyrosine phosphatase activity -2.6 -1.9 -1.5 -1.9 -1.1 -1.1 1.3 -1.0 1.6 
IPF9703.3f orf19.4880 -- -1.1 -1.3 -1.6 -1.8 -1.2 1.0 -1.9 -2.1 -1.8 
IPF9706 orf19.4883 -- -4.3 -1.9 -2.1 1.2 1.0 1.5 1.1 -1.2 1.2 
IPF9821.3f orf19.4142 -- -1.3 -1.7 -1.1 -2.5 -2.0 -3.0 1.0 1.6 -1.4 
IPF9898 orf19.3406 -- 1.0 -1.7 1.2 -1.2 -1.3 1.0 -1.6 -1.6 -1.9 
IPF993 orf19.4595 -- -1.5 -1.6 -1.5 -1.9 1.3 1.6 1.5 1.1 -3.1 
IPT1.5f orf19.4769 Transferase activity -1.4 -1.5 -1.0 -1.5 -1.8 -2.4 -1.2 1.2 -1.6 
KRE2.3f orf19.4377 -- -1.3 1.1 1.5 -1.8 -1.8 -2.5 1.1 1.8 -1.8 
KRE2.5f orf19.4349.6 -- -1.4 -1.2 1.9 -1.6 -1.6 -4.6 -1.0 1.7 1.5 
MAE1 orf19.3419 Malate dehydrogenase activity 1.2 1.2 -1.2 -1.6 -1.5 -1.6 1.0 1.3 -1.4 
MAL31 orf19.3981 Alpha-glucoside:hydrogen symporter activity -1.2 24.1 5.6 -1.9 -3.3 -2.5 -2.8 -2.0 -2.3 
MEP3 orf19.1614 Ammonium transporter activity -1.4 -1.5 -3.1 -2.6 -1.1 -1.6 -2.1 -2.5 -1.6 
MET1 orf19.5811 Uroporphyrin-III C-methyltransferase activity -1.2 -1.1 -1.6 -2.9 -2.9 -2.2 -1.2 1.1 -1.0 
MET10 orf19.4076 Sulfite reductase (NADPH) activity -1.9 -2.3 -1.7 -1.7 -1.5 1.1 -1.3 1.1 1.3 
MET14 orf19.946 Adenylylsulfate kinase activity -1.8 -1.7 -1.2 -2.1 -2.8 -3.1 1.2 1.2 1.8 
MET15 orf19.5645 O-acetylhomoserine aminocarboxypropyltransferase activity -1.2 1.2 -1.5 -1.8 -1.7 -1.8 -1.1 1.0 -1.3 
MET2 orf19.2618 Homoserine O-acetyltransferase activity 1.0 1.1 -1.9 -1.7 -1.6 -1.8 -1.6 -1.8 -2.1 
MET3 orf19.5025 Sulfate adenylyltransferase (ATP) activity -1.4 -1.3 -1.3 -7.8 -7.8 -8.1 -1.0 1.2 -1.7 
MLS1 orf19.4833 Malate synthase activity -1.5 1.1 -3.2 -1.5 1.2 1.1 -2.2 -1.7 -2.4 
MSC2 orf19.3132 Cation:cation antiporter activity -1.2 1.4 -1.5 -1.5 -1.5 -2.4 -1.1 -1.2 1.6 
MTD1 orf19.3810 Methylenetetrahydrofolate dehydrogenase (NAD+) activity -1.4 -1.5 -2.3 -1.0 -1.5 -2.0 -3.2 -2.6 -3.3 
MUP1 orf19.5280 L-methionine porter activity -1.5 -2.0 -2.2 -2.3 -1.3 -2.1 -1.4 -1.1 1.8 
MUP3 orf19.321 L-methionine porter activity -2.3 -1.7 -1.8 -2.1 -1.1 -1.2 -1.6 -1.3 -1.3 
NTA1 orf19.850 Protein N-terminal asparagine amidohydrolase activity -1.0 -1.4 -1.3 -1.5 -1.6 -1.6 1.4 -1.1 -2.9 
OAC1 orf19.7411 Oxaloacetate carrier activity -1.0 -3.4 -5.1 -1.7 -2.7 -3.5 -2.0 -1.5 -6.3 
OPT1 orf19.2602 Oligopeptide transporter activity -1.6 1.1 -2.2 -4.5 -2.4 -4.4 1.8 2.4 3.0 
OSM2 orf19.5005 Fumarate reductase (NADH) activity 1.2 3.1 1.5 -1.1 -1.3 1.1 -1.7 -1.7 -11.9 
PAD1 orf19.5731 Carboxy-lyase activity 1.2 1.0 -1.1 -1.7 -2.0 -1.8 -1.2 1.0 -2.2 
PAP11 orf19.3197 RNA binding 1.0 -1.0 -1.0 -114.9 -116.9 -119.7 1.1 1.2 2.1 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
PCK1 orf19.7514 Phosphoenolpyruvate carboxykinase (ATP) activity -1.4 1.2 -2.4 -4.8 -3.9 -2.9 -2.0 -1.4 -1.8 
PGA13 orf19.6420 -- -2.6 -1.6 -2.3 -1.6 -1.7 -3.8 2.1 2.9 4.5 
PGA18 orf19.301 -- -1.2 1.1 -1.5 -1.8 -1.5 -2.7 -1.3 1.0 -1.4 
PGA26 orf19.2475 -- -3.3 -2.2 -1.8 2.8 6.5 3.2 1.5 1.1 1.5 
PGA31 orf19.5302 -- 1.4 2.3 -1.3 -1.1 -1.6 -1.4 -1.7 -2.8 -2.8 
PGA35 orf19.4910 -- -2.2 -1.9 -2.1 -1.3 -1.0 -1.4 1.3 1.5 1.8 
PGA36 orf19.5760 -- 1.0 1.3 -1.6 -2.3 -1.9 -3.0 -2.0 -1.6 -2.2 
PGA49 orf19.4404 -- -6.6 2.2 1.7 -2.5 -1.9 -2.3 -1.0 1.1 -12.8 
PHO87 orf19.2454 Inorganic phosphate transporter activity -1.8 -1.9 -1.6 -2.5 -1.5 -1.9 -1.2 1.2 2.0 
PIK1 orf19.3199 1-phosphotidylinositol 4-kinase activity 1.1 -1.2 -1.4 -19.1 -30.5 -11.5 -1.0 -1.0 1.4 
PMT2 orf19.6812 Dolichyl-phosphate-mannose-protein mannosyltransferase 
activity 
-1.5 -1.9 -1.6 -1.9 1.0 -1.1 -1.1 1.1 1.4 
POL21.3f orf19.2669 Di-, tri-valent inorganic cation transporter activity -1.8 -1.7 -1.5 -2.4 1.0 -1.1 -3.1 -1.5 1.6 
POL21.5f orf19.2668 -- -1.7 -1.8 -1.7 -3.6 -1.5 2.0 1.1 -1.9 -2.0 
POT12 orf19.1704 Acetyl-CoA C-acyltransferase activity -1.2 1.9 2.0 1.5 -1.3 -2.3 -1.8 -1.6 -2.1 
POX18.3f orf19.3330.3 -- -1.1 -2.7 -1.9 -1.6 1.3 1.0 -1.6 -2.0 -6.6 
PRC3 orf19.2474 -- -1.9 -1.5 -1.5 -1.9 1.1 1.5 1.4 1.7 -1.4 
PRP9 orf19.3178 -- -1.6 1.1 1.3 -3.2 -2.2 -1.7 -1.1 -1.0 -2.4 
PST2 orf19.5285 -- -1.9 -1.2 -2.2 -1.7 -2.0 -1.8 -1.3 -1.7 -1.3 
PUT2 orf19.3974 1-Pyrroline-5-carboxylate dehydrogenase activity -1.4 1.5 1.1 -1.5 -1.7 -1.8 1.1 -1.0 -1.8 
RBT2 orf19.1415 Ferric-chelate reductase activity -2.0 -2.2 -2.8 -2.8 -3.1 -2.6 -4.3 -3.2 -3.2 
RDH54 orf19.5367 DNA topoisomerase activity -1.5 -1.5 -1.7 -2.0 -1.3 1.3 1.6 1.0 1.1 
RNR2 orf19.5845 Ribonucleoside-diphosphate reductase activity -2.5 -1.4 -2.0 1.3 -1.2 -2.0 -2.3 -1.5 -3.8 
RNR22 orf19.1868 Ribonucleoside-diphosphate reductase activity -3.0 -2.2 -3.3 -2.2 1.4 -1.3 2.8 1.1 -1.2 
ROM2 orf19.906 Rho-guanyl-nucleotide exchange factor activity 1.1 1.4 -1.3 -1.5 -1.6 -2.1 -1.0 -1.1 -2.2 
RTA2 orf19.24 Phospholipid-translocating ATPase activity -2.0 -1.9 -1.7 -1.2 -1.1 -1.1 -2.6 -1.6 -1.3 
RTA3 orf19.23 Phospholipid-translocating ATPase activity -3.0 -2.1 -1.5 1.0 1.4 2.3 -2.1 -1.5 -1.5 
SAP7 orf19.756 Aspartic-type endopeptidase activity -1.0 -1.3 -1.1 -3.0 -2.2 -1.8 -2.1 -1.6 -2.4 
SEO2 orf19.700 Transporter activity -1.9 -2.0 -1.6 -2.3 -2.8 -2.7 -2.1 -2.5 -2.8 
SER2 orf19.5838 Phosphoserine phosphatase activity -2.0 -2.3 -1.7 1.1 1.0 -1.0 -2.1 -1.6 -3.4 
SFT2 orf19.2342 -- -1.8 -1.6 -1.7 -3.1 -1.3 1.1 -1.0 -1.3 1.2 
SHM2 orf19.5750 Glycine hydroxymethyltransferase activity -2.1 -2.0 -1.8 -1.8 -1.2 -1.1 -2.2 -1.5 1.1 
SKN1.3 orf19.7362 -- 1.4 -1.1 1.5 -2.0 -2.2 -2.6 -1.2 -1.1 -1.9 
SMF3 orf19.5022 Manganese ion transporter activity -1.3 -1.4 -1.6 -1.5 -1.5 -2.1 -1.1 -1.2 1.2 
SMP3 orf19.5792 Alpha-1,2-mannosyltransferase activity -1.3 -1.3 1.1 -1.7 -1.5 -2.1 -1.0 1.2 1.3 
SNA2 orf19.4132 -- -1.9 -1.3 -1.0 -2.5 -2.1 -1.7 -1.2 1.0 -1.2 
SOU1 orf19.2896 2,4-dienoyl-CoA reductase (NADPH) activity -3.2 -2.3 -2.4 -9.2 -6.6 -8.5 -2.1 -1.2 -1.2 
SSU1 orf19.7313 Sulfite transporter activity -1.1 1.1 1.1 -1.5 -1.5 -1.4 -1.7 -1.7 -1.5 
SSY1 orf19.814 Amino acid binding -2.0 -1.5 -2.1 -2.1 1.2 1.6 -1.1 -1.3 -1.8 
STL1 orf19.5753 Glucose transporter activity -1.7 -1.6 -1.7 -4.5 -8.7 -10.8 -1.7 -1.1 1.4 
SUL1 orf19.2738 Sulfate transporter activity -2.5 -1.8 -2.8 -17.9 -6.0 -8.1 -1.4 -1.0 -1.5 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5 vs.   F1 G5 vs. G1 6692 vs. 5833 
1 2 3 1 2 3 1 2 3 
SUN42 orf19.5032 -- -1.5 -1.5 -1.6 -1.9 -1.3 -1.9 -1.2 1.1 1.1 
TAF25 orf19.3242 General RNA polymerase II transcription factor activity -1.1 -1.1 -1.3 -1.5 -1.6 -1.6 -1.1 -1.2 -1.9 
Tca5b orf19.2428.2 -- -2.3 4.1 1.0 -1.6 1.8 -1.7 -2.2 -1.7 -1.7 
TEC1 orf19.5908 Specific RNA polymerase II transcription factor activity -1.1 -1.0 -1.6 -2.6 -3.5 -2.9 -1.5 -1.3 -2.1 
TES12 orf19.4122 -- 1.6 1.1 1.5 -2.2 -1.8 -1.9 1.0 -1.1 -1.3 
TPK2 orf19.2277 cAMP-dependent protein kinase activity -2.0 -1.5 -2.3 -1.5 -1.4 1.0 -1.2 -1.1 -1.5 
UGA12.3f orf19.802 4-aminobutyrate transaminase activity -1.1 -1.8 -1.1 -1.6 -1.6 -1.7 -1.2 1.3 -1.9 
UGA12.5f orf19.802 4-aminobutyrate transaminase activity -1.0 -1.1 -1.1 -1.6 -1.9 -2.8 -1.0 -1.0 -1.4 
VCX1 orf19.405 Calcium ion transporter activity -2.1 -1.7 -1.7 -2.1 -1.3 -1.2 -1.1 1.0 -1.8 
VPS184 orf19.5543 Protein binding 5.1 1.5 -2.8 -1.8 1.1 -1.3 -1.6 -1.6 -2.3 
YHM1 orf19.685 Transporter activity -1.4 -1.2 -1.2 -1.8 -1.7 -2.0 -1.1 1.1 1.4 
YOR100 orf19.2599 Carnitine:acyl carnitine antiporter activity -1.4 -1.2 -1.0 -2.4 -1.8 -2.0 -1.3 -1.7 -1.4 
ZRT2 orf19.1585 Low affinity zinc ion transporter activity -2.0 -2.0 -2.3 -3.3 -1.2 -1.3 1.1 1.2 1.4 
 
a Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b orf19 nomenclature according to the Assembly 19 version. 
c GO annotation found at CGD (http://www.candidagenome.org/). 
 
  
151 
 
Table B-3. Genes down-regulated in the absence of MRR1. 
 
CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5Δmrr1 vs. F5 G5Δmrr1 vs. G5 
Strain A Strain B Strain A Strain B 
1 2 1 2 1 2 1 2 
AAF1 orf19.7436 -- -3.5 -3.7 -2.2 -2.9 -5.6 -1.9 -4.3 -1.8 
ACO1 orf19.6385 Aconitate hydratase activity 1.1 -1.8 1.0 -1.9 -2.7 -1.5 -2.0 -1.7 
AKL1 orf19.5357 Protein serine/threonine kinase activity -1.6 -1.8 -1.6 -1.7 -1.6 -1.9 -1.6 -1.5 
ALS7 orf19.7400 Carbohydrate binding -1.5 -2.1 -1.9 -1.8 1.2 -1.1 1.3 -1.1 
AMYG1 orf19.4899 Alpha-glucosidase activity -3.8 -1.9 -4.7 -1.7 1.1 -1.7 1.1 1.7 
ARD8 orf19.6322 2,4-dienoyl-CoA reductase (NADPH) activity -1.6 -3.3 -1.7 -2.4 -3.1 -2.3 -2.2 -1.7 
BFR2 orf19.7624 -- 1.6 -4.8 2.1 -2.5 -2.4 -1.7 -2.0 -2.2 
BMR1 orf19.5604 Multidrug transporter activity -21.4 -47.5 -35.0 -83.7 -168.9 -149.4 -143.0 -43.9 
CDC1 orf19.3083 -- 1.1 -2.1 -2.1 -1.8 -2.4 -1.6 -2.6 -2.4 
CDR11.5f orf19.918 ATP binding -4.9 1.2 -2.0 -1.0 -1.9 -1.8 -2.6 -1.5 
CDR3 orf19.1313 ATP binding -3.3 -1.7 -2.0 -1.8 -1.0 1.3 -1.3 3.6 
CHO2 orf19.169 Methylene-fatty-acyl-phospholipid synthase activity -1.2 -1.5 -1.2 -1.8 -3.7 -1.5 -2.0 -3.2 
CHS3.5f orf19.4937 Chitin synthase activity -25.6 -8.2 -2.3 -2.1 -4.7 5.6 -2.3 13.8 
CHS4 orf19.7349 Enzyme activator activity -2.0 -2.9 -1.8 -1.5 -1.7 1.0 -2.3 -1.5 
CLN21 orf19.6028 Cyclin-dependent protein kinase regulator activity -14.4 -8.8 -1.6 -4.6 -7.8 5.2 -1.2 3.6 
CNH1 orf19.367 Cation:cation antiporter activity -1.9 -2.0 -2.8 -1.8 -2.1 -1.2 -1.6 1.5 
CNH1 orf19.367 Cation:cation antiporter activity -3.3 -2.5 -10.7 -3.1 -2.6 -2.0 -1.9 1.6 
CPH1 orf19.4433 Transcription factor activity -2.0 -3.0 -1.8 -2.0 -3.4 -2.0 -2.6 1.6 
CTR1 orf19.3646 Copper ion binding -1.3 -2.2 -1.4 -1.7 -2.8 -1.6 -1.7 -1.7 
DHH1 orf19.6197 Protein binding -2.9 -1.8 -1.5 -1.6 -1.4 1.0 -1.7 1.4 
DLD3 orf19.5805 D-lactate dehydrogenase (cytochrome) activity -1.9 -4.1 -2.8 -2.5 1.3 -1.1 -1.1 1.1 
DNA2 orf19.1192 ATP-dependent DNA helicase activity -2.6 -2.2 -1.6 -1.5 -2.0 -1.1 -1.4 -1.2 
DRS1 orf19.7635 ATP-dependent RNA helicase activity 1.0 -2.2 1.1 -2.6 -2.4 -1.8 -3.2 -2.4 
DRS23 orf19.323 Phospholipid-translocating ATPase activity -1.6 -2.8 -1.6 -2.1 -2.2 -1.1 -1.2 1.1 
EBP4 orf19.3433 NADPH dehydrogenase activity -2.6 -1.6 -1.6 -1.9 -1.3 -2.1 -1.2 -1.0 
EFG1 orf19.610 Transcription factor activity -2.2 -2.9 -1.9 -1.5 -3.8 -2.2 -2.3 1.3 
FAS2.53f orf19.5949 3-oxoacyl-[acyl-carrier-protein] reducatase activity -17.0 -1.2 -1.4 1.2 -2.9 -2.0 -2.7 -1.8 
FRE30.3f orf19.6139 Ferric-chelate reductase activity -1.8 -5.5 -1.8 -3.8 -4.3 -1.9 -3.0 -2.5 
FRE30.53f orf19.6140 Ferric-chelate reductase activity -5.0 -4.3 -2.1 -2.5 -4.3 -1.7 -3.4 -1.7 
FRE7 orf19.7077 Ferric-chelate reductase activity -1.5 -2.2 -1.8 -3.3 -3.0 -1.6 -2.4 -1.7 
GAC1 orf19.7053 Protein phosphatase type 1 activity -1.5 -3.8 -1.5 -3.3 -3.9 -1.5 -4.8 -1.2 
GAL1 orf19.3670 Galactokinase activity -1.5 -1.5 -20.4 -4.4 -1.0 1.4 -1.3 -1.3 
GAP6 orf19.6659 Amino acid permease activity -1.8 -2.4 -1.6 -2.4 -2.0 -1.9 -1.5 -1.5 
GDH2 orf19.2192 Glutamate dehydrogenase activity -1.5 -2.6 -1.8 -2.9 -1.1 1.0 1.0 -1.2 
GPX1 orf19.86 Glutathione peroxidase activity -2.8 -1.1 -1.6 -1.4 -1.8 -2.0 -1.6 -1.7 
GRP2 orf19.4309 Oxidoreductase activity -2.1 -1.9 -1.8 -1.8 -3.7 -3.7 -3.5 -2.9 
GTS1 orf19.6393 Specific RNA polymerase II transcription factor activity -2.4 -1.7 -1.9 -1.7 -1.5 1.1 -1.4 1.2 
GUT1 orf19.558 Glycerol kinase activity -2.0 -3.5 -1.6 -3.8 -4.9 -1.9 -3.0 1.6 
HEM12 orf19.5369 Uroporphyrinogen decarboxylase activity -2.0 -1.7 -1.7 -1.6 -1.6 -1.2 -1.2 1.4 
HGT11 orf19.4527 Glucose transporter activity -4.1 -9.5 -3.9 -2.7 -8.5 -3.1 -5.7 -6.3 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5Δmrr1 vs. F5 G5Δmrr1 vs. G5 
Strain A Strain B Strain A Strain B 
1 2 1 2 1 2 1 2 
HGT12 orf19.3668 Glucose transporter activity -4.2 -2.3 -4.4 -2.2 -12.4 -5.6 -6.5 -4.2 
HIK1 orf19.5181 Osmosensor activity -8.1 -2.2 -2.1 -1.8 -3.7 -1.5 -2.5 1.9 
HSP78.5f orf19.882 ATP-dependent peptidase activity -1.4 1.3 -1.4 1.4 -1.5 -1.5 -1.7 -1.6 
IFA17.5f orf19.4511 -- -3.8 -2.7 -2.0 -1.7 -2.2 1.9 -1.8 1.3 
IFA18.53f orf19.4508 -- -3.9 -2.2 -1.8 -1.7 2.0 1.2 2.9 -2.3 
IFD2 orf19.771 Aryl-alcohol dehydrogenase activity -4.2 -2.3 -3.8 -2.0 -2.0 -4.1 -1.6 -3.4 
IFD4 orf19.4477 Aryl-alcohol dehydrogenase activity -2.7 -4.6 -2.4 -1.9 -4.0 -4.4 -3.4 -2.9 
IFD5 orf19.1048 Aryl-alcohol dehydrogenase activity -3.3 -2.1 -2.6 -2.6 -6.1 -5.2 -4.5 -2.9 
IFD5 orf19.1048 Aryl-alcohol dehydrogenase activity -15.0 -12.2 -15.8 -9.6 -4.9 -4.2 -4.1 -2.7 
IFD6 orf19.4476 Aryl-alcohol dehydrogenase activity -31.2 -41.8 -27.0 -21.3 -12.8 -22.1 -12.6 -78.1 
IFD7 orf19.629 Aryl-alcohol dehydrogenase activity -10.5 -4.3 -5.8 -6.0 -8.0 -8.2 -9.6 -6.5 
IFK3.3f orf19.857 -- -1.8 -8.8 -2.1 -5.6 -2.1 -1.9 -2.0 -5.9 
IMP2 orf19.1981 Peptidase activity 1.0 1.3 -1.4 -1.0 -2.4 -1.6 -1.8 -2.1 
IPF10062 orf19.1086 -- -1.9 -1.9 -1.5 -1.6 -2.0 -1.3 -1.5 1.4 
IPF11006 orf19.4658 -- -1.5 2.1 1.2 1.5 -2.1 -1.6 -3.0 -2.3 
IPF11090.5f orf19.4622 -- -8.4 -1.3 -1.2 1.1 -2.4 -1.5 -2.1 -1.6 
IPF11569 orf19.9 -- -1.3 -6.0 1.2 -1.1 -1.9 -1.9 -2.2 -2.6 
IPF11610 orf19.2146 H3/H4 histone acetyltransferase activity -1.6 -1.7 -1.8 -2.1 -1.6 -1.3 -1.9 -1.2 
IPF11694 orf19.4355 Nicotinamide mononucleotide permase activity -2.2 -1.6 -2.6 -3.0 -2.4 -1.9 -3.5 2.6 
IPF12105 orf19.5633 -- -1.8 -2.3 -1.6 -1.8 -2.3 -2.1 -2.6 1.4 
IPF12316 orf19.5069 -- -2.5 1.8 -1.7 -1.1 -2.4 -2.1 -3.0 -2.2 
IPF12513 orf19.5605 -- -2.7 -3.2 -1.7 -2.7 -1.5 -1.2 -1.2 1.1 
IPF12606.5eoc orf19.3288 -- -1.5 -3.7 -1.7 -4.4 -3.6 -1.4 -3.4 -1.2 
IPF1264 orf19.7371 Transcription factor activity -1.8 -3.4 -1.5 -2.0 -6.1 -1.4 -8.2 1.1 
IPF1292 orf19.7381 Transcription factor activity -1.8 -2.2 -1.9 -2.0 -3.5 -1.2 -5.3 -1.2 
IPF13042 orf19.2410 -- -1.4 1.1 1.7 1.6 -2.1 -1.6 -3.5 -2.0 
IPF13116 orf19.3463 -- 1.2 -3.3 1.3 -2.4 -3.5 -1.6 -2.2 -2.7 
IPF13202 orf19.215 -- -1.7 -1.6 -1.5 -1.9 -2.3 -1.1 -2.9 1.6 
IPF13361 orf19.2330 snoRNA binding 1.5 -1.3 1.7 -1.2 -5.3 -1.8 -4.1 -1.7 
IPF13383.53eoc orf19.1840 -- -3.9 -1.8 -1.6 -1.5 -1.4 -1.1 -1.5 1.5 
IPF13565 orf19.1609 -- -1.7 -1.9 -2.6 -1.8 3.4 2.8 3.3 3.2 
IPF13756.5f orf19.4479 -- -3.5 -1.3 1.6 -1.7 -6.6 -1.5 -6.5 -2.4 
IPF1382 orf19.6444 -- -1.0 -1.3 -1.2 -2.0 -2.3 -2.0 -1.6 -1.8 
IPF14888 orf19.4339 -- -1.1 -1.2 1.2 -1.2 -5.2 -2.3 -4.1 -1.6 
IPF14895 orf19.93 -- 1.2 -1.6 -1.2 -1.8 -2.6 -1.6 -2.5 -29.4 
IPF15013 orf19.5626 -- -1.7 -2.0 -1.5 -2.3 -1.9 -1.4 -2.4 -2.8 
IPF15153 orf19.5867 -- -2.0 -1.8 -1.6 -1.5 -1.1 1.5 -1.2 1.3 
IPF15183 orf19.1806 -- -2.3 -2.0 -2.0 -1.5 -1.2 -1.2 -1.2 1.6 
IPF15273 orf19.1822 Transcription factor activity -3.3 -12.7 -1.6 -3.3 -1.4 -1.2 -1.1 -4.1 
IPF1588 orf19.972 -- -1.5 -1.8 -2.5 -2.1 -1.7 -2.9 -1.1 -1.7 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5Δmrr1 vs. F5 G5Δmrr1 vs. G5 
Strain A Strain B Strain A Strain B 
1 2 1 2 1 2 1 2 
IPF16 orf19.5984 -- 1.0 -1.0 -1.6 -1.3 -2.4 -1.9 -1.8 -1.6 
IPF16189.5f orf19.5576 -- -1.1 1.1 1.2 1.1 -3.2 -1.6 -1.6 -1.7 
IPF1634 orf19.6578 Inorganic phosphate transporter activity -1.5 -2.4 -2.0 -3.6 -5.0 -1.5 -4.2 -2.6 
IPF16981 orf19.2458 Transcription factor activity -1.9 -1.7 -1.9 -1.6 1.7 -1.0 -1.1 -1.4 
IPF17186 orf19.251 -- -10.9 -11.0 -8.7 -6.2 -5.5 -9.5 -5.6 -7.4 
IPF17914.3eoc orf19.5124 -- -2.1 -1.5 -2.2 -1.9 -1.6 -2.0 1.1 1.3 
IPF17998 orf19.3147 -- -1.6 -2.6 -2.5 -2.3 2.4 1.0 3.1 1.0 
IPF18316 orf19.5145 -- -1.9 -1.8 -2.1 -1.7 -1.7 -2.1 1.2 -1.0 
IPF1837 orf19.5877 Alcohol O-acetyltransferase activity -1.5 -1.6 -2.1 -1.9 -1.6 -2.6 -1.3 1.0 
IPF18586 orf19.761 -- -1.6 -2.1 -1.7 -2.5 -7.9 -2.6 -3.2 1.3 
IPF18690.5eoc orf19.6621 Structural constituent of cytoskeleton -136.5 -2.1 -1.5 -1.5 -1.2 1.0 1.2 -1.0 
IPF1922 orf19.7148 -- -1.7 -1.8 -2.3 -2.8 -3.2 -1.7 -1.8 2.0 
IPF19538.3f orf19.6957.3 -- -1.5 -2.0 -2.1 -2.1 -7.6 -6.8 -4.1 -3.1 
IPF1956 orf19.7159 -- -1.6 1.8 -2.2 -1.5 -2.9 -1.5 -1.5 -1.7 
IPF19664 orf19.2510 Chaperone binding -7.4 -9.0 -1.5 -1.7 1.1 1.1 -1.2 -1.0 
IPF19700 orf19.1600 -- -1.5 -1.6 -1.6 -1.5 -2.0 1.1 -1.8 1.0 
IPF19810 orf19.1430 -- -2.4 -1.9 -2.1 -2.0 1.3 -1.1 -1.1 12.4 
IPF2050 orf19.5265 Structural constituent of cytoskeleton -2.3 -2.0 -1.7 -1.5 -1.1 -1.1 1.3 1.1 
IPF2111 orf19.4106 -- -2.3 1.4 -1.2 1.1 -1.6 -2.2 -1.9 -3.0 
IPF2130 orf19.7204 -- -2.8 1.2 -2.4 -1.5 -2.1 -4.4 -1.5 -3.6 
IPF2142 orf19.7197 -- 2.4 1.4 7.7 -12.7 -11.8 -1.6 -36.7 -1.7 
IPF2186 orf19.7166 -- -2.9 -3.5 -3.7 -3.4 -7.0 -5.1 -4.8 -2.7 
IPF3080 orf19.7042 -- -1.5 -1.2 -1.2 -2.3 -10.3 -6.3 -9.3 -2.6 
IPF3092 orf19.4445 -- -1.7 -3.1 -1.7 -12.5 -3.8 -1.4 -2.7 -3.2 
IPF3239 orf19.2875 Signal recognition particle binding 1.9 2.4 2.0 2.0 -1.5 -2.1 -1.6 -2.0 
IPF3277 orf19.4384 Fructose transporter activity -3.5 -4.2 -2.5 -2.9 -2.6 -1.4 -3.5 1.8 
IPF3329 orf19.7388 MAP kinase kinase activity -1.6 -3.4 -1.5 -2.3 -2.2 1.2 -2.3 1.4 
IPF3426 orf19.6173 -- -1.3 -3.7 -2.0 -3.0 -2.7 -1.6 -2.5 -1.6 
IPF3448 orf19.6185 -- -4.4 -18.6 -2.8 -2.1 -2.5 -2.9 -2.3 -1.2 
IPF3642 orf19.6726 DNA binding -1.7 -1.5 -2.0 -2.5 -1.7 1.2 -1.4 -1.8 
IPF3687 orf19.886 Cytoskeletal adaptor activity -1.6 -1.9 -2.3 -1.7 -2.8 -1.6 -2.2 1.4 
IPF3912 orf19.6514 Specific RNA polymerase II transcription factor activity -1.2 -1.4 -1.2 -1.3 -2.2 -1.8 -1.9 -2.5 
IPF3967 orf19.673 NADPH dehydrogenase activity -1.6 -1.2 -3.2 -1.5 -1.5 -1.5 -1.7 -3.0 
IPF4160 orf19.5459 -- -1.4 -3.5 -2.1 -1.3 -2.6 -1.6 -1.7 -1.5 
IPF4253 orf19.1630 -- -1.9 -1.7 -3.5 -2.5 -3.2 -1.5 -3.1 -1.3 
IPF4290 orf19.541 -- 1.4 -2.1 -1.0 -2.0 -1.8 -1.6 -2.3 -2.0 
IPF4799 orf19.3342 -- -1.6 -1.5 -2.0 -1.9 -1.2 -1.1 -1.0 -1.0 
IPF486 orf19.7065 -- -1.1 1.5 1.2 1.6 -2.2 -1.8 -1.9 -2.0 
IPF5064 orf19.804 Transporter activity -1.5 -1.8 -1.7 -1.5 -1.9 -1.0 -2.3 1.5 
IPF5149 orf19.6530 Signal recognition particle binding -1.4 1.1 -1.4 -1.3 -4.1 -2.2 -2.1 -2.3 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5Δmrr1 vs. F5 G5Δmrr1 vs. G5 
Strain A Strain B Strain A Strain B 
1 2 1 2 1 2 1 2 
IPF5217 orf19.7270 -- -1.2 -3.0 -2.1 -1.9 -3.2 -2.3 -1.6 -1.7 
IPF5228.5 orf19.7265 -- -1.9 -2.7 -2.4 -2.3 -1.2 -1.7 1.1 -1.1 
IPF525 orf19.7085 -- -2.9 -17.2 -2.4 -2.4 -1.7 -2.6 -1.7 -3.4 
IPF5291 orf19.3674 UDP-glucose 4-epimerase activity -1.3 -2.1 -1.5 1.1 -2.7 -1.9 -2.6 -3.9 
IPF564 orf19.7104 -- -1.5 -1.5 -1.7 -1.8 -1.7 -1.6 -1.6 -1.1 
IPF5987 orf19.7306 -- -7.4 -6.4 -9.0 -6.9 -8.6 -12.5 -7.4 -10.5 
IPF6011 orf19.1486 -- -2.4 -10.4 -1.8 -2.1 -5.7 -1.9 -3.8 1.2 
IPF6067 orf19.6734 General transcriptional repressor activity -2.0 -1.6 -1.9 -1.8 -3.7 -1.6 -4.4 1.4 
IPF6298 orf19.1964 -- 3.0 -1.1 1.5 1.3 -3.7 -1.8 -2.1 -1.8 
IPF6700 orf19.2459 -- -1.5 -2.5 -2.2 -1.8 -1.1 1.2 -1.0 1.3 
IPF690.5f orf19.7590 -- -4.3 -1.6 -1.6 -2.5 -1.6 1.6 -2.3 -1.2 
IPF708 orf19.5370 -- -1.5 -1.6 -2.3 -1.5 -2.6 -1.6 -1.1 1.8 
IPF7493 orf19.4682 Glucose transporter activity -1.5 -2.3 -6.0 -2.4 -7.5 -3.4 -9.1 -2.6 
IPF7666 orf19.4056 Transcription factor activity -4.8 -8.1 -2.0 -1.7 -8.2 1.0 -8.5 2.6 
IPF7685 orf19.1396 ARF GTPase activator activity -1.8 -1.8 -1.9 -1.7 -2.0 -1.9 -1.7 1.1 
IPF7686 orf19.1395 Inorganic phosphate transporter activity -1.7 -2.0 -1.7 -1.5 1.6 1.3 1.3 2.7 
IPF776 orf19.5338 Transcription factor activity -1.7 -2.8 -1.8 -3.0 -11.2 -1.0 -11.9 1.2 
IPF7817 orf19.3131 NADPH dehydrogenase activity -3.8 -4.7 -5.5 -3.6 -3.6 -2.8 -3.3 -2.1 
IPF7863 orf19.1449 -- -16.9 -6.9 -15.5 -8.0 -2.9 -4.5 -3.0 -4.3 
IPF7998 orf19.4191 -- -1.4 -2.1 1.4 -1.7 -3.2 -1.6 -4.7 -3.2 
IPF823 orf19.7245 tRNA (5-methylaminomethyl-2-thiouridylate)-methyltransferase activity 1.4 -1.1 1.1 -1.7 -2.2 -1.9 -2.0 -1.5 
IPF8405 orf19.1721 Carbonate dehydratase activity 1.5 1.0 1.2 -1.3 -6.1 -1.6 -4.1 -1.6 
IPF8464 orf19.6855 -- -1.9 -9.7 -2.7 -3.2 -2.4 -1.1 -3.9 -7.5 
IPF8627 orf19.3969 Specific transcriptional repressor activity -1.9 -4.0 -1.8 -1.5 -2.2 1.1 -2.0 1.3 
IPF9063 orf19.203 -- 1.0 -1.8 -1.9 -1.5 -2.4 -1.8 -1.8 -1.5 
IPF9238 orf19.6143 -- -1.7 -2.5 -18.5 -2.7 -1.6 -1.9 -1.2 -3.6 
IPF9538 orf19.271 2,4-dienoyl-CoA reductase (NADPH) activity -164.3 -548.1 -280.0 -137.2 -15.3 -16.6 -25.5 -13.3 
IPF9560 orf19.1942 -- -1.8 -1.6 -1.7 -1.8 -1.4 -1.0 -1.5 1.4 
LAT1 orf19.6561 Dihydrolipoyllysine-residue acetyltransferase activity -1.0 -3.1 -1.4 -2.2 -3.3 -2.7 -1.6 -1.7 
LEU42 orf19.1375 2-isopropylmalate synthase activity -2.0 -1.6 -2.0 -2.2 1.5 -1.1 1.8 1.5 
LSC2.3eoc orf19.1860 Succinate-CoA ligase (ADP-forming) activity -1.0 -2.1 -1.3 -2.1 -2.6 -1.5 -1.7 -2.2 
MDL2.3f orf19.5599 ATP binding 1.1 1.2 -1.1 -1.5 -1.9 -1.7 -1.9 -1.5 
MET3 orf19.5025 Sulfate adenylyltransferase (ATP) activity 2.7 2.0 1.1 1.2 -2.3 -1.5 -2.0 -2.0 
MRP1.5f orf19.1662 Structural constituent of ribosome 2.0 1.5 -1.2 -1.8 -2.0 -1.5 -1.7 -3.8 
MRR1 orf19.7372 RNA polymerase II transcription factor activity -74.6 -35.6 -17.1 -75.6 -69.9 -19.6 -83.5 -5.9 
MSB1.5eoc orf19.1133 -- -1.9 -2.4 -1.6 -2.8 -2.5 -1.1 -2.2 1.8 
NDH1 orf19.339 NADH dehydrogenase activity -1.2 -1.6 -1.1 -1.8 -1.8 -1.5 -1.5 -2.1 
NOP4 orf19.5198 RNA binding -1.3 -2.4 1.5 -1.2 -3.5 -1.5 -4.4 -2.4 
NUC2 orf19.6531 -- 1.1 -1.6 -1.2 -1.6 -2.8 -1.8 -1.6 -1.6 
OGG1 orf19.7190 Oxidized purine base lesion DNA N-glycosylase activity -2.2 -3.9 -1.4 -1.9 -4.3 -2.2 -5.4 -2.2 
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CandidaDB Namea orf19 Nameb GO Annotation (Molecular Function)c 
F5Δmrr1 vs. F5 G5Δmrr1 vs. G5 
Strain A Strain B Strain A Strain B 
1 2 1 2 1 2 1 2 
ORM1 orf19.5751 -- -1.3 -2.2 -1.3 -1.5 -2.3 -1.5 -1.6 -1.6 
PEX13 orf19.7282 Protein binding -1.5 -2.5 -2.0 -1.9 1.1 -1.3 1.1 -1.9 
PGA9 orf19.2108 Copper, zinc superoxide dismutase activity -1.2 1.1 -1.9 1.3 -2.3 -1.7 -2.5 -1.6 
PHR1 orf19.3829 1,3-beta-glucanosyltransferase activity -2.8 -7.8 -2.3 -1.7 -2.0 -1.3 -2.0 1.6 
PRP12 orf19.4379 Exonuclease activity -1.7 -1.8 -1.9 -1.7 1.3 -1.4 1.1 1.1 
PRP5 orf19.6831 ATP-dependent RNA helicase activity -1.1 1.5 -1.1 1.3 -2.3 -1.5 -1.8 -1.6 
PRY2 orf19.7218 -- -1.8 -1.6 -2.6 -2.7 -4.0 -7.0 -1.6 1.4 
RBT4 orf19.6202 -- -1.9 -2.5 -3.2 -1.6 -1.4 -1.2 -1.2 1.9 
RIP1 orf19.5893 Ubiquinol-cytochrome-c reductase activity 1.1 -1.4 1.1 -1.6 -1.6 -1.5 -1.5 -1.6 
RKI1 orf19.1701 Ribose-5-phosphate isomerase activity -1.7 -1.6 -1.6 -1.5 -1.7 1.2 -1.8 -1.6 
RPC31 orf19.2831 DNA-directed RNA polymerase activity 1.2 -4.1 2.3 -1.6 -3.4 -1.6 -2.4 -3.3 
RPN4 orf19.1069 Transcription factor activity -1.7 1.2 -1.6 -1.3 -2.0 -1.8 -2.3 -2.1 
SEC31 orf19.6217 -- -2.0 -1.8 -1.8 -1.6 -2.8 -1.6 -2.3 1.5 
SEN1 orf19.5938 ATP-dependent RNA helicase activity -2.1 -3.9 -1.5 -2.1 1.3 -1.9 3.1 2.5 
SEN2 orf19.2735 tRNA-intron endonuclease activity -1.5 -1.5 -1.6 -2.1 -5.1 -1.6 -3.8 3.2 
SIS2 orf19.7378 Protein phosphatase inhibitor activity -1.8 -1.9 -1.8 -2.1 1.1 -1.7 -1.2 -1.5 
SNF3 orf19.5962 Glucose transporter activity -1.7 -3.2 -2.2 -2.1 -3.0 -2.0 -2.0 -1.0 
SOD21 orf19.7111 Manganese superoxide dismutase activity -1.9 -5.2 -1.5 -1.5 -1.8 -2.0 1.5 -1.0 
SOU3 orf19.732 2,4-dienoyl-CoA reductase (NADPH) activity -1.6 1.1 -2.0 1.1 -1.7 -1.8 -1.6 -1.7 
TAF90 orf19.536 General RNA polymerase II transcription factor activity -1.2 -1.2 -1.2 -1.5 -2.2 -1.8 -1.5 -1.6 
TAO3.5f orf19.1693 Transcription factor activity -59.3 -1.7 -1.6 -1.7 -2.4 -1.2 -2.0 1.6 
TFB2 orf19.5846 General RNA polymerase II transcription factor activity -1.5 -2.0 -1.5 -1.8 -1.2 -1.2 -1.5 -1.2 
TIM22 orf19.1352 Protein transporter activity -1.1 -3.0 1.0 -2.0 -2.2 -2.1 -2.3 -3.1 
TOF1.5f orf19.4136 -- -1.7 1.0 -1.7 1.2 -2.4 -1.5 -1.7 -1.9 
TRK1.5f orf19.600 Chloride transporter activity -1.8 -2.6 -1.7 -2.4 -2.1 1.4 -2.1 1.6 
UGA2 orf19.345 Succinate-semialdehyde dehydrogenase activity -1.8 -2.7 -3.0 -2.4 -1.4 1.2 -1.1 1.5 
WHI3 orf19.6494 RNA binding -1.7 -1.9 -1.6 -2.0 -3.0 -1.6 -2.4 1.3 
YAE1 orf19.7037 -- -1.4 2.3 1.1 1.2 -1.9 -2.1 -1.5 -1.6 
YNK1 orf19.4311 Nucleoside diphosphate kinase activity -1.1 -1.0 1.3 -1.7 -2.8 -1.7 -1.6 -1.5 
 
a Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b orf19 nomenclature according to the Assembly 19 version. 
c GO annotation found at CGD (http://www.candidagenome.org/).
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Table C-1. Genes up-regulated in either resistant isolate S2 or gain-of-function S2 allele in SC5314. 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
BMR1 MDR1 orf19.5604 Multidrug transporter activity 2.1 3.7 5.4 2.5 3.5 5.1 
DDR48 DDR48 orf19.4082 -- 7.1 8.0 2.4 2.4 3.4 3.8 
ECM3 ECM3 orf19.1563 -- 1.6 1.5 1.7 2.9 4.1 3.2 
ERG1 ERG1 orf19.406 Squalene monooxygenase activity 2.4 1.6 1.5 1.6 1.7 1.8 
ERG24 ERG24 orf19.1598 Delta 14-sterol reductase activity 2.3 2.0 3.2 3.5 2.9 2.9 
ERG26 ERG26 orf19.2909 C-3 sterol dehydrogenase (C-4 sterol decarboxylase) activity 2.0 1.6 2.0 1.9 2.0 2.0 
ERG27 ERG27 orf19.3240 3-keto sterol reducatase activity 2.3 2.1 2.2 3.0 3.6 2.8 
FEN2 -- orf19.5535 Pantothenate transporter activity 2.2 2.2 2.3 2.7 2.7 2.8 
FTH1 FTH1 orf19.4802 -- 1.5 1.5 1.8 2.4 4.3 3.7 
IDP2 IDP2 orf19.3733 Isocitrate dehydrogenase (NADP+) activity 3.6 2.1 1.8 1.8 1.6 1.7 
IFA24.3 FGR51 orf19.156 -- 1.8 1.9 1.7 1.6 1.7 1.7 
NCP1 NCP1 orf19.2672 NADPH-hemoprotein reductase activity 2.5 1.5 1.9 1.7 2.2 1.8 
QRI8 -- orf19.7329 Ubiquitin-protein ligase activity 1.5 2.0 1.6 1.5 1.7 1.7 
TEF41 TEF4 orf19.2652 Translation elongation factor activity 4.1 3.4 18.8 19.0 28.9 14.9 
IPF12101 PGA7 orf19.5635 -- 1.6 2.7 5.4 6.0 8.8 9.0 
IPF1218 SOD4 orf19.2062 Copper, zinc superoxide dismutase activity 2.3 2.3 2.2 1.8 1.7 1.6 
IPF14119 DAG7 orf19.4688 -- 1.8 1.6 1.7 1.7 1.6 1.8 
IPF14652 -- orf19.2653 -- 4.3 1.6 1.7 4.3 2.8 1.9 
IPF18080 -- orf19.7357 -- 1.9 1.6 1.5 1.6 1.8 1.6 
IPF20010 -- orf19.5799 -- 2.0 2.2 2.2 1.6 2.8 2.0 
IPF20169 PGA10 orf19.5674 Heme binding 4.1 10.8 5.6 7.0 13.0 11.1 
IPF2903 -- orf19.7456 -- 1.8 2.3 2.0 2.2 1.7 1.6 
IPF3352 -- orf19.4013 -- 2.3 2.3 2.0 1.9 2.5 2.0 
IPF4059 -- orf19.1865 -- 1.6 2.1 2.7 1.9 2.5 2.4 
IPF4721 -- orf19.3737 -- 1.5 1.6 2.3 1.8 1.5 1.6 
IPF6298 -- orf19.1964 -- 3.0 1.6 1.7 2.3 1.7 1.7 
IPF6518 -- orf19.1691 -- 3.3 5.3 1.7 2.0 2.3 2.7 
IPF7289 UPC2 orf19.391 Transcription factor activity 1.6 2.4 2.1 2.4 2.5 2.5 
IPF7397 -- orf19.1800 -- 2.9 2.6 1.8 1.6 1.7 2.2 
IPF7432 -- orf19.6219 -- 2.0 2.3 1.9 2.1 2.4 2.2 
IPF867 SET3 orf19.7221 NAD-dependent histone deacetylase activity 2.1 1.7 3.6 3.2 2.9 2.4 
IPF8970 -- orf19.496 -- 1.9 2.5 2.2 1.6 1.9 1.8 
ALK3 -- orf19.7512 Catalytic activity 1.5 1.7 1.0 -1.1 1.5 -1.1 
ARG5,6 ARG5,6 orf19.4788 N-acetyl-gamma-glutamyl-phosphate reductase activity 7.4 12.7 1.6 -1.8 -1.2 -1.3 
ARP6 -- orf19.4904 -- 1.7 1.6 1.1 -1.3 -1.1 -1.4 
BET5 -- orf19.302 -- 1.8 1.5 -1.1 1.1 1.3 -1.1 
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Table C-1 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
CAN2 CAN2 orf19.111 Basic amino acid transporter activity 1.5 1.9 -2.1 1.1 3.2 2.7 
CBP1 CBP1 orf19.7323 Steroid binding 1.5 1.6 1.3 1.4 1.9 1.4 
CDR12 CDR11 orf19.918 ATPase activity 1.8 3.1 1.4 -1.7 1.9 1.4 
Cirt4a CIRT4B orf19.2839 -- 1.7 1.6 -1.0 1.1 1.9 1.7 
COQ4 COQ4 orf19.3008 -- 1.5 1.5 1.9 1.4 1.6 1.4 
CPA2 -- orf19.3221 Carbamoyl-phosphate synthase activity 3.4 2.2 1.6 -1.4 -1.2 -1.2 
CTA1 CAT1 orf19.6229 Catalase activity 1.5 1.6 1.4 1.5 1.2 1.3 
DAL51 DAL9 orf19.6956 Allantoate transporter activity 1.5 2.4 -1.1 1.2 2.1 1.6 
DNLI LIG4 orf19.5798 DNA ligase (ATP) activity 1.6 2.2 1.3 1.7 3.0 1.9 
ECM18 ECM18 orf19.6958 -- 2.1 1.5 -1.3 1.7 1.7 1.2 
ECM21.3 ECM21 orf19.4887 -- 1.5 2.1 -1.1 1.2 1.5 1.3 
ECM42 ECM42 orf19.6500 Amino-acid N-acetyltransferase activity 1.7 2.9 1.2 -2.0 -1.1 -1.0 
ERG3 ERG3 orf19.767 C-5 sterol desaturase activity 1.5 1.5 1.1 1.3 1.2 1.3 
ERG4 ERG4 orf19.5379 -- 1.5 1.6 1.3 1.7 1.3 1.7 
ERG7 ERG7 orf19.1570 Lanosterol synthase activity 1.5 1.9 1.6 1.4 1.9 1.4 
EXG1 XOG1 orf19.2990 Glucan 1,3-beta-glucosidase activity 2.1 1.6 1.2 -1.3 -1.0 -1.0 
FET34.3eoc FET34 orf19.4215 Ferroxidase activity 1.6 1.7 2.1 1.3 2.6 2.1 
FRP1 -- orf19.2496 -- 2.6 2.2 1.3 1.6 1.3 1.5 
FTR1 FTR1 orf19.7219 Ferrous iron transporter activity 1.5 2.4 1.4 1.5 1.3 1.5 
FUN34.5eoc -- orf19.2496 -- 2.7 1.7 1.4 2.3 1.7 1.5 
GAL1 GAL1 orf19.3670 Galactokinase activity 2.0 1.6 -1.1 -1.3 -1.2 -1.3 
GAL10 GAD1 orf19.1153 UDP-glucose 4-epimerase activity 1.6 1.7 -1.2 -1.5 -1.1 -1.3 
GDH2 GDH2 orf19.2192 Glutamate dehydrogenase activity 2.5 1.6 1.1 -1.0 1.1 1.2 
GLK1 GLK1 orf19.734 Glucokinase activity 1.6 1.8 1.1 1.2 1.5 1.4 
IFA4 IFA4 orf19.4510 -- 3.0 2.3 -2.4 1.4 -1.2 -1.2 
IFC3 IFC3 orf19.3749 Oligopeptide transporter activity 1.5 2.2 -1.4 -1.2 2.1 1.5 
IFK3 FMO2 orf19.857 -- 1.8 2.5 -1.1 1.1 1.0 -1.3 
IFR3 -- orf19.2908 -- 1.7 2.1 1.1 1.7 2.1 1.1 
ILV3 ILV3 orf19.4040 Dihydroxy-acid dehydratase activity 1.5 1.8 1.4 1.1 1.2 1.2 
LSC2.3eoc1 LSC2 orf19.1860 Succinate-CoA ligase (ADP-forming) activity 1.6 1.5 1.3 1.2 1.1 1.2 
LYP1 LYP1 orf19.651 Basic amino acid transmembrane transporter activity 1.5 2.5 -1.3 -1.3 1.4 1.5 
MEP3 MEP1 orf19.1614 Ammonium transporter activity 2.9 3.0 -1.1 1.5 2.3 2.0 
MSY1 -- orf19.109 Tyrosine-tRNA ligase activity 1.7 1.5 -1.4 -2.2 -1.5 -1.8 
NAM2 NAM2 orf19.5705 Leucine-tRNA ligase activity 1.8 1.5 -1.8 -2.4 -1.7 -2.4 
NEM1 -- orf19.4657 -- 3.0 1.8 1.0 1.2 -1.0 -1.3 
ORM1 -- orf19.5751 -- 1.7 1.6 1.6 1.4 1.3 1.3 
OSM2 OSM2 orf19.5005 Fumarate reductase (NADH) activity 1.6 1.5 -1.2 1.0 1.2 1.0 
PHR1 PHR1 orf19.3829 1,3-beta-glucanosyltransferase activity 1.8 2.3 1.3 1.5 1.0 1.2 
PLB5 PLB5 orf19.5102 Lysophospholipase activity 1.6 1.8 1.4 1.1 1.8 1.5 
POT14 ERG10 orf19.1591 Acetyl-CoA C-acetyltransferase activity 1.8 1.8 1.2 1.3 1.3 1.3 
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Table C-1 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
PRP6 -- orf19.6356 RNA splicing factor activity, transesterification mechanism 2.0 1.5 -1.0 -1.2 1.1 -3.9 
RAD1.3f RAD1 orf19.5318 Single-stranded DNA specific endodeoxyribonuclease activity 1.5 1.5 1.3 1.3 1.7 1.1 
RBT2 FRE10 orf19.1415 Ferric-chelate reductase activity 2.1 2.9 1.1 -1.2 -1.4 -1.2 
RBT4 RBT4 orf19.6202 -- 1.6 1.9 1.3 1.6 1.5 1.5 
RNH1 -- orf19.5614 Ribonuclease H activity 2.4 2.0 -1.0 -1.1 -1.1 -1.2 
SAP1 SAP1 orf19.5714 Aspartic-type endopeptidase activity 1.7 1.9 1.3 -1.1 1.5 -1.2 
SAP9 SAP9 orf19.6928 Aspartic-type endopeptidase activity 1.6 1.8 1.3 1.2 1.5 1.5 
SCW11.3eoc SCW11 orf19.3893 Glucan 1,3-beta-glucosidase activity 1.7 1.6 -1.2 -1.7 -1.3 -1.2 
SSU1 SSU1 orf19.7313 Sulfite transporter activity 1.8 1.6 1.5 1.1 1.3 1.6 
UGA12.3f UGA1 orf19.802 4-aminobutyrate transaminase activity 2.0 1.8 1.3 1.0 1.1 1.2 
UGA12.5f UGA1 orf19.802 4-aminobutyrate transaminase activity 1.8 1.6 1.5 1.4 1.2 1.0 
VPH2 -- orf19.5237 -- 1.8 2.0 -1.0 -1.1 1.5 -1.3 
IPF10001 -- orf19.6194 -- 1.6 1.8 -1.3 -1.0 1.5 -1.3 
IPF10431 -- orf19.2888 -- 1.5 2.1 -1.2 1.3 1.1 -1.2 
IPF11105 -- orf19.2262 -- 1.6 1.5 1.2 1.1 1.4 1.1 
IPF11812 SEC3 orf19.2911 -- 1.7 1.5 1.2 -1.1 1.1 -1.3 
IPF11849 -- orf19.4459 -- 3.8 3.3 2.9 1.2 -2.7 -4.1 
IPF1217 -- orf19.2063 -- 1.5 1.5 1.2 1.3 1.6 1.3 
IPF13131.3 HGT20 orf19.1587 Glucose transporter activity 1.6 1.9 -1.2 1.8 1.5 1.6 
IPF13176.3 ARG3 orf19.5610 Ornithine carbamoyltransferase activity 1.8 2.4 -1.2 -1.9 1.2 -1.1 
IPF13423 -- orf19.4128 -- 1.8 2.9 1.1 -1.1 -1.3 -1.3 
IPF13815 -- orf19.4553 -- 1.8 1.7 1.3 1.1 1.4 1.1 
IPF13967 -- orf19.5205 -- 1.6 2.3 -1.0 1.3 2.1 2.0 
IPF14109 PGA45 orf19.2451 -- 5.1 3.9 1.4 1.8 1.5 1.7 
IPF14968 -- orf19.3461 -- 1.7 2.3 1.5 1.4 1.1 1.1 
IPF15423 SOD6 orf19.2108 Copper, zinc superoxide dismutase activity 1.5 2.5 -1.3 1.2 1.3 1.6 
IPF16948 -- orf19.3285 -- 1.8 3.8 -1.2 -1.0 1.1 1.0 
IPF17054 -- orf19.5037 -- 3.2 2.1 1.2 1.2 1.2 1.2 
IPF17520.53eoc -- orf19.1021 -- 5.9 2.6 -- -- -- -- 
IPF18207 DAP1 orf19.489 -- 1.9 1.7 -1.0 1.7 2.0 1.8 
IPF18316.3f SSP96 orf19.5145 -- 4.8 1.6 -1.4 -1.2 -1.1 1.0 
IPF18418 -- orf19.5620 -- 2.0 2.6 1.4 1.3 1.2 1.3 
IPF19735 -- orf19.3215 -- 1.5 1.5 1.0 1.7 1.4 1.4 
IPF19772 -- orf19.5602 -- 1.7 1.7 -1.1 1.0 1.1 -1.0 
IPF19908 -- orf19.1344 -- 2.2 3.0 2.0 1.2 -1.0 1.0 
IPF19998 -- orf19.1344 -- 1.6 1.7 1.3 1.1 1.2 1.1 
IPF2065 -- orf19.5274 -- 1.7 2.5 1.4 1.2 1.2 1.1 
IPF227 -- orf19.3244 -- 2.2 1.5 -1.3 1.4 1.1 1.1 
IPF2561 -- orf19.6624 -- 1.5 2.2 1.1 -1.4 1.1 -1.0 
IPF2884 -- orf19.7449 -- 5.8 1.6 1.4 1.2 -1.1 -1.3 
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Table C-1 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
IPF3282 HXT5 orf19.4384 Fructose transporter activity 1.7 2.0 1.5 2.6 -1.0 -1.1 
IPF3355 -- orf19.4014 -- 2.0 2.0 1.7 1.1 1.5 1.0 
IPF3535 -- orf19.6840 -- 2.1 2.8 2.8 2.2 1.7 1.4 
IPF3598 -- orf19.3047 Transcription cofactor activity 1.5 1.5 -1.0 -1.4 1.2 -1.2 
IPF4729 -- orf19.3743 -- 1.5 1.6 -1.4 1.5 1.7 1.1 
IPF5723.exon1 -- orf19.6329 -- 1.9 1.6 1.0 1.3 1.3 1.2 
IPF5972 CDG1 orf19.7314 -- 2.1 1.8 -1.2 -1.2 -1.0 -1.0 
IPF6203 ZCF21 orf19.4166 -- 1.7 1.7 1.6 1.4 1.7 1.0 
IPF6375 -- orf19.520 -- 1.9 1.5 1.1 -2.4 -1.5 -1.4 
IPF6649 -- orf19.6704 -- 1.8 1.5 -1.2 1.0 2.0 1.1 
IPF6679 -- orf19.1306 -- 1.7 2.0 -1.1 -1.2 1.2 -1.5 
IPF6700 -- orf19.2459 -- 1.6 1.5 1.2 -1.2 -1.3 -1.5 
IPF721.3f -- orf19.5365 -- 1.5 1.6 1.8 -1.3 -1.3 -1.6 
IPF7260 -- orf19.2790 Histone-lysine N-methyltransferase activity 1.5 1.5 1.1 -1.2 1.0 -1.2 
IPF8311 -- orf19.6003 -- 1.6 1.6 1.2 1.1 1.3 1.4 
IPF8617 -- orf19.3705 Phosphoprotein phosphatase activity 1.8 1.7 1.1 1.0 1.6 1.2 
IPF8796 PGA4 orf19.4035 -- 1.6 1.6 -1.0 1.2 1.2 1.3 
IPF9425.3 -- orf19.6888 -- 1.8 1.6 1.2 -1.0 1.2 1.2 
IPF9466 -- orf19.4066 -- 2.0 2.0 -1.3 1.4 -1.3 -1.9 
IPF9483 -- orf19.3395 -- 1.6 1.5 1.1 1.3 1.6 1.4 
IPF9995 -- orf19.2286 -- 1.8 1.7 1.4 1.6 1.4 1.4 
IPF9996 -- orf19.2285 -- 1.8 1.8 1.1 1.0 1.9 1.8 
ALS11.5f ALS9 orf19.5742 -- -1.2 -1.0 1.5 4.9 2.7 1.9 
ALS9.5eoc ALS9 orf19.5742 -- -1.2 -1.1 1.5 5.2 2.9 2.1 
APC11 -- orf19.7644 Protein binding -1.2 -1.1 1.6 2.6 1.5 1.6 
CDR11.5f CDR11 orf19.918 ATP binding -1.4 1.3 1.6 3.5 1.6 1.5 
CHT1 CHT1 orf19.7517 Chitinase activity 1.3 1.4 1.7 1.6 1.8 1.6 
CLN2 CLN3 orf19.1960 Cyclin-dependent protein kinase regulator activity 2.0 -1.0 1.8 2.7 2.1 2.4 
CNH1.3f CNH1 orf19.367 Cation:cation antiporter activity -1.2 -1.3 1.5 3.4 2.4 1.5 
CNH1.5f CNH1 orf19.367 Cation:cation antiporter activity -1.1 -1.4 2.0 9.2 1.7 1.7 
DAL1 DAL1 orf19.5454 Allantoinase activity -1.9 1.0 2.2 2.3 1.5 2.0 
DSK2 -- orf19.5345 Protein binding 1.1 1.6 1.7 1.5 1.5 1.5 
ERG2 ERG2 orf19.6026 C-8 sterol isomerase activity 2.2 1.3 2.2 2.5 1.9 1.9 
ERG5 ERG5 orf19.5178 C-22 sterol desaturase activity 1.3 1.3 1.7 1.8 1.7 1.9 
ERG6 ERG6 orf19.1631 Sterol 24-C-methyltransferase activity 1.3 1.4 1.7 1.9 1.6 1.8 
FCY24 FCY24 orf19.7331 Transporter activity 1.3 1.1 1.8 2.2 1.9 1.9 
FET5 FET34 orf19.4215 Ferroxidase activity 1.7 1.3 2.3 2.4 2.7 2.4 
FRE5 FRP1 orf19.5634 Ferric-chelate reductase activity 2.1 2.8 19.3 40.7 24.8 29.6 
FRP4 -- orf19.6997 -- -1.5 -5.9 1.5 2.8 3.2 2.7 
FRP7 -- orf19.6995 -- -2.6 1.2 1.6 1.7 2.2 1.5 
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Table C-1 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
GDI1 -- orf19.7261 Rab GDP-dissociation inhibitor activity 1.1 1.4 1.5 2.4 1.7 1.8 
IFH2 -- orf19.6398 -- -1.4 1.1 1.6 1.6 1.7 1.9 
IFU5 IFU5 orf19.2568 -- 1.7 1.3 1.5 2.5 2.3 2.3 
PIF2 -- orf19.7538 DNA helicase activity 1.1 1.2 1.5 1.9 1.9 1.6 
RBT5 RBT5 orf19.5636 Heme binding 1.2 1.3 2.4 3.0 3.0 3.0 
SAP5 SAP5 orf19.5585 Aspartic-type endopeptidase activity 1.1 1.1 2.0 2.0 2.5 3.0 
SEC16.53f.eoc -- orf19.4346 Structural molecule activity -1.1 -1.8 1.5 2.2 2.0 1.5 
SIT1 SIT1 orf19.2179 Ferrichrome transporter activity -1.2 1.5 1.5 1.7 2.1 1.9 
WSC4 WSC4 orf19.7251 -- 1.2 1.3 1.6 1.6 1.8 2.2 
IPF11259 -- orf19.5210 Transcription factor activity 3.6 -1.4 3.0 2.1 4.5 2.9 
IPF11503 -- orf19.3902 -- -1.3 -1.4 1.9 1.5 2.5 2.3 
IPF11601 NAG6 orf19.2151 GTP binding 1.3 1.3 1.5 1.5 1.6 1.6 
IPF11607 -- orf19.2149 -- 1.6 1.2 2.0 2.1 2.5 1.5 
IPF12082.3f -- orf19.6832 -- 1.2 1.3 1.5 1.9 2.2 1.9 
IPF12082.5f -- orf19.6832 -- 1.2 -1.4 1.7 5.9 1.6 1.9 
IPF12262 FGR23 orf19.1616 -- 1.1 -1.4 2.1 2.2 2.6 2.1 
IPF12963 BUL1 orf19.5094 -- 1.2 -1.1 2.7 2.5 3.1 2.9 
IPF13377 -- orf19.2350 -- 1.2 1.4 1.8 2.4 2.2 2.2 
IPF13723 -- orf19.260 -- 2.7 -1.0 2.9 2.7 3.3 3.7 
IPF14981 -- orf19.3483 -- 1.1 3.6 2.1 1.8 3.0 2.2 
IPF1514 -- orf19.344 -- 1.1 12.2 3.0 17.3 3.5 2.4 
IPF1899 -- orf19.7131 -- 2.0 -1.1 1.9 3.8 2.0 1.9 
IPF20157 -- orf19.6696 -- -21.5 -1.5 1.5 4.0 3.0 1.8 
IPF20164 -- orf19.5809 Arylformamidase activity -1.3 -1.1 1.7 1.5 1.9 1.7 
IPF257.3 -- orf19.3261 -- -1.1 -1.4 2.4 2.3 3.0 2.8 
IPF2702 -- orf19.2163 -- -2.9 2.2 1.6 4.4 2.6 2.1 
IPF3274 -- orf19.4383 -- -1.4 -1.1 3.0 1.5 2.1 1.9 
IPF3444.5f -- orf19.6184 -- -1.7 1.2 1.5 1.9 1.5 1.8 
IPF3446 -- orf19.6186 -- -1.3 1.3 2.5 1.8 1.8 1.5 
IPF3468 -- orf19.4055 -- -1.1 -1.2 1.5 3.8 2.3 1.9 
IPF3687 PAN1 orf19.886 Cytoskeletal adaptor activity -1.1 1.0 1.5 2.1 2.2 1.7 
IPF4055 -- orf19.1867 Malate transmembrane transporter activity -1.9 2.2 1.7 2.1 2.3 1.9 
IPF4160 -- orf19.5459 -- -1.2 1.1 1.5 3.1 1.5 1.7 
IPF4649 -- orf19.6102 Specific RNA polymerase II transcription factor activity -1.2 1.4 1.7 2.0 2.0 1.5 
IPF4724 PGA23 orf19.3740 -- 1.3 -1.2 1.7 2.4 2.8 2.1 
IPF5217 -- orf19.7270 -- -2.3 -1.2 1.6 2.7 2.0 1.7 
IPF5556 PHO100 orf19.4424 Acid phosphatase activity 1.1 1.3 4.6 2.5 3.4 3.4 
IPF5661 -- orf19.7125 -- -2.0 -2.2 1.8 252.0 2.3 1.7 
IPF6067 TCC1 orf19.6734 General transcriptional repressor activity -1.2 1.1 1.7 1.6 1.7 1.5 
IPF6678 -- orf19.1307 -- -1.7 1.1 1.8 1.6 2.9 2.3 
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Table C-1 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
IPF708 -- orf19.5370 -- 1.1 -1.9 1.7 2.0 1.6 1.5 
IPF8904 -- orf19.1363 -- -2.4 1.3 2.4 1.5 1.8 1.7 
IPF9370 -- orf19.1424 -- -1.2 1.4 1.5 1.6 1.7 2.0 
 
a Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b Gene name at CGD (http://www.candidagenome.org/). 
c orf19 nomenclature according to the Assembly 19 version. 
d GO annotation found at CGD (http://www.candidagenome.org/). 
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Table C-2. Genes down-regulated in either S2 or gain-of-function S2 allele in SC5314. 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
COQ1 -- orf19.7478 Trans-hexaprenyltranstransferase activity -2.8 -2.9 -1.5 -2.5 -2.4 -3.8 
MAS2 -- orf19.6295 Mitochondrial processing peptidase activity -1.6 -1.7 -1.6 -2.3 -2.7 -2.9 
MET14 MET14 orf19.946 Adenylylsulfate kinase activity -5.6 -6.9 -2.3 -2.9 -3.5 -3.7 
MET3 MET3 orf19.5025 Sulfate adenylyltransferase (ATP) activity -4.2 -3.8 -3.3 -4.0 -3.5 -5.9 
PET127 -- orf19.2309 RNA binding -1.7 -1.8 -2.0 -4.4 -7.7 -5.9 
IPF11801 -- orf19.2798 Helicase activity -1.6 -1.7 -2.3 -2.2 -2.0 -1.8 
IPF14872 -- orf19.4133 -- -2.0 -1.8 -1.8 -3.5 -2.3 -4.0 
IPF20118 -- orf19.3846 -- -3.8 -4.4 -3.6 -3.1 -1.7 -1.6 
IPF525 -- orf19.7085 -- -2.4 -2.2 -1.7 -3.1 -1.7 -1.7 
IPF6504 -- orf19.1544 -- -2.1 -2.0 -1.8 -1.5 -1.7 -1.6 
IPF7334 -- orf19.3724 -- -2.3 -2.2 -1.6 -3.1 -1.8 -3.4 
BUL1 -- orf19.4629 -- -2.0 -1.7 -1.8 -1.1 -1.2 -1.1 
CDC11 CDC11 orf19.5691 Structural constituent of cytoskeleton -1.8 -1.8 -1.1 -2.0 -1.3 -1.9 
CDC62 -- orf19.5242 ATPase activity -1.6 -1.7 1.9 6.7 -1.3 1.6 
Cirt3 -- orf19.4918 -- -2.5 -2.5 -1.2 -1.4 1.3 -1.2 
COS162 -- orf19.4240 -- -1.6 -1.6 1.1 1.1 -1.3 -1.2 
CTF8 CTF8 orf19.576 -- -1.8 -1.7 -1.8 1.3 -1.6 -1.1 
CVB1 -- orf19.1970 -- -1.6 -1.7 -1.2 -1.3 1.3 -1.5 
DAP2 DAP2 orf19.4322 Dipeptidyl-peptidase and tripeptidyl-peptidase activity -1.8 -2.0 -1.1 -1.1 1.2 -1.1 
DCG1 DCG1 orf19.244 -- -1.8 -1.8 -2.1 -1.1 -1.1 -1.9 
FIP1 -- orf19.4258 -- -2.2 -2.4 1.3 4.5 -1.7 -1.1 
FOL2 -- orf19.3957 GTP cyclohydrolase I activity -1.6 -1.6 1.1 -1.4 -1.2 -1.3 
GCN2 GCN2 orf19.6913 Eukaryotic translation initiation factor 2alpha kinase activity -1.6 -1.6 -1.1 1.3 -1.2 -1.4 
GLR1 GLR1 orf19.4147 Glutathione-disulfide reductase activity -1.6 -1.6 -1.0 -1.1 -1.1 -1.2 
GNA1 GNA1 orf19.837 Glucosamine 6-phosphate N-acetyltransferase activity -1.7 -3.1 -1.0 1.6 -1.2 -1.0 
HNM3 HNM3 orf19.2587 Choline transporter activity -3.1 -2.3 1.1 1.0 -1.1 -1.1 
HSL1 HSL1 orf19.4308 Protein kinase activity -2.3 -1.8 1.1 -1.5 1.3 -1.4 
IFG4 DAO1 orf19.3065 -- -1.6 -1.6 1.0 -1.0 1.2 -1.0 
IFN2 GIT4 orf19.1980 Phospholipid transporter activity -2.0 -2.4 -1.2 -1.7 2.2 1.7 
IFQ3 RHD1 orf19.54 -- -1.8 -1.7 -1.2 -1.2 1.0 -1.2 
IMG1 -- orf19.1967 Structural constituent of ribosome -2.6 -1.8 -1.2 -1.0 -1.6 -2.1 
LEU3 LEU3 orf19.4225 Transcription factor activity -1.7 -2.1 1.4 -1.3 -1.1 -1.3 
MAC1 MAC1 orf19.7068 Specific RNA polymerase II transcription factor activity -1.8 -1.6 1.0 -1.4 -1.2 -1.2 
MAK31 -- orf19.1968.1 Amino acid N-acetyltransferase activity -3.0 -6.2 1.4 1.4 -1.2 -1.2 
MAL31 MAL31 orf19.3981 Alpha-glucoside:hydrogen symporter activity -2.1 -1.7 -1.9 -1.4 1.6 -1.4 
MIG1 MIG1 orf19.4318 Transcription factor activity -1.6 -1.7 -1.1 -1.4 -1.5 -1.8 
MNN22 MNN22 orf19.3803 Alpha-1,2-mannosyltransferase activity -2.2 -2.3 1.1 -1.8 1.5 1.0 
MRPL36 -- orf19.3205 Structural constituent of ribosome -2.1 -1.7 -1.3 -1.3 -2.1 -2.0 
MYO1 -- orf19.6294 Microfilament motor activity -1.6 -4.1 1.2 3.3 -1.0 1.0 
NMD2 -- orf19.864 Protein binding -2.0 -3.4 1.3 -3.8 -1.5 1.0 
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Table C-2 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
NUP2.3eoc -- orf19.3583 Structural molecule activity -2.0 -2.4 1.0 -1.6 1.2 -1.2 
NUP49 NUP49 orf19.4987 Structural molecule activity -1.6 -1.6 1.1 -1.1 -1.7 -1.1 
OGG1 -- orf19.7190 Oxidized purine base lesion DNA N-glycosylase activity -1.7 -1.6 -1.1 -2.0 -1.7 -2.2 
OPT1 OPT1 orf19.2602 Oligopeptide transporter activity -3.0 -2.2 -1.1 1.0 1.1 -1.1 
PAF1 -- orf19.3613 RNA polymerase II transcription elongation factor activity -1.6 -2.3 1.3 -1.0 -1.4 1.1 
PAP11 PAP1 orf19.3197 RNA binding -1.6 -2.9 1.1 -1.1 1.2 -1.1 
PEL1 PEL1 orf19.7072 CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase 
activity -1.8 -2.2 1.2 -2.4 -2.0 -2.6 
PRC2 PRC2 orf19.4135 Carboxypeptidase C activity -3.0 -2.0 -1.3 -1.2 1.2 1.3 
PSD2.3f -- orf19.3954 Phosphatidylserine decarboxylase activity -1.9 -2.5 1.2 -1.1 -1.2 -1.4 
PUS4 PUS4 orf19.1954 Pseudouridylate synthase activity -1.6 -2.2 1.2 -1.3 -1.2 -1.9 
PZF1 -- orf19.4125 RNA polymerase III transcription factor activity -1.8 -1.9 -1.2 1.4 -1.7 -2.4 
RAD51 RAD51 orf19.3752 Recombinase activity -1.6 -1.8 1.0 -1.3 -1.0 -1.2 
RET2 RET2 orf19.4236 Protein binding -1.8 -1.6 -1.1 -1.3 -1.0 -1.2 
RMT2 RMT2 orf19.920 -- -1.6 -1.9 1.3 -1.6 -2.2 -2.3 
RPC82 -- orf19.2847 DNA-directed RNA polymerase activity -2.6 -4.3 1.3 -1.5 -1.7 -2.8 
RVS161 -- orf19.7124 Cytoskeletal protein binding -1.9 -2.0 -1.0 -1.3 -1.1 -1.3 
SEF11.5eoc SEF2 orf19.1926 -- -1.7 -3.3 1.1 -1.4 -1.3 -1.7 
SMC4 -- orf19.964 ATPase activity -2.5 -1.7 -1.0 -1.6 1.3 -1.5 
SPE2 SPE2 orf19.568 Adenosylmethionine decarboxylase activity -1.6 -1.6 1.1 -1.4 -2.0 -2.2 
SSA4 HSP70 orf19.4980 Unfolded protein binding -4.2 -4.8 -3.4 -1.3 1.5 -1.1 
SSP120 -- orf19.3173 -- -1.6 -2.5 1.2 1.6 1.1 -1.3 
SUA5 -- orf19.7088 -- -1.8 -2.1 -1.0 -1.4 -4.0 -3.4 
SUL1 SUL2 orf19.2738 Sulfate transporter activity -2.5 -5.8 -1.9 -1.3 1.1 -1.5 
TOF1 YBL053 orf19.4136 -- -2.2 -2.9 1.1 -1.6 -1.2 -1.8 
TRX2 -- orf19.1976 Thiol-disulfide exchange intermediate activity -1.6 -2.3 -1.3 1.1 -1.8 -1.7 
VPS4 VPS4 orf19.4339 ATPase activity -2.9 -1.7 1.0 -1.2 1.1 1.1 
IPF1047 -- orf19.4563 -- -1.6 -2.1 1.2 -1.2 -3.1 -3.0 
IPF10521 -- orf19.4062 -- -1.6 -2.0 -1.2 -1.0 -1.5 -1.7 
IPF10711 -- orf19.3694 -- -2.0 -1.7 1.3 -1.4 1.0 -1.0 
IPF10785.exon1 -- orf19.5732 -- -1.8 -4.1 1.9 1.2 -1.5 -1.4 
IPF10795 CRZ2 orf19.2356 Transcription factor activity -1.6 -1.7 1.3 -2.2 -1.6 -3.3 
IPF11027 -- orf19.5722 -- -1.9 -1.7 -1.1 -1.5 -2.1 -2.7 
IPF11090.exon1 -- orf19.4622 -- -1.7 -1.7 1.3 3.1 1.2 -1.4 
IPF11161.3 MTLA1 orf19.3201 Transcription factor activity -2.4 -3.6 -1.4 1.1 -1.3 -1.8 
IPF11167 OBPA orf19.3198 Oxysterol binding -1.6 -2.3 -1.1 -1.3 -1.1 -1.5 
IPF1129 -- orf19.5431 -- -2.5 -1.8 -1.0 -1.2 -1.9 -3.1 
IPF11344 -- orf19.4030 -- -2.9 -3.5 -1.4 -1.8 -1.3 -1.6 
IPF11434.5f -- orf19.6462 -- -2.1 -1.9 1.2 -1.0 1.3 1.0 
IPF11492 -- orf19.2392 -- -1.6 -1.8 1.2 -1.1 -1.4 -1.6 
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Table C-2 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
IPF11756 -- orf19.7006 -- -2.1 -2.1 1.2 -1.8 1.4 1.2 
IPF11987.3eoc -- orf19.692 -- -3.9 -1.7 1.2 1.1 1.6 -1.4 
IPF11989 -- orf19.3625 -- -1.7 -2.9 -1.2 -12.7 -1.1 -1.5 
IPF12141 -- orf19.1952 -- -1.7 -1.7 -1.1 -2.2 -2.0 -2.1 
IPF12790 -- orf19.3180 Inositol-polyphosphate 5-phosphatase activity -1.7 -1.7 -1.2 -1.1 1.6 -1.0 
IPF12802 -- orf19.2513 -- -1.6 -2.0 3.6 -3.0 1.5 -5.0 
IPF13142 -- orf19.53 -- -2.0 -3.6 -1.5 -1.5 -1.0 -1.7 
IPF13247 -- orf19.3376 -- -7.4 -1.6 -1.1 1.2 1.4 1.2 
IPF13407 -- orf19.753 Alpha-1,3-mannosyltransferase activity -1.6 -4.2 -1.1 1.4 1.2 -1.1 
IPF13683 -- orf19.2547 -- -1.8 -1.7 1.3 -1.5 -6.6 -3.4 
IPF14348.3 -- orf19.1207 -- -1.6 -3.3 1.4 1.0 1.0 -1.2 
IPF14487 -- orf19.6346 -- -2.8 -2.8 -1.3 2.1 -1.7 -1.5 
IPF14506 -- orf19.1961 -- -2.4 -3.4 1.0 -1.2 1.3 1.1 
IPF14663 -- orf19.4316 -- -2.1 -2.0 1.1 -1.2 -1.2 -1.1 
IPF14743 -- orf19.3425 -- -1.7 -1.8 1.2 1.0 -1.0 1.0 
IPF14871 -- orf19.4132 -- -1.8 -2.1 -1.3 1.1 1.2 1.3 
IPF1497 -- orf19.351 -- -1.7 -1.6 -1.2 1.4 1.0 -1.0 
IPF14985 -- orf19.4134 -- -2.9 -2.2 -1.1 -1.0 1.3 1.0 
IPF1557 -- orf19.954 -- -1.6 -1.6 1.5 1.2 -1.2 -1.1 
IPF1567 -- orf19.961.2 Structural constituent of ribosome -1.7 -1.6 -1.5 1.3 -1.0 -1.1 
IPF15811 -- orf19.4280 -- -1.6 -2.5 -2.9 -1.3 -1.2 -1.1 
IPF15834 -- orf19.4675 -- -2.2 -1.9 -1.2 -1.3 -2.7 -2.1 
IPF16141 -- orf19.2260 Transcription factor activity -2.2 -2.0 -1.0 -2.2 -1.0 -2.1 
IPF16758 -- orf19.5043 -- -1.6 -2.5 -- -- -- -- 
IPF16947 -- orf19.3286 -- -2.9 -3.5 -1.2 1.2 1.6 -1.1 
IPF16988 -- orf19.4312 -- -2.7 -8.7 -- -- -- -- 
IPF17031 -- orf19.2544 -- -2.0 -2.1 1.2 -1.5 -2.1 -1.7 
IPF17050 -- orf19.1049 -- -1.5 -1.6 -3.1 -1.4 -1.7 -1.8 
IPF17186 -- orf19.251 -- -1.8 -2.2 -1.7 -1.6 -1.3 -1.3 
IPF17296 -- orf19.175 Transcription factor activity -3.3 -1.8 -12.3 1.1 -7.3 1.0 
IPF17998 -- orf19.3147 -- -1.8 -1.8 -1.1 -1.5 -1.6 -2.0 
IPF18517.5f -- orf19.4349 -- -3.7 -33.3 1.1 1.1 -1.8 -1.6 
IPF19310.3f -- -- -- -2.2 -14.6 -1.9 #DIV/0! 11.0 -1.9 
IPF1956 -- orf19.7159 -- -2.5 -1.7 1.1 -1.3 -1.2 -2.4 
IPF19622 -- orf19.115 -- -2.7 -1.7 -1.1 -2.2 -1.5 1.1 
IPF19775 -- orf19.4282 -- -2.2 -1.9 1.4 1.2 -1.0 -1.5 
IPF19814 -- orf19.7106 -- -1.6 -1.8 1.1 -1.0 1.8 1.2 
IPF19924 -- orf19.4324 -- -1.6 -6.7 -1.1 1.6 -1.8 -1.3 
IPF19937 -- orf19.4740 Aminoacyl-tRNA hydrolase activity -1.9 -1.6 -1.3 1.2 1.2 -1.1 
IPF2359 -- orf19.7022 -- -1.7 -2.1 -1.5 -1.7 -1.2 -1.8 
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Table C-2 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
IPF2522 -- orf19.7460 -- -1.7 -1.6 -1.1 -1.0 -1.2 1.3 
IPF2929 -- orf19.4306 -- -1.6 -1.6 -1.1 -1.5 -1.4 -1.6 
IPF2953 -- orf19.4294 -- -1.6 -2.4 1.0 -1.0 -1.9 -1.7 
IPF2997 -- orf19.6983 -- -1.8 -1.8 1.1 1.1 1.3 -1.4 
IPF3087 MET28 orf19.7046 Specific RNA polymerase II transcription factor activity -1.9 -1.8 -1.5 -2.3 -2.0 -2.8 
IPF3144 -- orf19.4220 -- -1.8 -1.6 -1.3 -1.2 -1.0 -1.3 
IPF3147 RIX7 orf19.4219 Helicase activity -1.7 -1.7 1.4 -1.1 -1.9 -1.7 
IPF3161 -- orf19.3161 -- -2.0 -1.9 -1.1 -2.4 -2.3 -2.6 
IPF3178 -- orf19.3170 -- -2.1 -1.8 1.2 -2.5 -2.1 -3.9 
IPF3621 -- orf19.6712 -- -1.7 -1.6 -1.2 -1.4 -1.3 -1.5 
IPF3903 -- orf19.760 Structural constituent of ribosome -1.6 -1.6 -1.3 1.7 -1.5 -1.7 
IPF4279 -- orf19.547 Flap endonuclease activity -1.8 -1.9 1.1 -3.3 -2.3 -2.2 
IPF4450 POL93 orf19.6078 -- -1.9 -1.7 -1.3 -1.2 -1.6 -2.4 
IPF448 -- orf19.7051 -- -1.6 -1.7 -1.2 -1.0 -1.8 -1.7 
IPF4531 -- orf19.6989 rRNA primary transcript binding -3.0 -1.7 -2.7 -1.1 -1.8 1.1 
IPF495 -- orf19.7069 -- -1.7 -1.6 1.2 -1.5 -1.3 -1.7 
IPF511 -- orf19.7078 -- -1.7 -1.7 -1.4 -1.3 -1.4 -1.6 
IPF5330 -- orf19.3448 -- -1.6 -1.9 -1.5 -2.0 -1.5 -1.4 
IPF539 -- orf19.7092 -- -2.1 -1.6 1.3 -1.0 1.3 -1.0 
IPF5466 -- orf19.5683 -- -3.1 -2.4 -1.1 1.6 1.4 1.3 
IPF560 -- orf19.7102 -- -1.7 -2.8 -1.2 -1.1 -1.0 -1.7 
IPF5615 -- orf19.7107 -- -1.7 -1.8 1.1 -1.7 -1.8 -1.6 
IPF5621 -- orf19.7111 -- -1.8 -2.1 -1.3 -1.1 1.1 -1.3 
IPF563 -- orf19.7103 -- -2.1 -1.6 1.1 -1.2 1.1 -1.2 
IPF5644 -- orf19.7116 RNA polymerase II transcription elongation factor activity -2.6 -2.4 1.0 -1.3 -1.3 -1.3 
IPF5661 -- orf19.7125 -- -2.0 -2.2 1.8 252.0 2.3 1.7 
IPF5818 -- orf19.3821 -- -1.6 -2.1 -1.3 -1.2 -1.1 -1.6 
IPF6252 -- orf19.1458 -- -1.9 -2.0 1.7 1.8 -1.5 -1.9 
IPF6296 -- orf19.1966 -- -2.8 -1.8 1.6 -4.6 -1.3 -1.9 
IPF6396 -- orf19.580 -- -2.3 -2.4 -1.3 -2.3 -1.2 -1.5 
IPF6617.repeat2 LDG3 orf19.6486 -- -37.3 -5.1 2.3 1.4 1.3 3.7 
IPF662 -- orf19.7601 rRNA (uridine-2'-O-)-methyltransferase activity -1.6 -1.8 -1.1 -1.5 -2.9 -2.6 
IPF6712.5f -- orf19.1414 -- -1.6 -2.2 1.2 -1.1 1.0 -1.0 
IPF7088 -- orf19.486 Microtubule binding -1.8 -1.6 1.1 -1.6 1.4 1.4 
IPF7204 PGA26 orf19.2475 -- -4.6 -3.0 -1.3 -1.2 -1.2 -1.2 
IPF7400 -- orf19.1802 -- -1.6 -1.6 -1.2 1.1 1.3 1.2 
IPF7466 -- orf19.2051 -- -1.7 -2.5 1.5 -1.0 -1.4 -1.4 
IPF7616 -- orf19.1159 Homoserine O-acetyltransferase activity -2.3 -1.9 -1.0 -2.6 -1.9 -1.9 
IPF7669.3 -- orf19.450 -- -3.5 -1.6 -1.6 1.1 1.1 1.3 
IPF7968 -- orf19.2693 Transcription corepressor activity -1.8 -1.8 -1.7 -1.4 1.3 -1.2 
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Table C-2 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
IPF8421 -- orf19.928 -- -1.7 -1.6 1.1 -1.4 1.4 -1.2 
IPF8535 PGA31 orf19.5302 -- -4.0 -2.6 1.3 1.5 1.5 -1.1 
IPF8741.5f RAD9 orf19.4275 -- -1.9 -2.5 -1.1 -1.3 -1.1 1.0 
IPF8901 -- orf19.3758 -- -2.5 -3.6 1.6 2.0 -1.4 1.3 
IPF8996 -- orf19.4634 -- -1.9 -1.8 -1.0 1.1 -2.0 -2.1 
IPF9417 CTA8 orf19.4775 Transcription factor activity -1.7 -1.8 1.8 -1.7 -1.9 -1.4 
IPF9522.53f SPR28 orf19.4266 Structural constituent of cytoskeleton -2.0 -1.9 -1.6 7.7 -1.0 -1.0 
IPF9525 -- orf19.4268 snoRNA binding -2.0 -2.4 1.1 -1.3 -2.7 -2.1 
IPF9529 -- orf19.4270 Alpha-1,3-mannosyltransferase activity -1.8 -1.7 1.1 -1.4 -1.3 -1.2 
IPF9566 -- orf19.1939 -- -1.8 -1.6 1.3 1.9 -2.0 -1.0 
IPF9568 -- orf19.1938 -- -1.7 -2.3 -1.4 -1.7 -1.7 1.2 
IPF9580 -- orf19.687 -- -1.7 -2.1 1.1 1.3 -1.1 -1.6 
IPF9841 -- orf19.3204 -- -1.8 -2.2 -2.3 -1.1 -3.0 -2.2 
IPF9972.3eoc -- orf19.4522 -- -1.6 -1.6 -1.9 1.6 -2.0 1.4 
ALS10 ALS10 orf19.2355 Cell adhesion molecule binding -1.1 -1.3 -2.4 -1.7 -1.7 -1.9 
ALS3.3eoc ALS10 orf19.2355 Cell adhesion molecule binding 1.5 -1.1 -2.3 -2.0 -2.2 -2.0 
ATP11 -- orf19.6916 -- 1.7 -2.1 -1.9 -2.0 -3.1 -2.1 
CUS2 -- orf19.5767 RNA binding -1.2 -1.2 -2.1 -2.0 -1.7 -1.6 
ECE1 ECE1 orf19.3374 -- -1.2 -6.0 -7.0 -3.8 -4.6 -3.5 
FRE7 -- orf19.7077 Ferric-chelate reductase activity -2.1 -1.1 -1.6 -1.6 -2.3 -2.5 
GCN5 -- orf19.705 Histone acetyltransferase activity 1.1 1.0 -1.7 -1.7 -1.7 -2.1 
HGT11 HGT1 orf19.4527 Glucose transporter activity -1.4 1.0 -3.2 -1.8 -3.0 -2.8 
HGT12 HGT2 orf19.3668 Glucose transporter activity -1.1 1.1 -2.0 -6.6 -3.0 -2.7 
HWP1 HWP1 orf19.1321 -- 1.0 -1.9 -4.8 -4.5 -3.2 -2.7 
MRPL10.3 MRPL10 orf19.3532 Structural constituent of ribosome 1.5 -1.2 -1.5 -2.2 -2.1 -2.6 
MRS2 MRS2 orf19.2597 Magnesium ion transporter activity -1.1 -1.6 -1.8 -1.9 -1.8 -2.2 
MTF1 -- orf19.1528 Transcription factor activity -1.5 -1.4 -1.6 -4.0 -3.7 -4.9 
NAM2 NAM2 orf19.5705 Leucine-tRNA ligase activity 1.8 1.5 -1.8 -2.4 -1.7 -2.4 
NCB2 -- orf19.5825 Transcription corepressor activity 1.1 -1.6 -1.6 -1.9 -1.7 -4.9 
PAC10.3 -- orf19.5985 -- 1.0 -1.1 -1.6 -1.7 -2.3 -1.9 
PHB2 -- orf19.5973 -- -1.2 -1.4 -1.7 -2.1 -1.8 -1.9 
RRP45 -- orf19.4078 3'-5'-exoribonuclease activity 1.3 -3.3 -1.7 -1.9 -3.3 -2.3 
SEC9 -- orf19.117 -- 1.5 -1.5 -1.9 -2.2 -1.9 -1.8 
SOU1 SOU1 orf19.2896 2,4-dienoyl-CoA reductase (NADPH) activity -1.2 -1.4 -3.0 -2.2 -2.1 -2.2 
TLG1 -- orf19.3898 t-SNARE activity 1.6 -2.0 -2.3 -5.7 -1.6 -3.3 
IPF10399 -- orf19.3367 Structural constituent of ribosome 1.1 -1.6 -1.8 -1.9 -2.6 -3.0 
IPF10455 -- orf19.104 -- -3.2 -1.6 -2.0 -1.8 -1.8 -1.9 
IPF10716 -- orf19.3691 -- -1.2 -1.9 -1.8 -2.1 -2.4 -1.6 
IPF12047 -- orf19.3471 -- -1.7 -1.3 -1.7 -2.1 -2.2 -3.0 
IPF1209 -- orf19.2068 -- -1.5 1.2 -1.7 -4.4 -2.2 -2.6 
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Table C-2 (continued). 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
S2vS1 
UPC2S2-1 vs. UPC2S1-1 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B 
1 2 1 2 1 2 
IPF12152 -- orf19.6236 -- -1.1 -5.0 -1.7 -2.0 -3.2 -3.3 
IPF1242 -- orf19.7360 -- 1.1 1.0 -1.6 -2.3 -2.3 -2.1 
IPF12844 -- orf19.2362 -- 1.1 -1.8 -1.8 -1.9 -3.8 -5.0 
IPF13221 -- orf19.1697 -- 1.7 -1.7 -1.8 -3.7 -2.5 -2.5 
IPF13402 -- orf19.36 -- 1.0 -1.9 -1.6 -1.6 -1.7 -2.0 
IPF13552 -- orf19.1300 -- -1.2 -1.2 -1.6 -2.7 -2.3 -2.7 
IPF13613 -- orf19.725 -- -1.1 -1.3 -1.8 -4.6 -2.4 -1.7 
IPF13782 -- orf19.2314 -- 1.9 -3.0 -2.0 -2.4 -3.4 -5.1 
IPF14574 -- orf19.1083 -- 1.4 -1.2 -1.7 -1.7 -1.9 -2.4 
IPF14921 -- orf19.1527 -- 3.4 -1.3 -1.8 -1.9 -2.1 -3.2 
IPF2232 -- orf19.6899 -- 3.9 -7.0 -1.5 -5.6 -1.9 -1.8 
IPF2555 -- orf19.6628 Structural constituent of cytoskeleton -1.2 -2.9 -1.9 -2.0 -1.8 -3.6 
IPF2839 -- orf19.7296 -- -1.0 1.3 -2.0 -3.1 -3.3 -2.5 
IPF2998 -- orf19.6982 -- -1.9 -1.4 -2.8 -8.0 -4.9 -9.4 
IPF3015 MODF orf19.5029 ATP binding -1.1 -1.6 -1.8 -2.4 -1.8 -2.5 
IPF312 -- orf19.3154 -- 1.0 -1.1 -1.6 -2.4 -1.6 -2.0 
IPF3857 -- orf19.25 -- 1.1 -1.4 -1.6 -2.0 -2.7 -2.6 
IPF4080 MRP8 orf19.3844 Structural constituent of ribosome 1.5 -1.7 -1.6 -1.6 -1.6 -1.7 
IPF4671 -- orf19.1849 -- 1.6 -1.7 -1.8 -2.2 -1.7 -1.7 
IPF4880 -- orf19.6266 3'-5'-exoribonuclease activity -1.1 -1.2 -1.7 -1.6 -2.2 -2.9 
IPF4991 CSP37 orf19.2531 -- 1.1 -1.5 -4.3 -2.4 -1.6 -1.9 
IPF5149 -- orf19.6530 Signal recognition particle binding -1.8 -1.9 -1.9 -1.8 -1.9 -3.5 
IPF61 -- orf19.5959 snoRNA binding 6.6 -20.0 -2.4 -2.9 -1.7 -2.7 
IPF6339 -- orf19.2724 -- 1.3 -1.0 -1.6 -2.1 -1.7 -2.0 
IPF7166 -- orf19.1202 -- -1.3 -1.4 -1.7 -1.8 -1.8 -2.2 
IPF8114 -- orf19.2939 -- -1.2 -1.6 -1.6 -1.7 -2.2 -1.5 
IPF8422 -- orf19.927 -- -1.2 -2.7 -1.9 -2.3 -2.6 -3.5 
IPF8727 -- orf19.1794 -- -1.8 -3.2 -2.0 -11.5 -1.6 -9.8 
IPF8854 -- orf19.4900 Alpha-1,3-mannosyltransferase activity -1.3 -2.0 -1.6 -2.2 -1.6 -2.2 
 
a Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b Gene name at CGD (http://www.candidagenome.org/). 
c orf19 nomenclature according to the Assembly 19 version. 
d GO annotation found at CGD (http://www.candidagenome.org/). 
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Table C-3. Genes down-regulated in the absence of UPC2. 
 
CandidaDB 
Namea 
CGD 
Nameb 
orf19 
Numberc GO Annotation (Molecular Function)d 
Δupc2 vs. SC5314 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B Strain A Strain B 
1 2 1 2 1 2 1 2 
CHA12 CHA1 orf19.1996 L-serine ammonia-lyase activity -1.7 -1.9 -1.5 -1.9 1.1 1.1 -1.7 -1.2 
FDH4.3f -- orf19.1774 Formate dehydrogenase activity -1.7 -2.5 -1.7 -1.8 -1.1 -3.3 -6.4 -3.5 
IPF14026 -- orf19.718 Transcription factor activity -1.9 -2.3 -2.2 -2.2 -1.2 -1.7 1.6 -3.0 
IPF15335 -- orf19.4970 -- -3.0 -2.0 -1.6 -2.0 -2.8 1.1 -1.4 2.4 
IPF7289 UPC2 orf19.391 Transcription factor activity -262.2 -196.2 -1573.0 -164.5 2.1 2.5 2.4 2.5 
 
a Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b Gene name at CGD (http://www.candidagenome.org/). 
c orf19 nomenclature according to the Assembly 19 version. 
d GO annotation found at CGD (http://www.candidagenome.org/). 
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Table C-4. Genes up-regulated in the absence of UPC2. 
 
CandidaDB Namea CGD Nameb orf19 Numberc GO Annotation (Molecular Function)d 
Δupc2 vs. SC5314 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B Strain A Strain B 
1 2 1 2 1 2 1 2 
AAF1 AAF1 orf19.7436 -- 1.6 1.5 1.7 1.7 1.4 -1.1 1.2 -1.6 
ALS10 ALS10 orf19.2355 Cell adhesion molecule binding 1.6 1.8 1.8 2.7 -2.4 -1.7 -1.7 -1.9 
ALS3.3eoc ALS10 orf19.2355 Cell adhesion molecule binding 1.6 1.5 1.8 2.3 -2.3 -2.2 -2.0 -2.0 
ALS3.5eoc ALS3 orf19.1816 Cell adhesion molecule binding 1.5 1.7 1.9 2.6 -2.1 -1.8 -1.2 -1.4 
ARG1 ARG1 orf19.7469 Argininosuccinate synthase activity 1.6 1.5 2.5 1.5 1.6 1.2 -1.1 1.1 
CAN2 CAN2 orf19.111 Basic amino acid transporter activity 1.7 1.6 2.1 1.7 -2.1 3.2 1.1 2.7 
DDR48 DDR48 orf19.4082 -- 4.4 5.2 8.2 11.5 2.4 3.4 2.4 3.8 
ECM331 ECM331 orf19.4255 -- 5.0 4.5 13.0 10.9 1.2 1.3 -2.1 1.9 
FRP2 -- orf19.6169 -- 1.8 1.6 1.8 1.6 -1.1 -1.3 -1.6 -1.1 
GLG2 GLG2 orf19.7434 Glycogenin glucosyltransferase activity 1.8 1.9 2.9 1.6 -1.8 1.4 -1.0 -2.0 
HGT12 HGT2 orf19.3668 Glucose transporter activity 1.8 3.0 2.2 7.9 -2.0 -3.0 -6.6 -2.7 
IFC4 OPT4 orf19.176 Oligopeptide transporter activity 1.5 1.5 1.7 1.5 -1.0 4.5 2.9 4.4 
INO1 INO1 orf19.7585 Inositol-3-phosphate synthase activity 2.0 2.5 3.4 3.6 1.7 1.3 1.2 1.3 
MIF2 MIF2 orf19.5551 Centromeric DNA binding 1.7 1.6 1.5 1.6 -1.1 -1.4 -2.4 -1.9 
OSM2 OSM2 orf19.5005 Fumarate reductase (NADH) activity 1.6 1.6 1.8 1.6 -1.2 1.2 1.0 1.0 
RIM8 RIM8 orf19.6091 -- 1.8 1.6 1.8 1.9 1.1 2.5 1.3 -1.4 
RTA4 RTA4 orf19.6595 Phospholipid-translocating ATPase activity 1.5 1.6 1.8 2.4 -1.5 1.2 1.1 1.1 
SNF31 HGT12 orf19.7094 Fructose transmembrane transporter activity 15.4 2.4 12.0 2.9 1.0 3.4 1.2 -1.0 
YOX1 -- orf19.7017 -- 1.6 2.1 1.8 1.6 1.1 -2.8 -1.1 -1.8 
IPF10171.exon3 HGT9 orf19.644 Glucose transmembrane transporter activity 41.5 1.8 21.0 1.5 1.1 1.8 -1.7 1.1 
IPF11801 -- orf19.2798 Helicase activity 2.2 2.4 2.0 2.5 -2.3 -2.0 -2.2 -1.8 
IPF11876 -- orf19.5295 -- 2.0 1.8 1.7 1.5 1.4 -1.2 -1.3 1.5 
IPF12312 -- orf19.5070 -- 1.8 1.5 1.7 1.8 1.3 -1.0 1.1 -1.1 
IPF13409 -- orf19.751 -- 2.3 1.8 2.3 1.9 -1.9 -1.1 1.0 -2.3 
IPF1341 PGA13 orf19.6420 -- 1.9 2.5 2.8 4.1 1.0 1.2 -1.6 -1.1 
IPF14119 DAG7 orf19.4688 -- 1.8 1.9 2.1 2.7 1.7 1.6 1.7 1.8 
IPF14618 -- orf19.6079 -- 1.6 2.0 1.8 3.0 -1.3 -1.2 5.3 -1.1 
IPF16253 -- orf19.3932 -- 1.8 1.9 2.4 2.2 -1.5 -2.5 -1.6 -1.9 
IPF16843 -- orf19.2397 -- 1.8 1.6 1.8 1.8 -1.1 -1.2 -1.3 -1.8 
IPF18732 -- orf19.711 -- 1.9 2.8 2.7 4.5 -1.1 1.4 -1.5 1.8 
IPF19749 -- orf19.94 -- 1.5 1.6 1.5 1.6 -2.2 -1.5 -2.0 -1.4 
IPF2839 -- orf19.7296 -- 3.3 2.2 4.3 3.1 -2.0 -3.3 -3.1 -2.5 
IPF300 -- orf19.3282 -- 2.0 1.9 2.4 2.2 1.0 1.2 -1.2 1.0 
IPF4443 -- orf19.4706 -- 1.9 2.0 2.0 2.9 1.3 -1.6 1.2 -1.2 
IPF4724 PGA23 orf19.3740 -- 5.6 3.5 9.9 8.4 1.7 2.8 2.4 2.1 
IPF7109 -- orf19.7350 -- 1.5 1.6 1.6 1.7 -1.1 1.1 1.1 1.0 
IPF743 -- orf19.5353 -- 2.3 2.3 2.8 3.4 -2.1 -1.1 -1.1 -1.1 
IPF7493 HGT17 orf19.4682 Glucose transmembrane transporter activity 2.0 2.1 2.3 2.7 1.3 -1.2 1.1 -1.1 
IPF7666 GAT2 orf19.4056 Transcription factor activity 1.6 1.6 1.5 1.5 -1.2 -1.1 1.1 -1.4 
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Table C-4 (continued). 
 
CandidaDB Namea CGD Nameb orf19 Numberc GO Annotation (Molecular Function)d 
Δupc2 vs. SC5314 UPC2S2-1 vs. UPC2S1-1 
Strain A Strain B Strain A Strain B 
1 2 1 2 1 2 1 2 
IPF9955 -- orf19.3499 -- 3.2 4.2 4.6 9.7 -1.3 3.0 1.5 1.9 
IPF9996 -- orf19.2285 -- 6.1 1.9 4.8 2.2 1.1 1.9 1.0 1.8 
 
a Gene name at CandidaDB (http://genolist.pasteur.fr/CandidaDB/). 
b Gene name at CGD (http://www.candidagenome.org/). 
c orf19 nomenclature according to the Assembly 19 version. 
d GO annotation found at CGD (http://www.candidagenome.org/). 
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